• SHOP
  • SAMPLES
  • COMBOS
  • SCIENCE
  • INGREDIENTS
  • TESTIMONIALS
  • CART
  • ABOUT
  • HOME
  • CONTACT
  • TELEGRAM PORTAL
  • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
  • THE ULTIMATE DRY FASTING RESOURCE
  • MY ACCOUNT
  • RESET PASSWORD
0
ANTI CARIOGENIC (Protecting From Tooth Decay)
April 30, 2022
HSP70, THE ANTI-AGING PROTEIN
May 10, 2022
  1. Regulation of inflammatory responses by natural anticoagulants
  2. natural anticoagulants and the liver
  3. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?
  4. natural anticoagulants, aging, and thromboembolism
  5. natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies
  6. Changes in the natural anticoagulants following bone marrow transplantation.
  7. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients
  8. Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin
  9. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S
  10. natural anticoagulants: A missing link in mild to moderate bleeding tendencies
  11. Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants
  12. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis.
  13. natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation
  14. Predictors of stroke outcome: the role of hemorheology, natural anticoagulants, and serum albumin
  15. Prognostic significance of D-dimer, natural anticoagulants and routine coagulation parameters in acute pancreatitis
  16. Changes in plasma levels of natural anticoagulants in disseminated intravascular coagulation: high prognostic value of antithrombin and protein C in patients …
  17. 5 The natural anticoagulants
  18. Plasma concentrations of the natural anticoagulants protein C and protein S in patients with proteinuria
  19. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial …
  20. … , protein C and protein S in the general Chinese population. Results of the Chinese Hemostasis Investigation on natural anticoagulants Study I Group
  21. natural anticoagulants can be useful predictors of severity in chronic liver disease
  22. natural anticoagulants (antithrombin III, protein C, and protein S) in patients with mild to moderate ischemic stroke
  23. natural anticoagulants in systemic lupus erythematosus. Deficiency of protein S bound to C4bp associates with recent history of venous thromboses, antiphospholipid …
  24. The fibrinolytic response to venous occlusion and the natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus …
  25. Differential kinetics of coagulation factors and natural anticoagulants in patients with liver cirrhosis: potential clinical implications
  26. Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis.
  27. Coagulopathy of childhood nephrotic syndrome–a reappraisal of the role of natural anticoagulants and fibrinolysis
  28. Do age and anticoagulants affect the naturalhistory of acute subdural hematomas?
  29. Interactions between naturalhealth products and oral anticoagulants: spontaneous reports in the Italian Surveillance System of naturalHealth Products
  30. Origin of the gender differences of the naturalresistance to antivitamin K anticoagulants in rats
  31. Determinants of elevated levels of natural anticoagulants in healthy subjects
  32. Characterization of the coagulation system in healthy dolphins: the coagulation factors, natural anticoagulants, and fibrinolytic products
  33. VTE recurrence in patients with inherited deficiencies of natural anticoagulants
  34. Superficial venous thrombosis: role of inherited deficiency of natural anticoagulants in extension to deep veins
  35. natural anticoagulants and their pathways
  36. Deficiencies of the natural anticoagulants–novel clinical laboratory aspects of thrombophilia testing
  37. Sulfated polysaccharide anticoagulants suppress naturalkiller cell activity in vitro
  38. Heparinase: II. Distribution of enzyme in various tissues and its action on naturalheparins and certain synthetic anticoagulants
  39. … disease in pediatric patients after hematopoietic stem cell transplantation: relevance of activated coagulation and fibrinolysis markers and natural anticoagulants
  40. natural anticoagulants in disseminated intravascular coagulation and sepsis
  41. Normal levels of the natural anticoagulants (proteins C & S and antithrombin III) and the fibrinolytic factors (tPA and PAI) in Arab children
  42. The level of natural anticoagulants in transfusion dependent thalassemia patients in Kelantan, Northeastern Malaysia
  43. The effect of delayed analysis or freeze-thawing on the measurement of natural anticoagulants, resistance to activated protein C and markers of activation of the …
  44. natural anticoagulants and fibrinolytic activity following interferon therapy in chronic viral hepatitis
  45. ST-elevation myocardial infarction, pulmonary embolism, and cerebral ischemic stroke in a patient with critically low levels of natural anticoagulants
  46. Principal coagulation factors and natural anticoagulants in the armadillo Chaetophractus villosus (Mammalia, Xenarthra, Dasypodidae)
  47. Recombinant natural anticoagulants: a review.
  48. The evaluation of natural anticoagulants in systemic lupus erythematosus in children
  49. Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD–A longitudinal study
  50. Cerebral infarctions in young patients related to deficiency of natural anticoagulants. Protein C and protein S
  51. Deficiency of natural anticoagulants: how should we manage cardiovascular prevention?
  52. A survey of the clinical course and management of Japanese patients deficient in natural anticoagulants
  53. Genetic variation and natural anticoagulants
  54. Protein Z and natural anticoagulants in children on peritoneal dialysis and hemodialysis
  55. Anticuagulants: An overview of naturaland Synthetic Therapeutic anticoagulants
  56. Stability of prothrombin times in sheep dosed with naturaland synthetic anticoagulants
  57. naturalregulatory anticoagulants proteins among Sudanese patients with dengue virus infection
  58. Comparison of plasma levels of natural anticoagulants (protein C and protein S) among Jordanian smokers and non-smokers
  59. Alteration of some natural anticoagulants in dogs with chronic renal failure
  60. The interactions among B2-glycoprotein I, natural anticoagulants, and complement: significance for the antiphospholipid syndrome
  61. Assessment of risk factors for deep vein thrombosis associated with natural anticoagulants and fibrinolytic regulatory proteins.
  62. Levels of natural anticoagulants Protein C, Protein S and Antithrombin III in Patients with Solid Malignancies
  63. Deficiency of natural anticoagulants
  64. Predictive role of natural anticoagulants in Prognosis of Chronic Liver Disease in Pediatric Age Group
  65. PB2232 THE natural anticoagulants IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
  66. natural anticoagulants in sepsis—Too much of a good thing?
  67. natural anticoagulants deficiencies and transient ischemic attacks
  68. CHANGES IN THE LEVEL OF natural anticoagulants BLOOD PRETERM POSTNATAL.
  69. Experimental and clinical research on the interaction between inflammation and coagulation and its control by natural anticoagulants
  70. Coagulation factors and natural anticoagulants in polycythemia vera patients, relation with JAK2V617F mutation load
  71. Genetic thrombophilia and natural anticoagulants: importance of polymorphisms within and outside the genes
  72. Levels of natural anticoagulants, antithrombin III and protein C in diabetic vascular disease
  73. Effects of living at 300 meters below sea level on coagulation and natural anticoagulants.
  74. natural anticoagulants protein c and protein s in acute ischemic stroke in young adults
  75. An evaluation of natural anticoagulants and coagulation factors in patients with congenital disorders of glycosylation type I
  76. Inhibition of Pulmonary Coagulopathy by Nebulized natural anticoagulants during Streptococcus Pneumoniae Pneumonia in Rats
  77. natural anticoagulants and activated protein C resistance in patients with antiphospholipid antibodies (aPL) and in patients with pirmary venous thrombosis without …
  78. Preliminary Characterization of Occipodins, naturalProduct anticoagulants from Hematophagous Marine Parasites, Isopod Elthusa vulgaris and Copepod …
  79. Epoxidation of some skin-photosensitizes and anticoagulants of naturalcoumarin and furocoumarins as potential alkylating agents of DNA
  80. … open abdomen: an analysis of physiologic subgroups. The anticoagulated trauma patient: the Ontario experience in the era of direct oral anticoagulants. The effect of …
  81. naturalanticoagulant mechanisms.
  82. The regulation of naturalanticoagulant pathways
  83. A pharmacological review of dicoumarol: An old naturalanticoagulant agent
  84. New mechanisms for vascular control of inflammation mediated by naturalanticoagulant proteins
  85. Biochemistry of heparin antithrombin interactions, and the physiologic role of this naturalanticoagulant mechanism
  86. Profile of naturalanticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients
  87. Beta2‐glycoprotein I in thrombosis: evidence for a role as a naturalanticoagulant
  88. Interaction between interleukin-6 and the naturalanticoagulant system in acute stroke
  89. Genome wide association study for plasma levels of naturalanticoagulant inhibitors and protein C anticoagulant pathway: the MARTHA project
  90. Deficiency of naturalanticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon?
  91. Contribution of naturalanticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients
  92. Modulation of monocyte function by activated protein C, a naturalanticoagulant
  93. The role of naturalanticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis
  94. naturalanticoagulant pathways in normal and transplanted human hearts.
  95. … (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a naturalanticoagulant
  96. naturalanticoagulant protein levels in Turkish patients with inflammatory bowel disease
  97. Studies of naturalanticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant
  98. naturalanticoagulant inhibitors: activated Protein C
  99. Activated protein C, a naturalanticoagulant protein, has antioxidant properties and inhibits lipid peroxidation and advanced glycation end products formation
  100. Antithrombin III in fresh and cultured human endothelial cells: a naturalanticoagulant from the vascular endothelium
  101. Age-specific onset and distribution of the naturalanticoagulant deficiency in pediatric thromboembolism
  102. Colloid transfusion, naturalanticoagulant depletion, and symmetric peripheral gangrene
  103. Targeting protease nexin-1, a naturalanticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
  104. naturalanticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus.
  105. Increased risk of venous thrombosis in carriers of naturalanticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia …
  106. Analysis of inherited thrombophilic mutations and naturalanticoagulant deficiency in patients with idiopathic portal hypertension
  107. Alterations in naturalanticoagulant levels during allogeneic bone marrow transplantation: a prospective study in 27 patients.
  108. Targeted gene disruption of naturalanticoagulant proteins in mice
  109. The endothelial heparan sulfate-antithrombin III naturalanticoagulant pathway in normal and transplanted human kidneys.
  110. Anticoagulant drugs increase naturalkiller cell activity in lung cancer
  111. naturalanticoagulant deficiencies in Thais: A population-based study
  112. Anticoagulant and antiprotease profiles of a novel naturalheparinomimetic mannopentaose phosphate sulfate (PI-88)
  113. naturalanticoagulant and fibrinolytic pathways in renal allograft failure.
  114. The naturalanticoagulant protein S is decreased in male smokers
  115. Uncovering the genetic background of naturalanticoagulant deficiencies: time to look behind the scenes
  116. Chemically sulfated naturalgalactomannans with specific antiviral and anticoagulant activities
  117. naturalanticoagulant proteins in the regulation of autoimmunity: potential role of protein S
  118. A review on anticoagulant/antithrombotic activity of naturalplants used in traditional medicine
  119. Structural features and anticoagulant activities of a novel naturallow molecular weight heparin from the shrimp Penaeus brasiliensis
  120. Association of the urine homocysteine/creatinine ratio to proinflammatory cytokine, naturalanticoagulant, and nitric oxide levels in cerebrovascular disease
  121. Effect of pulmonary tuberculosis on naturalanticoagulant activity in therapy-naïve Ghanaian adults; a case-control study
  122. naturalanticoagulant system in children with beta-thalassemia major
  123. … a new liquid chromatography-tandem mass spectrometry ion-trap technique for the simultaneous determination of thirteen anticoagulant rodenticides, drugs, or natural…
  124. … structural studies of two naturalisoforms of ammodytoxin, phospholipases A2 from Vipera ammodytes ammodytes which differ in neurotoxicity and anticoagulant …
  125. Type II protein C deficiency: identification and molecular modelling of two naturalmutants with low anticoagulant and normal amidolytic activity.
  126. Cerebral microbleeds in murine amyloid angiopathy: naturalcourse and anticoagulant effects
  127. Effects of anticoagulant, serum, and temperature on the naturalkiller activity of human peripheral blood mononuclear cells stored overnight
  128. Anticoagulant activity of a naturalprotein purified from Hypomesus olidus
  129. Anticoagulant activity screening of an in-house database of naturalcompounds for discovering novel selective factor Xa inhibitors; a combined in silico and in vitro …
  130. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a naturalmixture of glycosaminoglycans
  131. Bioactive naturalCompounds with Antiplatelet and Anticoagulant Activity and Their Potential Role in the Treatment of Thrombotic Disorders
  132. Purification of Protein C, a naturalAnticoagulant, from Human Plasma by Affinity Chromatography with Convanavalin A
  133. naturalinhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant.
  134. Pulmonary hypertension in adult Egyptian patients with b-thalassemia major: correlation with naturalanticoagulant levels
  135. Functional characterization of twelve naturalPROS1 mutations associated with anticoagulant protein S deficiency
  136. Activity levels of naturalanticoagulant proteins in childhood acute lymphoblastic leukemia: relation to thromboembolic complications and treatment
  137. Impact of sustained virus elimination on naturalanticoagulant activity in patients with chronic viral hepatitis C
  138. Membrane binding and anticoagulant properties of protein S naturalvariants
  139. Molecular modelling, 3D-QSAR, and drug docking studies on the role of naturalanticoagulant compounds in antithrombotic therapy
  140. Analysis of levels of naturalanticoagulant proteins and activated protein C resistance in venous thromboembolism patients referred to Iranian Blood …
  141. Congenital deficiencies of naturalanticoagulant systems responsible for recurrent thromboembolism
  142. Lupus anticoagulant and thromboembolism: evaluation of fibrinogen, naturalinhibitors and molecular markers of thrombosis.
  143. Impact of erythrocytapheresis on naturalanticoagulant levels in children with sickle cell disease: A pilot study
  144. IN VITRO AND IN VIVO ANTICOAGULANT ACTIVITY OF IMPERATA CYLINDRICA A NOVEL ANTICOAGULANT LEAD FROM naturalORIGIN.
  145. 3 The Heparan Sulfate-Antithrombin Pathway: A naturalAnticoagulant Mechanism of the Blood Vessel Wall
  146. Mechanisms of the antimetastatic effects of anticoagulant drugs: dependence on naturalkiller (NK) cell activity
  147. Haemorheological, naturalAnticoagulant and Homocysteine Profiles in Coeliac Disease: a Case-control Study
  148. Effects of acrolein, a naturaloccurring aldehyde, on the anticoagulant serpin antithrombin
  149. Effects of pulse-therapy on naturalanticoagulant system of the endothelium in nonspecific aortoarteritis
  150. A STUDY OF naturalOCCURRING ANTICOAGULANT AND ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH HISTORY OF THROMBOSIS IN TEHRAN
  151. THE POTENTIAL OF NYAMPLUNG LEAF EXTACT AS A naturalANTICOAGULANT
  152. Extraction of Sulphated Polysaccharides (SPs) from Different Species of Marine Macroalgae and Studying their Role as naturalAnticoagulant
  153. Pathogenetic Substantiation of the Usability of the naturalAnticoagulant Sulodexide in a Combine Treatment of Pregnant Women with Premature Delivery
  154. The anticoagulant, hepatic lipase-releasing and lipoprotein lipase-releasing activities of several naturaland chemically modified heparins differ
  155. naturalanticoagulant and antifibrinolysis in patients with chronic renal failure with and without hemodialysis
  156. Haemorheological, naturalAnticoagulant and Homocysteine Profiles in Coeliac Disease: A Case-control Study
  157. naturalANTICOAGULANT-PROTEIN S DEFICIENCY AND PREGNANCY OUTCOME-A RARE CASE REPORT
  158. Zinc Binds and Regulates the Activity of the naturalAnticoagulant Protein Z
  159. Anticoagulant and Antiprotease Profiles of a Novel naturalHeparinomimetic Mannopentaose Phosphate Sulfate (PI-88)
  160. Marine Sulfated Polysaccharides with Unusual Anticoagulant Action through an Additional Unrelated naturalInhibitors Mechanism
  161. Hereditary deficiency of all vitamin K‐dependent procoagulants and anticoagulants
  162. Antithrombin, protein S and protein C and antiphospholipid antibodies in systemic lupus erythematosus.
  163. < The> natural anticoagulants
  164. The effects of alcohol on coagulation and fibrinolytic factors: a controlled trial.
  165. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies.
  166. Beta 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome.
  167. Prothrombotic states in young people with idiopathic stroke. A prospective study.
  168. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation.
  169. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism.
  170. Hemostatic parameters and platelet activation by flow-cytometry in normal pregnancy: a longitudinal study
  171. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma.
  172. Postoperative changes in coagulant and anticoagulant factors following abdominal aortic surgery
  173. High levels of factor VIII and venous thrombosis
  174. Coagulation factors in nephrotic syndrome
  175. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes
  176. Risk factors for thromboembolism: pathophysiology and detection
  177. Lupus anticoagulant and protein S deficiency in otherwise healthy children with acute varicella infection
  178. Thrombophilia in pregnancy
  179. Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy
  180. The Significance of TFPI in Clotting Assays–Gomparison and Combination with other anticoagulants
  181. Nature’s anticoagulants: controlling the clotting cascade
  182. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver
  183. Are there markers of the blood-vessel wall interaction and of thrombus formation that can be used clinically?
  184. Arg506–Gln mutation in factor V and risk of thrombosis during pregnancy
  185. Epidemiology of coagulation disorders
  186. Familial coagulation-inhibiting and fibrinolytic protein deficiencies in juvenile transient ischaemic attacks.
  187. Congenital deficiency of histidine-rich glycoprotein: failure to identify abnormalities in routine laboratory assays of hemostatic function, immunologic function, and trace …
  188. Factors in xenograft rejection
  189. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing …
  190. Risk of thromboembolic complications in patients with inflammatory bowel disease
  191. Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate.
  192. Factor Vila and other haemostatic variables following bone marrow transplantation
  193. Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden
  194. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia
  195. Factor V Cambridge: A New Mutation (Arg306→Thr) Associated With Resistance to Activated Protein C
  196. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′‐untranslated region of the prothrombin gene
  197. Protein C, isolation and potential use in prevention of thrombosis.
  198. Disseminated intravascular coagulation findings in 100 patients.
  199. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial
  200. Changes in the plasma levels of proteins C and S in young women on low-dose oestrogen oral contraceptives.
  201. Thrombosis promoting changes in chronic liver diseases.
  202. Markers of thrombin and plasmin generation in patients with inherited thrombophilia.
  203. Protein S deficiency associated to anti-protein S antibodies in a patient with mixed connective-tissue disease and its reversal by danazol
  204. Relationship between vitamin K dependent coagulation factors and anticoagulants (protein C and protein S) in neonatal vitamin K deficiency.
  205. Significant elevation of protein C and protein S levels in thrombotic disorders by low dose danazol.
  206. Antiphospholipid antibody and antiphospholipid antibody syndrome.
  207. A prospective evaluation of atherosclerotic risk factors and hypercoagulability in young adults with premature lower extremity atherosclerosis
  208. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism
  209. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with …
  210. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid
  211. Changes of hemostatic factors in patients with hemoglobinopathies.
  212. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss
  213. Overtight nappy precipitating thrombosis in antithrombin III deficiency.
  214. EFFECT OF PORCINE ENDOTHELIAL TISSUE FACTOR PATHWAY INHIBITOR ON HUMAN COAGULATION FACTORS1
  215. Alpha2-macroglobulin levels are high in adult patients with congenital antithrombin deficiency
  216. Activated protein C and antithrombin-III activity during arterial thrombolysis with recombinant tissue-type plasminogen activator in rabbits.
  217. Protein C deficiency: summary of the 1995 database update
  218. Effect of thymalin on blood coagulation and fibrinolysis
  219. Acute fibrinolysis following craniotomy and removal of metastatic tumor of the cerebellum: case report
  220. Hypercoagulable states in arterial thromboembolism
  221. Treatment of deep vein thrombosis using temporary vena caval filters after allogeneic bone marrow transplantation
  222. Hypercoagulability in patients with veno-occlusive disease after bone marrow transplantation
  223. Protein C, protein S and antithrombin III levels in the course of bone marrow and subsequent liver transplantation due to veno-occlusive disease.
  224. Hemostasis activation in patients with liver cirrhosis
  225. The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis
  226. Hereditary protein S deficiency and familial thrombosis. A review with description of a Danish family with protein S deficiency
  227. Effect of intravenous infusions of thrombin and heterogenous blood on lymph coagulability
  228. Protein C, protein S and heparin cofactor II–their significance as the regulatory factors in the blood coagulation cascade
  229. A search for autoantibodies to thrombomodulin in patients with documented thrombosis
  230. Venous thrombosis: antithrombin III deficiency.
  231. Hemostatic changes in Rocky Mountain spotted fever and Mediterranean spotted fever
  232. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state
  233. Naturally occurring anticoagulants and bone marrow transplantation
  234. Thrombophilia: some recent advances in understanding.
  235. Hypercoagulability syndrome due to heparin co-factor deficiency
  236. Ischemic stroke due to deficiency of coagulation inhibitors. Report of 10 young adults.
  237. Laboratory test utilization in the diagnosis of hypercoagulability
  238. Correlation of haemostatic variables and structural changes of major arteries of the head in ischemic stroke patients
  239. Effects of recombinant human erythropoietin [rHuEPo] on haemostasis in patients maintained on chronic hemodialysis
  240. Role of the parasympathetic division of the autonomic nervous system in regulating blood coagulation and fibrinolysis following intravenous injection of thrombin
  241. A Case of Congenital Vitamin K Dependent Coaguation Factor Defeciency
  242. Hemostatic Abnormalities Related to Bone Marrow Transplantation
  243. New agents for the treatment of thrombosis
  244. EXPRESSION OF HUMAN THROMBOMODULIN COFACTOR ACTIVITY IN PORCINE AORTIC ENDOTHELIAL CELLS.
  245. PCR screening method to detect factor v leiden mutation in tia and stroke
  246. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation
  247. Is inherited thrombophilia a risk factor for arterial stroke?
  248. Inherited fibrinogen abnormality causing thrombophilia
  249. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis
  250. Infrequency of stroke caused by specific coagulation disorders
  251. Organization of a Randomized Clinical Trial for the Prevention of Recurrent Thrombosis in the Antiphospholipid Syndrome: the WAPS Project (Warfarin in …
  252. Fortnightly review: Disseminated intravascular coagulation: Diagnosis and treatment
  253. Cerebral infarction and familial protein S deficiency.
  254. Effect of vitamin-E-modified dialysers on dialyser clotting, erythropoietin and heparin dosage: a comparative crossover study
  255. Budd‐chiari syndrome associated with factor V leiden mutation: A report of 6 patients
  256. FV-ARG-506-GLN-mutation-associated resistance to activated protein C in ischemic stroke
  257. Antiphospholipid syndrome patients’ monocytes are “primed” to express tissue factor
  258. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of …
  259. Disseminated intravascular coagulation (DIC)
  260. Protein S deficiency and factor V Leiden gene in pregnancy
  261. L-asparaginase treatment reduces the anticoagulant potential of the protein C system without affecting vitamin K-dependent carboxylation
  262. The Methylenetetrahydrofolate Reductase TT677 Genotype Is Associated with Venous Thrombosis Independently of the Coexistence of the FV Leiden and the …
  263. Fibrinolysis, inhibitors of blood coagulation, and monocyte derived coagulant activity in acute malaria
  264. The investigation of patients with retinal vascular occlusion
  265. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans
  266. Comparison of coagulation parameters for healthy subjects and Behçet disease patients with and without vascular involvement
  267. The therapeutic potential of novel anticoagulants
  268. Isolated familial plasminogen deficiency may not be a risk factor for thrombosis
  269. preparation: pre-analytical variation
  270. The Biologic Impact of Hereditary Defects that Cause Thrombosis
  271. Anticoagulation in patients with acute renal failure treated with continuous renal replacement therapies
  272. EXPRESSION OF HUMAN THROMBOMODULIN COFACTOR ACTIVITY IN PORCINE ENDOTHELIAL CELLS1, 2
  273. Cerebral Infarction in PeopleUnder 40 Years I
  274. Inhibition of endothelial cell thromboresistance by homocysteine
  275. Progressive intracranial occlusive disease associated with deficiency of protein S. Report of two cases.
  276. Thrombophilia testing: what do we think the tests mean and what should we do with the results?
  277. Blood coagulation and its alterations in hemorrhagic and thrombotic disorders.
  278. Obstetric Complications: Consumption Coagulopathy
  279. Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients
  280. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses
  281. Changes in the plasma levels of vitamin K‐dependent proteins C and S and of C4b‐binding protein during pregnancy and oral contraception
  282. The molting cycle of the spiny lobster, Panulirus argus Latreille. III. Physiological changes which occur in the blood and urine during the normal molting cycle
  283. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of …
  284. A Rapid and reliable PCR based method for detecting the blood coagulation Factor V Leiden mutation
  285. Acquired protein S deficiency with multiple thrombotic complications after orthotopic liver transplant
  286. Hemostatic and metabolic abnormalities in diabetes mellitus. The search for a link
  287. Recombinant tissue plasminogen activator (rt‐PA) for veno‐occlusive liver disease in pediatric autologous bone marrow transplant patients
  288. Hypercoagulable abnormalities and postoperative failure of arterial reconstruction
  289. Prevalence of anti–protein S antibodies in patients with systemic lupus erythematosus
  290. Protein C and S response to danacrine in end-stage renal disease
  291. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment
  292. Diffuse arterial thrombosis in a young man with elevated lipoprotein (a) and minimal atherosclerosis
  293. Relationship between maternal antithrombin III and protein C/protein S levels before, during and after delivery
  294. Prothrombotic risk factors and acute kidney transplant rejection
  295. Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation
  296. The diagnosis and clinical management of thrombophilia
  297. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study
  298. Thromboelastography identifies sex-related differences in coagulation
  299. Cardiovascular materials
  300. In‐vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with β‐thalassaemia major
  301. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis
  302. Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke
  303. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit
  304. Mathematical Model of Serine Protease Inhibition in the Tissue Factor Pathway to Thrombin (∗)
  305. The thrombophilic state induced by therapeutic agents in the cancer patient
  306. The prothrombin gene G20210A variant: prevalence in a UK anticoagulant clinic population
  307. Hypercoagulable states: molecular genetics to clinical practice
  308. Inherited thrombophilia and pregnancy
  309. Cerebral venous sinus thrombosis associated with hepatic cirrhosis
  310. Prothrombotic states associated with retinal venous occlusion in young adults
  311. An abnormal plasma distribution of protein S occurs in functional protein S deficiency
  312. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders
  313. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment
  314. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke …
  315. Hypercoagulable states in patients with leg ischaemia
  316. Multiple organ dysfunction syndrome in bone marrow transplantation
  317. Early hemostatic alterations following bone marrow transplantation: a prospective study
  318. Evaluation of the hypercoagulable state: whom to screen, how to test and treat
  319. Thrombin inhibition in discordant xenograft rejection
  320. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L …
  321. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters
  322. THROMBOSIS IN CHURG—STRAUSS SYNDROME. BEYOND VASCULITIS?
  323. Hereditary protein C deficiency and portal-vein thrombosis.
  324. Cancer, thrombosis, and anticoagulants
  325. Why do patients with antiphospholipid antibody clot?
  326. Does thrombophilia play an aetiological role in Legg-Calvé-Perthes disease?
  327. Age-related differences in outcome and severity of DIC in children with septic shock and purpura
  328. Post-chemotherapy Sweet’s syndrome in three patients with AML
  329. Coagulation abnormalities in sepsis: relation with inflammatory responses
  330. Physiologic changes in coagulation and fibrinolysis during normal pregnancy
  331. Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus
  332. Investigations for thrombotic tendencies
  333. Thrombophilia: a genetic predisposition to thrombosis.
  334. High level of protein C and protein S in nephrotic syndrome
  335. Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis
  336. Presence of serum antibodies to coagulation protein C in patients with systemic lupus erythematosus is not associated with antigenic or functional protein C …
  337. Arterial thrombosis in nephrotic syndrome due to minimal change glomerulonephritis
  338. Prevalence of protein C deficiency in the healthy population
  339. Neurology and the blood: haematological abnormalities in ischaemic stroke
  340. Mesenteric venous thrombosis: a case report
  341. Reduced blood levels of coagulation inhibitors in chronic hemodialysis compared to CAPD
  342. Detection of the prethrombotic state due to procoagulant imbalance
  343. Effect of acetylcholine and atropine on the secretion of blood clotting compounds into the blood stream by the kidneys
  344. Efficacy of danazol in a patient with congenital protein s deficiency: Paradoxical evidence for decreased platelet activation with increased thrombin generation
  345. Veno‐occlusive disease of the liver after hemopoietic cell transplantation
  346. Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study
  347. Lower extremity arterial occlusions in young patients with Crohn’s colitis and premature atherosclerosis: report of six cases.
  348. Influence of demographic factors on antithrombin III activity in a healthy population
  349. Warfarin-induced skin necrosis
  350. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial [see …
  351. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism
  352. Pathogenesis of Thrombotic Complications of Haematological Malignancies
  353. Laboratory markers of coagulation activation
  354. A hirudin catching ELISA for quantitating the anticoagulant in biological fluids
  355. Basic analytical parameters as the predictive factors for 30‐day case fatality rate in stroke
  356. The role of platelets in the coagulopathy of heatstroke a study of platelet aggregation in heatstroke patients during the Makkah pilgrimage (Haj) to
  357. Hydroxylation of styrene-diene triblock copolymers in solution and on the surface
  358. Reversal of thrombocytopenia following oral anticoagulation in two patients with primary antiphospholipid syndrome
  359. Sustained bleeding after a leech bite in the apparent absence of hirudin
  360. Antiphospholipid antibodies, prethrombotic states, and stroke.
  361. Protein C pathway, antiphospholipid antibodies and thrombosis
  362. Antiphospholipid antibodies, haemostatic variables and thrombosis–a survey of 144 patients
  363. Lower extremity amputations in adults less than forty years of age: an underestimated risk from premature atherosclerosis
  364. High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria
  365. Strokes in Thai children: etiology and outcome.
  366. Stroke in relapsing thrombotic thrombocytopenic purpura.
  367. Disseminated intravascular coagulation
  368. Evaluation of hemostatic and coagulation factor abnormalities in patients undergoing the Fontan operation
  369. Hypercoagulability and the management of anticoagulant therapy in surgical patients: review and recommendations
  370. Benign intracranial hypertension: a non-thrombotic complication of the primary antiphospholipid syndrome?
  371. Effects of annexin V on the activity of the anticoagulant proteins C and S
  372. Contraceptive choices in women with coagulation disorders
  373. Frequency of protein S deficiency in general Japanese population
  374. 7 Antiphospholipid antibodies and thrombosis
  375. Basic, laboratory and clinical aspects of thromboembolic diseases
  376. Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors
  377. Is there a need for antithrombin III substitution early after burn injury?
  378. Enhancement of protein S anticoagulant function by β2-glycoprotein I, a major target antigen of antiphospholipid antibodies
  379. Acidosis induced disseminated intravascular microthrombosis and its dissolution by streptokinase
  380. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?
  381. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general …
  382. Hemostasis in dentistry, with special reference to hemocoagulation: I. The basic theory of hemostasis
  383. Immunology: Antiphospholipid antibodies and β2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach
  384. Transient global amnesia in a young woman on prolonged treatment with oral contraceptive drugs
  385. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to β2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays
  386. Association of osteonecrosis in systemic lupus erythematosus with abnormalities of fibrinolysis
  387. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors
  388. Recent advances in understanding clotting and evaluating patients with recurrent thrombosis
  389. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans–associated meningococcemia
  390. Preparation for regional anaesthesia induces changes in thrombelastography
  391. The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation?
  392. Thrombotic risk during pregnancy and puerperium in women with APC-resistance–effective subcutaneous heparin prophylaxis in a pregnant patient
  393. Superior sagittal sinus and inferior vena cava thrombosis with acute Budd-Chiari syndrome.
  394. Coagulation and anticoagulation systems in newborns–correlation with their mothers at delivery
  395. Cells and the activation of factor VII
  396. Diagnosis and management of pulmonary embolism in pregnancy
  397. Factor V Leiden and the risk of proximal venous thrombosis after total hip arthroplasty
  398. Passive smoking adversely affects the haemostasis/fibrinolytic parameters in healthy non-smoker offspring of healthy smokers
  399. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis
  400. Enhancement of plasminogen binding and fibrinolysis by chloropeptin I
  401. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies-a crucial role for acquired free protein S deficiency
  402. Is testing for inherited coagulation inhibitor deficiencies in young stroke patients worthwhile?
  403. Pharmacokinetic study of the low-molecular-weight heparin fraxiparin in patients with nephrotic syndrome
  404. Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud’s phenomenon and thrombosis
  405. Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism
  406. The antiphospholipid syndrome
  407. Oral anticoagulation in the community
  408. A hypercoagulable state in activated protein C resistant patients with ischemic stroke
  409. Childhood stroke associated with protein C or S deficiency and primary antiphospholipid syndrome
  410. Is veno-occlusive disease a specific syndrome or the exacerbation of physiopathologic hemostatic changes in hematopoietic stem cell transplantation (HSCT)?
  411. Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts
  412. Familial thrombophilia and activated protein C resistance: thrombotic risk in pregnancy?
  413. Blood collection and sample preparation: pre-analytical variation
  414. Recurrent renal vein thrombosis and renal failure associated with antithrombin-III deficiency
  415. The nephrotic syndrome and its complications
  416. Risk factors for venous thromboembolism in pregnancy
  417. Disseminated intravascular coagulation in elective primary total hip replacement
  418. Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion
  419. Clotting for the clinician: an overview of thrombosis and antithrombotic therapy
  420. Placental pathology in antiphospholipid antibody syndrome
  421. Effects of recombinant human erythropoietin on physiological inhibitors of coagulation in children on continuous ambulatory peritoneal dialysis
  422. Arterial thrombosis associated with immune thrombocytopenia: presence of a platelet aggregating IgG synergistic with thrombin and adrenalin
  423. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment
  424. Aprotinin in deep hypothermic circulatory arrest
  425. Endothelial cell injury in cardiovascular surgery
  426. Arterial thrombosis of the arm in infant of diabetic mother
  427. Circulating anticoagulants: physiologic and pathophysiologic
  428. Hypercoagulable state and graft rejection—is there a link?
  429. The role of heparin in intrinsic blood coagulation
  430. Haematological manifestations of systemic lupus erythematosus
  431. Hepatic veno-occlusive disease after bone marrow transplant
  432. Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism
  433. Patient management of pulmonary embolism
  434. Changes in plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) by the interferon treatment for chronic hepatitis C
  435. Study of the Pharmacological Effect of the Bile Salt, Sodium Scymnol Sulfate, from Rhizoprionodon acutus. II.: Prophylactic Effect of Scymnol on Lesion Development …
  436. Low‐dose warfarin decreases coagulability without affecting prothrombin complex activity
  437. A comparative study of the clotting power of the blood and lymph
  438. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
  439. Free protein S deficiency: a possible association with cerebrovascular occlusion.
  440. Effect of tamoxifen on measurements of hemostasis in healthy women
  441. Clinical Associations of Antibodies to Phospholipids and/or
  442. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis
  443. Hyperhomocysteinemia: a risk factor for arterial and venous thrombotic disease
  444. Interleukin-1 in haemophilic arthritis
  445. Portal vein thrombosis associated to prothrombin G20210A mutation and protein C deficiency
  446. Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in northern Sweden
  447. Coumarin necrosis, neonatal purpura fulminans, and protein C deficiency
  448. Effect of acupuncture on monoamines and adenosine triphosphatase activity in lateral hypothaiamic area of obese rats
  449. Cutaneous necrosis associated with the antiphospholipid syndrome and mycosis fungoides
  450. Cranial sinus thrombosis and preeclampsia.
  451. The effect of n-3 fatty acids on blood coagulation
  452. Response to activated protein C upon storage of whole blood and plasma
  453. Vascular-bed–specific hemostasis and hypercoagulable states
  454. Visual scotomata resulting from lupus anticoagulant in a patient with lymphoma in remission
  455. Disseminated Intravascular Coagulation in Individuals with Cancer
  456. Prevalence of mutated factor V ARG506 to GLN in Italians
  457. Polyion sensors as liquid junction‐free reference electrodes
  458. Cerebral venous thrombosis in the nephrotic syndrome
  459. Relation of the changes in hemorheologic indices and the site and size of cerebral infarction
  460. Effect of hemodialysis on protein C, protein S, and antithrombin III levels
  461. Venous surgery in patients with congenital antithrombin III deficiency
  462. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile
  463. 35 LABORATORY INVESTIGATION OF HAEMOSTASIS
  464. Effect of subcutaneous administration of recombinant human erythropoietin on plasma protein C, protein S, and antithrombin III levels in patients on continuous …
  465. Functional activity of protein C in liver cirrhosis and acute viral hepatitis on the Ivory Coast.
  466. Transcranial Doppler patterns in patients with anticardiolipin antibodies
  467. Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature
  468. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome
  469. Analysis of blood coagulation in the zebrafish
  470. Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature
  471. Thromboembolic disease in pregnancy
  472. Protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis and hemodialysis
  473. The antiphospholipid-protein syndrome
  474. Overview of the Hypercoagulable States
  475. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow …
  476. The syndrome of hepatic veno-occlusive disease after marrow transplantation
  477. Department of Dermatology
  478. Transient correction of partial congenital factor V deficiency in nephrotic syndrome
  479. Anticuerpos antifosfolipido: Valoracion de los sistemas de la hemostasia.
  480. Classification of Pressure Ulcers-Reply
  481. Venous thromboembolism and cancer: a two-way clinical association
  482. Antithrombotics/serine proteases
  483. Pulmonary embolism in a patient with coagulopathy from end-stage liver disease
  484. The prothrombin response to the parenteral administration of large doses of vitamin K in subjects with normal liver function and in cases of liver disease: a …
  485. Venous thromboembolism after hip fracture surgery in a patient with haemophilia B and factor V Arg506Gln (factor V Leiden)
  486. Treatment of patients with antiphospholipid antibodies during pregnancy
  487. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S
  488. A comparison of postoperative thrombotic potential following abdominal aortic surgery, carotid endarterectomy, and femoro-popliteal bypass
  489. Tissue factor pathway inhibitor and the revised theory of coagulation
  490. Computer-aided design of thrombin inhibitors
  491. Current concepts of anticoagulant therapy in pregnancy
  492. Resolution of Budd‐Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria
  493. Evaluation of the haemostatic system during ketoacidotic deterioration of diabetes mellitus
  494. The expression of coagulation factors during murine development
  495. Fundamental research in molecular biology: relevance to medicine
  496. How to detect activated coagulation
  497. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease
  498. Thrombosis and hemostasis in renal disease
  499. Vascular homeostasis, adhesion molecules, and macrovascular disease in non‐insulin‐dependent diabetes mellitus
  500. Clinical trials for the antiphospholipid syndrome
  501. Protein S deficiency in lupus erythematosus secondary to hereditary angio‐oedema
  502. Arg sup 506-Gln Mutation in Factor V and Risk of Thrombosis During Pregnancy
  503. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis
  504. Early prediction of stroke severity: role of the erythrocyte sedimentation rate
  505. The G20210A polymorphism in the 3′-untranslated region of the prothrombin gene in Mexican mestizo patients with primary antiphospholipid syndrome
  506. The effect of near‐normoglycaemic control on plasma levels of coagulation factor VII and the anticoagulant proteins C and S in insulin‐dependent diabetic patients
  507. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes
  508. The effect of epidural blockade on postoperative hypercoagulability following abdominal aortic bypass surgery
  509. Cerebral venous thrombosis in patients with nephrotic syndrome
  510. The control of thrombin generation in haemoglobinopathies and other haemolytic red cell disorders in children
  511. Catastrophic antiphospholipid syndrome
  512. Thrombophilia: how far should a clotter be investigated?
  513. Hypercoagulable states and lower limb ischemia in young adults
  514. Administration of autologous fetal membranes: effects on the coagulation in pregnant mini-pigs
  515. Hemorheological and hemostatic parameters in children with nephrotic syndrome undergoing steroid therapy
  516. The prediction of thromboembolism
  517. Ischemic stroke in Korean young adults
  518. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
  519. Isolation and characterization of americanin, a specific inhibitor of thrombin, from the salivary glands of the lone star tickAmblyomma americanum (L.)
  520. Protein C deficiency and portal thrombosis in liver transplantation in children
  521. Platelets abolish the profibrinolytic effect of activated protein C
  522. An investigation of the role of antiphospholipid antibodies and [beta] 2 glycoprotein-I in the modulation of haemostatic reactions
  523. Management of thrombophilia in pregnancy
  524. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis
  525. Deep cerebral venous thrombosis and hereditary tissue plasminogen activator (t-PA) deficiency
  526. Premature closure of foramen ovale and renal vein thrombosis in a stillborn twin homozygous for methylene tetrahydrofolate reductase gene polymorphism: A …
  527. Lupus anticoagulant in patients with peripheral vascular disease: a prospective study
  528. Previous cytomegalovirus infection and risk of coronary thrombotic events after stent placement
  529. The effect of n‐3 polyunsaturated fatty acids on lipids, haemostasis, neutrophil and monocyte chemotaxis in insulin‐dependent diabetes mellitus
  530. Early pathophysiology of osteonecrosis
  531. Abnormalities in the protein C anticoagulant pathway detected by a novel assay using human thrombomodulin
  532. Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human α‐thrombin
  533. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli
  534. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy
  535. Diagnostic value of hemostatic parameters in bone marrow transplant-associated thrombotic microangiopathy
  536. A new blood-clotting theory
  537. Antiphospholipid syndrome
  538. Increased Risk for Venous Thrombosis in Carriers of the Prothrombin G→A20210 Gene Variant
  539. Medical Perspective Antiphospholipid Antibodies, Thrombosis and Atherosclerosis in Systemic Lupus Erythematosus: a Unifying’Membrane Stress Syndrome’ …
  540. Acute coronary syndromes: unstable angina and non–Q-wave myocardial infarction
  541. Heparin, its chemistry, pharmacology and clinical use
  542. Acquired free protein S deficiency in children with steroid resistant nephrosis
  543. The role of thrombosis in severe pulmonary hypertension
  544. Analysing early liver dysfunction after bone marrow transplantation
  545. Rapid detection of anticardiolipin antibodies
  546. Warfarin-induced complete bilateral breast necrosis
  547. Serum anti-β2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients
  548. Meconium and amniotic fluid embolism: effects on coagulation in pregnant mini-pigs
  549. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings
  550. α-Thalassemia among pediatric Nb S homozygotes
  551. On the nature of hypercoagulability
  552. Absence of thrombosis in subjects with heterozygous protein C deficiency
  553. Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome
  554. Contents, Vol. 26, 1996
  555. Anticardiolipin and acquired protein S deficiency in early childhood
  556. Drug Treatment of Stroke in Patients with Antiphospholipid Antibodies
  557. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases
  558. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
  559. Pregnancy outcome in women with antiphospholipid antibodies
  560. Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis
  561. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients
  562. Recombinant Hirudin
  563. Effectiveness and safety of blood transfusion: have we lost the plot?
  564. Practical haemodialysis began with cellophane and heparin: the crucial role of William Thalhimer (1884–1961)
  565. THE SEQUENTIAL IN UTERO DEATH OF HETEROKARYOTIC MONOZYGOTIC TWINS. A CASE REPORT AND LITERATURE REVIEW
  566. anticoagulants in women
  567. Plasma thrombin-antithrombin complexes, latent coagulation disorders and metastatic spread in lung cancer: a longitudinal study
  568. LOW MOLECULAR WEIGHT HEPARIN FOR THE PREVENTION OF VENO-OCCLUSIVE DISEASE OF THE LIVER IN BONE MARROW TRANSPLANTATION …
  569. Protein S deficiency occurs in the nephrotic syndrome
  570. Human genetic diseases of proteolysis
  571. Protein S and protein C anticoagulant activity in acute and chronic cardiac ischemic syndromes. Relationship to inflammation, complement activation and in vivo …
  572. Multicenter comparison of five functional and two immunological assays for protein C
  573. Prevalence of the prothrombin gene variant 20210 G→ A among patients with myocardial infarction
  574. Hypercoagulable states in patients with retinal venous occlusion
  575. Prothrombotic and antithrombotic factors are elevated in patients with type 1 diabetes complicated by microalbuminuria
  576. anticoagulants in pregnancy
  577. Protein S and C antigen levels in proteinuric patients: Dependence on type of glomerular pathology
  578. Cerebral venous thrombosis in patients with nephrotic syndrome
  579. Classification of pressure ulcers
  580. Cerebral venous thrombosis and procoagulant factors: a case study
  581. The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns
  582. Haemostatic factors in human peripheral afferent lymph
  583. The endothelium and thrombosis
  584. Primary thrombophilia in Mexico: a prospective study
  585. State-of-the-Art Review: Chemotherapy and Thrombosis in Gynecologic Malignancy
  586. The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S
  587. Hypercoaguable State Associated with a Deficiency of Protein C in a Thoroughbred Colt
  588. Fibrinolytic Abnormalities and Antiphospholipid Antibodies
  589. Lower extremity ischemia in adults younger than forty years of age: a community-wide survey of premature atherosclerotic arterial disease
  590. The Effect of n-3 Fatty Acids on Lipids and Haemostasis in Patients with Type lla and Type IV Hyperlipidaemia
  591. Thrombin signalling and protease-activated receptors
  592. α1-antitrypsin, an inhibitor for thrombin and plasmin
  593. Production of phospholipid antibodies in selected thrombophilic women differing in genotype at the 506 site of factor V
  594. Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation
  595. Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation
  596. Anticoagulation in pregnancy
  597. Endothelial cell injury in cardiovascular surgery: an overview
  598. Anticoagulation in
  599. Circulating levels of endothelial function are modulated by dietary monounsaturated fat
  600. Prothrombotic abnormalities in inflammatory bowel disease
  601. Significance of glomerular deposition of protein S in various glomerulopathies
  602. The kaleidoscope of autoimmunity
  603. Endothelial dysfunction in critically ill patients: the effect of haemofiltration
  604. Gender differences in IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist secretion from mononuclear cells and urinary excretion.
  605. Management of the Septic Patient in the Operating Room
  606. Stroke in childhood
  607. 2 Congenital thrombophilia
  608. Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus
  609. Problems with anticoagulation for continuous renal replacement therapies
  610. Low-dose oral contraceptive usage and coagulation
  611. Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance, and therapeutic options
  612. Plasma levels of D‐dimer and circulating endothelial adhesion molecules in veno‐occlusive disease of the liver following allogeneic bone marrow transplantation
  613. Cerbral venous thrombosis in ulcerative colitis and review of the literature
  614. Thromboembolic risks and complications in nephrotic children
  615. A familial hemorrhagic diathesis due to an antithrombin
  616. A missense mutation in γ-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors
  617. Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives
  618. Muscle infarction in diabetes: Clinical manifestations and course
  619. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects
  620. Advances in antithrombotic drug therapy for coronary artery disease
  621. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range
  622. Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK.
  623. An overview of thrombolytic agents
  624. An experimental investigation into the causes of disseminated intravascular coagulation in hemorrhagic shock
  625. Deep venous thrombosis and pulmonary embolism in pregnancy
  626. Hemostasis in malignancy
  627. The effects of human thrombomodulin on the inactivation of thrombin by its serum inhibitors
  628. Turbulent Mass Transport and Flame Spreading Rates Within Turbulent Flames Confined in a Variable Area Duct
  629. Central venous catheters for hemodialysis: How to overcome the problems
  630. Prothrombotic abnormalities in children with venous thromboembolism
  631. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus
  632. Broadsheet number 53: activated protein c resistance: diagnosis and clinical management
  633. Homocysteine, coagulation, platelet function, and thrombosis
  634. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease
  635. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation
  636. Dealing with Drug-Induced Thrombocytopenia: Case Commentary
  637. The serial hemostasis-related changes in patients with cerebral infarction: comparison between progressing and non-progressing stroke
  638. Potentiation of the Action of Warfarin by Bezafibrate in Patients with the Nephrotic Syndrome
  639. Hypercoagulability in vascular surgery patients
  640. Young women with advanced aortoiliac occlusive disease: new insights
  641. Antithrombin: the principal inhibitor of thrombin
  642. The alterations of the activities of coagulation inhibitors and fibrinolytic factors in stored cord blood could affect the yield of progenitor cells during processing
  643. Coagulation for blood bankers
  644. Pathogenic role of antiprotein-phospholipid antibodies
  645. Mechanisms of hypercoagulation in malignancy and during chemotherapy
  646. Blood cardiolipin in haemodialysis patients. Its implication in the biological action of platelet-activating factor
  647. Thromboembolic complications of polycythemia: Polycythemia vera versus smokers’ polycythemia
  648. Arterial thrombosis in the nephrotic syndrome.
  649. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment
  650. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism.
  651. Prevalence of antiphospholipid antibodies in deep vein thrombosis and their relationship to blood coagulation and fibrinolysis
  652. The changing epidemiology of asthma
  653. Hysterectomy techniques and their effect on the blood markers of thrombogenicity
  654. Sequential treatment of recurrent mesenteric desmoid tumor
  655. Serum antibodies to distinct epitopes of the tissue‐type plasminogen activator (t‐PA) in patients with systemic lupus erythematosus
  656. Proposed classification and pathologic mechanisms of purpura fulminans and skin necrosis
  657. Homocysteine and oxidized low density lipoprotein enhance platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic …
  658. Normal fetal growth in women with antiphospholipid syndrome treated with high‐dose intravenous immunoglobulin (IVIG)
  659. Lupus anticoagulant testing with optical end point automation
  660. Thromboembolism after hip and knee arthroplasty: diagnosis and treatment
  661. Coagulation changes in the neonatal period and in early infancy
  662. Prevalence of factor V Leiden in young adults with retinal vein occlusion
  663. The Subcutaneous Use of Heparin: A Summary of Observations
  664. Thrombomodulin gene regulation by cAMP and retinoic acid in F9 embryonal carcinoma cells
  665. Vascular endothelium, haemostasis and thrombosis
  666. Stroke and antiphospholipid antibodies
  667. Antiphospholipid antibodies: lupus anticoagulant and anticardiolipin antibody
  668. Acute aortic thrombosis associated with spinal cord infarction in nephrotic syndrome
  669. Familial coexistence of primary antiphospholipid syndrome and factor VLeiden
  670. Clinical and biological aspects of juvenile thrombophilia
  671. Evaluation of Ischemic Stroke and Recurrent Ischemic Attack
  672. Oral contraceptives and blood coagulation: a critical review
  673. Topical diagnosis: prechiasmal visual pathways
  674. Variations in hemostatic parameters after near-maximum exercise and specific tests in athletes
  675. Venous thrombosis and women’s health: Identification of risk factors and long terms effects
  676. 3 Megakaryocytic cell lines
  677. Increased levels of protein C activity, protein C concentration, total and free protein S in nephrotic syndrome
  678. Management of Antepartum Fetal Death
  679. Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients
  680. Fibrinolysis in patients with the 1691 G→ A mutation in factor V gene and history of deep vein thrombosis
  681. Thromboembolism in obstetrics
  682. Structure and function of endothelial cell integrins
  683. Thrombosis risk in the trauma patient: prevention and treatment
  684. Blood coagulation from the beginning until to-day
  685. Hypercoagulability following multiple trauma
  686. Effect of xuefu zhuyu decoction on the function of platelets and human umbilical vein endothelial cell
  687. Postpartum pyometra: a case report
  688. ACUTE CORONAR’Y SYNDROMES
  689. Strategies for the design of novel thrombolytic and antithrombolytic agents
  690. Antiphospholipid syndrome and the skin
  691. β2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis
  692. Venous thromboembolism
  693. Intravascular agglutination of the formed elements of blood
  694. Effect of plasma from patients with primary antiphospholipid syndrome on platelet function in a collagen rich perfusion system
  695. Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates
  696. Pathogenesis of and potential therapies for delayed xenograft rejection
  697. 11a Thrombosis and embolism
  698. Factor V Leiden: should all women be screened prior to commencing the contraceptive pill?
  699. A sensitized clotting time
  700. Antiphospholipid antibodies and the antiphospholipid antibody syndrome
  701. Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells
  702. Hemostasis in renal disease: pathophysiology and management
  703. Modulation of hemostatic mechanisms in bacterial infectious diseases
  704. Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation
  705. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients
  706. Deep vein thrombosis in pregnancy and the puerperium: a comprehensive review
  707. Protein C and protein S clinical perspectives
  708. CLINICO-PATHOLOGICAL EVALUATION OF PREGNANCY INDUCED HYPERTENSION
  709. PACU and ICU care: Evaluation and management of postoperative cardiovascular complications
  710. Protein C activity and antigen
  711. Prevalence of the C677T methylenetetra-hydrofolate reductase mutation in Thai patients with deep vein thrombosis
  712. Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy
  713. A Summary of Observations
  714. Regulation of blood coagulation
  715. Hereditary protein S deficiency in a large New Jersey kindred
  716. The prognostic value of the acute‐phase response in stroke recurrence
  717. Animal studies clearly indicate that dietary marine oils have antithrombotic effects, especially when they replace saturated fany acids in the diet. This chapter reviews …
  718. Fibromyalgia and interleukin-2 therapy for malignancy
  719. The syndrome of veno-occlusive disease after blood or marrow transplantation
  720. The progressive nature of peripheral arterial disease in young adults: a prospective analysis of white men referred to a vascular surgery service
  721. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation
  722. State-of the-Art Review: Prevention of Thrombosis in Gynecologic Malignancy
  723. Sex hormone binding globulins and atherosclerotic risk in systemic lupus
  724. Pharmacological actions of sulodexide
  725. Pulmonary embolism: diagnosis and treatment
  726. Analysis of hemostasis in the zebrafish
  727. Antiphospholipid Syndromes and the Nervous System Clinical Features, Mechanisms, and Treatment
  728. Pre-and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease-a preliminary study
  729. Studies on Thrombin Formation
  730. Deep venous thrombosis and pulmonary embolism
  731. Antithrombotic and thrombolytic therapy for coronary heart disease: consensus and controversy
  732. A review of tissue plasminogen activator in the treatment of veno‐occlusive liver disease after bone marrow transplantation
  733. Plasma levels of lipoprotein (a) are elevated in patients with the antiphospholipid antibody syndrome
  734. Endothelium-derived haemostatic factors and the antiphospholipid syndrome
  735. Physiology of blood coagulation
  736. Poly‐(2‐hydroxyethyl methacrylate) particles for preoprative endovascular occulusion of extensive angiodysplasias
  737. Intensive Treatment of the Patient with Hepatic Trauma
  738. Venocclusive disease of the liver after bone marrow transplantation: the role of hemostasis
  739. Newer strategies for the treatment of heparin‐induced thrombocytopenia
  740. Bleeding in Transplantation Surgery
  741. Analysis of prothrombotic effects of two human monoclonal IgG antiphospholipid antibodies of apparently similar specificity
  742. Anticoagulant activity of sulfated polysaccharides isolated from Codium fragile
  743. Genetic markers: genes involved in thrombosis
  744. Interactions Between Malignancy and Coagulation
  745. The pathogenesis, diagnosis and treatment of strokes: a progress report
  746. Prothrombin G20210A gene mutation, heparin cofactor II defects, primary (essential) thrombocythemia, and thrombohemorrhagic manifestations
  747. Estimating true fractional calcium absorption
  748. The anticoagulant properties of a modified form of protein S
  749. Resistance to activated protein C and a novel factor V gene mutation
  750. Protein C in acute stroke.
  751. Mechanism of blood coagulation in normal and pathologic conditions
  752. Risk factors for stroke in young Indonesian women
  753. The retinoic acid and cAMP-dependent up-regulation of 3-O-sulfotransferase-1 leads to a dramatic augmentation of anticoagulantly active heparan sulfate …
  754. Combination oral contraceptives and cardiovascular disease
  755. Anti-phospholipid antibody syndrome: medical zebra: or, just the stripes
  756. Acute ischemic stroke: update on treatment and prevention
  757. Rheumatoid arthritis and connective tissue diseases
  758. Fibrinogen Bellingham: A γ‐chain R275C substitution and a β‐promoter polymorphism in a thrombotic member of an asymptomatic family
  759. Coagulation parameters in maternal and cord blood at delivery
  760. The physiological significance of phospholipase A (2) activity in the saliva of the lone star tick, Amblyomma americanum (L.)
  761. Inhibitory mechanism of blood coagulation by the anticoagulant polysaccharide from Coriolus versicolor
  762. Adsorption of proteins in the processes of interaction of polymers with blood and model solutions
  763. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno …
  764. Extrahepatic expression and regulation of protein C in the mouse
  765. Recurrent TIPS failure associated with biliary fistulae: treatment with PTFE-covered stents
  766. Thrombophilic state in breast cancer
  767. Dietary fish oil and experimental atherosclerosis
  768. Enalapril and pregnancy-induced hypertension
  769. Primary sclerosing cholangitis associated with membranous nephropathy
  770. Pentasa in lieu of sulfasalazine
  771. Risks of coronary heart disease in women: current understanding and evolving concepts
  772. Tamoxifen-Induced Changes in the Plasma Fibrinolytic Factors in Menopausal Women with Breast Cancer.
  773. Fibrositis and the chronic fatigue syndrome
  774. COAGULACIÓN FIBRINÓLISIS
  775. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability
  776. Fish oils in rheumatoid arthritis
  777. Nonbacterial thrombotic endocarditis associated with gold-induced pulmonary disease
  778. Blood: physical characteristics, formed elements, hemoglobin, and coagulation
  779. Protein S deficiency and skin necrosis associated with continuous ambulatory peritoneal dialysis
  780. Kala-azar and the acquired immunodeficiency syndrome (AIDS)
  781. Resistance to Activated Protein C and Inherited Thrombosis—Molecular Mechanism, Diagnosis and Clinical Management
  782. Preventive treatment for tuberculosis in elderly persons
  783. Guidelines for infection with the human immunodeficiency virus (HIV) and health care workers
  784. The genetic dynamics of disease
  785. The pathogenesis, prevention and medical management of peripheral arterial thrombosis
  786. Vasoactive peptides and the carcinoid syndrome
  787. Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions
  788. The early dumping syndrome and propranolol
  789. New antithrombotics for the intensive care unit setting: GP IIb/IIIa inhibitors, low-molecular-weight heparins, and direct thrombin inhibitors
  790. Varicella-Zoster Virus Infection
  791. Perioperative Nutrition
  792. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients
  793. The molecular mechanism of factor Va inactivation by activated protein C
  794. Immunologic abnormalities in the antiphospholipid syndrome
  795. Stopping Antibiotics in Neutropenic Patients
  796. Correction: Intravenous Verapamil and Multifocal Atrial Tachycardia
  797. Pulse Methotrexate Therapy in Rheumatoid Arthritis
  798. Asymptomatic Cardiac Ischemia in Diabetic Persons
  799. Testing for the Human Immunodeficiency Virus (HIV) by Insurance Carriers
  800. Migratory Erythema and Glucagonoma: Descriptive Nomenclature
  801. The Doctor-Patient Relationship
  802. Omissions from A Library for Internists
  803. Antithrombin III in hematopoietic stem cell transplantation
  804. Venous Thromboembolism and Advanced Cancer
  805. Stroke: antithrombin versus antiplatelet therapy
  806. cated as a mechanism in the development of the disease (1-3). Nonbacterial thrombotic endocarditis can occur in gold-in-duced lung disease and may be a …
  807. Neurological complications of organ transplantation
  808. Selective transcriptional augmentation of hepatic gene expression in the rat with Heymann nephritis
  809. Bispectral index (BIS) monitoring of ICU patients on continuous infusion of sedatives and paralytics reduces sedative drug utilization and cost
  810. Antithrombotic therapy in high-risk pregnancy
  811. Beverly J. Pennell
  812. Functional food science and the cardiovascular system
  813. An investigation of antiphospholipid antibody associated obstetric complications
  814. Activated protein C resistance in pregnancy
  815. Anticoagulation and hemostasis in cardiac surgical patients
  816. Abnormalities of coagulation in experimental nephrotic syndrome
  817. Plasminogen Activation and Fibrinolysis in the Antiphospholipid Syndrome
  818. Blood clotting and hemostasis
  819. Genetics and ischaemic stroke
  820. Abdominal sepsis in patients 65-onwards after non-scheduled laparotomy
  821. Case 11-1990: A 38-Year-Old Woman with Fever, Skin Lesions, Thrombocytopenia, and Venous Thromboses
  822. Antiphospholipid antibodies or not? The role of β2 glycoprotein 1 in autoantibody-mediated pregnancy loss
  823. Severity evaluation in acute pancreatitis: the role of SOFA score and general severity scores
  824. Plasma composition in the nephrotic syndrome
  825. Therapeutic Intervention Scoring System (TISS)-a method for calculating costs in the intensive care unit (ICU) and intermediate care unit (IMCU)
  826. The fibrinolytic system in neoplasia
  827. Thrombosis and atherosclerosis
  828. The clinical relevance of the fluid balance in critically ill patients
  829. Structure-function relationships in histidine-rich glycoprotein, a putative plasma pH-sensor
  830. Stress in nursing staff: a comparative analysis between intensive care units and general medicine units
  831. Changes in vascularization of human breast cancer xenografts responding to antiestrogen therapy
  832. Myocardial Infarction
  833. Comorbidity risk parameters associated with advanced breast cancer and systemic disease: Management of nonbreast disease
  834. Tamoxifen induces hypoxia in MCF-7 xenografts
  835. PROTEIN C AND PROTEIN S: METHODOLOGICAL
  836. Role of hyperbaric oxygen therapy (HBOT) in recovery of cardiopulmonary function: survival of patients developing ARDS following closed chest trauma (CCT)
  837. Bacteremia and systemic inflammatory response syndrome (SIRS) in confirmed post-partum endometritis
  838. Collaborative practice and clinical outcomes in the ICU
  839. Effects of artificial changes in chest wall compliance on respiratory mechanics and gas exchange in patients with acute lung injury (ALI)
  840. Bacterial versus viral meningitis: comparison of the old and the new clinical prediction models
  841. Decreased protein C, protein S and antithrombin III levels are predictive of poor outcome in gram-negative sepsis caused by Burkholderia pseudomallei
  842. Frequency, mortality and risk factors of candidemia at a tertiary care hospital
  843. The incidence of ARDS, interim results of the East Anglian ARDS Registry
  844. Relationship between superimposed pressure and pleural pressure gradient in an experimental model of ARDS
  845. Laboratory diagnosis of inherited protein S deficiency
  846. Incidence of cortisol deficiency in patients with traumatic brain injury
  847. ARDS before and after the start of mechanical ventilation
  848. Anxiety and depression in family members of ICU patients: ethical considerations regarding decision-making capacity
  849. Translaryngeal tracheostomy: prospective experience in two Canadian tertiary intensive care units
  850. Glutamine-enriched parenteral nutrition during postoperative catabolic state
  851. Serum albumin and mortality risk in critically ill patients
  852. Hemostasis
  853. Hypoglycemia masquerading as acute psychosis in young age
  854. Organization and staffing of intensive care units in Brazil
  855. Propofol-induced inhibition of intestinal peristalsis involves enteric opioidergic pathways
  856. Induced moderate hypothermia markedly exacerbates pulmonary hypertension and dysoxia in a neonatal piglet model of elevated pulmonary vascular resistance
  857. A comparison between oesophageal Doppler and continuous thermodilution for the measurement of cardiac output in critically ill patients
  858. An audit of unplanned extubations in a medical intensive care unit
  859. Cytokines and sepsis-just black smoke?
  860. Immediate complications of central venous cannulation in ICU
  861. Continuous monitoring of gastric carbon dioxide with optical fibers: European project COMOCADOF, in vitro evaluation
  862. Renal disease in the elderly
  863. Are IL-6, IL-10 and PCT plasma concentrations more reliable than APACHE-III or SAPS-II for the individual mortality risk prediction in severe sepsis?
  864. Evaluation of thoracic fluid contents in patients with acute myocardial infarction
  865. Delivery of parenteral nutrition byall in one bag'(AIO) versus single bottle system (SBS) in critically ill patients: a prospective randomized trial
  866. Decrease of red blood cell sialic acid membrane content in septic patients
  867. Respiratory mechanics studied by multiple regression and the end-inspiratory pause technique during mechanical ventilation
  868. 13C-stable isotope analyses technique for ICU patients
  869. Evaluation of a new wireless ECG electrode built in a telemeter in critically ill patients
  870. Transthoracic cardioversion with damped biphasic waveform shocks
  871. A prospective trial of surgical resident performed focused abdominal sonography for trauma (FAST): an easy training method
  872. Evaluation of PCO2 measurements using a gastric air tonometer located in non-mixing solution
  873. Gastric-arterial pCO2 gradient, but not lactate levels, is related to multiple organ dysfunction assessed by SOFA score in septic patients
  874. Interleukin-17 stimulates intraperitoneal neutrophil infiltration through the release of the chemokine GROα from peritoneal mesothelial cells
  875. Epidemiology of cardiac arrhythmias in a medical-cardiologic intensive care unit: single center experience
  876. Endotoxin-induced pulmonary hyporesponsiveness to inhaled nitric oxide is improved by nitric oxide synthase 2 inhibition
  877. Hemostasis and coagulation
  878. Meeting the needs of ICU patient families: a multicentre study
  879. The change in Bispectral Index with stimulation indicates depth of sedation in intensive care
  880. Therapeutic activity in elderly medical intensive care patients
  881. Comparison of pressure-related performance data with data measured by thermodilution in heart failure and sepsis
  882. Selected biochemical values and organ dysfunction assessment in prediction of difficult to wean patients
  883. Timing of extubation after esophagectomy
  884. The predictive value of serial acute physiology score (APS) and simplified acute physiology score II (SAPS II) in post-operative liver transplant patients
  885. Use of Combitube airway to protect the airway from methylene blue dye
  886. Secretory phospholipase A2 (sPLA2), procalcitonin (PCT) and C-reactive protein (CRP) for the diagnosis and differentiation of septic shock and non-septic shock
  887. Dexmedetomidine for sedation in the medical ICU
  888. Phagocytosis of granulocytes is decreased in most patients with severe sepsis or septic shock
  889. Newly developed thrombocytopenia in medical intensive care patients
  890. The influence of empiric antimicrobial therapy on acquired pulmonary infection in patients with a chest injury on ICU
  891. Severe mushroom poisoning due to amatoxin in children
  892. Measurement of gastric emptying in ICU patients with 13C-acetate
  893. Would the blood volume analyzer-100 (BVA-100) be an alternative to pulmonary artery catheter (PAC) in critically ill patients
  894. The effect of using a heparin-free flush system for central venous and pulmonary artery catheters on a general medical and surgical intensive care unit
  895. Antithrombin (AT) improves inflammation induced microcirculatory disturbance in rat mesentery
  896. G-protein-and phosphodiesterase-dependent regulation of neutrophil migration by antithrombin III involving CXC-receptor 1
  897. Automatic tube compensation combined with pressure support ventilation-improved work of breathing pattern and less work
  898. Lipopolysaccharide induced procoagulant activity and cytokine production: influence of antithrombin
  899. Proportional pressure support in acute lung injury: an observational study
  900. Systemic and splanchnic hemodynamics, metabolism and PCO2-gap during septic shock induced by live E. coli infusion in dogs
  901. Effects of antithrombin III (ATIII) treatment (high dose) in severe pre-eclampsia and HELLP syndrome with alterations of coagulation inhibitors and inflammatory …
  902. Triiodothyronine (T3) ameliorates the cytokine storm in rats with sepsis
  903. Influence of enoximone and dobutamine upon liver perfusion and function in fluid optimized septic patients
  904. Timing and incidence density of upper gastrointestinal bleeding acquired by critically ill children
  905. Procalcitonin concentrations in blood after long-distance running
  906. Effects of a lung recruitment maneuver keeping PEEP before and after L-Pflex on gas exchange in child ARDS patients
  907. Effects of PEEP and tidal volume on elastances and distribution of volume changes of the different chest wall compartments
  908. The Effect of Tourniquet Application On Systemic Coagulation
  909. TISS 76 and TISS 28: outcome discrimination and correlation with length of ICU/hospital stay in 303 consecutive patients of a medical intensive care unit
  910. Clinical and economic study of the use of somatostatin 14 AA (amino-acids) in the treatment of enterocutaneous and pancreatic fistulas
  911. Prognostic factors in severe ARDS-patients
  912. A comparison of pulmonary artery occlusion pressure (PaOP) measurements using pressure controlled ventilation (PCV) versus airway pressure release ventilation …
  913. Management and outcome of symptomatic hyponatremia in emergency department
  914. The role of gallium-67 scintigraphy in diagnosing sources of fever in critically ill patients in ICU
  915. Central neuroaxial blockade improves case-mix adjusted mortality of the critically ill surgical patient
  916. Comparison of pulmonary arterial and arterial trans-cardiopulmonary thermodilution cardiac output in porcine septic shock
  917. Decrease in urine output during mesenteric traction syndrome is an early predictor of multiorgan dysfunction
  918. Treatment of hypophosphataemia in critically ill patients with a two day dosing regimen
  919. Effects of angiotensin II on the renal excretion of urodilatin in the isolated rat kidney
  920. A prospective study of the incidence of critical illness polyneuropathy
  921. Tumor necrosis factor receptor I, II and tumor necrosis factor-α levels in patients with burns
  922. Plasma endothelin-1 and natriuretic peptide levels and antioxidant capacity of heart transplanted patients
  923. CI/SVRI relationship during different phases of inflammatory response
  924. Earthquake, rescued victims, crush injury and their follow up
  925. Is the volume of a pleural effusion predictable using the thickness of the pleural lamella measured by sonography as a reference?
  926. The lower inflection point of the inspiratory pressure-volume curve overestimates optimal PEEP in surfactant-treated immature lambs
  927. Differences in phagocytosis by polymorphonuclear leucocytes (PMNs) and monocytes (Mos) in endotoxemia and endotoxin (ET) tolerance
  928. Inhibition of inducible nitric oxide synthase (iNOS) reduces multi-organ failure (MOF) in the thioacetamide (TAA) rat model
  929. Partial liquid ventilation combined with two different gas ventilation strategies in acute lung injury in piglets
  930. The combination of lactate and bicarbonate buffers in continuous venovenous hemodiafiltration and its impact on serum lactate levels and homeostasis
  931. Muscular mass and subcutaneous fat changes according to duration of ICU hospitalization with corticosteroid and muscle relaxant intake
  932. The ex vivo production of tumor necrosis factor-α (TNF-α) in men: relationship to cytokine balance during cardiopulmonary bypass
  933. Severity of illness, critical events, organ failure assessment and ICU outcome
  934. Relationship between systemic arterial pressure (SAP) and EtCO2 in patients with hemorrhagic shock
  935. Cardiopulmonary resuscitation with cardiopulmonary bypass after cardiac surgery
  936. Accidental hypothermia and active rewarming: the metabolic changes observed above and below 32° C
  937. Influence of prone position on gastric mucosal-arterial PCO2 gradient
  938. Effective pulmonary capillary pressure during hyperdynamic porcine endotoxemia
  939. Effects of mercaptoethylguanidine during long-term hyperdynamic porcine endotoxemia
  940. Effect of continuous hemofiltration (CVVHF) on inflammatory parameters
  941. A new diagnostic and severity marker in patients with SIRS, sepsis, severe sepsis and septic shock; procalcitonin
  942. Effect of different tidal volumes and PEEP levels on gas exchange and FRC
  943. Hospital urinary infection epidemic by Candida famata: reduction of mortality after therapy with fluconazole and identification of the risk factors related to the infection
  944. Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy
  945. Ileal microcirculation and mucosal acidosis during hyperdynamic porcine endotoxemia
  946. Experience with brain death and organ donation in a tertiary care hospital in Riyadh, Saudi Arabia
  947. Protection of spinal cord ischemic injury with the β-agonist Clenbuterol
  948. In contrast to CD64 expression, CD14 expression is persistently downregulated on polymorphonuclear cells (PMN) but not on monocytes of patients with septic shock
  949. Effects of epinephrine and norepinephrine on endotoxin-induced tissue factor expression in blood monocytes
  950. Managing cost in ICU-a report of an experience
  951. The new way of postoperative pulmonary complications prophylaxis in oesophageal cancer surgery
  952. Change in the provision of out-of-hours consultant cover improves case-mix adjusted mortality in a district general (university-affiliated) hospital intensive care unit
  953. Results of transplantation with kidneys from non-heart-beating donors
  954. Using fraxiparin in patients with gestosis
  955. Influence of different PEEP levels and tidal volumes on the regional nonaerated tissue: experimental study
  956. The changes in platelet function in SIRS, sepsis and MODS-a tight connection to the changes in the immune and hemostatic system
  957. Effects of PEEP above the L-Pflex on gas exchange, hemodynamic and gastric tonometry in ARDS patients
  958. Relationship between TNFα and IL10 release during cardiac operations and the development of apoptosis
  959. Pre-admission functional status and outcome in medical intensive care
  960. An alternative, and more sensitive, approach to detecting differences in outcome in sepsis
  961. Indocyanine green clearance monitoring during liver transplant for fulminant hepatic failure: preliminary results
  962. The use of percutaneous tracheostomy in patients with severe acute or chronic liver disease
  963. Impact of carrier solution on biological insulin availability
  964. Routine blood gas analysis does not provide information on regional metabolism of the stomach obtained by gastric tonometry in patients with left ventricular failure
  965. Is redistribution of microcirculatory blood flow within the small intestinal wall the cause of prolonged paralytic ileus in the critically ill?
  966. Alteration of current perception threshold in severely injured patients
  967. Effect of iNOS inhibition on exhaled NO and serum nitrate in hyperdynamic porcine endotoxemia
  968. Evaluation of different CPAP systems in ICU population
  969. Sepsis increases accumulation of cell-free hemoglobin in intima of submucosal arterioles in rats
  970. Epinephrine is more effective than other sympathomimetics in correcting cerebral hypoperfusion associated with mesenteric ischemic reperfusion insult
  971. Gastric mucosal tonometry: should we adjust PiCO2 and CO2-gap to temperature?
  972. Management of children with severe traumatic brain injury in an adult ICU: evaluation of outcome
  973. A comparison of the effects of conventional and balloon laryngoscopy on the sagittal dimensions of the space available for the cord at the level of the …
  974. An experience with surgical admissions to a Paediatric ICU (PICU) in Harare Zimbabwe
  975. The relationship between data of gastric tonometry by determination of polymorphonuclear leukocytes (PMNs, ie, myeloperoxidase activity) and gut mucosal …
  976. Mortality and outcome in different subgroups of patients admitted in an ICU
  977. Non-invasive two-point estimation of arterial PCO2 and alveolar deadspace
  978. Outcome after major trauma: 12-month follow-up
  979. Work up to rule out perioperative myocardial infarction: is it overused?
  980. Detection of perfusion failure during open heart surgery with sublingual PCO2
  981. Urgent orotracheal intubation induces transient bacteremia in critically ill patients
  982. Experience of medical examination and health consultation for public exposed to neutrons caused by criticality incident in Japan
  983. Clonidine concentration-dependently inhibits intestinal peristalsis in vitro
  984. Diaspirin cross-linked hemoglobin (DCLHb) ensures tissue oxygenation during hemodilution below the critical hematocrit
  985. Renal blood flow in critically ill cardiac patients: effect of dobutamine on total flow and selective redistribution of the cardiac index
  986. Endotoxin-induced capillary perfusion failure and leukocyte adhesion is not prevented by the thrombin inhibitor hirudin: an intravital microscopic study
  987. Are we allocating limited resources to patients in most need?
  988. Computer tomography of chest organs in the diagnosis of acute respiratory distress-syndrome of patients with severe brain injury
  989. The formation of platelet microvesicles in septic pigs treated with different kinds of volume replacement
  990. Elevated levels of adhesion molecules in septic patients with pre-existing coronary artery disease
  991. How does major abdominal surgery induce procalcitonin and IL-6 in the postoperative period?
  992. Ten years of blood cultures surveillance in an intensive care unit of a tertiary hospital in Israel
  993. Expression and regulation of procalcitonin in different human cells
  994. Is muscular mass affected by L-Carnitine levels in critically ill patients?
  995. A comparison between some standardized scales of evaluation of anxiety and depression in nursing staff
  996. Functional status and quality of life (QoL) in long-term survivors of cardiac arrest after cardiac surgery
  997. Effect of mechanical ventilation and respiratory tract colonization on bronchial immunoglobulin A and G levels in ICU patients
  998. Lactic acid clearance in the emergency department prognosticates multisystem organ failure and death
  999. In vitro study of a new vaporization humidifying device: DAR HC 2000®
  1000. The Bair Hugger patient warming system in prolonged surgery
  1001. Oxygenation response to prone positioning in pulmonary and extrapulmonary ARDS
  1002. Procalcitonin helps to discriminate between septic and non-septic underlying disease at admission in ICU
  1003. Health-related quality of life after heart surgery
  1004. Effects of Antithrombin III on body cavity effusions, fluid balance, colloid osmotic pressure and hemodynamics in porcine septic shock
  1005. High incidence of positive fungal DNA in the blood of critically ill patients
  1006. Falciparum malaria in ICU
  1007. Withdrawing life-prolonging medical treatment in 246 patients
  1008. Usefulness of vancomycin serum concentration monitoring in the critically ill patient
  1009. Quality of life 6 and 12 months after discharge from the intensive care unit
  1010. Non invasive mechanical ventilation (NINMV) in cardiac surgery
  1011. Risk factors associated with vancomycin-resistant enterococcal colonization in a general ICU and the effect of surveillance and prevention over respiratory tract and …
  1012. Procalcitonin serum concentrations do not differentiate severity of septic shock in postoperative patients
  1013. Evaluation of the logistic organ dysfunction system for the assessment of organ dysfunction and mortality
  1014. Is postoperative ICU care needed for high-risk patients after major elective surgery?
  1015. Open lung strategies in patients with intracranial lesions and acute lung injury
  1016. Acute necrotizing pancreatitis—histological study focusing on necrosis and apoptosis
  1017. Effects of volume replacement on plasma volume and albumin escape rate in a porcine model of fecal peritonitis
  1018. Compliance or failure and improvement or deterioration diagnosis of patients from performance diagrams
  1019. Acute psychological reactions in relatives of patients treated in the intensive care unit (ICU)
  1020. The early management of pain in casualty wards
  1021. Early enteral nutrition after Pancreas Kidney Transplantation (PKTx) with enteral drainage (a pilot study in five patients)
  1022. Role of platelet activating factor (PAF) on leukocyte-independent plasma extravasation and mast cell activation during endotoxemia
  1023. Plasma Cl: Na ratio: a simple alternative to Stewart’s Strong Ion equation for detection of elevated lactate or unmeasured anions in metabolic acidosis
  1024. The GH/IGF-I axis in children with a meningococcal septic shock: striking differences between survivors and non-survivors
  1025. Baseline audit of manipulation and management of intravenous therapy delivery systems
  1026. Norepinephrine-induced blood pressure increase to pre-shock levels worsens regional flow distribution in porcine septic shock
  1027. Assessment of a handy-type blood gas analyzer for measuring intramucosal pH (pHi)
  1028. Intraluminal antibiotic treatment of central venous catheter infection in patients receiving total parenteral nutrition
  1029. Is the ecarin clotting time (ECT) a valid monitoring parameter for r-hirudin-based anticoagulation in continuous renal replacement therapy?
  1030. Hypocapnic and normocapnic ventilation in hepatic encephalopathy: a comparision
  1031. Influence of iloprost on hepato splanchnic metabolic activity and energy balance in patients with septic shock
  1032. Neurosurgical patients admitted to intensive care units (ICU) exhibit a systemic inflammatory response
  1033. Inflammatory response, prognostic scores and mortality in acute pancreatitis
  1034. Relationship between cardiac troponin I (cTnI) release during cardiac operations and myocardial cell death
  1035. Treatment of severe heat stroke in an intensive care unit: clinical course, acute outcome and implications for management
  1036. Risk factors of infection and molecular typing in ICU colonized patients with Enterobacter aerogenes
  1037. Increased intestinal permeability accompanies the development of sepsis in ICU patients
  1038. Vancomycin as a single daily dose in critically ill patients on an intensive care unit
  1039. Beneficial effects of lung recruitment with PEEP after cardiac surgery
  1040. Carbon dioxide elimination during continuous venovenous hemodiafiltration (CVVHD)-laboratory experiment
  1041. Emergency department evaluation of orthotopic liver transplant recipients
  1042. Respiratory burst activity of PMN is increased in most patients during septic shock
  1043. Impact of CVVH on monocyte activation in the critically ill
  1044. Efficacy of the endotoxin absorption method (PMX) in patients with septic shock associated with intraperitoneal infections
  1045. Evolution of micro-organisms isolated in nosocomial bloodstream infections in Belgian Intensive Care Units, 1992-1999
  1046. Hemodynamic effects of the inspiratory flow rate in patients with septic shock
  1047. Effects of bronchoalveolar lavage (BAL) fluids of patients with ventilator-associated bronchopneumonia (VAP) on alveolar cells in culture
  1048. Ward death following ICU discharge-can it be predicted? Development and validation of a predictive model
  1049. Evaluation of transesophageal atrial pacing in the prone and lateral position
  1050. Tetanus-following up 285 patients in ICU
  1051. Prospective randomized study of hemodialysis membrane biocompatibility in acute renal failure
  1052. The role of selected biochemical values in graft quality prediction in brain death organ donors
  1053. Pseudocholinesterase and albumin in infants with cirrhosis
  1054. Metabolism in abdominal organs, as evaluated by microdialysis, in experimental severe acute pancreatitis
  1055. Data from the US Army field surgical hospital intensive care unit in post-war Kosovo
  1056. Acute weakness in the ICU-electrophysiological and pathological findings
  1057. Does metoclopramide prevent bacterial translocation (BT)?
  1058. Leptospirosis in intensive care units: report of 33 cases
  1059. Therapy of malignant intracranial hypertension by lumbar cerebrospinal fluid drainage
  1060. Parenteral nutrition (PN) depresses hepatic albumin synthesis in septic rats
  1061. The impact of late-onset ventilator-associated pneumonia on mortality in a Saudi-Arabian hospital
  1062. Prolonging ICU stay reduces the number of ward deaths: evaluation of a model for triaging ICU discharges
  1063. Respiratory effects of dexmedetomidine in the ICU
  1064. Variation of early auditory evoked potentials (EAEP) in severe hyponatremia
  1065. Preload assessment in septic shock
  1066. Changes in the C-type Natriuretic peptide (CNP) and NO derivatives in the plasma and CSF of the patients with subarachnoid hemorrhage (SAH)
  1067. Monitoring of sedation with BIS Index, comparison with Ramsay and Cook sedation scores
  1068. Role of decisive markers in diagnosis and outcome of patients with septic shock
  1069. The interactions between human antithrombin and heparin
  1070. Tamoxifen and HRT: Synergistic or Antagonistic?
  1071. Septic Shock with Purpura in Children: an experimental and clinical approach
  1072. 21 Thromboembolic Disease
  1073. Hemostasis and the surgical patient
  1074. The intracellular serpin proteinase inhibitor 6 is expressed in monocytes and granulocytes and is a potent inhibitor of the azurophilic granule protease, cathepsin G
  1075. Protein S and thrombotic disease
  1076. Coagulation defects
  1077. Childhood essential thrombocythaemia without evidence of myeloproliferation: how many investigations should be done?
  1078. Physiology and Pathology of Blood Coagulation A Review of the Literature of 1961 (First Series)
  1079. Fulminant meningococcemia (purpura fulminans)
  1080. Oral contraceptives and arterial and venous thrombosis: a clinician’s formulation
  1081. Physiology and Pathology of Blood Coagulation
  1082. Selective estrogen receptor modulators: clinical spectrum
  1083. Reproductive Physiology in the Human Female With Age
  1084. Novel anticoagulant and prohemostatic strategies
  1085. The effect of blood chemistry on the rheological properties of the fluid
  1086. Role of cysteine proteinases in IGF-1R turnover, invasion and metastasis
  1087. Studies on coagulation and acute-phase response in the horse
  1088. Psychological aspects of gastrointestinal illness among Israeli medical outpatients
  1089. A study of platelet aggregation in whole blood from normal and prothrombotic subjects
  1090. Mechanisms of stimulus-response coupling in platelet-activating factor stimulated platelets
  1091. Inflammation and thrombosis
  1092. New anticoagulants for venous thromboembolic disease.
  1093. Role of coagulation inhibitors in inflammation
  1094. Activity of naturalcoagulation inhibitor proteins in the acute phase of ischaemic stroke
  1095. The interactions between inflammation and coagulation
  1096. What can we learn from the three megatrials using anticoagulants in severe sepsis?
  1097. New aspects of the blood coagulation cascade, anticoagulants and vein thrombosis in Asia.
  1098. Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability, and fibrinolysis
  1099. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia
  1100. New antithrombin‐based anticoagulants
  1101. Frequency of thrombophilia in patients with adverse pregnancy outcome
  1102. In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial†‡
  1103. Coagulation disorders in uremia
  1104. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and …
  1105. Why do animal models (sometimes) fail to mimic human sepsis?
  1106. Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation
  1107. Drug intervention trials in sepsis: divergent results
  1108. Interactions between the innate immune and blood coagulation systems
  1109. Tifacogin, recombinant tissue factor pathway inhibitor
  1110. Air travel and thrombosis.
  1111. The relationship between protein C, protein S and cytokines in acute ischemic stroke
  1112. Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors
  1113. High levels of factor VIIIc and risk of venous thrombosis: critical analysis of case-control studies
  1114. Evaluation of the blood coagulation mechanism and platelet aggregation in individuals with mechanical or biological heart prostheses
  1115. Understanding and preventing the coagulation disorders associated with xenograft rejection
  1116. Thrombotic complications during induction chemotherapy of acute childhood lymphoblastic leukemia.
  1117. The liver and the haemeostatic system
  1118. Free protein S (PS) in normal pregnancy: a comparison between two analytical methods
  1119. Central retinal vein occlusion and thrombophilia risk factors
  1120. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis
  1121. Inflammation and coagulation
  1122. Coagulation defects and platelets function in splenectomized and non-splenectomized beta-thalassemic children
  1123. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy …
  1124. anticoagulants: to bleed or not to bleed, that is the question
  1125. Thrombosis in children with acute lymphoblastic leukemia: Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and …
  1126. Portal vein thrombosis after hematopoietic cell transplantation: frequency, treatment and outcome
  1127. Thrombosis and a hypercoagulable state in HIV-infected patients
  1128. Genetic polymorphisms associated with venous and arterial thrombosis: an overview
  1129. A boy with Churg-Strauss syndrome and thrombosis associated with eosinophilia
  1130. Gene polymorphism of factor V and variceal bleeding in infants and children
  1131. Antithrombin III activity in the elderly–association with cardiovascular disease risk factors
  1132. Portal vein thrombosis in pregnancy: case report and review of the literature
  1133. The state of hemostasis in patients after mini-invasive aorta and coronary artery bypass surgery
  1134. The state of hemostasis in patients after mini-invasive aorta and coronary artery bypass surgery
  1135. Venous thromboembolism: which patients are truly at risk
  1136. The blood coagulation system as a molecular machine
  1137. Anti-thrombin III, Protein C, and Protein S deficiency in acute coronary syndrome
  1138. The causes of early disorders of cerebral circulation in patients undergoing carotid endarterectomy.
  1139. The complex nature of the prothrombotic state in acute lymphoblastic leukemia of childhood
  1140. Hemostasis disorders in severe infections: state of the art
  1141. Struggle for implementation of new strategies in intensive care medicine: anticoagulation, insulin, and lower tidal volumes
  1142. Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?
  1143. Recurrent Thrombosis Is Frequently Associated with Increased Microparticle-Mediated Thrombin Generation.
  1144. Antithrombin–Heparin Complexes
  1145. Extracorporeal anticoagulation for intermittent and continuous forms of renal replacement therapy in the intensive care unit
  1146. A Case of Protein S Deficiency with Cerebral Infarction
  1147. Anticoagulant and Anti-Inflammatory Effects of Recombinant Human Antithrombin in Man after LPS Challenge.
  1148. The liver and the haemeostatic system
  1149. Frequency of thrombophilia in patients with adverse pregnancy outcome
  1150. TWINS DEVELOPING ARTERIAL THROMBOSIS IN THE EARLY NEONATAL PERIOD: AN ELUSIVE DIAGNOSIS?
  1151. Chronic Arterial Occlusion by Hypercoagulable State 2 cases report (Antiphospholipid syndrome and Polycythemia vera)
  1152. Relation between thrombin activatable fibrinolysis inhibitor and haemostatic alterations in patients with chronic liver disease and portal vein thrombosis
  1153. Coagulation and Innate Immunity
  1154. Effect of CMF-chemotherapy on blood coagulation in patients with breast cancer
  1155. Activation of Endothelial Cells, Coagulation and Fibrinolysis in Thai Children with Dengue Virus Infection.
  1156. High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis
  1157. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis
  1158. Platelets and anticoagulant capacity in patients with inflammatory bowel disease
  1159. Masterclass series in peripheral arterial disease: Inherited thrombophilia
  1160. Role of tissue factor in thrombosis. Coagulation-inflammation-thrombosis circuit
  1161. Hematologic risk factors for stroke in Saudi children
  1162. Diagnostic issues in thrombophilia: a laboratory scientist’s view
  1163. “Baffled” by the conclusions
  1164. Hemostasis and thrombosis: physiological and pathological aspects
  1165. Variable effect of prothrombotic factors on fetomaternal circulation
  1166. Anticoagulation for continuous renal replacement therapy
  1167. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?
  1168. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes
  1169. Clinical trials in sepsis.
  1170. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model
  1171. Haemostatic disorders during liver transplantation
  1172. Clinical trials in sepsis
  1173. Coagulation in sepsis
  1174. Coagulation and atherothrombotic disease
  1175. Blood and bone marrow pathology
  1176. The impact of the inflammatory response on coagulation
  1177. Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis
  1178. Hemostatic markers with bolus versus prolonged heparin after carotid artery stenting
  1179. Hereditary thrombophilia in ethnic Omani patients
  1180. Thrombophilia in coronary artery disease: A double jeopardy
  1181. Indwelling catheter-related central venous thrombosis during bone marrow transplantation
  1182. Acquired and inherited thrombophilia in women with unexplained fetal losses
  1183. A novel anticoagulant purified from fish protein hydrolysate inhibits factor XIIa and platelet aggregation
  1184. Tissue factor pathway inhibitor in childhood nephrotic syndrome
  1185. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome
  1186. Platelet and endothelial-cell markers in meningococcal septicaemia: a report of two cases
  1187. Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations
  1188. A family history can display a synergistic effect of atherogenic and prothrombotic risk in pregnancy
  1189. Abciximab inhibits procoagulant activity but not the release reaction upon collagen‐or clot‐adherent platelets
  1190. Normalization of multiple hemostatic abnormalities in uremic type 1 diabetic patients after kidney-pancreas transplantation
  1191. Year in review 2005: Critical Care–resource management
  1192. Central nervous system listeriosis confused with leptomeningeal carcinomatosis in cancer patients
  1193. Prospective assessment of risk factors for recurrent stroke during childhood-a 5-year follow-up study
  1194. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults …
  1195. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism
  1196. Normal responses to injury prevent systemic inflammation and can be immunosuppressive
  1197. CASE REPORT-MYOCARDIAL INFARCTION IN A YOUNG PATIENT WITH METHYLENE TETRAHYDROFOLATE REDUCTASE (MTHFR) GENE MUTATION
  1198. CASE REPORT-MYOCARDIAL INFARCTION IN A YOUNG PATIENT WITH METHYLENE TETRAHYDROFOLATE REDUCTASE (MTHFR) GENE MUTATION
  1199. The thrombophilic fetus
  1200. Cerebral metastases in patients with advanced breast cancer treated with trastuzumab
  1201. anticoagulants for acute respiratory distress syndrome: can they work?
  1202. Plasminogen activator inhibitor‐1 is an independent diagnostic marker as well as severity predictor of hepatic veno‐occlusive disease after allogeneic bone marrow …
  1203. Morphological and functional differences in haemostatic axis between kidney transplanted and end‐stage renal disease patients
  1204. Hemostasis and thrombosis
  1205. Management of sepsis
  1206. On the need of biopsy confirmation at suspected first recurrence of cancer
  1207. Cost effectiveness of aromatase inhibitors
  1208. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study
  1209. Myocardial injury in meningococcus-induced purpura fulminans in children
  1210. Management of preterm infants with intracardiac thrombi
  1211. Inherited thrombophilic risk factors in a large cohort of individuals referred to Italian thrombophilia centers: distinct roles in different clinical settings
  1212. Pathophysiological basis for anticoagulant and antithrombotic therapy in pulmonary hypertension
  1213. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state
  1214. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis
  1215. Endothelial cell gene regulation
  1216. Testing for thrombophilia: an evidence-based approach
  1217. Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia
  1218. Use of laserotherapy in multimodality treatment and prevention of obstetric pathology
  1219. Familial thrombophilia and lifetime risk of venous thrombosis
  1220. Dermatologic aspects of antiphospholipid antibody syndrome
  1221. Microvascular thrombosis: What is the importance?
  1222. Thrombocytopenia in the parturient
  1223. What causes the antiphospholipid syndrome?
  1224. Feasibility of lmw heparin prophylaxis for management of thrombophilia investigation in patients on oral anticoagulation therapy
  1225. The nexus between systemic inflammation and disordered coagulation in sepsis
  1226. Complementary effects of Mediterranean diet and moderate red wine intake on haemostatic cardiovascular risk factors
  1227. Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature
  1228. The pivotal role of the endothelium in haemostasis and thrombosis
  1229. Direct thrombin inhibitors
  1230. Premature lower extremity atherosclerosis: clinical aspects
  1231. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach
  1232. Thrombophilia in sickle cell disease: the red cell connection
  1233. Acute Dialysis Quality Initiative
  1234. Disorders of Thrombosis and Haemostasis
  1235. Effect of a combined oral contraceptive containing 20 μg ethinyl estradiol and 75 μg gestodene on hemostatic parameters
  1236. Purpura fulminans in sepsis
  1237. FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile
  1238. Detection of an Ala601Thr mutation of plasminogen gene in 3 out of 36 Korean patients with deep vein thrombosis
  1239. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity
  1240. The crucial role of systemic responses in the innate (non-adaptive) host defense
  1241. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis?
  1242. Evaluation of coagulation, fibrinolysis and protein C in risk patients and patients presenting coronarian diseases
  1243. Inflammation and the activated protein C anticoagulant pathway
  1244. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia
  1245. Procoagulant activity on platelets adhered to collagen or plasma clot
  1246. Anticoagulant 1, 2, 3, 4, 6-pentagalloyl-β-d-glucopyranose isolated from geranium (Pelargonium inquinans Ait)
  1247. Hirudin as alternative anticoagulant-a historical review
  1248. Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study
  1249. The effects of continuous venovenous hemofiltration on coagulation activation
  1250. Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes
  1251. High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease
  1252. Importance of anticoagulant proteins in chronic liver diseases
  1253. Elevated D-dimer level predicts recurrent VTE
  1254. By what mechanism do leeches help to salvage ischaemic tissues?: A review
  1255. Congenital and acquired hemorrhagic problems
  1256. Pathophysiology of sepsis
  1257. Hormone replacement therapy, thrombosis and thrombophilia
  1258. Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms
  1259. Coagulopathy of sepsis
  1260. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia
  1261. Designing and funding clinical trials of novel therapies
  1262. Novel anticoagulants for the prevention and treatment of venous thromboembolism
  1263. Associations of thrombophilia, hypofibrinolysis, and retinal vein occlusion
  1264. Thrombophilia and Pregnancy Complications: Preeclampsia,(Late) Intrauterine Fetal Death, and Thrombosis
  1265. Air Travel and Thrombosis
  1266. Anti-Thrombin III in the Management of Hematopoietic Stem-Cell Transplantation—Associated Toxicity
  1267. Haemostatic abnormalities in liver disease: could some haemostatic tests be useful as liver function tests?
  1268. The elevated markers of hypercoagulability in children with Henoch–Schönlein purpura
  1269. Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats
  1270. Obesity and reproduction
  1271. Haemostatic changes in pregnancy
  1272. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in amniotic fluid and blood plasma: implications for the mechanism of amniotic fluid embolism
  1273. The prevalence of protein C, protein S, and antithrombin III deficiency in non-APS/SLE Chinese adults with noncardiac cerebral ischemia
  1274. Paradoxical neutrophil activation and coagulopathy during the recovery phase after endotoxemia
  1275. Thrombin generation and mortality during Staphylococcus aureus sepsis
  1276. Fatal deep vein thrombosis after allogeneic reduced intensity hematopoietic stem cell transplantation for the treatment of metastatic gastric cancer
  1277. Major and potential prothrombotic genotypes in a cohort of patients with venous thromboembolism
  1278. Tissue factor in infection and severe inflammation
  1279. anticoagulants in pregnancy
  1280. Unraveling severe sepsis: why did OPTIMIST fail and what’s next?
  1281. Effects of anticoagulant treatment on intestinal ischaemia and reperfusion injury in rats
  1282. Morphological and functional differences in haemostatic axis between kidney transplanted and end-stage renal disease…
  1283. Blood Group Non-O May Be Associated with an Increased Risk of Venous Thrombosis: Taiwan Thrombophilia Study
  1284. Improving pregnancy outcome in women with thrombophilia
  1285. Fibrin(ogen)-αMβ2 Interactions Regulate Leukocyte Function and Innate Immunity In Vivo
  1286. Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway
  1287. Hypercoagulability risk factors in children with minimal change disease and the protective role of protein-C activity
  1288. Disseminated intravascular coagulation syndrome and protein C
  1289. Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia
  1290. Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation
  1291. Enhanced tissue factor pathway inhibitor response as a defense mechanism against ongoing local microvascular events of Legg-Calve-Perthes disease
  1292. Inherited thrombophilia and obstetric complications
  1293. The prothrombotic state in cancer: pathogenic mechanisms
  1294. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis
  1295. Cocaine by internal mail: two surgical cases
  1296. Neurological manifestations in severe acute respiratory syndrome
  1297. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-κB
  1298. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia—a review
  1299. Cryoprecipitate-induced mesenteric venous thrombosis during L-asparaginase therapy for acute lymphoblastic leukaemia
  1300. Upper extremity deep venous thrombosis
  1301. Two-way interactions between inflammation and coagulation
  1302. Low protein Z levels and risk of occurrence of deep vein thrombosis
  1303. Antiphospholipid syndrome in a human immunodeficiency virus 1-infected child
  1304. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome
  1305. The wheelchair thrombosis syndrome.
  1306. The immunopathogenesis of sepsis
  1307. Treatment of bleeding with recombinant factor VIIa in a patient with extensive burns
  1308. Impact of screening on thrombophilia for patients with venous thrombosis
  1309. New subsets of the antiphospholipid syndrome in 2006:“PRE-APS”(probable APS) and microangiopathic antiphospholipid syndromes (“MAPS”)
  1310. Pre-eclampsia and thrombophilia
  1311. Recurrent thromboembolism in infants and children suffering from symptomatic neonatal arterial stroke: a prospective follow-up study
  1312. D-dimer predicts outcome after aneurysmal subarachnoid hemorrhage: no effect of thromboprophylaxis on coagulation activity
  1313. Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shock.
  1314. Protein S and congenital protein S deficiency: the most frequent congenital thrombophilia in Japanese
  1315. Evidence-based medicine in the ICU: important advances and limitations
  1316. Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells
  1317. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation
  1318. Plasma levels of heparin cofactor II (HCII) and thrombin-HCII complex in patients with disseminated intravascular coagulation
  1319. MHC class II and III polymorphisms and the antiphospholipid syndrome
  1320. C hapter 5 0 Management of Disseminated Intravascular Coagulation
  1321. Calciphylaxis: a rare association with alcoholic cirrhosis. Are deficiencies in protein C and S the cause?
  1322. Fetuses are exposed to a hypoxic environment in utero. The placenta delivers 35–40 mm
  1323. Congenital thrombophilia associated to obstetric complications
  1324. Intravascular thrombosis in discordant xenotransplantation
  1325. Cardiovascular and thrombophilic risk factors for central retinal vein occlusion
  1326. Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure
  1327. Emergent cardiovascular risk factor: Homocysteine
  1328. Protein Z and vitamin K in kidney disease.
  1329. Graft protein C entrapment is associated with reduced phagocyte activation during reperfusion in human liver transplantation
  1330. Catastrophic antiphospholipid syndrome
  1331. Thrombophilia and the risk of venous thromboembolism in cancer
  1332. Genetic hyper-coagulation predisposition for myocardial infarction in the Newfoundland population
  1333. A safety evaluation of drotrecogin alfa (activated) in hematopoietic stem cell transplant patients with severe sepsis: lessons in clinical research
  1334. The normal role of Activated Protein C in maintaining homeostasis and its relevance to critical illness
  1335. Magnetic resonance imaging of mouse spinal cord
  1336. Transition to an oral anticoagulant in patients with heparin-induced thrombocytopenia
  1337. Novel and usual associations
  1338. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status
  1339. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case …
  1340. Haemostatic cardiovascular risk factors: differential effects of red wine and diet on healthy young
  1341. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C–deficient mice
  1342. Warfarin induced massive and bilateral skin necrosis of the breasts: a case report and review of the literatures
  1343. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention
  1344. Are D-dimer levels after aneurysmal subarachnoid hemorrhage predictive of outcome?
  1345. Behçet’s disease and thrombophilia
  1346. Pathogenesis of venous thromboembolism
  1347. Some aspects of hemostasis in kidney transplant recipients maintained on cyclosporine, azathioprine, and prednisone in comparison to patients treated with …
  1348. Distinctive effects of red wine and diet on haemostatic cardiovascular risk factors
  1349. Continuous renal replacement therapy for liver disease
  1350. Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy
  1351. Enhancement of study on hemostatic and thrombotic disorders
  1352. Hyperhomocysteinemia and venous thromboembolism
  1353. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium
  1354. Continued Investigation of Immune Competence in Navy Marine Mammals: Implications for Health Viability and Mission Readiness
  1355. Paraoxonase 192 Gln→ Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults
  1356. Procoagulant protein levels are differentially increased during human endotoxemia
  1357. Mechanism of action of drotrecogin alfa activated (rhAPC)
  1358. Surgery in Carriers of Blood-borne Infections
  1359. Effect of short course high dose methylprednisolone on endothelin-1 and nitric oxide in children with acute lymphoblastic leukemia: a preliminary study
  1360. Protein S deficiency is common in a healthy Thai population
  1361. Practical tips for warfarin dosing and monitoring
  1362. Hormone replacement therapy and coagulation
  1363. Serial changes in markers measuring coagulation, fibrinolysis, and vasoactivity in patients with ischemic stroke
  1364. An evaluation of thrombophilia screening in an urban tertiary care medical center: A “real world” experience
  1365. Successful treatment of fulminant pneumococcal sepsis with recombinant tissue plasminogen activator
  1366. The 21st international symposium on intensive care and emergency medicine, Brussels, Belgium, 20-23 March 2001
  1367. Lipaemia: an overrated interference
  1368. Deep vein thrombosis and air travel
  1369. APC stripped bare
  1370. Thromboprophylaxis after vaginal delivery: A district generalhospital experience
  1371. Laboratory Testing and the Thrombophilia Workup
  1372. P0238 ANTITHROMBIN SUPPLEMENTATION AFTER LIVER TRANSPLANTATION
  1373. Hemostasis and aging
  1374. Venous thromboembolism: disease burden, outcomes and risk factors
  1375. Investigation of the Anticoagulant Activity of Several Low-Molecular-Weight Endogenous Ligands of Blood Plasma by Methods of Computer Simulation and Universal …
  1376. Recurrent acute stent thrombosis associated with protein C and S deficiencies
  1377. Should plasma be transfused prophylactically before invasive procedures?
  1378. Genomic medicine and thrombotic risk: who, when, how and why?
  1379. Pseudo-heparin-induced thrombocytopenia
  1380. Tissue factor upregulation drives a thrombosis–inflammation circuit in relation to cardiovascular complications
  1381. WARFARIN INDUCED MASSIVE AND BILATERAL SKIN NECROSIS OF THE BREASTS: A CASE REPORT AND REVIEW OF THE LITERATURES
  1382. Neurological symptoms of Adamantiades–Behçet’s syndrome
  1383. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects
  1384. Thrombosis of the portal venous system after splenectomy for trauma
  1385. β2-glycoprotein I, anti-β2-glycoprotein I, and fibrinolysis
  1386. Sepsis and disseminated intravascular coagulation
  1387. Homocysteine and brain atrophy
  1388. Does disseminated intravascular coagulation lead to multiple organ failure?
  1389. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome
  1390. Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening
  1391. Physiologic inhibitors of coagulation in patients on chronic hemodialysis
  1392. Dual antibody reactivity to β2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome
  1393. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke
  1394. Hemostasis alterations in metabolic syndrome
  1395. Hemostatic effects of tamoxifen in hereditary hemorrhagic telangiectasia
  1396. Acute arterial thrombotic purpura complicating varicella and the role of hyperbaric oxygen as an adjunctive therapy
  1397. Massive blood transfusion
  1398. Hemostasys system disorders in acute pankreatitis
  1399. Protein S modulates the anticoagulant action of recombinant human activated protein C: a comparison between neonates and adults
  1400. Veno-occlusive disease: cytokines, genetics, and haemostasis
  1401. Inherited thrombophilias
  1402. Effects of replacement fluids on coagulation system used for therapeutic plasma exchange
  1403. Unravelling the confusion about HRT in women
  1404. Thrombophilia, clinical factors, and recurrent venous thrombotic events
  1405. Hematologic changes in sepsis and their therapeutic implications
  1406. Genetic susceptibility to venous thrombosis
  1407. Hormone therapy and venous thromboembolism
  1408. Evaluation of coagulation in pediatric bone marrow transplantation patients
  1409. Thrombophilic risk factors in patients with central retinal vein occlusion
  1410. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management
  1411. Management of sepsis in the critically ill patient: key aspects
  1412. Immunologic manipulation for the threatened fetus
  1413. Ximelagatran—promises and concerns
  1414. Protease-activated receptors in vascular biology
  1415. Antithrombin Modulates the Leukocyte–Endothelial Cell Interaction in the Staphylococcal Enterotoxin B-Challenged Mouse
  1416. Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction
  1417. Pediatric reference intervals for seven common coagulation assays
  1418. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation
  1419. Mechanisms of the inflammatory response
  1420. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation
  1421. State-of-the-Art Review: Thrombophilia and Pregnancy: Review of the Literature and Some Original Data
  1422. Microcoagulation processes after xenotransplantation
  1423. Thrombotic disorders in infancy and childhood
  1424. Warfarin skin necrosis associated with protein S deficiency and a mutation in the methylenetetrahydrofolate reductase gene
  1425. Antineoplastic treatment and venous thrombosis
  1426. Genetic epidemiology of sepsis and septic shock
  1427. Prothrombotic disorders in patients with mesenteric vein thrombosis
  1428. Endothelial apoptosis: the missing link between atherosclerosis and SLE?
  1429. Thrombophilia in pregnancy: maternal and fetal implications
  1430. Pro-thrombotic states in stroke
  1431. Stroke in sickle cell disease
  1432. Diabetes mellitus: a hypercoagulable state
  1433. Acute myelogenous leukemia associated with extreme symptomatic thrombocytosis and chromosome 3q translocation: case report and review of literature
  1434. The future of plasma‐derived clotting factor concentrates
  1435. Endothelium and allotransplantation
  1436. Drug interactions between herbal and prescription medicines
  1437. Serendipitous diagnosis of protein S deficiency
  1438. Maternal issues in thrombosis and thrombophilia
  1439. Does Ginkgo biloba Special Extract EGb 761® Provide Additional Effects on Coagulation and Bleeding when Added to Acetylsalicylic Acid 500mg Daily?
  1440. Creepy crawly medicine–does it work?
  1441. Antiphospholipid antibodies in a heterogeneous group of patients: experience from a central laboratory
  1442. Factor V Leiden
  1443. Traitements antitumoraux et complications thromboemboliques: thrombose et cancer
  1444. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology
  1445. Moyamoya-like vasculopathy (moyamoya syndrome) in children
  1446. Fever six weeks after trauma
  1447. Pharmacodynamics of active site‐inhibited factor VIIa in endotoxin‐induced coagulation in humans
  1448. Atypical warfarin‐induced skin necrosis
  1449. Treating heparin-induced thrombocytopenia
  1450. Con: antifibrinolytics are not safe and effective in patients undergoing liver transplantation
  1451. The impact on coagulation of an intravenous loading dose in addition to a subcutaneousregimen of low-molecular-weight heparinin the initial treatment of acute …
  1452. Spinal cord infarction as a severe complication of meningococcal meningitis
  1453. Central venous line thrombosis in children and young adults with thalassemia major
  1454. Haemostatic changes in pregnancy
  1455. Female hormones and thrombosis
  1456. Fibrinolysis in disseminated intravascular coagulation
  1457. Overview of New Anticoagulant Drugs
  1458. Hazards from naturalorigins
  1459. Heparin-derived oligosaccharides as potential therapeutic agents in senile dementia and stroke
  1460. Interactions between coagulation and inflammation
  1461. Cerebral venous sinus thrombosis in a neonate with homozygous prothrombin G20210A genotype
  1462. The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort …
  1463. Antithrombin-III in Pediatric Systemic Lupus Erythematosus
  1464. updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome
  1465. Levels of plasma des-γ-carboxy protein C and prothrombin in patients with liver diseases
  1466. Heparin cofactor II deficiency
  1467. Platelet aggregation in children with acute lymphoblastic leukemia during induction of remission therapy
  1468. Going with the flow of anticoagulant therapy
  1469. Coagulation and inflammation in acute lung injury
  1470. Molecular diagnostics in coagulation
  1471. Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death
  1472. Hikmat N. Abdel-Razeq, MD, ABIM (Hema&Onco)
  1473. Design, synthesis and evaluation of graftable thrombin inhibitors for the preparation of blood-compatible polymer materials
  1474. Protein C, protein S, and thrombomodulin in amniotic fluid. A preliminary study
  1475. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly
  1476. Widespread cutaneous necrosis associated with antiphospholipid antibodies: report of four cases
  1477. Thrombophilia in cancer
  1478. Thrombin generation in platelet-poor plasma is normal in patients with hereditary mucocutaneous haemorrhages
  1479. Impact of preoperative steroids administration on ischemia‐reperfusion injury and systemic responses in liver surgery: a prospective randomized study
  1480. Editorial III: Inflammation and the coagulation system
  1481. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
  1482. Isquemia miocárdica y manejo postoperatorio
  1483. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD
  1484. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis
  1485. Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases
  1486. Low protein Z levels in children with nephrotic syndrome
  1487. Effects of high-dose methylprednisolone therapy on coagulation factors in patients with acute immune thrombocytopenic purpura
  1488. Different circumstances of the first venous thromboembolism among younger or older heterozygous carriers of the G20210A polymorphism in the prothrombin gene
  1489. Influence of blood collection techniques on platelet function
  1490. D-dimer is not a long-term prognostic marker following acute cerebral ischemia
  1491. Efficacy and safety of a prothrombin complex concentrate (Octaplex®) for rapid reversal of oral anticoagulation
  1492. Hemostatic alterations in patients with acute, unilateral vestibular paresis
  1493. Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia
  1494. The hematologic system as a marker of organ dysfunction in sepsis
  1495. Effect of Nigella sativa on blood hemostatic function in rats
  1496. Thromboelastograph in cardiac surgery: state of the art
  1497. Antiphospholipid syndrome in an eight‐month‐old infant with sickle cell trait
  1498. Mouse Models for Arterial Thrombosis: Does Clotting Make a Difference in Human Cardiovascular Disease?
  1499. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin …
  1500. Prenatal screening for thrombophilia: the background and the approach
  1501. Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model
  1502. Anticoagulant therapy for acute lung injury or pneumonia
  1503. Coagulation inhibition for sepsis
  1504. Thrombosis and cancer
  1505. Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: Results from the thrombolysis in …
  1506. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment
  1507. The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis
  1508. Prothrombin 20210 mutation (factor II mutation)
  1509. The causes of coagulopathy are multiple and can be classified into congenital and acquired causes as follows
  1510. Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications
  1511. High-dose antithrombin therapy for sepsis: mechanisms of action
  1512. Effect of cyclosporine A on total homocysteine level in a rabbit model
  1513. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia
  1514. The anatomy of the kidney and ureter
  1515. Qualitative platelet disorders
  1516. Linking the sepsis triad of inflammation, coagulation, and suppressed fibrinolysis to infants
  1517. Multiorgan failure due to rapid occlusive vascular disease in antiphospholipid syndrome: the ‘catastrophic’antiphospholipid syndrome
  1518. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies
  1519. The immunopathogenesis of sepsis in elderly patients
  1520. Targeting the coagulation cascade in sepsis: Did we find the “magic bullet”?
  1521. A cutaneous manifestation of antiphospholipid antibody syndrome
  1522. CME REVIEWARTICLE
  1523. Pathogenesis of increased risk of thrombosis in cancer
  1524. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole …
  1525. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell …
  1526. The anti‐inflammatory actions of antithrombin–a review
  1527. Factor V Leiden: association with venous thromboembolism in pregnancy and screening issues
  1528. Tumor necrosis factor-α is associated with increased protein C activation in nonobese type 2 diabetic patients
  1529. Novel therapeutic agents in the management of hemorrhage and thrombosis
  1530. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes
  1531. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial
  1532. The contact system
  1533. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)
  1534. Liver transplant surgery and transfusion
  1535. Evaluation of Plasma Protein C Antigen, Protein C Activity and Thrombomodulin Levels in Type 2 Diabetic Patients
  1536. Prevention of endothelial cell injury by activated protein C: the molecular mechanism (s) and therapeutic implications
  1537. Beyond sepsis: activated protein C and ischemia–reperfusion injury
  1538. Treatment of the Antiphospholipid Syndrome
  1539. Sepsis in adults and foals
  1540. Percutaneous mechanical thrombectomy: a new approach in the treatment of acute renal‐vein thrombosis
  1541. Hepatic Veno-Occlusive Disease
  1542. Static and dynamic assessment of biomarkers in surgical patients with severe sepsis
  1543. Sepsis and coagulation
  1544. Hyperhomocysteinemia in patients with Cushing’s syndrome
  1545. Prevalence of hereditary factors predisposing to thrombosis in 260 patients diagnosed as thrombosis and investigated at Hospital Israelita Albert Einstein, São …
  1546. Tissue factor as an evolutionary conserved cytokine receptor: Implications for inflammation and signal transduction
  1547. Bidirectional relation between inflammation and coagulation
  1548. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature
  1549. Budd‐Chiari syndrome as the first manifestation of polycythemia vera in young women with inherited thrombophilic state: an aggressive form of myeloproliferative …
  1550. Thrombophilic risk factors and homocysteine levels in Behçet’s disease in eastern Spain and their association with thrombotic events
  1551. Increased circulating platelet–leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count
  1552. Impaired factor XIIa–dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications
  1553. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome
  1554. LDL and cAMP cooperate to regulate the functional expression of the LRP in rat ovarian granulosa cells
  1555. Up-regulation interleukin-6 and interleukin-8 by activated protein C in lipopolysaccharide-treated human umbilical vein endothelial cells
  1556. Basic mechanisms of hemostasis
  1557. 19 Treatment of the Antiphospholipid
  1558. Effects of estrogen and selective estrogen receptor modulators on hemostasis and inflammation: potential differences among drugs
  1559. Risk factors for venous thromboembolism in children
  1560. The complexity of treatment with warfarin
  1561. Radiation toxicity and proteinase‐activated receptors
  1562. Venous thrombosis: the role of genes, environment, and behavior
  1563. Oral anticoagulants in development
  1564. Activated Partial Thromboplastin Time (APTT) Testing
  1565. HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: When Heparin Causes Thrombosis: Significance, Recognition, and Management of Heparin‐Induced …
  1566. Tissue factor pathway inhibitor does not influence inflammatory pathways
  1567. The blood coagulation mechanism in multiple myeloma
  1568. Probing the Hirudin−Thrombin Interaction by Incorporation of Noncoded Amino Acids and Molecular Dynamics Simulation,
  1569. Hemostasis in chronic renal failure
  1570. Lepirudin Dose Recommendations for Treatment of Heparin-Induced Thrombocytopenia in Patients Undergoing Intermittent Hemodialysis
  1571. Genetic analysis of plasma von willebrand factor antigen levels as a risk factor for arterial and venous thrombosis
  1572. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation
  1573. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day …
  1574. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis
  1575. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation
  1576. Low levels of protein C are associated with poor outcome in severe sepsis
  1577. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure
  1578. The Acute Dialysis Quality Initiative—part VI: access and anticoagulation in CRRT
  1579. The diagnosis and prognosis of pulmonary embolism
  1580. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C
  1581. Altered blood coagulation in patients with posttraumatic stress disorder
  1582. Hypercoagulability: too many tests, too much conflicting data
  1583. Update on diagnosis and management of essential thrombocythemia
  1584. Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies
  1585. Homocysteine and arterial disease: experimental mechanisms
  1586. Abdominoplasty: Thromboembolic risks for both sexes
  1587. Which antiphospholipid antibody tests are most useful?
  1588. Coagulation disorders in patients with cirrhosis and severe sepsis
  1589. Genetic variations of the hemostatic system as risk factors for venous and arterial thrombotic disease
  1590. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation
  1591. Antiphospholipid syndrome
  1592. Selective inhibition of coagulation factors: advances in antithrombotic therapy
  1593. Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment
  1594. Extrahepatic portal vein obstruction
  1595. Cerebral ischemic events after diagnosis of mitral valve prolapse: a community-based study of incidence and predictive factors
  1596. Heparin‐induced thrombocytopenia during renal replacement therapy
  1597. Anticoagulation options for pediatric hemodialysis
  1598. Protein C pathway in infants and children
  1599. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation
  1600. Bleeding disorders in pregnancy
  1601. FGFR3 DYSREGULATION AND CLINICAL OUTCOME IN MYELOMA
  1602. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT)
  1603. Quality of life and the duration of treatment with vitamin K antagonists in patients with deep venous thrombosis
  1604. Consumption coagulopathy
  1605. Protein C levels in severe sepsis
  1606. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia
  1607. Activated protein C and sepsis
  1608. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebo-controlled, double-blind study in …
  1609. Disseminated intravascular coagulation
  1610. Veno-occlusive disease of the liver in renal transplant patients
  1611. Spectrum and classification of inflammatory demyelinating diseases of the central nervous system
  1612. Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders
  1613. Risk factors for thromboembolism in teens: when should I test?
  1614. Coagulation interventions in experimental human endotoxemia
  1615. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders
  1616. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury
  1617. The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia–reperfusion injury
  1618. Paraoxonase 192 Gln→ Arg Polymorphism
  1619. Thrombophilia: A new potential risk factor for cervical insufficiency
  1620. Animal models to study adult stem cell-derived, in vitro-generated islet implantation
  1621. Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia
  1622. Recent strategies to overcome the hyperacute rejection in pig to human xenotransplantation.
  1623. Labor analgesia in protein S deficient patient: case report
  1624. Coagulation: consultative hemostasis
  1625. Pharmacoeconomic implications of new therapies in sepsis
  1626. Portal vein thrombosis: etiology, diagnostic strategy, therapy and management
  1627. Tissue factor pathway inhibitor in thrombosis and beyond
  1628. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis
  1629. Promoters can contribute to the elucidation of protein function
  1630. Pulmonary thromboembolism in children
  1631. Regulation of Vascular Bed–Specific Prothrombotic Potential
  1632. Development of a biohybrid lung
  1633. Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion
  1634. Advances in treating patients with severe sepsis: role of drotrecogin alfa (activated)
  1635. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes
  1636. Pathogenesis and treatment of disseminated intravascular coagulation
  1637. Antithrombin deficiency: issues in laboratory diagnosis
  1638. Bivalirudin in percutaneous coronary intervention
  1639. DEBATE-Recurrent miscarriage: Does any treatment help?
  1640. DEBATE-Recurrent miscarriage: Does any treatment help?
  1641. Antiphospholipid syndrome: multiple mechanisms
  1642. Evaluation of the marker of hypercoagulability prothrombin fragment F 1+ 2 in patients with mechanical or biological heart valve prostheses
  1643. Ultrafiltration in diuretic-resistant volume overload in nephrotic syndrome and patients with ascites due to chronic liver disease
  1644. Proteinaceous protease inhibitors: structural features and multiple functional faces
  1645. The protein C pathway
  1646. The usefulness of laboratory data in the differential diagnosis of anemia
  1647. Beneficial effect of low-molecular-weight heparin against lipopolysaccharide-induced disseminated intravascular coagulation in rats is abolished by coadministration …
  1648. Haematology in pregnancy
  1649. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size
  1650. Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver
  1651. Drotrecogin alfa (activated) in the treatment of severe sepsis
  1652. New anticoagulants
  1653. The relationship between inflammation and the anticoagulant pathway: the emerging role of endothelial nitric oxide synthase (eNOS)
  1654. The Therapeutic Use and Safety of Common Herbal Beverages
  1655. Anticoagulation strategies for treatment of ischemic stroke and antiphospholipid syndrome: case report and review of the literature
  1656. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease
  1657. UltraRapid Communication
  1658. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club
  1659. Lipid oxidation enhances the function of activated protein C
  1660. Infection and inflammation and the coagulation system
  1661. Pathogenesis and pathology of different types of xenotransplant rejection
  1662. Thrombin and protease-activated receptors in cancer
  1663. Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways
  1664. Thrombotic microangiopathic antiphospholipid syndromes: a continuum of conditions?
  1665. Chemotherapy-induced thrombosis
  1666. Coagulation and inflammation
  1667. Risk factors for cryptogenic ischaemic stroke
  1668. Bleeding disorders in renal failure
  1669. Use of anticoagulants in diagnostic laboratory investigations
  1670. Cancer and thrombosis in women
  1671. Effect of post-operative analgesia on patient morbidity
  1672. Coagulation disorders
  1673. Successful treatment of mesenterial venous thrombosis with recombinant hirudin—a report of five cases
  1674. Kruppel-Like Factor 2 (KLF2) Regulates Endothelial Thrombotic Function
  1675. Patients with inferior vena caval filters should receive chronic thromboprophylaxis
  1676. Effects of B vitamin supplementation on homocysteine levels in cardiac patients at Rush Preventive Cardiology Center
  1677. Disseminated intravascular coagulation
  1678. Olive oil and haemostasis
  1679. New therapies and vaccines for meningococcal disease
  1680. Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C, and protein S defects
  1681. The last 100 years of sepsis
  1682. Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects
  1683. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia
  1684. Management of sepsis
  1685. Comparison of hepatic coagulant, fibrinolytic, and anticoagulant functions between Banna Minipig Inbred line and humans
  1686. Anticoagulation advances: outpatient treatment of venous thrombosis
  1687. Clinical impact of novel anticoagulation strategies in sepsis
  1688. A case of membranous glomerulonephritis presenting as pulmonary embolism and acute hyperlipidaemia
  1689. Bleeding and thrombotic complications in critically ill patients with cancer
  1690. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins
  1691. Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process
  1692. Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia
  1693. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies.
  1694. Assessment of the coagulation profile in hemato-oncological patients receiving ATG-based conditioning treatment for allogeneic stem cell transplantation
  1695. Pathogenesis of thrombosis in patients with malignancy
  1696. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery
  1697. French maritime pine bark extract Pycnogenol dose-dependently lowers glucose in type 2 diabetic patients
  1698. Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin
  1699. Beyond antibody-mediated rejection: hyperacute lung rejection as a paradigm for dysregulated inflammation
  1700. Heparin attenuates symptoms and mast cell degranulation induced by AMP nasal provocation
  1701. RETRACTED ARTICLE: Influence of different volume replacement strategies on inflammation and endothelial activation in the elderly undergoing major abdominal …
  1702. Antithrombotic agents in the treatment of severe sepsis
  1703. Coagulation for the clinician
  1704. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis
  1705. Tissue factor pathway inhibitor in thrombosis and beyond: role of heparin
  1706. Effects of intravenous infusion of highly purified vitamin B2 on lipopolysaccharide-induced shock and bacterial infection in mice
  1707. Assessment of hemostatic risk factors in predicting arterial thrombotic events
  1708. Pathogenesis of thrombosis in cancer
  1709. Homocysteine plasma concentration is related to severity of lung impairment in scleroderma.
  1710. Homocysteine and neuropsychiatric disorders
  1711. Avoiding hepatic veno-occlusive disease: what do we know and where are we going?
  1712. Low molecular weight heparins in special populations
  1713. Prothrombotic states in HIV disease and stroke complications
  1714. Liver failure, transplantation, and critical care
  1715. Low‐Molecular‐Weight Heparins in Thrombosis and Cancer: Emerging Links
  1716. Predictive value of circulating oxidized LDL for cardiac events in type 2 diabetic patients with coronary artery disease
  1717. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis
  1718. Porcine hematopoietic cell xenotransplantation in nonhuman primates is complicated by thrombotic microangiopathy
  1719. Pro: Antifibrinolytics are safe and effective in patients undergoing liver transplantation
  1720. Laboratory issues in diagnosing abnormalities of protein C, thrombomodulin, and endothelial cell protein C receptor
  1721. Evolution, innate immunity and the pathogenesis of septic shock
  1722. Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with …
  1723. Calciphylaxis associated with acute, reversible renal failure in the setting of alcoholic cirrhosis
  1724. Adult respiratory distress syndrome
  1725. Antithrombin III prevents early pulmonary dysfunction after lung transplantation in the dog
  1726. The cerebrovascular risks associated with tamoxifen use
  1727. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality …
  1728. Haemostatic alterations in colorectal cancer: perspectives for future treatment
  1729. Oral administration of geranylgeranylacetone improves survival rate in a rat endotoxin shock model: administration timing and heat shock protein 70 induction
  1730. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?
  1731. Effect of all‐trans‐Retinoic acid on the hypercoagulable state of patients with breast cancer
  1732. Thrombophilias and recurrent pregnancy loss
  1733. Antiphospholipid syndrome: current diagnostic and therapeutic issues; answers to 6 clinical questions about a complex disorder
  1734. The gene expression profile of human umbilical vein endothelial cells stimulated with lipopolysaccharide using cDNA microarray analysis
  1735. Pasteurization of antithrombin without generation of the prelatent form of antithrombin
  1736. Subsets of the Antiphospholipid Syndrome
  1737. The mechanisms of thrombotic risk induced by hormone replacement therapy
  1738. Gabexate mesilate, a synthetic protease inhibitor, attenuates carbon tetrachloride-induced liver injury in rats
  1739. Preventing warfarin-related bleeding
  1740. Oral anticoagulant therapy in venous thromboembolism
  1741. Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis
  1742. Noncirrhotic portal hypertension and portal vein thrombosis
  1743. Coagulopathic States
  1744. INHERITED THROMBOPHILIA AND RECURRENT PREGNANCY LOSS
  1745. Unfractionated heparin: focus on a high‐alert drug
  1746. Recombinant factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential
  1747. Separation of latent, prelatent, and native forms of human antithrombin by heparin affinity high-performance liquid chromatography
  1748. Inherited thrombophilia
  1749. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future …
  1750. A Filipino patient with fulminant type 1 diabetes
  1751. Speculum medicinae: reflections of a medievalist-clinician
  1752. Structural and functional consequences of methionine oxidation in thrombomodulin
  1753. Evaluation of anticoagulant system in Turkish children with Perthes disease
  1754. Antiphospholipid antibodies induce monocyte chemoattractant protein-1 in endothelial cells
  1755. Haemostatic function and cerebrovascular disease
  1756. Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment
  1757. Antiphospholipid syndrome
  1758. Hemostatic abnormalities
  1759. Speculum medicinae: Reflections of
  1760. The effects of ultrafiltration on e-Aminocaproic acid: An in vitro analysis
  1761. Characterization of a mouse model for thrombomodulin deficiency
  1762. Case 1—2005: Cardiac surgery in congenital afibrinogenemia with thrombo-occlusive disease
  1763. Endothelial cell heterogeneity
  1764. Autoimmune process participation in the oral pathologies
  1765. The spleen of a specially adapted mammal, the little hairy armadillo Chaetophractus vellerosus,(Xenarthra, Dasypodidae). A light and electron microscopic …
  1766. Urinary trypsin inhibitor reduces LPS-induced hypotension by suppressing tumor necrosis factor-α production through inhibition of Egr-1 expression
  1767. BIRD SCHISTOSOMES: NEW CAUSATIVE AGENT OF THE CNS INJURIES?
  1768. Thrombotic manifestations in the antiphospholipid syndrome
  1769. Antithrombotic Agents in the Management of Sepsis
  1770. Protease-activated receptors in the cardiovascular system
  1771. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics
  1772. The cancer stem cell: evidence for its origin as an injured autoreactive T cell
  1773. Thrombophilia related issues in women and children
  1774. Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine …
  1775. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life
  1776. Coagulation Abnormalities in Critical Illness
  1777. THE ANTIPHOSPHOLIPID SYNDROME: PATHOGENESIS AND IMPLICATIONS FOR SYSTEMIC LUPUS ERYTHEMATOSUS
  1778. El Bazo de un Mamífero con Adaptaciones Especiales: el” Peludo Chico” Chaetophractus vellerosus,(Xenarthra, Dasypodidae). Estudio con Microscopía de …
  1779. Rapid-SF: a rapid whole-blood screen for soluble fibrin monomer
  1780. 4-2. Fundamental Concepts in the Pharmacokinetics and Pharmacodynamics of Antithrombotic Agents
  1781. Anaesthetic implications of anticancer chemotherapy
  1782. The epidemiology and clinical pathophysiology of thromboembolic disease
  1783. Role of current and emerging antithrombotics in thrombosis and cancer
  1784. Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations
  1785. Blood: principles and practice of hematology
  1786. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production
  1787. Hemorrhagic Disorders in the Surgical Patient
  1788. Drugs affecting the coagulation process
  1789. Clinical Thrombosis Unit, Department of Haematology, Royal Perth Hospital, University of Western Australia, GPO Box X2213 Perth WA 6001, Tel: 61–9–224–2897 …
  1790. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese …
  1791. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective…
  1792. Venous thrombosis in pregnancy
  1793. Tissue factor pathway inhibitor induces expression of JUNB and GADD45B mRNAs
  1794. Relevance of plasma D-dimer measurement in patients with acute peripheral vertigo
  1795. Pig peripheral blood mononuclear cells are directly associated with the thrombotic microangiopathy that complicates the induction of chimerism in pig‐to‐baboon …
  1796. Antiphospholipid syndrome
  1797. Coagulation system abnormalities in human immunodeficiency virus (HIV) positive African (Black) patients with acute upper segment deep vein thrombosis (DVT) of …
  1798. Inhibition of thrombin by iopromide in vitro
  1799. Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis
  1800. Exogenous sex hormones and thrombophilia
  1801. Relationship Between the Inflammation and Coagulation Pathways in Patients with Severe Sepsis
  1802. Interplay between the hemostatic and inflammatory systems
  1803. Arterial thromboembolism in pregnancy
  1804. Biomarkers for Placental Abnormality
  1805. Protease-activated receptors
  1806. Study of Sepsis Related Changes in Platelet Adhesion, Aggregation and Angiogenic Growth Factor Release
  1807. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)
  1808. How to Implement Evidence Into Practice to Improve Diabetes Care: Response to Ilag et al.
  1809. A case-control study examining the association between travel and deep venous thrombosis
  1810. 15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes
  1811. Therapeutic applications of serine protease inhibitors
  1812. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature
  1813. Normal Physiology (short lection course for the students of dental department)
  1814. Current issues regarding tamoxifen and the genital tract: a review
  1815. Key topics in neonatology
  1816. Utility of B-Type Natriuretic Peptide as a Screen for Left Ventricular Dysfunction in Patients With Diabetes: Response to Liew et al.
  1817. Protein C replacement in severe meningococcemia: rationale and clinical experience
  1818. Comparative biochemical and pharmacological studies on heparin-derived oligosaccharides
  1819. Monogenic causes of ischemic stroke
  1820. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-α production by inhibiting activation of both nuclear factor …
  1821. Proteinase‐activated receptors (PARs) in the nervous system: Roles in neuroplasticity and neurotrauma
  1822. Plasminogen activation, fibrinolysis, and cell proteolytic activity in antiphospholipid syndrome
  1823. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure
  1824. New treatments for antiphospholipid syndrome
  1825. The pathogenetic role of apoptosis in hypercoagulable states
  1826. Hypoalbuminemia in the Patient with Renal Disease: Its Causes and Consequences
  1827. Critical care clotting catastrophies
  1828. Dissertation Submitted In Partial Fulfillment Of The
  1829. Quand évoquer un syndrome myéloprolifératif en pathologie vasculaire?
  1830. Factor VIII expression in azoxymethane-induced murine fulminant hepatic failure
  1831. The role of evidence-based medicine in the management of critically ill patients
  1832. Primary’,’Secondary’,’Seronegative’,’Catastrophic’and other Subsets of the Antiphospholipid Syndrome
  1833. Cobalamin and Folate Deficiency and their Relation to Activated Protein C Resistance as Risk Factors for Thrombosis in Diabetic Patients
  1834. The Last 100 Years of Sepsis
  1835. Coordinated increase in albumin, fibrinogen, and muscle protein synthesis during hemodialysis: role of cytokines
  1836. Acute respiratory tract infections and (athero) thrombotic disease
  1837. Thromboembolic complications in children with cancer
  1838. deduced that they represented excess a chains
  1839. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays
  1840. Clinical developments for treating ARDS
  1841. Effects of antithrombin III on myeloperoxidase activity, superoxide dismutase activity, and malondialdehyde levels and histopathological findings after spinal cord …
  1842. Vascular function in hemostasis
  1843. Use of Heparin Preparations in Older Patients
  1844. A Novel Approach to Cancer Treatment
  1845. 6 VENOUS THROMBOEMBOLISM
  1846. P Clark, M Greaves, ID Walker, P Langhorne, I Brenkel, L Regan and IA Greer
  1847. Non Endoscopic Predictors of Oesophageal Varices in Patients with Cirrhosis of the Liver
  1848. THE EXPRESSION OF THROMBOMODULIN, TISSUE FACTOR, TISSUE FACTOR PATHWAY INHIBITOR AND ENDOTHELIAL PROTEIN C RECEPTOR IN NORMAL …
  1849. Haemostatic studies in subarachnoid haemorrhage
  1850. Tamoxifen Induces Hypoxia in MCF-7 Xenografts’
  1851. Sugar Shock!: How Sweets and Simple Carbs Can Derail Your Life, and how You Can Get Back on Track
  1852. Prevalence of antiphospholipid syndrome in Sudanese women with recurrent miscarriage
  1853. Human Physiology: Lectures
  1854. Procoagulant activity of adherent platelets
  1855. Molecular and structural analysis of human Factor X deficiency
  1856. Aetiology and treatment of venous thromboembolism
  1857. The importance of platelets and complement in material-induced leukocyte activation in vitro
  1858. Anticoagulation in severe sepsis and the multiple organ dysfunction syndrome
  1859. Antithrombotic agents under flow conditions
  1860. General practitioners’ reasons for not participating in a pharmacy-initiated randomized comparison of community pharmacy and physician-based warfarin …
  1861. 11. Excretion/Secretion, Ionic and Osmotic Regulation
  1862. Cardiovascular disease in systemic lupus erythematosus
  1863. THERAPEUTIC ENZYMES
  1864. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
  1865. Vascular regulation of hemostasis and fibrinolysis: with special focus on vein graft disease
  1866. Safety issues surrounding the use of aromatase inhibitors in breast cancer
  1867. Fibrinogen Vlissingen/Frankfurt IV: Studies with recombinant fibrinogen and gene-targeted mice
  1868. 36 Annexins in Antiphospholipid Syndrome
  1869. Essential Thrombocythaemia: Diagnosis, Prognostic Aspects, and the Outcome of Finnish patients
  1870. DISSEMINATED INTRAVASCULAR
  1871. Urinary vitamin E metabolites in sepsis using tandem mass spectrometry
  1872. Blueprints Notes and Cases, Pharmacology
  1873. Hypercoaugulability
  1874. Obstetric Anaesthesia
  1875. Somatostatin receptor-mediated negative modulation of HER2 phosphorylation, signaling, and in vitro invasive potential in breast cancer
  1876. Atherosclerosis; aspects of a multicultural disease
  1877. Identifying nutritional and life-style risk factors associated with the development of osteoporosis in women of Asian origin at the Aga Khan University Hospital, Nairobi …
  1878. Haemostatic variables in African adolescents: the PLAY study
  1879. Analysis of membrane dependent reactions in blood coagulation: Comparison of factor VIIa variants with enhanced membrane affinity
  1880. Measurement of venous blood flow using photoplethysmography.
  1881. The case records and commentaries in obstetrics and gynaecology
  1882. Beyond heparin and warfarin: the new generation of anticoagulants
  1883. Basic mechanisms and pathogenesis of venous thrombosis
  1884. Hemostasis and inflammation: two of a kind?
  1885. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of …
  1886. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function
  1887. Deep vein thrombosis in patients with advanced liver cirrhosis: a rare condition?
  1888. A review of pulmonary coagulopathy in acute lung injury, acute respiratory distress syndrome and pneumonia
  1889. Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection
  1890. Plasma-coagulation hemostasis in physically active subjects during adaptation to physical exercise
  1891. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats
  1892. Coagulant and fibrinolytic status in tuberculous meningitis
  1893. The physiopathology of the catastrophic antiphospholipid (Asherson’s) syndrome: compelling evidence
  1894. Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature
  1895. Incidence and risk factors for venous thromboembolism
  1896. Venous thromboembolism: a public health concern
  1897. Clinical significance of anticoagulant proteins detection in patients with thrombotic events
  1898. Hemostatic changes in patients with type 2 diabetes mellitus
  1899. Deficiencies of proteins C, S and antithrombin and activated protein C resistance–their involvement in the occurrence of arterial thromboses
  1900. Protein Z g-42a variant and the risk of pregnancy-related venous thromboembolism in a cohort of Italian patients
  1901. Effective hemostasis during minor surgery in a case of hereditary combined deficiency of vitamin K-dependent clotting factors
  1902. Sepsis, coagulation, and antithrombin: old lessons and new insights
  1903. Antithrombin-III as a non-invasive marker of chronic liver disease
  1904. Hereditary combined deficiency of the vitamin K-dependent clotting factors
  1905. Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy: correlations with PAI-1 and t-PA plasma levels
  1906. Modern concepts of the diagnosis and treatment of purpura fulminans
  1907. A novel mechanism of thrombosis in antiphospholipid antibody syndrome
  1908. The epidemiology of venous thromboembolism in the community: implications for prevention and management
  1909. Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity
  1910. Haemostasis impairment in patients with obstructive jaundice
  1911. Thrombophilia risk factors are associated with intrauterine foetal death and pregnancy‐related venous thromboembolism
  1912. Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus
  1913. Synthetic and naturalpeptides as antithrombotic agents—a view on the current development
  1914. Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats
  1915. Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies
  1916. Catastrophic cerebral antiphospholipid syndrome presenting as cerebral infarction with haemorrhagic transformation after sudden withdrawal of warfarin in a patient …
  1917. Hemostasis and thrombosis in critically ill patients
  1918. Laboratory testing in disseminated intravascular coagulation
  1919. Management and investigation of neonatal thromboembolic events: genetic and acquired risk factors
  1920. Therapeutic consequences of thrombophilic testing
  1921. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin
  1922. Risk factors analysis in 672 hospitalized patients with venous thromboembolism
  1923. Genetic Risk Factors of Thrombosis.
  1924. Warfarin and calcific uremic arteriolopathy
  1925. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit
  1926. naturalheparinoids isolated from Halymenia sp.(Rhodophyceaes) delivery on the Ceará coast.
  1927. Emerging anticoagulant drugs
  1928. Low levels of protein C and antithrombin III could suggest the presence of microcirculatory dysfunction and predict the severity of sepsis and the appearance of …
  1929. Neutral styrene divinylbenzene copolymers for adsorption of toxins in liver failure
  1930. Activated protein C resistance test using factor VIII-deficient plasma: A new approach to the venous thrombotic risk?
  1931. Alterations of coagulation in metformin intoxication
  1932. New anticoagulants: a replacement for coumadin, heparin?
  1933. Past and future of genetic research in thrombosis
  1934. Antithrombin, Protein C, Protein S and Activated Protein C Resistance in the General Healthy Chinese Population: Normal Plasmatic Ranges and Genetic …
  1935. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature
  1936. Unexpected outcome (positive or negative) including adverse drug reactions: Catastrophic cerebral antiphospholipid syndrome presenting as cerebral …
  1937. General Introduction and Outline of the Thesis
  1938. Alterations in serum prothrombotic markers induced by treatment with bevacizumab-based chemotherapy regimens
  1939. Inhibitors of coagulation and severe sepsis.
  1940. Use of Autoplasma in the Prevention of Venous Thromboses during Endoprosthetic Replacement of the Hip Joint
  1941. < The> effect of genetically related risk factors on the recurrence rate of acute pulmonary embolism in a tertiary teaching hospital in Jordan
  1942. Inherited thrombophilia is associated with pregnancy losses that occur after 12th gestational week in Serbian population
  1943. Protein C and Protein S Levels Are Correlated with Bleeding Symptoms In Thai Population.
  1944. Portal vein thrombosis and thrombophilia in liver cirrhosis: a role for hyperhomocysteinemia?
  1945. The Mechanism of Protein S as An Anticoagulant Independent of Activated Protein C.
  1946. Analysis of Ordering Practice of Thrombophilia Testing at a Single Large Teaching Hospital
  1947. Genetics of venous thrombosis
  1948. Diagnostic algorithm for thrombophilia screening
  1949. Establishment of reference intervals for kaolin-activated thromboelastography in dogs including an assessment of the effects of sex and anticoagulant use
  1950. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests
  1951. Laboratory investigation of thrombophilia: the good, the bad, and the ugly
  1952. Tissue Factor− 1208D> I Polymorphism Is Associated with D-dimer Levels in Patients with Inflammatory Bowel Disease
  1953. GlideScope® intubation assisted by fiberoptic scope
  1954. Venous thromboembolism and cancer: a systematic review
  1955. ANTICOAGULANT SYSTEM ACTIVITY IN SPLENECTOMIZED VERSUS NON-SPLENECTOMIZED IRANIAN PATIENTS WITH β-THALASSEMIA MAJOR
  1956. Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease
  1957. Long-term stability of coagulation variables: protein S as a biomarker for preanalytical storage-related variations in human plasma
  1958. Thrombolysis in antiphospholipid syndrome: current hematologic perspectives
  1959. Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game
  1960. Ultrasonography May Help Guide Decisions to Discontinue Anticoagulation Therapy for Deep Venous Thrombosis
  1961. Low level of factor V is associated with development of deep-vein thrombosis in Japanese patients
  1962. Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection
  1963. Practical hemostasis and thrombosis
  1964. Case reports of the use of immunoadsorption or plasma exchange in high‐risk pregnancies of women with antiphospholipid syndrome
  1965. Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome
  1966. Growth arrest-specific gene 6 (GAS6)
  1967. Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature
  1968. Effects of leptin replacement on risk factors for cardiovascular disease in genetically leptin-deficient subjects
  1969. Trombosis mesentérica y déficit de proteínas C y S en un paciente con hepatitis C crónica en tratamiento con interferón y ribavirina
  1970. 299: The Relation Between the Frequency of Presence of Thrombophilia and Thromboembolic Complications After Allogeneic Hematopoietic Cell Transplantation …
  1971. 300: Once Daily Busulfan Cyclophosphamide is Well Tolerated and Effective Prior to Allogeneic Hematopoietic Stem Cell Transplantation
  1972. Adjunctive therapies for severe sepsis
  1973. Elevated Red Cell Microparticles (RMP) as Risk Factor for Thrombosis in Patients with Renal Failure.
  1974. Endotoxemia alters nucleotide hydrolysis in platelets of rats
  1975. Assessment of hypercoagulability markers and lipid levels in postmenopausal women undergoing either oral or transdermal hormone replacement therapy
  1976. Snakebite-induced coagulopathy and bleeding disorders
  1977. Clinical review: patency of the circuit in continuous renal replacement therapy
  1978. Antithrombin Inhibits Bronchoalveolar Activation of Coagulation and Limits Lung Injury during
  1979. Editorial [Hot Topic: Sepsis (Guest Editor: David E. Joyce)]
  1980. Antiphospholipid antibodies and syndromes: relevance for the GP
  1981. Medical Journal Watch: Context and Applications
  1982. Hypercoagulable state, pathophysiology, classification and epidemiology
  1983. The coagulant response in sepsis and inflammation
  1984. Hereditary thrombophilic risk factors for recurrent pregnancy loss
  1985. Hypercoagulability after trauma: hemostatic changes and relationship to venous thromboembolism
  1986. Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea
  1987. Clinical variability of haemophilia A and B in Mexican families by factor V Leiden G1691A, prothrombin G20210A and MTHFR C677T/A1298C
  1988. A novel mutation (g2172→ c) in the factor V gene in a Chinese family with hereditary activated protein C resistance
  1989. Outcome of pregnancies in women with thrombophilic disorders
  1990. Combined hormonal contraceptive use during the postpartum period: 26 January 2010, Geneva, Switzerland: statement
  1991. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium—a register-based case-control study
  1992. A Tribute to Eberhard F. Mammen, MD (1930–2008)
  1993. Testing for Inherited and Acquired Thrombotic Disorders
  1994. 35 Drugs affecting blood coagulation, fibrinolysis, and hemostasis
  1995. Antibodies to heparin–platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis
  1996. Guidelines for the diagnosis and management of disseminated intravascular coagulation
  1997. Effects of exposure to air pollution on blood coagulation
  1998. Association of high tidal volume with postpneumonectomy failure
  1999. Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose …
  2000. Does thrombophilia testing help in the clinical management of patients?
  2001. Vascular thrombosis associated with aprotinin and deep hypothermic circulatory arrest: Where are we in 2006?
  2002. Oral contraception and thrombophilia
  2003. ANTITHROMBIN LEVELS IN HEALTHY PAKISTANI MALES
  2004. Thrombophilic factors in idiopathic intracranial hypertension: a report of 51 patients and a meta-analysis
  2005. MORTALITY IN OUTXOFXHOURS EMERGENCY MEDICAL ADMISSIONS
  2006. Association of High Tidal Volume with Postpneumonectomy Failure
  2007. Impact of Terlipressin on Hepatosplanchnic Perfusion:“Only the Dose Makes a Thing Not a Poison”(Paracelsus)
  2008. Risk factors for umbilical venous catheter‐associated thrombosis in very low birth weight infants
  2009. Prevention and Treatment of Bruising
  2010. Thrombin physiology and pathophysiology
  2011. Sulfated polysaccharide purified from Ecklonia cava accelerates antithrombin III-mediated plasma proteinase inhibition
  2012. The relationship between insulin resistance and hypercoagulability in acute ischemic stroke
  2013. Survival Patterns Without Cardiac Surgery or Interventional Catheterization: A Narrowing Base
  2014. Look on the “air side” in pneumonia
  2015. Altered reference ranges for protein C and protein S during early pregnancy: Implications for the diagnosis of protein C and protein S deficiency during pregnancy
  2016. Fibrinolytic system of the armadillo Chaetophractus villosus (Xenarthra, Dasypodidae)
  2017. The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome
  2018. Venous thrombosis in the elderly
  2019. Thrombophilic conditions in the adolescent: the gynecologic impact
  2020. Haemostasis and thrombosis in liver disease
  2021. Haemostatic changes and acquired activated protein C resistance in normal pregnancy
  2022. Sepsis, coagulation and anticoagulants
  2023. Hypercoagulation testing in ischemic stroke
  2024. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade
  2025. Retroperitoneal hemorrhagic shock in a patient on warfarin therapy
  2026. Blood coagulation in falciparum malaria—a review
  2027. Is Familial Mediterranean Fever a thrombotic disease or not?
  2028. Genetic basis of thrombosis
  2029. Cerebral Hemodynamics in Asymptomatic Patients with Sickle Cell Disease and Thalassemia: Correlation with Hemostatic State
  2030. Coagulopathy in liver diseases
  2031. Venous thromboembolism and ethnicity
  2032. Asparaginase‐related venous thrombosis in UKALL 2003‐re‐exposure to asparaginase is feasible and safe
  2033. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients
  2034. Platelets, frozen plasma, and cryoprecipitate: what is the clinical evidence for their use in the neonatal intensive care unit?
  2035. Hemostasis factors and aging
  2036. A Young Man with Chest Pain Following a Knee Injury
  2037. Family history as a risk factor for venous thromboembolism
  2038. Chemotherapy-induced hemostatic activation and thrombosis in cancer
  2039. 17 Diagnosis and Management of Disseminated Intravascular Coagulation
  2040. Thromboelastometry in patients with severe sepsis and disseminated intravascular coagulation
  2041. Tissue factor and its measurement in whole blood, plasma, and microparticles
  2042. Thrombin in myocardial ischemia-reperfusion during cardiac surgery
  2043. Laboratory reporting of hemostasis assays: the final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis?
  2044. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double …
  2045. Haemostatic problems in liver surgery: A review
  2046. Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury
  2047. Venous thromboembolism in women taking hormonal contraceptives
  2048. The psychological impact of testing for thrombophilia: a systematic review
  2049. Thrombelastography
  2050. Early coagulation disorders after severe burn injury: impact on mortality
  2051. Haemostasis
  2052. Effects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women
  2053. Haplotype M2 in the annexin A5 (ANXA5) gene and the occurrence of obstetric complications
  2054. Pleading for the routine introduction in the investigation of the late spontaneous abortion etiology of the exploration of resistance to activated C protein along …
  2055. Effects of nucleotides and nucleosides on coagulation
  2056. Thrombophilia: grading the risk
  2057. Effect of corticosteroids on hemostasis and pulmonary arterial pressure during chronic obstructive pulmonary disease exacerbation
  2058. Global hemostasis in pregnancy: are we using thromboelastography to its full potential?
  2059. A cell-based model of coagulation and its implications
  2060. Protein C concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy: a pilot study
  2061. Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C
  2062. Use of complementary and alternative medicine among adults with skin disease: results from a national survey
  2063. 24 Obstetrics, contraception, and estrogen replacement
  2064. The two tales of coagulation in liver transplantation
  2065. Thrombophilia-A clinical approach to thrombophilia testing
  2066. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents
  2067. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo
  2068. Less benefit from warfarin in diabetics after myocardial infarction?
  2069. The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia
  2070. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings
  2071. Advances in pathogenesis and management of sepsis
  2072. Hemorrhagic complications in pediatric hematologic malignancies
  2073. Thrombophilic variables do not increase the generation or procoagulant activity of thrombin during cardiopulmonary bypass
  2074. Pharmacological treatments for acute respiratory distress syndrome
  2075. Coagulation in pregnancy
  2076. Oral Contraception and Thrombophilia
  2077. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage
  2078. Statins for community-acquired pneumonia: current state of the science
  2079. Management of recurrent thrombosis in liver transplant recipients: a case report
  2080. Improved body mass index after mesenterico-portal bypass
  2081. Hemostasis and ageing
  2082. Hypercoagulability in sickle cell disease and beta-thalassemia
  2083. Association between factor V Leiden mutation and poor pregnancy outcomes among Palestinian women
  2084. Pancreas allograft thrombosis
  2085. Hemodynamic disorders
  2086. Portal vein thrombosis
  2087. Thrombophilia and venous thromboembolism: implications for testing
  2088. Cancer and thrombosis: an increasingly important association
  2089. Prothrombotic factors and the risk of acute onset non-cardioembolic stroke in young Asian Indians
  2090. Late onset ulcerative colitis complicating a patient with Budd–Chiari syndrome: a case report and review of the literature
  2091. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa …
  2092. Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment
  2093. The role of bronchoalveolar hemostasis in the pathogenesis of acute lung injury
  2094. Impaired binding of thrombin to thrombomodulin is associated with risk of deep vein thrombosis
  2095. The epidemiology of venous thromboembolism in the community
  2096. Effects of anticoagulant strategies on activation of inflammation and coagulation
  2097. Lipoprotein (a) levels in childhood arterial ischemic stroke
  2098. Cytokine gene variants and venous thrombotic risk in the BRATROS (BRAZILIAN THROMBOSIS STUDY)
  2099. Inflammation and hemostasis: a bidirectional interaction
  2100. Thrombophilia and pregnancy complications: cause or association?
  2101. Developing a public health research agenda for women with blood disorders
  2102. Management of pregnant women with thrombophilia or a history of venous thromboembolism
  2103. Coagulation and anticoagulation in acute lung injury, pneumonia, and ventilator-associated lung injury
  2104. Risk assessment for recurrent venous thrombosis
  2105. Transgenic mouse models of venous thrombosis: fulfilling the expectations?
  2106. Calculation of chemical equilibria in CaCl2-heparin-sodium adenosinetriphosphate and MgCl2-heparin-sodium adenosinetriphosphate systems in physiological …
  2107. Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome
  2108. Pathogenesis of venous thromboembolism in cancer
  2109. BEHÇET HASTALIĞINDA TROMBOFİLİK FAKTÖRLER VE KLİNİK BULGULARLA BİRLİKTELİĞİ
  2110. Microvascular thrombosis in sepsis and septic shock: an autopsy study
  2111. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation
  2112. The hemostatic system through aging and menopause
  2113. Intrahepatic portal cavernoma as an indication for liver transplantation
  2114. The paraoxonase gene polymorphism in stroke patients and lipid profile
  2115. Cerebral venous sinus thrombosis in an adolescent with Ewing sarcoma
  2116. Increased Plasma and Optic Nerve Levels of IL-6, TNF-α, and MIP-2 Following Induction of Ischemic Optic Neuropathy in Mice
  2117. Miscellaneous b leeding d isorders
  2118. #ERROR!
  2119. Combined thrombophilia and obstetric complications
  2120. Subject Index Vol. 36, 2007–08
  2121. Inflammation and coagulation
  2122. Evaluation of polymer matrices for an adsorptive approach to plasma detoxification
  2123. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development
  2124. Thrombophilia
  2125. The prevalence of factor V Leiden (G1691A), prothrombin G20210A and methylenetetrahydrofolate reductase C677T mutations in Jordanian patients with β …
  2126. Haemostatic disorders in patients with breast cancer at Kenyatta national hospital, Kenya
  2127. Thrombophilia screening or screaming
  2128. An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: The Women’s Genome Health Study
  2129. Thrombotic risk factors: basic pathophysiology
  2130. Antithrombotic therapy in children with venous thromboembolism
  2131. Design and synthesis of a candidate α-human thrombin irreversible inhibitor containing a hydrophobic carborane pharmacophore
  2132. The role of coagulation in arterial and venous thrombosis
  2133. Coagulopathies and thrombosis: usual and unusual causes and associations, part II
  2134. HEMATOLOGIC CONDITIONS AS CAUSE OF ISCHAEMIC STROKE IN YOUNG ADULTS.
  2135. Correlation of vascular endothelial growth factor with the severity of thalassemia intermedia
  2136. Toxicity assessment of naturaland chemical coagulants using brine shrimp (Artemia salina) bioassay
  2137. Prevalence of anticoagulant rodenticide poisoning in humans and animals in France and substances involved
  2138. Mechanisms of thrombosis related to hormone therapy
  2139. Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats
  2140. Microcirculatory endothelial dysfunction during endotoxemia-insights into pathophysiology, pathologic mechanisms and clinical relevance
  2141. Gender and inter-species influence on coagulation tests of rats and mice
  2142. Anticoagulation for acute dialysis
  2143. Pathogenesis, diagnosis, and management of disseminated intravascular coagulation: a literature review
  2144. HIV disease in thrombocardiology
  2145. Hypercoagulable State and Methylenetetra-hydrofolate Reductase (MTHFR) C677T Mutation in Patients with Beta-Thalassemia Major in Kuwait
  2146. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile
  2147. The inflammation–coagulation axis as an important intermediate pathway in acute lung injury
  2148. Etiology and naturalhistory: diagnosis and evaluation
  2149. The influence of the age in the risk of the prothrombin G20210A mutation for spontaneous venous thrombosis
  2150. Inherited thrombophilia and early pregnancy
  2151. Thrombin activatable fibrinolysis inhibitor (TAFI): A role in pre-eclampsia?
  2152. Heparin‐like effect contributes to the coagulopathy in patients with acute liver failure undergoing liver transplantation
  2153. Role of thrombophilia in adverse obstetric outcomes and their prevention using antithrombotic therapy
  2154. Risk factors for thrombophilia in young adults presenting with thrombosis
  2155. A novel splice site mutation in intron C of PROS1 leads to markedly reduced mutant mRNA level, absence of thrombin-sensitive region, and impaired secretion and …
  2156. Recombinant anticoagulant factors for adjunctive treatment of sepsis
  2157. Is there an overlap between sudden neurosensorial hearing loss and cardiovascular risk factors?
  2158. Antiphospholipid antibodies may impair factor XIIa–dependent activation of fibrinolysis in pregnancy: in vitro evidence with human endothelial cells in culture and …
  2159. Venous stasis and activation of coagulation
  2160. Blood transfusion and the anaesthetist: management of massive haemorrhage
  2161. Tissue factor pathway inhibitor [Tfpi]: a naturalcoagulation inhibitor and potential therapeutic agent–a review
  2162. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis
  2163. Rickettsiae and rickettsial infections: the current state of knowledge
  2164. The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardiovascular events
  2165. Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis
  2166. The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome
  2167. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation
  2168. Hereditary and acquired antithrombin deficiency
  2169. Activation and regulation of hemostasis in acute liver failure and acute pancreatitis
  2170. Lemierre syndrome variant: Staphylococcus aureus associated with thrombosis of both the right internal jugular vein and the splenic vein after the exploration of a river …
  2171. Thrombophilia screening–at the right time, for the right patient, with a good reason
  2172. High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait
  2173. Thrombosis in multiple myeloma
  2174. Pleural mesothelioma and venous thrombosis: the eosinophilia link
  2175. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis
  2176. Therapeutic approaches to coagulopathy in cancer patients
  2177. The protective effect of the arginine-heparin complex under simulation of insulin-dependent diabetes
  2178. Pregnancy failure and heritable thrombophilia
  2179. Gestational thrombocytopenia complicated with macrosomia, failure to progress in active labor, and postpartum hemorrhage
  2180. Sepsis and septic shock: a history
  2181. THROMBOPHILIA: THE LABORATORY ASSESSMENT AND MANAGEMENT
  2182. Ultrasonography-guided oral anticoagulant therapy reduced recurrent venous thromboembolism
  2183. Defective Fibrinolysis and Genetic or Acquired Pro-coagulant Changes Synergistically Increase the Risk of Venous Thrombosis
  2184. Low-molecular-weight heparins: what is their thera-peutic usefulness?
  2185. Subject Index Vol. 64, 2010
  2186. Genetic susceptibility to VTE: A primary care approach
  2187. Genetic variation and susceptibility to venous thrombosis: Etiology and risk assessment
  2188. Thrombophilia ad dies vitae
  2189. Traveller’s Thrombosis’–Does It Exist and Are We Ready to Give Prophylaxis?
  2190. A Case of Superior Mesenteric Vein and Portal Vein Thrombosis Associated with Normal Delivery Presented by Acute Pancreatitis
  2191. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity
  2192. Genome-wide scan in affected sibling pairs reveals two novel susceptibility regions for venous thromboembolism: The Genetics In Familial Thrombosis (GIFT) …
  2193. 301: The Impact of the Disparities of Short Tandem Repeats (STR) between Doonor-recipient Pair on the Allogeneic Hematopoietic Cell Transplantation (AHCT) …
  2194. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms
  2195. The protein C pathway: implications for the design of the RESPOND study
  2196. The association between vascular function-related genes and age at naturalmenopause
  2197. Retinal vein occlusion: pathophysiology and treatment options
  2198. Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2–dependent fibrinolysis
  2199. Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates
  2200. Massive pulmonary embolism simulating electrocardiographic pattern of Brugada syndrome
  2201. Screening, testing, or personalized medicine: where do inherited thrombophilias fit best?
  2202. Sepsis and multiple organ failure
  2203. Thrombomodulin and GFC levels in Legg–Calve–Perthes disease
  2204. Heparin and maternal fetal interface: why should it work to prevent pregnancy complications?
  2205. Pharmacological treatment of sepsis
  2206. Congenital and Acquired Hypercoagulable Syndromes
  2207. Thrombophilia and cerebral vein thrombosis
  2208. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms
  2209. Changes in cardiovascular risk factors associated with wine consumption in intervention studies in humans
  2210. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome
  2211. Predictive value of D-dimer test, persistent residual venous thrombosis, and thrombophilia for venous thromboembolism recurrence
  2212. Inherited trombophilic states and pulmonary embolism
  2213. Clinical and genetic risk factors for venous thromboembolism in Chinese population
  2214. Fiabilidad de los tests diagnósticos no invasivos en la recurrencia de la trombosis venosa profunda
  2215. rhAPC Inhibits Local and Systemic Activation of Coagulation without Influencing Inflammation during P. aeruginosa
  2216. Venous thromboembolism: risk factors for recurrence
  2217. Protein C deficiency
  2218. Update on Physiological Anticoagulant Factor Concentrates in Patients with Sepsis
  2219. Production of bioactive chitosan oligosaccharides and their potential use as nutraceuticals
  2220. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis
  2221. Coagulation, platelet activation and thrombosis in xenotransplantation
  2222. Thrombophilia and cancer
  2223. Overview of the postulated mechanisms linking cancer and thrombosis
  2224. Clinical guidelines for testing for heritable thrombophilia
  2225. A new era for oral anticoagulation? Old and new anticoagulant drugs
  2226. Role of the M2 haplotype within the annexin A5 gene in the occurrence of pregnancy-related venous thromboembolism
  2227. Tissue factor as an initiator of coagulation and inflammation in the lung
  2228. Blood coagulation as an intrinsic pathway for proinflammation: a mini review
  2229. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia
  2230. Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse
  2231. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry
  2232. Deep vein thrombosis: risks and diagnosis
  2233. Genetic susceptibility to VTE: a primary care approach
  2234. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome
  2235. Mechanisms of venous thrombosis and resolution
  2236. The clinical application of CRRT—current status: continuous renal replacement therapies in patients with liver disease
  2237. Inherited antithrombin deficiency: a review
  2238. Prophylaxis with AT III for thromboembolism in nephrotic syndrome: why should it be done?
  2239. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis
  2240. Vitamin K‐dependent actions of Gas6
  2241. Hemostatic and thrombotic markers in patients with hemoglobin E/β‐thalassemia disease
  2242. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial
  2243. Heparin oligosaccharides as potential therapeutic agents in senile dementia
  2244. Inflammation and coagulation in HIV infection contributes significantly to patient mortality
  2245. The nephrotic syndrome: an unusual case of multiple embolic events
  2246. Protein Z, a protein seeking a pathology
  2247. Venous thromboembolism in HIV-positive women during puerperium: a case series
  2248. Sex-related type of venous thromboembolism in patients with and without thrombophilia
  2249. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences
  2250. The coagulation cascade in sepsis
  2251. Enterocutaneous fistula secondary to purpura fulminans in a preterm infant
  2252. Retinal vascular disease
  2253. Epidemiology of venous thromboembolism
  2254. Polyphosphate and omptins: novel bacterial procoagulant agents
  2255. Role of recombinant human activated protein C (Drotrecogin Alfa, Activated, Xigris®) for severe sepsis
  2256. The role of thrombophilia in splanchnic vein thrombosis
  2257. Early intravenous unfractionated heparin and mortality in septic shock
  2258. Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis
  2259. Understanding haemostasis
  2260. Viral cirrhosis: an overview of haemostatic alterations and clinical consequences
  2261. Tourniquet Use Improves Varicose Vein Stripping
  2262. Molecular basis of protein S deficiency
  2263. Valporic acid: is it safe to use in epileptic pediatric patient
  2264. Thrombophilia: common questions on laboratory assessment and management
  2265. Pleural mesothelioma and venous thrombosis: the eosinophilia link.
  2266. Anticoagulation for Continuous Renal Replacement Therapy-Heparin or Citrate?
  2267. Comparative vertebrate fibrinolysis
  2268. Amyloidosis and vascular thrombosis
  2269. Type 2 diabetes mellitus and heart failure
  2270. Update on hemostasis: neurosurgery
  2271. BCR‐ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia
  2272. Diagnosis of inherited thrombophilia in pediatrics
  2273. Cross talk between the inflammation and coagulation systems
  2274. Risk factors for thrombosis in cancer patients
  2275. Biological influence of physical exercise on hemostasis
  2276. Disseminated intravascular coagulation
  2277. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy
  2278. Deep venous thrombosis in the antenatal period in a large cohort of pregnancies from western India
  2279. the mind-body configuration to disease is being stressed, the
  2280. Novel Approaches to the Treatment of Sepsis Syndrome
  2281. Anticoagulant heparan sulfate: to not clot—or not?
  2282. Death by clot: acute coronary syndromes, ischemic stroke, pulmonary embolism, and disseminated intravascular coagulation
  2283. Laboratory predictors of dengue shock syndrome during the febrile stage
  2284. Causes of venous thrombosis
  2285. Liver disease, coagulation testing, and hemostasis
  2286. Risk of future arterial cardiovascular events in patients with idiopathic venous thromboembolism
  2287. In vitro anti-bacterial activities of Ankaferd medicinal plant extract
  2288. Skin autoimmunity and blood coagulation
  2289. Durée optimale du traitement anticoagulant au décours d’un premier épisode de maladie veineuse thromboembolique
  2290. Milestones and perspectives in coagulation and hemostasis
  2291. Coagulation, Inflammation, and Tissue Remodeling
  2292. Current knowledge regarding Asherson’s syndrome
  2293. Chasing clot: thrombophilic states and the interventionalist
  2294. Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations
  2295. Hereditary and acquired thrombophilia
  2296. Antiphospholipid syndrome in dermatology: An update
  2297. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease
  2298. 12 Disseminated intravascular coagulation and other microangiopathies
  2299. The Hypercoagulable States
  2300. Pathogenesis and risk factors in retinal vein occlusions
  2301. Arterial Insufficiency
  2302. Inherited antithrombin deficiency and pregnancy: maternal and fetal outcomes
  2303. Skin necrosis induced by vitamin K antagonists
  2304. Coagulation Disorders in Acute Lung Injury
  2305. Sepsis: from bench to bedside
  2306. The role of protein C in sepsis
  2307. The promise of systems biology in clinical applications
  2308. Hemostatic dysfunction in paraproteinemias and amyloidosis
  2309. Hemodynamically driven stent strut design
  2310. The naturalHistory of Venous Thromboembolism
  2311. Oryginal article Relationship between inflammatory markers and clinical patterns of atrial fibrillation in patients with congestive heart failure
  2312. Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study
  2313. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study
  2314. Venous thrombosis in the elderly: incidence, risk factors and risk groups
  2315. Trypsin and Chymotrypsin Inhibitors in Insects and Gut Leeches: an update
  2316. Sexual dimorphism in the mandible of the armadillo Chaetophractus villosus (Desmarest, 1804)(Dasypodidae) from northern Patagonia, Argentina
  2317. Interruption of the blood supply of femoral head: an experimental study on the pathogenesis of Legg-Calve-Perthes Disease
  2318. Gene variants associated with deep vein thrombosis
  2319. Thrombohemostatic Disorder in HIV Infection
  2320. Thrombosis associated with angiogenesis inhibitors
  2321. Blood coagulation and inflammation in acute lung injury
  2322. Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys
  2323. Purpura Fulminans Due to Staphylococcus Aureus: An Emerging
  2324. Activated protein C for H1N1 influenza? More work to do!
  2325. Uncoupling of protein C and antithrombin III activity in cerebral ischemia patients associated with cutis marmorata
  2326. Heparin-induced thrombocytopenia in surgical patients
  2327. Coagulopathy of Chronic Liver Disease
  2328. Life threatening chylothorax in a patient with congenital thrombophilia: Case report
  2329. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy
  2330. Non-enzymatic glycation in diabetic complications
  2331. Venous thrombosis in patients with chronic liver disease
  2332. HYPERCOAGULATION TESTING
  2333. Cardiovascular events in patients with antiphospholipid antibodies: strategies of prevention
  2334. Thrombin-antithrombin III complex, proinflammatory cytokines, and fibrinolytic indices for assessing the severity of inflammation in pleural effusions
  2335. Modulation of sepsis outcome with variants of activated protein C
  2336. Venous thromboembolism in the neonatal period
  2337. Theories of blood coagulation
  2338. The host response to sepsis and developmental impact
  2339. Factor V Leiden homozygous genotype and pregnancy outcomes
  2340. Ocular vascular thrombotic events: a diagnostic window to familial thrombophilia (compound factor V Leiden and prothrombin gene heterozygosity) and thrombosis
  2341. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera
  2342. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma
  2343. The correspondence department ofthe Archives is meant to provide forumfor exchange
  2344. Aneurysmal frontal bone cyst in a child with history of acute lymphoblastic leukemia: a case of rare location and history
  2345. New Aspects of Antiinflammatory Activity of Antithrombin: Molecular Mechanism (s) and Therapeutic Implications
  2346. Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation
  2347. Haematology and neurology
  2348. Deep venous thrombosis in a young woman
  2349. Thrombophilia: 2009 update
  2350. Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism
  2351. How to tackle bleeding and thrombosis in the newborn
  2352. Vascular complications after splenectomy for hematologic disorders
  2353. Management of thromboembolism in hematologic malignancies
  2354. Ischaemic stroke patients with heterozygous factor V Leiden present with multiple brain infarctions and widespread atherothrombotic disease
  2355. Deep vein thrombosis and pulmonary embolism in cirrhosis patients
  2356. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations
  2357. Identifying women at high risk of venous thrombosis before administration of hormone therapy
  2358. An overview of heparin-induced thrombocytopenia
  2359. Haemostatic Issues in Cancer Development and Progression:” The Role of Coagulation and Haemostatic Factors in cancer Development and Metastasis”
  2360. Host-cell interactions with pathogenic Rickettsia species
  2361. Thrombophilia/prothrombotic disorders
  2362. Thrombophilia states and markers of coagulation activation in the prediction of pediatric venous thromboembolic outcomes: a comparative analysis with respect to …
  2363. Soluble endothelial protein C receptor level in obesity
  2364. von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report …
  2365. Postoperative care
  2366. Portal Vein and Superior Mesenteric Vein Thrombosis in Nephrotic Syndrome: A Case Report and Review of Literature
  2367. Purpura fulminans: a rare presentation of a common disease
  2368. Principles of perioperative coagulopathy
  2369. Preventing thrombophilia-related complications of pregnancy
  2370. Effects of red blood cells on hemostasis
  2371. La Hipertrofia de la Bula Timpánica en Tres Especies de Dasipódidos (Mammalia, Xenarthra) de Argentina
  2372. A model for the formation, growth, and lysis of clots in quiescent plasma. A comparison between the effects of antithrombin III deficiency and protein C deficiency
  2373. 03 Postoperative care
  2374. Sublingual administration of warfarin: a novel form of delivery
  2375. How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?
  2376. The pulmonary protein C system: preventive or therapeutic target in acute lung injury?
  2377. 298: Higher CD 34 Cell Doses Reduce Non Relapse Mortality (NRM) and do not Increase the Incidence of Graft Versus Host Disease (GVHD) following Unrelated …
  2378. Recanalization and its correlation to outcome after cerebral venous thrombosis
  2379. Randomized Controlled Trials in Sepsis
  2380. Age-related changes in fibrin networks and platelets of individuals over 75: a scanning electron microscopy study showing “thrombotic preparedness”
  2381. Venous Thromboembolism: Mechanisms, Treatment, and Public Awareness
  2382. Long-term prospective study of recurrent venous thromboembolism in a Hispanic population
  2383. The use angiogenesis stimulators for the treatment of chronic ischemia of lower extremities
  2384. Coagulation activity in liver disease
  2385. Combination of a SAW-biosensor with MALDI mass spectrometric analysis
  2386. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT
  2387. Pharmacogenetics of warfarin: current status and future challenges
  2388. TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus
  2389. In vivo effect of adhesion inhibitor heparin on Legionella pneumophila pathogenesis in a murine pneumonia model
  2390. Thrombophilias: when should we test and how does it help?
  2391. Protective effects of activated protein C in sepsis
  2392. Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications
  2393. An Update on Pathogenic Mechanisms Mediated by Antiphospholipid Antibodies.
  2394. Pathogenesis, immunity, pathology, and pathophysiology in rickettsial diseases
  2395. Pregnancy and thrombophilia
  2396. Laboratory diagnostics in septic disseminated intravascular coagulation
  2397. The effects of tamoxifen on homocysteine levels in breast cancer patients
  2398. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial
  2399. Does hemodilution by the crystalloid priming solution derange the efficacy of anticoagulation during cardiopulmonary bypass?
  2400. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?
  2401. Management of Pulmonary Embolism: 2010 State-of-the-Art Update
  2402. Once and only once
  2403. Inherited thrombophilia and the eye
  2404. Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays
  2405. Design implications for endovascular stents and the endothelium
  2406. Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia
  2407. Fondaparinux for the treatment of patients with acute heparininduced thrombocytopenia
  2408. Skin biopsies demonstrate site-specific endothelial activation in mouse models of sepsis
  2409. Oral anticoagulants: Pharmacogenetics: Relationship between genetic and non-genetic factors
  2410. Drugs affecting coagulation
  2411. The use of recombinant tissue plasminogen activator in the management of infective intracardiac thrombi in pre‐term infants with thrombocytopaenia
  2412. CLINICAL CASE
  2413. Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy
  2414. Old versus new anticoagulants: focus on pharmacology
  2415. Plasma protein C is a useful clinical marker for hepatic veno‐occlusive disease (VOD) in stem cell transplantation
  2416. Kaikov Y, Wadsworth LD, Hall CA et al.(1991) Transcobalamin II deficiency: case report and review of the literature. Eur J Pediatr 150, 841–843. Seeliger MW …
  2417. The sepsis text
  2418. Complement and coagulation: strangers or partners in crime?
  2419. Beyond unfractionated heparin and warfarin: current and future advances
  2420. Darwin, earthworms & circadian rhythms: A fertile field for science fair experiments
  2421. Influence of the factor II G20210A variant or the factor V G1691A mutation on symptomatic recurrent venous thromboembolism in children: an international multicenter …
  2422. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
  2423. Fatal pulmonary embolism in a premature neonate after twin-to-twin transfusion syndrome
  2424. Thrombohemorrhagic complications of myeloproliferative disorders
  2425. Drotrecogin alfa (activated): the treatment for severe sepsis?
  2426. Accuracy of D-dimers to rule out venous thromboembolism events across age categories
  2427. Elevated risk of thrombosis in neonates undergoing initial palliative cardiac surgery
  2428. Assessment of thrombotic risk factors predisposing to thromboembolic complications in prosthetic orthopedic surgery
  2429. Heparin-like effect in liver disease and liver transplantation
  2430. Impact of neutrophil apoptosis on haemostatic activation in chronic liver disease patients
  2431. Pulmonary embolism and fever: when should right-sided infective endocarditis be considered?
  2432. Effects of β2-glycoprotein-I on platelet aggregation in cord versus adult whole blood
  2433. FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragm in® a dded to standard t herapy in patients with lung c ancer
  2434. biology: its relevance to medicine
  2435. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies
  2436. Endothelial cell infection and hemostasis
  2437. Genetics of ischemic stroke
  2438. Quantitative changes in serum IL-8, TNF-α and TGF-β1 levels depending on compensation stage in type 2 diabetic patients
  2439. Evaluation of hypercoagulable states and molecular markers of acute venous thrombosis
  2440. Relation between coagulation/fibrinolysis and lactate in the course of human septic shock
  2441. Prothrombotic status in Myeloproliferative neoplasms: the role of JAK2V617F allele burden and platelets/leukocytes activation
  2442. THE FOLLOWING GUIDELINES ARE NOT MEANT TO REPLACE GOOD SOUND CLINICAL JUDGMENT
  2443. Perioperative coagulation profile in living liver donors as assessed by rotational thromboelastometry
  2444. CHAPTER MYOCARDIAL ISCHEMIA AND INFARCTION
  2445. Heparin-Induced thrombocytopenia (HIT): a case study
  2446. Elevated homocysteine, glutathione and cysteinylglycine concentrations in patients homozygous for the Chuvash polycythemia VHL mutation
  2447. Predictive value of thrombopath determination in women with infertility and pregnancy complications
  2448. Cocaine cardiotoxicity
  2449. 13 The Therapeutic Use and Safety of Common Herbal Beverages
  2450. Study of proinflammatory responses induced by Yersinia pestis in human monocytes using cDNA arrays
  2451. A Simple Tool to Educate Laboratory Staff About Anticoagulation
  2452. Biophysical characterization of anticoagulant hemextin AB complex from the venom of snake Hemachatus haemachatus
  2453. Hypercoagulable states
  2454. Recombinant fibrinogenase from Agkistrodon acutus venom protects against sepsis via direct degradation of fibrin and TNF-α
  2455. Evaluation of protein C in Nigerian patients with sickle cell anaemia in steady state
  2456. Antithrombin prevents reperfusion-induced hepatic apoptosis by enhancing insulin-like growth factor-I production in mice
  2457. Plasma Products and Indications for Their Use
  2458. Thromboelastographic evaluation of coagulation in patients with extrahepatic portal vein thrombosis and non‐cirrhotic portal fibrosis: a pilot study
  2459. Hepatic function after genetically-engineered pig liver transplantation in baboons
  2460. Thrombosis and acute lymphoblastic leukaemia
  2461. Management of venous thromboembolism.
  2462. Glycocalyx protection reduces leukocyte adhesion after ischemia/reperfusion
  2463. Acute venous thrombosis: pathogenesis and evolution
  2464. Physiological changes of pregnancy and monitoring
  2465. I. Palomo1, F. Segovia1, C. Ortega1, S. Pierangeli2
  2466. The role of coagulation in ventilator-associated pneumonia
  2467. TRANSFUSION PRACTICE: Liver donor’s age and recipient’s serum creatinine predict blood component use during liver transplantation
  2468. Shock, blood transfusion and coagulation
  2469. Thalidomide–dexamethasone as up‐front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and …
  2470. A comprehensive review of thrombogenic mechanisms in APS
  2471. Cerebral Venous Thrombosis
  2472. Current role of activated protein C therapy for severe sepsis and septic shock
  2473. Renal and cardiac endothelial heterogeneity impact acute vascular rejection in pig‐to‐baboon xenotransplantation
  2474. The safety profile of drotrecogin alfa (activated)
  2475. Use of defibrotide in the treatment and prevention of veno-occlusive disease
  2476. Portal vein thrombosis in Egyptian patients with liver cirrhosis: Role of methylenetetrahydrofolate reductase C677T gene mutation
  2477. Perioperative haemostasis and coagulation management in cardiac surgery: a European survey
  2478. Beneficial effects of recombinant human activated protein C in a ewe model of septic shock
  2479. Nephrotic syndrome complicated by life-threatening pulmonary embolism in an adult patient
  2480. The phenotypic heterogeneity of severe hemophilia
  2481. Portal vein thrombosis and haematemesis in chronic liver disease. Are P-selectin and PSGL-1 clues?
  2482. Acute venous thrombosis: pathogenesis and
  2483. Thrombophilias and pre-eclampsia
  2484. Stress Hyperglycemia-An independent risk factor for multivessel coronary artery disease in Post Myocardial Infarction Patients.
  2485. Rocky Mountain Fever: A Review
  2486. Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis
  2487. Role of thrombin in coronary artery bypass grafting
  2488. Combining early coagulation and inflammatory status improves prediction of mortality in burned and nonburned trauma patients
  2489. High availability of intravascular tissue factor in neonates
  2490. What have we Learned Regarding Pregnancy Morbidity and Antiphospholipid Syndrome?
  2491. Thromboembolism in pregnancy: recurrence and its prevention
  2492. Drugs affecting coagulation
  2493. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with esse…
  2494. Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio
  2495. Venous thromboembolism
  2496. The coagulant response in sepsis
  2497. Haemostasis in Neurosurgery
  2498. Drug-induced thromboembolic events in patients with malignancy
  2499. Clinical guidelines for testing for heritable thrombophilia
  2500. Lower incidence of procoagulant abnormalities during follow-up after creation of the Fontan circulation in children
  2501. Hematological and coagulation changes in sepsis
  2502. Evaluating the efficacy and safety of unfractionated heparin in patients diagnosed with sepsis
  2503. Antiphospholipid syndrome: a challenging hypercoagulable state with systemic manifestations
  2504. Raised LIGHT levels in pulmonary arterial hypertension: potential role in thrombus formation
  2505. Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events
  2506. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation
  2507. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis
  2508. Nadroparine activated fibrinolysis and improvement of glomerular filtration rate in patients with FIGO IIB–IIIB cervical cancer treated with radiochemotherapy
  2509. Computational modeling and simulation of thrombus formation
  2510. A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: recommendations of the “ …
  2511. Urgent warfarin reversal: know your options
  2512. The cost-benefit ratio of screening pregnant women for thrombophilia
  2513. Laboratory evaluation of the antiphospholipid syndrome
  2514. Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units
  2515. Monitoring high-dose heparinization during cardiopulmonary bypass–A comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti …
  2516. Effect of pregnancy on the hemostatic and metabolic systems
  2517. High factor XI, recurrent pregnancy loss, enoxaparin
  2518. Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy
  2519. Human protein C concentrates for replacement therapy in congenital and acquired protein C deficiency
  2520. Emerging technologies and quality assurance in hemostasis: a review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program
  2521. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion
  2522. Tuscan study on the appropriateness of fresh-frozen plasma transfusion (TuSAPlaT)
  2523. Coagulation disorders: Quality in laboratory diagnosis
  2524. Chemotherapy-associated thrombosis
  2525. Activated protein C in sepsis and beyond: update 2006
  2526. Antiphospholipid syndrome: Current diagnostic and therapeutic issues–Answers to 6 clinical questions about a complex disorder
  2527. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis?
  2528. Disseminated intravascular coagulation in obstetric and gynecologic disorders
  2529. Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri
  2530. Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW; Liver and Thrombosis Study Group
  2531. Drug therapy of cardiac diseases in children.
  2532. Venous thromboembolism during pregnancy and the impact of thrombophilia in pregnancy complications
  2533. Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American society for …
  2534. Thrombophilia and direct thrombin inhibitor lepirudin: clinical and monitoring aspects
  2535. Pulmonary Embolism and vascular injury: What is the role of thrombin?
  2536. Evaluation of Protein-Z and Antithrombin III Plasma Levels in Children with Minimal Change Nephrotic Syndrome
  2537. Coagulation Disorders: Diagnostic Standards of Care
  2538. Renuka Gera, Anjali Pawar, Elna N. Saah
  2539. 25 Noncirrhotic Portal Hypertension and Portal Vein Thrombosis
  2540. Noncirrhotic Portal Hypertension
  2541. Overview of hemostasis and platelet physiology
  2542. Antithrombin deficiency and its laboratory diagnosis
  2543. Endothelial activation and dysfunction in sepsis
  2544. Posttraumatic massive bleeding: a challenging multidisciplinary task
  2545. Hereditary protein C deficiency caused by the Ala267Thr mutation in the protein C gene is associated with symptomatic and asymptomatic venous thrombosis
  2546. Protein Engineering with Noncoded Amino Acids: Applications to Hirudin
  2547. Prevention of murine antiphospholipid syndrome by BAFF blockade
  2548. Review of the relationship between venous thromboembolism, malignancy and its treatment
  2549. 100 Questions & Answers About Deep Vein Thrombosis and Pulmonary Embolism
  2550. Promising therapeutic agents for sepsis
  2551. Thromboembolic complications in pediatric hematologic malignancies
  2552. A review of the prevention and treatment of venous thromboembolism
  2553. Controversies of surviving sepsis campaign bundles: should we use them?
  2554. Profile of Venous Thromboembolism in India.
  2555. Danaparoid sodium reduces ischemia/reperfusion-induced liver injury in rats by attenuating inflammatory responses
  2556. RNA-binding Protein HuR Interacts with Thrombomodulin 5′ Untranslated Region and Represses Internal Ribosome Entry Site–mediated Translation under IL-1β …
  2557. Blood Diseases and Their Diagnosis (1)
  2558. Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment
  2559. Sauchinone, a lignan from Saururus chinensis, reduces tumor necrosis factor-α production through the inhibition of c-raf/MEK1/2/ERK 1/2 pathway activation
  2560. Overfatness, stunting and physical inactivity are determinants of plasminogen activator inhibitor-1activity, fibrinogen and thrombin–antithrombin complex in African …
  2561. Inhibition of thrombin during reperfusion improves immediate postischemic myocardial function and modulates apoptosis in a porcine model of cardiopulmonary …
  2562. Blue (or purple) toe syndrome
  2563. Venous thromboembolism in cervical cancer
  2564. Drug-induced thrombosis—experimental, clinical, and mechanistic considerations
  2565. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency
  2566. Thromboembolism in hematologic malignancies
  2567. Crosstalk between inflammation and coagulation in acute pancreatitis
  2568. Hepatic Veno-Occlusive Disease
  2569. RNA-binding Protein HuR Interacts with Thrombomodulin 5’UTR and Represses IRES-mediated Translation under IL-1 {beta} treatment
  2570. HIV-associated vascular diseases: structural and functional changes, clinical implications
  2571. Bleeding risks in interventional radiology
  2572. ExoU-induced procoagulant activity in Pseudomonas aeruginosa-infected airway cells
  2573. Surgeon General’s call to action to prevent deep vein thrombosis and pulmonary embolism
  2574. Liposomal formulations of thrombomodulin increase engraftment after intraportal islet transplantation
  2575. Fundamental Mechanisms in Venous Thrombosis
  2576. Antithrombin reduces ischemic volume, ameliorates neurologic deficits, and prolongs animal survival in both transient and permanent focal ischemia
  2577. An investigation into the biochemistry of glycoprotein I and the interaction of the fibrinolytic system with antiphospholipid antibodies
  2578. Genetics of pre-eclampsia and counseling the
  2579. Salutary roles of CD39 in transplantation
  2580. Supernatant of Aged Erythrocytes Causes Lung Inflammation and Coagulopathy in a “Two-Hit”In Vivo Syngeneic Transfusion Model
  2581. Recurrence of venous thromboembolism….. PAGE 3 and its prevention
  2582. Toxicity as a result of immunostimulation by biologics
  2583. Production of bacterial and fungal polysaccharides
  2584. Update on the use of aromatase inhibitors in early-stage breast cancer
  2585. Low-molecular-weight heparin for thromboprophylaxis
  2586. Alveolar but not intravenous S-ketamine inhibits alveolar sodium transport and lung fluid clearance in rats
  2587. Parametri hemostaze u holecistektomiji
  2588. Supernatant of stored platelets causes lung inflammation and coagulopathy in a novel in vivo transfusion model
  2589. Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study
  2590. Essential Thrombocythemia
  2591. Venous thromboembolism
  2592. Rhythm and Conduction Disorders
  2593. Management of acquired bleeding problems in cancer patients
  2594. Evaluation of Novel Laboratory Methods Using Whole Blood Testing in Different Disturbances of Haemostasis
  2595. EVALUATION OF NOVEL LABORATORY METHODS USING WHOLE BLOOD TESTING IN DIFFERENT DISTURBANCES OF HAEMOSTASIS
  2596. Profile of patients with Thrombosis evaluated in a Tertiary Care Center.
  2597. Thromboelastography in the assessment of coagulation changes in peripheral vascular disease
  2598. A Cell Culture Model of Lipopolysaccharide-induced Endothelial Activation
  2599. Molecularly engineered materials for selective albumin binding to reduce the risk of thrombus formation
  2600. A functional polymorphism (− 603A→ G) in the tissue factor gene promoter is associated with adult-onset asthma
  2601. Novel therapies for the antiphospholipid syndrome
  2602. RB119. P375 2009 616.07076–dc22 2008034795 Acquisitions Editor: Jim Merritt Developmental Editor: Barbara Cicalese
  2603. Antithrombotic therapy
  2604. Hemostatic Studies Sudanese Patients with Sickle ceel anemia
  2605. MEDICAL DISORDERS IN PREGNANCY
  2606. 26 Disordered and Renal Disorders Hemostasis
  2607. Thromboembolic disease
  2608. Inflammatory and coagulation disturbances in acute pancreatitis
  2609. Molecular biology of inflammation and sepsis: a primer
  2610. Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss
  2611. Antithrombin reduces ischemic volume, ameliorates neurologic deficits, and prolongs animal survival in both…
  2612. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair
  2613. Best Practice & Research Clinical Anaesthesiology
  2614. Candidate gene studies on cardiovascular traits
  2615. Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery
  2616. Thrombosis in Children
  2617. Effects of Resistance Training and Ambulation on Cardiovascular Risk Factors in African-American Women
  2618. Leonotis leonurus: The anticoagulant and antidiabetic activity of Leonotis leonurus
  2619. 2008 ASPHO Abstracts
  2620. Atherosclerosis: in vivo characterization
  2621. OS-1-1 Evi1 expression marks long-term repopulating hematopoietic stem cells○ Keisuke Kataoka1, Tomohiko Sato1, Akihide Yoshimi1, Susumu Goyama1, Shunya …
  2622. Factor V Leiden and activated protein C resistance
  2623. Research Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study
  2624. Coagulation State In Diabetic Retinopathy In Type 2 Diabetic Sudanese Patients
  2625. Release of Cardiac Biomarkers and Inflammatory Response during Cardiopulmonary Bypass: Comparison of Different Biocompatible Materials Used in …
  2626. Hematological diseases and stroke
  2627. A Practical Approach to the FBC and Hemostatic Screen
  2628. Management of venous thrombo-embolic disease in childhood
  2629. Role of citrate and other methods of anticoagulation in patients with severe liver failure requiring continuous renal replacement therapy
  2630. THE IMPACT OF THE G58A POLYMORPHISM ON FIBRINOGEN A-CHAIN GENE ON FACTORS V, X AND THROMBIN IN PATIENTS WITH ADVANCED …
  2631. Hemostasis and thrombosis
  2632. Applications in critical care medicine
  2633. Severe sepsis in neutropenic haematological patients
  2634. Molecularly engineered materials for selective albumin binding to reduce the risk of thrombus formation
  2635. Placental Angiogenesis and Angiogenesis Related Risk Factors in Severe Pre-eclampsia
  2636. An introduction to wounds
  2637. Intraoperative cerebral microembolisation and neuropsychological outcome following total hip and knee arthroplasty
  2638. Components of Metabolic Syndrome
  2639. Antiphospholipid antibodies and the protein C pathway
  2640. Hematologic disorders 6
  2641. Pro-thrombotic effects during anthrax pathogenesis
  2642. Genetic Variation and Susceptibility to Venous Trombosis
  2643. Inflammatory signaling in macrophages: Regulation by G-protein coupled receptor kinase-2 and 5
  2644. Darier Disease
  2645. Adjunctive Therapies in a Clinical Relevant Ovine Model of Septic Shock
  2646. The metabolic syndrome in clinical practice
  2647. Mathematics and transfusion medicine
  2648. Design and synthesis of peptides that neutralize bacterial endotoxins as therapeutic agents for the treatment of sepsis
  2649. Extracorporeal membrane oxygenation for severe systemic inflammatory response: development of a rabbit model
  2650. Severe sepsis, coagulation, and fibrinolysis: dead end or one way?
  2651. Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region
  2652. General mechanisms of coagulation and targets of anticoagulants (Section I)
  2653. ABO blood groups and the risk of venous thrombosis in patients with inherited thrombophilia
  2654. Hemostasis in patients with acute kidney injury secondary to acute liver failure
  2655. Venous thromboembolism in Asia–an unrecognised and under-treated problem?
  2656. Hereditary Thrombophilia and thrombotic events in pregnancy: single-center experience
  2657. Reference values for thrombotic markers in children
  2658. Naturally Occurring anticoagulants and Their Association With Thromboembolism In Patients With β-Thalassemia Major
  2659. Plasma pentraxin-3 and coagulation and fibrinolysis variables during acute Puumala hantavirus infection and associated thrombocytopenia
  2660. Purpura fulminans: recognition, diagnosis and management
  2661. Targeting factor Xa and thrombin: impact on coagulation and beyond
  2662. Thrombophilia testing for prevention of recurrent venous thromboembolism
  2663. Enhanced thrombin generation and depressed anticoagulant function in children with pneumonia
  2664. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis
  2665. Anticoagulant therapy for sepsis‐associated disseminated intravascular coagulation: the view from Japan
  2666. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives
  2667. Thrombophilia in childhood: to test or not to test
  2668. Should adult patients be routinely tested for heritable thrombophilia after an episode of venous thromboembolism?
  2669. Successful treatment of arterial thrombus in an extremely low-birth-weight preterm neonate
  2670. Protein C and protein S deficiency: practical diagnostic issues
  2671. The optimal duration of anticoagulation in patients with venous thromboembolism: how long is long enough?
  2672. Testing for inherited thrombophilia in recurrent miscarriage
  2673. Protein C, protein S and von Willebrand factor levels correlate with bleeding symptoms: a population‐based study
  2674. Thrombophilia testing and diagnostic dilemma–a tertiary centre experience
  2675. Replacement of specific coagulation factors in patients with burn: a review
  2676. The thromboelastometric criteria of hemostasis disorders correction during liver transplantation
  2677. Heerlen polymorphism associated with type III protein S deficiency and factor V Leiden mutation in a Polish patient with deep vein thrombosis
  2678. CARDIOlOGy PATIENT PAGE
  2679. Protein C and protein S deficiency presenting as Budd-Chiari syndrome
  2680. New therapeutic options for patients with sepsis and disseminated intravascular coagulation
  2681. Familial Mediterranean fever and hypercoagulability
  2682. Evaluation of coagulation and fibrinolytic parameters in adult onset GH deficiency and the effects of GH replacement therapy: a placebo controlled study
  2683. Prophylaxis of thrombotic complications in patients after reconstructive operations on the main arteries of the lower extremities, made for arteriosclerosis obliterans in a …
  2684. Does anticoagulant therapy improve pregnancy outcome equally, regardless of specific thrombophilia type?
  2685. Innate immunity and coagulation
  2686. Non-severe allergic asthma is associated with elevated plasma protein C and protein S
  2687. Procoagulant abnormalities in cirrhosis with portal vein thrombosis
  2688. Hereditary thrombophilia in an unselected cohort of venous thrombosis patients in Singapore
  2689. Microparticles and pregnancy complications
  2690. Perioperative disorders of coagulation and fibrinolysis in patients subjected to colorectal cancer resection
  2691. Study of associated genetic variants in Indian subjects reveals the basis of ethnicity related differences in susceptibility to venous thromboembolism
  2692. Sepsis-Associated Coagulopathy: Diagnosis With Hematologic Biomarkers and Role in the Development of Multiple Organ Dysfunction Syndrome and Mortality
  2693. Platelet function in pre-eclampsia
  2694. The Severity of Sepsis-Associated Coagulopathy Is Linked With the Amount of Dysfunctional Organs and the Overall Outcome of the Patient
  2695. Elderly trauma patients have high circulating noradrenaline levels but attenuated release of adrenaline, platelets, and leukocytes in response to increasing injury …
  2696. A CROSS SECTIONAL STUDY TO ASSESS THE SPECTRUM OF INHERITED THROMBOPHILIA IN ADULT (20 TO 50 YEARS OF AGE)
  2697. The system of hemostasis in patients with diabetic foot syndrome undergoing surgical treatment
  2698. Fresh frozen plasma transfusion fails to alter the hemostatic balance in critically ill patients with a coagulopathy
  2699. Tissue Factor Pathway Inhibitor Modulates Fibrin Deposition In The Brain In a Manner That Is Independent Of Thrombomodulin and Activated Protein C
  2700. The Efficacy and Safety Of Therapeutic Aheresis In Sepsis and Septic Shock: A Systematic Review and Meta-Analysis
  2701. HEMORHEOLOGIC DISTURBANCES IS VTE RISK FACTOR IN CHILDREN WITH ALL
  2702. PS 0078; Cardiology: Changes of Parameters of the Blood Coagulation System in Patients with Essential Arterial Hypertension with Concomitant Microalbuminuria
  2703. 818: THE ADDITION OF PROTEIN-C AND ANTITHROMBIN-III TO THE DIC SCORING SYSTEM MAY BE HELPFUL TO IDENTIFY PATIENTS WITH SEVERE SEPSIS …
  2704. Optimal duration of anticoagulation in patients with venous thromboembolism
  2705. Thrombophilia screening
  2706. Mechanistic view of risk factors for venous thromboembolism
  2707. Haemostatic and fibrinolytic changes in obese subjects undergoing bariatric surgery: The effect of different surgical…
  2708. Inflammatory bowel disease and thrombosis
  2709. Pathology consultation on the laboratory evaluation of thrombophilia: when, how, and why
  2710. The tick-derived anticoagulant madanin is processed by thrombin and factor Xa
  2711. The role of platelets in coagulation dysfunction in xenotransplantation, and therapeutic options
  2712. In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband
  2713. Distinct frequencies and mutation spectrums of genetic thrombophilia in Korea in comparison with other Asian countries both in patients with …
  2714. Evaluation of coagulation parameters in patients with chronic liver diseases
  2715. A practical approach to thrombophilia testing
  2716. Thrombophilia: From Benchside To Bedside
  2717. Inherited thrombophilic disorders
  2718. Hereditary thrombophilia in Korean patients with idiopathic pulmonary embolism
  2719. Evaluation of the host response to endotoxemia of FVIII and FIX deficient mice
  2720. Frequency of hereditary thrombophilia in women with recurrent pregnancy loss in N orthern P akistan
  2721. Clinical significance of haemostatic tests in chronic liver disease
  2722. Coagulation and sepsis: a winding road ahead
  2723. Venous thromboembolism and thrombophilia testing
  2724. The incidence and magnitude of fibrinolytic activation in trauma patients: a rebuttal
  2725. Aging hemostasis: changes to laboratory markers of hemostasis as we age—a narrative review
  2726. Low Antithrombin Level Correlates With Failing Fontan Circulation and Predicts the Mortality
  2727. DYNAMICS OF PLASMA HEMOSTASIS IN WOMEN WITH THROMBOGENIC PREGNANCY AND DELIVERY COMPLICATIONS.
  2728. Haemostatic Changes Associated with Thrombosis in Long Term Hemodialysis Treatment
  2729. Upregulation of anticoagulant proteins, protein S and tissue factor pathway inhibitor, in the mouse myocardium with cardio-specific TNF-α overexpression
  2730. Delicate balance of bleeding and thrombosis in end-stage liver disease and liver transplantation
  2731. The thrombophilic pattern of different clinical manifestations of venous thromboembolism: a survey of 443 cases of venous thromboembolism
  2732. Thrombosis: balancing act
  2733. Journal of Gastrointestinal & Digestive System
  2734. Arterial thromboembolic complications may be more common than expected in inflammatory bowel diseases
  2735. Acute traumatic coagulopathy: from endogenous acute coagulopathy to systemic acquired coagulopathy and back
  2736. Blood Coagulation
  2737. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization
  2738. The clinical significance of coagulation and the inflammatory response in autoimmunity
  2739. Impaired Thrombin Generation in Patients with Dengue.
  2740. Inherited and acquired thrombophilias
  2741. Reduced thrombin formation and excessive fibrinolysis are associated with bleeding complications in patients with dengue fever: a case–control study …
  2742. Pregnancy loss and thrombophilia: the elusive link
  2743. Deep Vein Thrombosis, Tranexamic Acid, and a Negative d-Dimer
  2744. Retinal vein occlusion: genetic predisposition and systemic risk factors
  2745. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation
  2746. Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis—effect of different treatments
  2747. Crosstalk between the coagulation and complement systems in sepsis
  2748. Exploring the biological basis of haemophilic joint disease: experimental studies
  2749. Hemostatic markers in congestive heart failure dogs with mitral valve disease
  2750. Rare double heterozygous mutations in antithrombin underlie hereditary thrombophilia in a Chinese family
  2751. Treatment responses for disseminated intravascular coagulation in 25 children treated with recombinant thrombomodulin: a single institution experience
  2752. Clinical utility of antithrombotic prophylaxis in ART procedures: an Italian experience
  2753. Polymorphonuclear neutrophils from JAK2V617F positive MPD patients do not support hypercoagulability: A study with calibrated automated thrombography (CAT)
  2754. Debate: Should Thromboprophylaxis Be Used in Hereditary Thrombophilias with Recurrent Pregnancy Loss? Yes
  2755. sEPCR Levels in Chronic Myeloproliferative Diseases and Their Association with Thromboembolic Events: A Case-Control Study
  2756. Venous thromboembolism in multiple myeloma
  2757. Chronic hepatopathy: bleeding vs. thrombosis
  2758. The coagulopathy of liver disease: does vitamin K help?
  2759. Dysfunction of protein C anticoagulant system, main genetic risk factor for venous thromboembolism in northeast Asians
  2760. Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation
  2761. Chronic hepatopathy: bleeding vs. thrombosis
  2762. Studies on coagulation incompatibilities for xenotransplantation
  2763. Hereditary thrombophilic risk factors for recurrent pregnancy loss
  2764. Snake Venom and Hemostasis
  2765. Nebulized anticoagulants limit coagulopathy but not inflammation in pseudomonas aeruginosa-induced pneumonia in rats
  2766. Risk of venous thromboembolism during the postpartum period: a systematic review
  2767. Trauma-induced coagulopathy: standard coagulation tests, biomarkers of coagulopathy, and endothelial damage in patients with traumatic brain injury
  2768. Thromboembolism in pregnancy: challenges and controversies in the prevention of pregnancy-associated venous thromboembolism and management of …
  2769. Thrombosis From a Prothrombin Mutation Conveying Antithrombin-Resistance
  2770. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab
  2771. PROTEIN C IN CHRONIC LIVER DISEASE
  2772. 72.1 INHERITED DISORDERS OF THE COAGULATION CASCADE
  2773. Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?
  2774. Historical perspective and future direction of coagulation research
  2775. The impact of coagulation parameters on the outcomes of patients with severe community-acquired pneumonia requiring intensive care unit admission
  2776. Pregnancy-related venous thromboembolism: risk and the effect of thromboprophylaxis
  2777. Global laboratory assays in hemophilia
  2778. Increased ADAMTS13 activity in patients with venous thromboembolism
  2779. Crystallization and preliminary crystallographic characterization of three peptidic inhibitors in complex with α-thrombin
  2780. Idiopathic venous thromboembolism and thrombophilia
  2781. In vitro anticoagulant activities of Melastoma malabathricum Linn. aqueous leaf extract: A preliminary novel finding
  2782. Pharmacogenetics and the Treatment of Thrombophilia
  2783. Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome
  2784. Hypercoagulability in dogs: pathophysiology
  2785. Diagnosis and management of heritable thrombophilias
  2786. Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography
  2787. Live liver donors: Are they at a higher risk for post-operative thrombotic complications?
  2788. Blood transfusion practices in obstetric anaesthesia
  2789. Hemostatic abnormalities in sickle cell disease
  2790. Physiological changes in hematological parameters during pregnancy
  2791. Effect on thrombin generation of the “in vitro” addition of low-dose LMWH to plasma of healthy pregnant and nonpregnant women
  2792. The utility of thrombophilia testing
  2793. Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation
  2794. Oral contraception in women with mild thrombophilia: What have we learned recently?
  2795. Venous thromboembolism and prothrombotic parameters in Klippel-Trenaunay syndrome
  2796. Acute pulmonary embolus in the course of cancer
  2797. Thrombosis from a prothrombin mutation conveying antithrombin resistance
  2798. Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality: impact of impaired thrombin generation
  2799. Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery
  2800. Hemostasis in Pregnancy and Obstetric Surgery
  2801. Evaluation of coagulation abnormalities in acute liver failure
  2802. Prothrombotic disorders in abdominal vein thrombosis
  2803. activation [version 1; peer review: 3 approved]
  2804. Citrate anticoagulation for continuous renal replacement therapy in small children
  2805. Evaluation for hypercoagulable states
  2806. Therapeutic plasma exchange in the management of sepsis and multiple organ dysfunction syndrome: a report of three cases
  2807. The emerging role of neutrophils in thrombosis—the journey of TF through NETs
  2808. Pre-eclampsia: relationship between coagulation, fibrinolysis and inflammation
  2809. Inherited and Acquired Thrombophilias
  2810. Inherited thrombophilia in children
  2811. GENETIC AND BIOCHEMICAL THROMBOSIS RISK MARKERS IN PREGNANCY. I. COAGULATION PATHWAYS
  2812. Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor …
  2813. A non–complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome
  2814. Characterisation of changes in the haemostasis system in dogs with thrombosis
  2815. The new direct oral anticoagulants in special indications: rationale and preliminary data in cancer, mechanical heart valves, anti-phospholipid syndrome, and heparin …
  2816. Activated protein C resistance, endogenous anticoagulants and coagulation parameters in recurrent pregnancy loss
  2817. Thromboelastography: New concepts in haemostasis physiology and correlation with trauma associated coagulopathy
  2818. Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency
  2819. Biological activities of carrageenan
  2820. Polymorphisms of plasminogen activator inhibitor-1, angiotensin converting enzyme and coagulation factor XIII genes in patients with recurrent spontaneous abortion
  2821. Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: hypercoagulability in patients with vascular access thrombosis
  2822. Cerebral thrombosis complicating Crohn’s disease: Two cases
  2823. Heparin infusion to prevent umbilical venous catheter related thrombosis in neonates
  2824. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy …
  2825. Venous thrombosis during assisted reproduction: novel risk reduction strategies
  2826. Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state
  2827. Association between early glycemic control and improvements in markers of coagulation and fibrinolysis in patients with septic shock–induced stress hyperglycemia
  2828. A short contemporary history of disseminated intravascular coagulation
  2829. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis
  2830. Blood component support in acquired coagulopathic conditions: is there a method to the madness?
  2831. Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status
  2832. Exercise perspective on common cardiac medications
  2833. Venous thromboembolism caused by testosterone abuse in a young man with previously undiagnosed genetic thrombophilia
  2834. Bleeding and management of coagulopathy
  2835. Evaluation of recurrent venous thromboembolism in patients with Factor V Leiden mutation in heterozygous form
  2836. The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism
  2837. Clinical use and the Italian demand for antithrombin
  2838. Polymorphisms of PAI-1 and platelet GP Ia may associate with impairment of renal function and thrombocytopenia in Puumala hantavirus infection
  2839. Evidence-based approach to thrombophilia testing
  2840. The multivalent activity of the tissue factor–thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention
  2841. Thrombin generation and atherosclerosis
  2842. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls
  2843. Hormonal contraception and cardiovascular system
  2844. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
  2845. Blood clotting enzymology
  2846. Optimal use of fresh frozen plasma
  2847. Tissue factor and thrombin in sickle cell anemia
  2848. anticoagulants in cirrhotic patients: controversies and certainties in PVT management
  2849. Decreased levels of circulating CD4+ CD25+ Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome
  2850. Viral infections and mechanisms of thrombosis and bleeding
  2851. Coagulopathy as a therapeutic target for TRALI: rationale and possible sites of action
  2852. Prothrombotic profile in children with peripheral gangrene: a single center experience
  2853. Coagulation and fibrinolytic disturbances are related to carotid intima thickness and arterial blood pressure in Turner syndrome
  2854. Blood and bone marrow pathology e-book
  2855. Coagulation and the vessel wall in thrombosis and atherosclerosis
  2856. Catastrophic antiphospholipid syndrome (CAPS)
  2857. Sex, thrombosis and inherited thrombophilia
  2858. Venous thrombosis: who should be screened for thrombophilia in 2014
  2859. Crystallization and preliminary crystallographic characterization of three peptidic inhibitors in complex with α-thrombin
  2860. Coagulation factor levels in neurosurgical patients with mild prolongation of prothrombin time: effect on plasma transfusion therapy
  2861. Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation
  2862. Thrombotic risk factors in Chinese Budd-Chiari syndrome patients
  2863. Old and new paradigms for cirrhosis associated coagulation abnormalities
  2864. Coagulation and inflammation
  2865. The link between vascular features and thrombosis
  2866. Bullous hemorrhagic dermatosis distant from the site of heparin injection
  2867. Coagulation disorders: risk of thrombosis in the newborn
  2868. Some hemostatic parameters in women with obstetric hemorrhage in Sokoto, Nigeria
  2869. Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure
  2870. Xeno-kidney transplantation: from idea to reality
  2871. Impairment of thrombin generation in the early phases of the host response of sepsis
  2872. Four factor prothrombin complex concentrate (human): review of the pharmacology and clinical application for vitamin K antagonist reversal
  2873. 1 Antithrombin–Heparin
  2874. FIGHTING HEART DISEASE FROM THE KITCHEN—ONE RECIPE AT A TIME
  2875. Endothelial and platelet function alterations in HIV-infected patients
  2876. Seminars in thrombosis & hemostasis 2010: Impact Factor and highest-cited articles from 2008 to 2009
  2877. Coagulation response in dogs with and without systemic inflammatory response syndrome–Preliminary results
  2878. New oral anticoagulants: comparative pharmacology with vitamin K antagonists
  2879. Procoagulant activity in patients with gynaecological malignancies and the effect of neoadjuvant chemotherapy
  2880. Long-term coagulation changes after resection of thoracoabdominal malignancies
  2881. Gender differences in response to chronic treatment with 17β-oestradiol and 17β-aminoestrogen pentolame on hemostasis in rats
  2882. Deficiencies of antithrombin, protein C and protein S–practical experience in genetic analysis of a large patient cohort
  2883. Comparison of the hemostatic effects of a levonorgestrel-releasing intrauterine system and leuprolide acetate in women with endometriosis: A randomized clinical trial
  2884. Expression and shedding of endothelial protein C receptor in prostate cancer cells
  2885. Outcome of modified portal vein anastomosis for recipients with portal vein thrombosis or stenosis before living donor liver transplantation
  2886. Nebulized anticoagulants for acute lung injury-a systematic review of preclinical and clinical investigations
  2887. Clinical characteristics of first venous thrombosis among women under and over 45 years of age
  2888. Reducing inpatient heritable thrombophilia testing using a clinical decision-making tool
  2889. Blood levels of histone-complexed DNA fragments are associated with coagulopathy, inflammation and endothelial damage early after trauma
  2890. Coagulopathy in the intensive care unit
  2891. High prevalence of three prothrombotic polymorphisms among Palestinians: factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase C677T
  2892. Myocardial infarction and pregnancy
  2893. Factors that influence the bleeding phenotype in severe hemophilic patients
  2894. The new oral anticoagulants and the future of haemostasis laboratory testing
  2895. Mechanisms of hormonal therapy related thrombosis
  2896. Increased prevalence of activated protein C resistance during pregnancy may implicate venous thrombo embolic disorders as a common cause of maternal mortality …
  2897. Contribution of protein Z and protein Z-dependent protease inhibitor in generalized Shwartzman reaction
  2898. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines
  2899. Role of microparticles in recurrent miscarriages and other adverse pregnancies: a review
  2900. Unique thrombin inhibition mechanism by anophelin, an anticoagulant from the malaria vector
  2901. Ph-Negative Chronic Myeloproliferative Neoplasm (Primary Myelofibrosis)–as One of the Reasons of the Budd-Chiari Syndrome
  2902. Factor V Leiden and inflammation
  2903. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease
  2904. How does number of risk factors affect prognosis in young patients with ischemic stroke?
  2905. High mobility group B1 levels in sepsis and Disseminated Intravascular Coagulation.
  2906. Current consideration and management of disseminated intravascular coagulation
  2907. Diagnostic and prognostic significance of neutrophil gelatinase-associated lipocalin in disseminated intravascular coagulation
  2908. Global fibrinolytic activity, PAI-1 level, and 4G/5G polymorphism in Thai children with arterial ischemic stroke
  2909. Late onset Warfarin induced skin necrosis in human immunodeficiency virus infected patient with pulmonary tuberculosis
  2910. Genetic Thrombophilias: When to Consider and What to Do
  2911. DIC: which laboratory tests are most useful
  2912. Risk of obstetric and thromboembolic complications in family members of women with previous adverse obstetric outcomes carrying common inherited thombophilias
  2913. Use of tissue plasminogen activator to treat intracardiac thrombosis in extremely low-birth-weight infants
  2914. Pulmonary thromboembolism in a child with sickle cell hemoglobin D disease in the setting of acute chest syndrome
  2915. Heterogeneous lengths of copy number mutations in human coagulopathy revealed by genome-wide high-density SNP array
  2916. Pathogenesis of antiphospholipid syndrome: understanding the antibodies
  2917. Leech Therapy-Why I am doing!
  2918. Hemostasis in acute liver and kidney failure: nothing is as it seems
  2919. Hematologic Changes with Aging
  2920. Haemostatic and cytokine changes in gestational diabetes mellitus
  2921. Engineering novel anticoagulant proteins by motif grafting
  2922. Anti-annexin V IgG and IgM antibodies in sickle cell disease patients with vaso-occlusive crisis
  2923. Antithrombin levels and the risk of a first episode of venous thromboembolism. A case-control study
  2924. Recurrent thrombosis in an HIV-1 infected child
  2925. Physiology of pregnancy: clinical anaesthetic implications
  2926. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome
  2927. Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model
  2928. FUNDAMENTAL MECHANISMS IN VENOUS THROMBOSIS
  2929. Budd-Chiari syndrome in a patient with ulcerative colitis and no inherited coagulopathy
  2930. Laboratory testing of anticoagulants: the present and the future
  2931. Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia
  2932. Antithrombin Rybnik: a new point mutation (nt 683 G> T) associated with type I antithrombin deficiency in a patient with venous thromboembolism and recurrent …
  2933. Effect of Factor V Leiden on thrombosis in childhood leukemia
  2934. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia
  2935. Hypocoagulability, hypercoagulability and the interpretation of ‘normal’kaolin-activated thrombelastographs in the perioperative period
  2936. Preservation of small bowel with the selective use of heparin and second look laparotomy in acute mesenteric ischaemia: A case report
  2937. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”
  2938. Functional assay or antigen test for protein C and protein S in ischemic stroke: which shows the greatest change?
  2939. Coagulation factors and antithrombin levels in young and elderly subjects in Pakistani population
  2940. Coagulation abnormalities in diabetes mellitus
  2941. Prohemostatic interventions in obstetric hemorrhage
  2942. Combined deficiency of proteins C and S: ischaemic stroke in young individuals
  2943. Laboratory referral rates of genetic tests for thrombophilia workup in a major referral center
  2944. Family history of VTE: An easy tool to score the individual risk
  2945. Increased transfusion‐free survival following auxiliary pig liver xenotransplantation
  2946. Neonatal renal vein thrombosis
  2947. Evaluation of Protein C and Protein S in Young Patients with Thrombosis
  2948. USE OF ENZYMES IN COMPLEX TREATMENT OF ANTIPHOSPHOLIPID SYNDROME IN WOMEN WITH REPRODUCTIVE LOSSES OF ANDIJAN STATE
  2949. Thrombophilia-related complications in the treatment of a left atrial appendage thrombus: A case report
  2950. AORTIC THROMBOEMBOLISM IN DOGS–SIGNS AND TREATMENT
  2951. Splenic implant assessment in trauma
  2952. A Case of Deep Vein thrombosis due to Protein C, Protein S Deficiency and Hyper-Homocystinaemia, A Rare Genetic Abnormalities
  2953. Thoracentesis and the risks for bleeding: a new era
  2954. Venous thromboembolism and pregnancy
  2955. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation
  2956. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient
  2957. Inhibition of cellular growth and migration by suppression of endothelial protein C receptor (EPCR) in lung carcinoma cells
  2958. “Why Did My CPAP Beat Me Up?” Bilateral Periorbital Ecchymosis Associated with Continuous Positive Airway Pressure Therapy
  2959. It is time to adopt a strategy of routine some thrombophilias screening in women with a confirmed history of venous thromboembolism or recurrent fetal loss
  2960. Clotting activation and hyperfibrinolysis in cirrhosis: implication for bleeding and thrombosis
  2961. Low molecular weight heparin in portal vein thrombosis of cirrhotic patients: only therapeutic purposes?
  2962. Pathophysiology of ischemic acute kidney injury
  2963. Inherited and acquired risk factors for venous thromboembolism
  2964. A flare of ulcerative colitis accompanied with cerebral sinus venous thrombosis and bilateral thalamic infarctus: a case report
  2965. Patient safety and quality in laboratory and hemostasis testing: a renewed loop?
  2966. Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity
  2967. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G> A) mutations in adults with a …
  2968. Factor V Leiden 1691G/A and prothrombin gene 20210G/A polymorphisms as prothrombotic markers in adult Egyptian acute leukemia patients
  2969. Ruolo patogenetico delle alterazioni emocoagulative nell’insorgenza di sindrome poliabortiva e di patologie ostetriche
  2970. Predictive value of anti-annexin V autoantibodies in the follow-up of vaso-occlusive crisis associated with sickle cell disease
  2971. Von Willebrand Factor-Mediated Thrombotic Microangiopathies
  2972. Atypical Clinical Picture Observed in Three Patients with Thrombosis of the Cerebral Sinuses
  2973. John Ross Ainsworth Birmingham Heartlands and Solihull Hospitals U niversity of Birmingham, UK
  2974. Factor V Leiden and prothrombin 20210A mutations among Turkish pediatric leukemia patients
  2975. Hemocoagulative Aspects of Solid Organ Transplantation
  2976. Differential haemostatic risk factors for pregnancy-related deep-vein thrombosis and pulmonary embolism
  2977. Estimation of Fibrinogen level in Pregnant Women at 3rd Trimester in Different Ages in Khartoum State
  2978. Thrombomodulin is silenced in malignant mesothelioma by a poly (ADP-ribose) polymerase-1-mediated epigenetic mechanism
  2979. Coronary artery bypass grafting in a patient with protein S deficiency: perioperative implications
  2980. Silent myocardial ischaemia in diabetic patients after general anaesthesia with 24 h intravenous opioids or with epidural analgesia
  2981. Combination of antithrombin and recombinant thrombomodulin attenuates leukocyte–endothelial interaction and suppresses the increase of intrinsic damage …
  2982. New anticoagulants in the treatment of VTE
  2983. Developmental hemostasis: clinical implications from the fetus to the adolescent
  2984. Factors associated with the development of superficial vein thrombosis in patients with varicose veins
  2985. Circulating nucleosomes and severity of illness in children suffering from meningococcal sepsis treated with protein C
  2986. Genome‐wide linkage scan in affected sibling pairs identifies novel susceptibility region for venous thromboembolism: genetics in familial thrombosis study
  2987. From mice to men: Treating sepsis with heparin
  2988. Thrombosis in systemic lupus erythematosus: role of impaired fibrinolysis
  2989. Platelet-rich fibrin (PRF): an autologous packing material for middle ear microsurgery
  2990. Crossroads of coagulation and innate immunity: the case of deep vein thrombosis
  2991. A case of fulminant varicella infection with purpura fulminans, hepatitis, and rhabdomyolysis
  2992. Innumerable studies on single nucleotide polymorphisms: What could be its utility?
  2993. Deficiency of antithrombin and protein C gene in 202 C hinese venous thromboembolism patients
  2994. Effect of gamma irradiation with 30 gy on the coagulation system in leukoreduced fresh frozen plasma
  2995. Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications
  2996. New insights into modulation of thrombin formation
  2997. Thromboembolism risk following recurrent miscarriage
  2998. Venous and arterial thrombosis: associations and risk factors
  2999. Venous thromboembolism in neonates and children
  3000. Venous Thromboembolism—-An Overview
  3001. Impact of reduced levels of protein C, free protein S and antithrombin in normal frozen plasma on the interpretation of patients’ results
  3002. Bilateral and simultaneous central retinal vein occlusion in a patient with obstructive sleep apnea syndrome
  3003. A systematic update on the state of novel anticoagulants and a primer on reversal and bridging
  3004. Venous thrombosis in the nephrotic syndrome
  3005. Question From the ClinicianRisk of Thrombophilia
  3006. Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the “CAPS Registry”
  3007. Plasma alternatives in acquired bleeding disorders—factor concentrates
  3008. Midventricular obstructive hypertrophic cardiomyopathy during pregnancy complicated by pulmonary embolism: a case report
  3009. Thrombotic complications–prevention and treatment of venous thromboembolism in cancer patients
  3010. Systemic versus localized coagulation activation contributing to organ failure in critically ill patients
  3011. Catastrophic antiphospholipid syndrome
  3012. Ocular manifestations of the antiphospholipid syndrome
  3013. Recurrent ischemic cerebrovascular events in a patient with type I antithrombin deficiency caused by 9788 G> A splice site mutation: a case report
  3014. Haematological interventions for treating disseminated intravascular coagulation during pregnancy and postpartum
  3015. Identification of a novel frameshift mutation causing a premature stop codon in a young Nigerian man with type I antithrombin deficiency
  3016. Changes in coagulation and hemodynamics during pregnancy: a prospective longitudinal study of 58 cases
  3017. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines
  3018. Thrombophilia and arteriovenous fistula survival in ESRD
  3019. Anticoagulant effect of polyphenols-rich extracts from black chokeberry and grape seeds
  3020. Current concepts in the management of disseminated intravascular coagulation
  3021. Antithrombin-resistant prothrombin Yukuhashi mutation also causes thrombomodulin resistance in fibrinogen clotting but not in protein C activation
  3022. Update on Physiological Anticoagulant Factor
  3023. Prevention of high-mobility group box 1-mediated early loss of transplanted mouse islets in the liver by antithrombin III
  3024. Deep Vein Thrombosis Following Non-myeloablative Allogeneic Stem Cell Transplantation: Presentation of Three Cases and Literature Review
  3025. Deep venous thrombosis in patients with liver cirrhosis: Incidence and management
  3026. Endogenous anticoagulants
  3027. Treatment of warfarin-associated coagulopathy with vitamin K
  3028. Heparin-induced thrombocytopenia
  3029. Seasonality of thrombogenic disorders in coronary atherosclerosis recrudescence
  3030. Coagulopathy of chronic liver disease
  3031. Thrombophilia and venous thromboembolism: RIETE experience
  3032. Effect of antithrombin, protein C and protein S on portal vein thrombosis in liver cirrhosis: a meta-analysis
  3033. Progestin-only contraception and venous thromboembolism
  3034. Perioperative strategies and thrombophilia in children with extrahepatic portal vein obstruction undergoing the meso-Rex bypass
  3035. Unilateral Renal Vein Thrombosis and Adrenal Hemorrhage in A Newborn with Homozygous Factor V Leiden and Heterozygous Of MTHFR-677T, MTHFR-1298C …
  3036. Association of thrombophilia and polycystic ovarian syndrome in women with history of recurrent pregnancy loss
  3037. Pulmonary embolism in intensive care unit “literature review”
  3038. Doping and thrombosis in sports
  3039. Bevacizumab-based therapy for patients with brain metastases from non-small-cell lung cancer: preliminary results
  3040. Plasma anticoagulants or Inhibitors
  3041. Platelet functions and coagulation changes in Indian children with nephrotic syndrome
  3042. Familial Mediterranean fever presenting with pulmonary embolism.
  3043. Controversies in postpartum contraception: when is it safe to start oral contraceptives after childbirth?
  3044. Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis–a concise review
  3045. How to manage children and young adults with myeloproliferative neoplasms
  3046. Bleeding and clotting disorders in pediatric liver disease
  3047. 14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome
  3048. Venous Thromboembolism in Pregnancy
  3049. Common genetic determinants of coagulation and fibrinolysis
  3050. Successful treatment of right-sided heart thrombus with pulmonary embolism with thrombolytic therapy
  3051. Mesenteric vein thrombosis after laparoscopic sleeve gastrectomy
  3052. The risk of postpolypectomy bleeding during colonoscopy in patients with early liver cirrhosis
  3053. Venous thromboembolism in cirrhosis
  3054. Long-term consequences of pregnancy-related venous thrombosis
  3055. Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: a randomized controlled trial
  3056. Coagulation update: what’s new in hemostasis testing?
  3057. A Pragmatic Dilemma: A Case of Lung Adenocarcinoma Presenting as Upper and Lower Extremity Venous Thromboembolism and Protein C and S Deficiency
  3058. Postvaricella thrombosis—report of two cases and literature review
  3059. The role of tissue factor in systemic inflammatory response syndrome
  3060. Livedoid vasculopathy as a coagulation disorder
  3061. Stroke in pregnancy: A rare case of protein C and protein S deficiency
  3062. Treatment with recombinant human activated protein C: one size does not fit all
  3063. Polymorphisms and Mutations in vWF and ADAMTS13 Genes and Their Correlation With Plasma Levels of FVIII and vWF in Patients With Deep Venous Thrombosis
  3064. Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases
  3065. Retinal vein occlusions: a review for the internist
  3066. Semi‐Synthetic Polysaccharide Sulfates as Anticoagulant Coatings for PET, 1–Cellulose Sulfate
  3067. Venous thromboembolism in pediatric nephrotic syndrome
  3068. The rare inherited coagulation disorders
  3069. The real value of thrombophilia markers in identifying patients at high risk of venous thromboembolism
  3070. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients
  3071. Molecular mechanisms of sepsis
  3072. Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin
  3073. sex, thrombosis and inherited thrombophilia
  3074. Correlation of thromboelastometry with conventional hemostatic tests in critically ill patients with a coagulopathy treated with fresh frozen plasma
  3075. Inherited thrombophilia: diagnosis and anticoagulation treatment in pregnancy
  3076. Causes of adult splanchnic vein thrombosis in the mediterranean area
  3077. Superficial thrombophlebitis in varicose vein disease: the particular role of methylenetetrahydrofolate reductase
  3078. Thrombosis in myeloproliferative neoplasms
  3079. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation
  3080. Calcified right atrial thrombus in HIV infected patient
  3081. Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia
  3082. Increased risks of deep vein thrombosis and pulmonary embolism in Sjögren syndrome: a nationwide cohort study
  3083. Coagulation problems in the critically ill
  3084. Expression and functional characterisation of naturalR147W and K150del variants of protein C in the Chinese population
  3085. Evaluation of Pro-C global for identification of defects in protein C/S anticoagulant pathway
  3086. Medical management of venous thromboembolism: What the interventional radiologist needs to know
  3087. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis
  3088. Disseminated intravascular coagulation
  3089. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis
  3090. Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome
  3091. Inappropriate use of protein C, protein S, and antithrombin testing for hereditary thrombophilia screening: an experience from a large university hospital
  3092. Blood loss, predictors of bleeding, transfusion practice and strategies of blood cell salvaging during liver transplantation
  3093. Thrombosis as an intravascular effector of innate immunity
  3094. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
  3095. Urgent cesarean delivery and prolonged ventilatory support in a parturient with Fontan circulation and undiagnosed pseudocholinesterase deficiency
  3096. Leukocyte-derived microparticles in vascular homeostasis
  3097. Cerebral venous sinus thrombosis in HIV-infected patients: report of 2 cases
  3098. Intensive care unit management of liver-related coagulation disorders
  3099. Changes of coagulation factors in patients with carcinomas and carcinomas of the breast; perioperative influence of local anesthetics
  3100. Prevalence of thrombophilic mutations in patients with unprovoked thromboembolic disease. A comparative analysis regarding arterial and venous disease
  3101. Warfarin resistance-mechanisms and management
  3102. Protein Z, an anticoagulant protein with expanding role in reproductive biology
  3103. Disseminated Intravascular
  3104. Pregnancy-related venous thromboembolism
  3105. Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genes
  3106. Venous thromboembolism and hypercoagulable states
  3107. Thrombophilia testing in neonates and infants with thrombosis
  3108. Protein C and acute inflammation: a clinical and biological perspective
  3109. Polycations Selectively Blocking Tissue Factor-Dependent FVII Activation: Collective In Vitro Anticoagulation Studies §
  3110. eComment. Recombinant activated factor VII in pediatric cardiac surgery: possibilities and limitations
  3111. Complement the hemostatic system: an intimate relationship
  3112. Urine Protein Electrophoresis
  3113. Antiphospholipid syndrome: laboratory testing and diagnostic strategies
  3114. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure
  3115. Fluid management in obstetric patients
  3116. Role of hemostatic factors on the risk of venous thrombosis in people with impaired kidney function
  3117. ADVANCES IN HEMATOLOGY
  3118. Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival
  3119. Beta-fibrinogen (-455 G/A) and Integrin beta-3 (PLA1/A2) polymorphisms and recurrent pregnancy loss in Gaza strip-Palestine
  3120. Dermatological signs of the most frequently systemic bacterial infections
  3121. Nanoscale elements of limnology
  3122. The risk of oestrogens in contraceptives
  3123. Disseminated intravascular coagulation as a possible cause of acute coronary stent thrombosis: a case report and literature review
  3124. Revisiting extra hepatic portal vein obstruction in children from the north Indian gangetic plain
  3125. Infection and inflammation as risk factors for thrombosis and atherosclerosis
  3126. Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment
  3127. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?
  3128. Hypercoagulability risk factors associated with venous thromboembolic events in patients with idiopathic membranous nephropathy and nephrotic syndrome: a …
  3129. Obstetric and vascular APS: same autoantibodies but different diseases?
  3130. Evaluation of hemostatic balance in blood from patients with polycythemia vera by means of thromboelastography: The effect of isovolemic erythrocytapheresis
  3131. Interplay between coagulation and vascular inflammation in sickle cell disease
  3132. Infections, coagulation and thrombosis
  3133. Controlling coagulation dysregulation in xenotransplantation
  3134. Neurologic complications in multiple myeloma and plasmacytoma
  3135. Endogenous heparinoids induced massive hemorrhage postoperatively following THA
  3136. Pregnancy-induced hypertension, but not gestational diabetes mellitus, is a risk factor for venous thromboembolism in pregnancy
  3137. Role of investigating thrombophilic disorders in young stroke
  3138. Disseminated intravascular coagulation as the laboratory hallmark of acute Q fever
  3139. Peripartum pulmonary embolism: Anesthetic and surgical considerations
  3140. Transfusion-related acute lung injury in cardiac surgery patients is characterized by pulmonary inflammation and coagulopathy: a prospective nested case-control …
  3141. Regulation of human platelet aggregation by genetically modified pig endothelial cells and thrombin inhibition
  3142. Inhaled unfractionated heparin improves abnormalities of alveolar coagulation, fibrinolysis and inflammation in endotoxemia-induced lung injury rats
  3143. Polymorphism of clotting factors in Hungarian patients with Raynaud’s phenomenon
  3144. Pregnancy and venous thromboembolism
  3145. New insights into pathways that determine the link between infection and thrombosis
  3146. Pre-analytical variables in coagulation testing associated with diagnostic errors in hemostasis
  3147. Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production
  3148. Hemoptysis in TB Endemic Area. Think Again!
  3149. Internal jugular vein thrombosis associated with venous hypoplasia and protein S deficiency revealed by ultrasonography
  3150. The mechanism of action of rivaroxaban–an oral, direct Factor Xa inhibitor–compared with other anticoagulants
  3151. Therapeutic apheresis in autoimmune diseases
  3152. Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation
  3153. Antithrombin and mortality in severe pneumonia patients with sepsis‐associated disseminated intravascular coagulation: an observational nationwide study
  3154. Diagnosis and prognosis of coagulopathies in horses with colic
  3155. Cytoprotective-selective activated protein C therapy for ischaemic stroke
  3156. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation
  3157. Clinical applications of 4-factor prothrombin complex concentrate: a practical pathologist’s perspective
  3158. Impact of anticoagulation on the effectiveness of loop diuretics in heart failure with cardiorenal syndrome and venous thromboembolism
  3159. The role of PAR-1, PAR-2 and Tissue factor in the development of hepatic fibrosis
  3160. Thrombotic disease in critically ill children
  3161. Prevention and treatment of venous thromboembolism in pregnancy
  3162. Bleeding and thrombosis in cirrhotic patients: what really matters?
  3163. Comparative fibrinolysis
  3164. Whole Grains, Multiple Grains: Health or Hype
  3165. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia
  3166. Obesity, non-alcoholic fatty liver disease, and atherothrombosis: a role for the intestinal microbiota?
  3167. Use of saline flush to prevent filter clotting in continuous renal replacement therapy without anticoagulant
  3168. Coagulation Disorders After Central Nervous System Injury
  3169. Regional Difference of Alginates Extracted from Different Brown Seaweeds
  3170. Investigation of Haemostatic Status in the Elderly Male and Female Using Some Parameters; PT, APTT and PC Count (A Case Study in Owerri Metropolis)
  3171. Kidney endothelial dysfunction: ischemia, localized infections and sepsis
  3172. ST-elevation myocardial infarction due to a spontaneous thrombus in the left anterior descending artery in a young HIV-infected patient
  3173. Influence of blood collection technique on platelet function and coagulation variables in dogs
  3174. Update on disseminated intravascular coagulation: when to consider it, when to expect it, when to treat it
  3175. Molecular basis and thrombotic manifestations of antithrombin deficiency in 15 unrelated Chinese patients
  3176. Sonoclot signature analysis in patients with liver disease and its correlation with conventional coagulation studies
  3177. Development of a new laboratory test to evaluate antithrombin resistance in plasma
  3178. Evaluation of coagulation abnormalities among women with vaginal bleeding in the first trimester of pregnancy
  3179. Postpartum contraception
  3180. Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population‐based cohort study
  3181. Statins role in the prevention and treatment of sepsis
  3182. Relation of soluble endothelial protein C receptor and cytokines after allogeneic hematopoietic stem cell transplantation
  3183. Hematologic failure
  3184. DEFINING SEPSIS AND ITS CLINICAL MANIFESTATIONS
  3185. An integrative approach to the patient with thrombophilia
  3186. New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study
  3187. Antithrombotics
  3188. Interactions between coagulation and complement—their role in inflammation
  3189. Global coagulation in myeloproliferative neoplasms
  3190. Anticoagulant and Fibrinolytic Drugs–Possible Agents in Treatment of Lung Cancer?
  3191. Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminans
  3192. The effect of insulin resistance on inflammatory response and oxidative stress in acute cerebral ischemia
  3193. Pro-and anti-angiogenic agents
  3194. Recurrent venous thromboembolism: what is the risk and how to prevent it
  3195. Management of extra hepatic portal venous obstruction (EHPVO): current strategies
  3196. Recurrent pediatric thrombosis: the effect of underlying and/or coexisting factors
  3197. Hemostatic derangement in dengue hemorrhagic fever
  3198. Comparison of Fibrinogen Level Changes between Pregnancy with History of Abortion and Normal Pregnancy
  3199. Left atrium thrombus in an extremely low‐birthweight infant with late‐onset circulatory dysfunction
  3200. Coagulation, Anticoagulation, and Inflammatory Response
  3201. Pregnancy and puerperium-related strokes in Asian women
  3202. Venous thrombosis in athletes
  3203. When and How to Investigate
  3204. Effects of chitin and sepia ink hybrid hemostatic sponge on the blood parameters of mice
  3205. Evaluation and management of a patient with possible cerebral venous thrombosis
  3206. General introduction and outline of this thesis
  3207. Mild Antithrombin Deficiency and the Risk of Recurrent Venous Thromboembolism: A Prospective Cohort Study
  3208. Management of atrial fibrillation: direct factor IIa and Xa inhibitors or “warfarin shotgun”?
  3209. Drug-induced immune thrombocytopenia
  3210. Coffee consumption is associated with a reduced risk of venous thrombosis that is mediated through hemostatic factor levels
  3211. Venous thrombosis: understanding the paradoxes of recurrence
  3212. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature
  3213. Bivalirudin in Combination with Heparin to Control Mesenchymal Cell
  3214. Novel insights in genetics of arterial thrombosis
  3215. Risk factors for venous and arterial thrombosis
  3216. Copy number variations of the F8 gene are associated with venous thromboembolism
  3217. Hemostasis and Thrombosis-Platelet Disorders
  3218. Inherited and acquired thrombophilia in pregnancy
  3219. Early prediction of acute traumatic coagulopathy
  3220. Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism
  3221. Evaluation of the presence of hereditary and acquired thrombophilias in Brazilian children and adolescents with diagnoses of portal vein thrombosis
  3222. Sickle cell disease and β‐thalassaemia major in pregnancy
  3223. Superior vena cava syndrome causing chylothoraces in a preterm neonate: a case report and literature review
  3224. Different impact of two mutations of a novel compound heterozygous protein C deficiency with late onset thrombosis
  3225. Clinical profile, common thrombophilia markers and risk factors in 85 young Indian patients with arterial thrombosis
  3226. Climacteric lowers plasma levels of platelet-derived microparticles: a pilot study in pre-versus postmenopausal women
  3227. Republished review: Ocular manifestations of the antiphospholipid syndrome
  3228. Antiphospholipid Antibodies–Detection and Clinical Importance
  3229. Risk factors for thrombosis in an African population
  3230. Tissue factor pathway inhibitor and P-selectin as markers of sepsis-induced non-overt disseminated intravascular coagulopathy
  3231. Pulmonary activation of coagulation and inhibition of fibrinolysis after burn injuries and inhalation trauma
  3232. Involvement of coagulation and hemostasis in inflammatory bowel diseases
  3233. Differential diagnosis of heparin-induced thrombocytopenia and scoring systems
  3234. Thrombophilia Issue
  3235. Tamoxifen-associated Budd-Chiari syndrome complicated by heparin-induced thrombocytopenia and thrombosis: a case report and literature review
  3236. Recombinant Factor VIIa in the Treatment of Hemostatic Disorders in Patients with Solid Tumors
  3237. Prophylaxis of thromboembolic events in patients with nephrotic syndrome
  3238. Hemostasis, Bleeding, Blood-sparing Strategies, and Allogeneic Transfusions in Thoraco-Abdominal Aortic Aneurysm Surgery
  3239. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial …
  3240. A missense mutation G109R in the PROC gene associated with type I protein C deficiency in a young Polish man with acute myocardial infarction
  3241. Effect of combination doses of citrus limon and Punica granatum juice on blood parameters in rabbits
  3242. Managing clotting: a North American perspective
  3243. Fatal pulmonary thromboembolism. A retrospective autopsy study: Searching for genetic thrombophilias (Factor V Leiden (G1691A) and FII (G20210A) gene variants) …
  3244. Inflammatory bowel disease and thromboembolism
  3245. Epidemiology of venous thrombosis in children with cancer
  3246. Haematological problems in intensive care
  3247. Recanalization after acute deep vein thrombosis
  3248. Prevalence of hypercoagulable disorders in inflammatory bowel disease
  3249. Liver Endothelial Cells: Hemostasis, Thrombosis, and Hepatic Vascular Diseases
  3250. An approach to the patient with non-surgical bleeding and a normal coagulation screen
  3251. Thrombosis in children
  3252. Transfusion and coagulation management in liver transplantation
  3253. Thrombosis and occlusion of vascular access in hemodialyzed patients
  3254. Paraneoplastic syndromes in daily clinical practice
  3255. The utility of thromboelastometry (ROTEM) or thromboelastography (TEG) in non-bleeding ICU patients
  3256. Critical determinants of cardiovascular risk in rheumatoid arthritis
  3257. Budd-Chiari Syndrome: A Clinical Approach
  3258. Recommendations for the prevention of pregnancy‐associated venous thromboembolism
  3259. Thromboembolism in children with cancer
  3260. Association between thrombophilia and seated immobility venous thromboembolism
  3261. Inherited and acquired thrombophilic alterations in patients with superficial vein thrombosis of lower limbs
  3262. Venous thromboembolism in women: an assessment of hormonal, genetic and other risk factors
  3263. Role of vitamin K-dependent proteins in the arterial vessel wall
  3264. VKORC1 rs2359612C allele is associated with increased risk of coronary artery disease in the presence of coronary calcification
  3265. Diagnosis of infection in critical care
  3266. The significance of F139V mutation on thrombotic events in compound heterozygous and homozygous protein C deficiency
  3267. Condom tamponade in the management of massive obstetric hemorrhage: an experience at a teaching hospital
  3268. Endothelial dysfunction in sepsis
  3269. Interaction between oral estrogen plus progestogen therapy and ABO blood groups on coagulation activation in postmenopausal women
  3270. Therapeutic translation in acute kidney injury: the epithelial/endothelial axis
  3271. Effects of the gene carrier polyethyleneimines on structure and function of blood components
  3272. Coagulopathy and hemostatic monitoring in cardiac surgery: an update
  3273. VENOUS THROMBOEMBOLISM IN WOMEN
  3274. Current concepts and new trends in the diagnosis and management of recurrent miscarriage
  3275. Haemostatic parameters in patients with Behcet’s disease
  3276. Massive transfusion in children and neonates
  3277. Understanding the biological mechanisms underlying acquired risk factors for venous thrombosis: studies in mice Date: 2012-06-07
  3278. Immunological Causes Associated to Foetal Death: An Update
  3279. Kocher-Debre-Semelaigne syndrome diagnosed by autopsy associated with disseminated intravascular coagulation
  3280. Multiple markers of hypercoagulation in patients with history of venous thromboembolic disease
  3281. Findings that shed new light on the possible pathogenesis of a disease or an adverse effect: Tamoxifen-associated Budd-Chiari syndrome complicated by …
  3282. Thrombophilia: clinical and laboratory assessment and management
  3283. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities
  3284. Genetic background analysis of protein C deficiency demonstrates a recurrent mutation associated with venous thrombosis in Chinese population
  3285. Characterization of a Kunitz-type protease inhibitor peptide (Rusvikunin) purified from Daboia russelii russelii venom
  3286. A new warfarin dosing algorithm including VKORC1 3730 G> A polymorphism: comparison with results obtained by other published algorithms
  3287. Reducing mortality in severe sepsis and septic shock
  3288. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences
  3289. Hemostasis and coagulation
  3290. Aetiology of Venous Thrombosis
  3291. A LONGITUDINAL STUDY OF PROTEIN C ACTIVITY IN PREGNANT NIGERIANS IN SOUTH EASTERN NIGERIA
  3292. Perioperative coagulation management in the intensive care unit
  3293. Inflammation markers, D-dimer and the risk of recurrent venous thrombosis
  3294. Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH)–a review of a new treatment paradigm
  3295. Novel insights into genetics of arterial thrombosis
  3296. Hemostasis and complement activation in Puumala hantavirus infection
  3297. Autoantibodies in lupus: culprits or passive bystanders?
  3298. Trans-fatty acids, dangerous bonds for health? A background review paper of their use, consumption, health implications and regulation in France
  3299. Looking again at VTE 2: new oral anticoagulants
  3300. Definitions, epidemiology and pathophysiology
  3301. Preventing thrombophilia-related complications of pregnancy: an update
  3302. Vitamin K1 monitoring in pregnancies after bariatric surgery: a prospective cohort study
  3303. Current challenges in contraception in adolescents and young women
  3304. Modulation of the immuno-coagulative response in a pneumococcal infection in malnourished mice nasally treated with Lactobacillus casei
  3305. Management of pulmonary embolism: state of the art treatment and emerging research
  3306. Resuscitation beyond Advanced Trauma Life Support: damage control
  3307. Hemoglobinopathies in pregnancy
  3308. Post-traumatic pulmonary embolism in the intensive care unit
  3309. Coagulation in kidney disease
  3310. Erythrocytic phosphatidylserine exposure and hemostatic alterations in β-thalassemia intermediate patients
  3311. A moderate aseptic local inflammation does not induce a significant systemic inflammatory response
  3312. Primary nephrotic syndrome in adults as a risk factor for pulmonary embolism: an up-to-date review of the literature
  3313. NEPHROTIC AND ANTI‐PHOSPHOLIPID SYNDROMES: MULTISYSTEM CONDITIONS ASSOCIATED WITH ACUTE MYOCARDIAL INFARCTION IN YOUNG …
  3314. Anti-platelet therapy is associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients
  3315. Prolonged PT
  3316. The role of complement C3 in Diabetes
  3317. Pulmonary embolism associated with oral contraceptive use-case report
  3318. Sepsis, severe sepsis, and septic shock: current evidence for emergency department management
  3319. The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and …
  3320. Is Inherited Thrombphilia in Pregnancy a Risk Factor for Familial Stroke?
  3321. Characterization of a novel variant of the second domain of bikunin with increased leukocyte elastase inhibitory activity
  3322. Thrombosis and Cancer: A Major Complication of Cancer Care
  3323. Antiphospholipid antibodies in relation to sterility/infertility
  3324. Epidemiology and pathophysiology of nephrotic syndrome–associated thromboembolic disease
  3325. Peripartum cardiomyopathy: current state of knowledge, new developments and future directions
  3326. Management of coagulopathy
  3327. Transforming growth factor (TGF)-β levels and unprovoked recurrent venous thromboembolism
  3328. Hemostatic risk factors for pregnancy-related venous thrombosis
  3329. A New Era of Oral Anticoagulation in Atrial Fibrillation: Implications in Clinical Practice
  3330. Perioperative factor concentrate therapy
  3331. Evaluation of coagulation factors and platelet function from an off-line modified ultrafiltration technique for post-cardiopulmonary bypass circuit blood recovery
  3332. Clinical and genetic features of protein C deficiency in 23 unrelated Chinese patients
  3333. Evaluation of platelet aggregation in the presence of antiphospholipid antibodies: Anti-β2GP1 and anticardiolipin
  3334. Comparative evaluation of Tissue factor and Thrombomodulin activity changes during normal and idiopathic early and late foetal loss: The cause of hypercoagulability …
  3335. Comparative, double-blind, retrospective study for the role of heparin in septic shock
  3336. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: A Sonoclot in vitro study
  3337. The protein Z/protein Z-dependent protease inhibitor complex
  3338. Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics
  3339. Coagulation and regional o anesthesia 4
  3340. Thromboembolism and venous thrombosis of the deep veins in surgical children—an increasing challenge?
  3341. Uncommon ophthalmologic disorders in intensive care unit patients
  3342. Fibrin clot properties and their modulation in thrombotic disorders
  3343. Clinical analysis of living donor liver transplantation in patients with portal vein thrombosis
  3344. Disseminated Intravascular Coagulation
  3345. Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies
  3346. 3.4 Clinical predictivity of genetic tests for thromboembolism
  3347. Apolipoprotein M and the risk of unprovoked recurrent venous thromboembolism
  3348. Distant Testing in Laboratory Hematology and Flow Cytometry—The Indian Experience
  3349. The significance of antiphospholipid antibodies in liver recipients
  3350. Sleep apnea and risk of deep vein thrombosis: a non-randomized, pair-matched cohort study
  3351. Association of haemostasis activation markers with thrombophilia and venous thromboembolism
  3352. Design of simultaneous antimicrobial and anticoagulant surfaces based on nanoparticles and polysaccharides
  3353. The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A
  3354. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement
  3355. Thrombophilias-Pregnancy Related Risk Categories
  3356. Invertebrate models for biomedical research, testing, and education
  3357. Thrombosis and hemostatic abnormalities in hematological malignancies
  3358. Anticoagulant therapy during pregnancy for maternal and fetal acquired and inherited thrombophilia
  3359. In vivo profile of the anticoagulant effect of 17ß-amino-1, 3, 5 (10) estratrien-3-ol
  3360. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis
  3361. African–Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation
  3362. Inside Diagnostics
  3363. SOME HAEMOSTATIC CHANGES IN WOMEN ON HORMONAL CONTRACEPTIVES ATTENDING FAMILY PLANNING CLINIC AT AHMADU BELLO UNIVERSITY …
  3364. Correction of disorders in tissue perfusion, blood coagulation and fibrinolysis with Orbita apparatus on terahertz waves of cell metabolites
  3365. Thromboelastometry and organ failure in trauma patients: a prospective cohort study
  3366. Inflammation, thrombogenesis, fibrinolysis, and vein wall remodeling after deep venous thrombosis
  3367. Biomarkers of ALI/ARDS: pathogenesis, discovery, and relevance to clinical trials
  3368. Thrombophilia in assisted reproductive technology-place and needs for thromboprophylaxis
  3369. Infection-associated platelet dysfunction of canine platelets detected in a flow chamber model
  3370. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera
  3371. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential …
  3372. Evaluation of a new formula for calculating heparin dose for cardiopulmonary bypass patients
  3373. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease
  3374. The Excessively Clotting Cancer Patient
  3375. Sepsis and pregnancy
  3376. Acute Liver Failure in Intensive Care
  3377. Coagulopathies in the PICU: DIC and liver disease
  3378. Hematologic malignancies and thrombosis
  3379. Activated protein C does not alleviate the course of systemic inflammation in the APCAP trial
  3380. Recurrent venous thrombosis: a disorder of thrombin generation stimulus-response coupling?
  3381. Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach
  3382. Hemostasis in children
  3383. Prospective study on haematological and coagulation changes in acute pancreatitis.
  3384. Dynamic changes in thrombin generation in abdominal sepsis in mice
  3385. Prevelence of Hyperhomocystenemia deep vein Thrombosis
  3386. Preoperative liver function assessments to estimate the prognosis and safety of liver resections
  3387. Deep Vein Thrombosis-ECAB
  3388. Blood type, lymphadenectomy and blood transfusion predict venous thromboembolic events following radical prostatectomy with pelvic lymphadenectomy
  3389. Recent Insights into the Molecular and Cellular Contributions to Venous Thrombosis
  3390. HAEMOSTATIC PROFILE AND GLYCAEMIC CONTROL OF PATIENTS WITH TYPE TWO DIABETES MELLITUS IN SOUTH SOUTH NIGERIA
  3391. Miscellaneous rare bleeding disorders
  3392. 14.1 SEPSIS IN OBSTETRICS
  3393. Developments in factor Xa inhibitors for the treatment of thromboembolic disorders
  3394. Bacteria under stress by complement and coagulation
  3395. The hemostatic system as a modulator of atherosclerosis
  3396. Vitamin K antagonist therapy can be evaluated by whole blood CAT and results in high plasma levels of factor VIII as well as fibrinogen
  3397. The pathogenesis of nephropathia epidemica: new knowledge and unanswered questions
  3398. Haemostatic challenges in the cancer patient: focus on the perioperative period
  3399. Factor V G1691A (Leiden) and prothrombin G20210A gene mutation status, and thrombosis in patients with chronic myeloproliferative disorders
  3400. Factor IXa as a target for anticoagulation in thrombotic disorders and conditions
  3401. Platelets in pulmonary vascular physiology and pathology
  3402. A brief review of 50 years of perioperative thrombosis and hemostasis management
  3403. Molecular characterization of ph-negative myeloproliferative neoplasms in ukraine
  3404. The rete mirabile of the tail, an effective site for sampling sterile blood from armadillos (Dasypodidae, Xenarthra)
  3405. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X
  3406. Transforming growth factor (TGF)-levels and unprovoked recurrent venous thromboembolism.
  3407. Intensive Treatment of the Patient with Hepatic
  3408. Thrombotic complications of neonates and children with congenital nephrotic syndrome
  3409. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology
  3410. Left ventricular thrombus during cardiopulmonary bypass as the primary manifestation of heparin-induced thrombocytopenia
  3411. Risk factors for thrombosis in Serbian children
  3412. 4Lipid levels do not influence the risk of venous thromboembolism: results of
  3413. The identification and management of heparin-induced thrombocytopenia in the vascular patient
  3414. Pathogenic mechanisms of thrombosis in antiphospholipid syndrome (APS)
  3415. Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy
  3416. The use of anticoagulation proteins in the management of systemic inflammatory response associated with sepsis
  3417. The risk of occurrence of venous thrombosis: focus on protein Z
  3418. Risque de maladie veineuse thromboembolique chez la femme en âge de procréer
  3419. Treatment of acute coagulopathy associated with trauma
  3420. The short term effects of Endovascular Aneurysm Repair (EVAR) on coagulation and cardiovascular morbidity and mortality in patients with infra-renal Abdominal …
  3421. Richard O. Francis, Jeffrey S. Jhang
  3422. Nebulized fibrinolytic agents improve pulmonary fibrinolysis but not inflammation in rat models of direct and indirect acute lung injury
  3423. Venous Thromboembolism among Cancer Patients: A Review
  3424. Bothrops jararaca Venom Metalloproteinases Are Essential for Coagulopathy and Increase Plasma Tissue Factor Levels during Envenomation
  3425. Calcitonin gene-related peptide ameliorates hyperoxia-induced lung injury in neonatal rats
  3426. Venous Thromboembolic Disease
  3427. Age-related differences in plasma proteins: how plasma proteins change from neonates to adults
  3428. Independent and combined effects of prednisone and acetylsalicylic acid on thromboelastography variables in healthy dogs
  3429. Systemic autoimmune diseases and pregnancy
  3430. Pharmacology of hemostasis and thrombosis
  3431. Metabolic effects of combined oral
  3432. A new peptide (Ruviprase) purified from the venom of Daboia russelii russelii shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor …
  3433. The M2 haplotype in the ANXA5 gene is an independent risk factor for idiopathic small-for-gestational age newborns
  3434. Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: associação brasileira de hematologia, hemoterapia e terapia celular guidelines …
  3435. Pregnancy-associated venous thromboembolism: prevention and treatment
  3436. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence …
  3437. Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety
  3438. The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients
  3439. Snakebite envenomation in children: critical care issues
  3440. Danaparoid 16 for the treatment of heparin-induced thrombocytopenia
  3441. 10th International Winter Meeting on Coagulation. Basic, Laboratory and Clinical Aspects of Venous and Arterial Thromboembolic Diseases. Bormio, Italy, April …
  3442. Coagulation activation in an experimental pneumonia model in malnourished mice
  3443. Pediatric thrombophilia
  3444. Transcriptome Profiles Associated to VHSV Infection or DNA Vaccination in Turbot (Scophthalmus maximus)
  3445. Mechanisms of thrombogenesis
  3446. PREVENTION OF RECURRENT MISCARRIAGE
  3447. To Find out the Association of Antiphospholipid Antibody Syndrome and Chronic Leg Ulcers
  3448. Thromboelastometry and multiple organ failure in trauma patients
  3449. Links between allergy and cardiovascular or hemostatic system
  3450. Obstetric haemorrhage
  3451. Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women’s interagency HIV study (WIHS)
  3452. A cross sectional survey on the prevalence of protein c deficiency among patients previously treated for venous Thromboembolism at the kenyatta national hospital
  3453. Coagulation and inflammation in scrub typhus and murine typhus—a prospective comparative study from Laos
  3454. Obstetric Haemorrhage
  3455. Platelet reactivity and thrombogenicity in postmenopausal women
  3456. Familial aggregation of stroke
  3457. Kidney complications of hematopoietic stem cell transplantation
  3458. Endothelium-dependent and independent dilation capability of peripheral arteries in patients with systemic lupus erythematosus and antiphospholipid …
  3459. Effects of tetrastarch administration on hemostatic, laboratory, and hemodynamic variables in healthy dogs and dogs with systemic inflammation
  3460. Pharmacology in pictures and schemes. Vol. 2.
  3461. The link between inflammation and coagulation: influence on the interpretation of diagnostic laboratory tests
  3462. The evolution of drug discovery: from traditional medicines to modern drugs
  3463. Clinical syndromes associated with acquired antithrombin deficiency via microvascular leakage and the related risk of thrombosis
  3464. Liver transplantation in human immunodeficiency virus–infected patients: Procoagulant, but is antithrombotic prophylaxis required?
  3465. Silencing of tissue factor by antisense deoxyoligonucleotide prevents monocrotaline/LPS renal injury in mice
  3466. Designing direct and indirect factor Xa inhibitors
  3467. Neonatal portal vein thrombosis: diagnosis and management
  3468. The future of treatment for antiphospholipid syndrome
  3469. Thrombotic disease in the myeloproliferative neoplasms
  3470. Investigation of inherited thrombophilias in patients with pulmonary embolism
  3471. VENOUS THROMBOEMBOLISM IN WOMEN
  3472. Press review
  3473. In vivo depletion of leukocytes and platelets following injection of T cell-specific antibodies into mice
  3474. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets—an updated view
  3475. Global assays of hemostasis
  3476. Hematological problems in pediatric intensive care
  3477. Main Types of Clinical Appearance of Thrombophilic States During Pregnancy–Target Groups for Thrombophilia Testing
  3478. Venous Thromboembolism in Neonates, Children and Patients with Chronic Renal Disease–Special Considerations
  3479. Venous thromboembolism in women: risk factors and long term follow-up
  3480. Sepsis immunopathology: perspectives of monitoring and modulation of the immune disturbances
  3481. Effects of pegylated interferon α on fibrinolytic parameters in patients with chronic hepatitis C
  3482. Coagulation and thrombotic disorders associated with xenotransplantation
  3483. Elevated numbers and altered subsets of procoagulant microparticles in breast cancer patients using endocrine therapy
  3484. Effects of in vitro fertilization on thrombosis and haemostasis and the relationship between infertility and cardiovascular disease
  3485. Modeling thrombin generation: plasma composition based approach
  3486. Protein C Deficiency
  3487. Laboratory Analysis of Coagulation
  3488. Hemostatic Soluble Plasma Proteins During Acute-Phase Response and Chronic Inflammation
  3489. The role of coagulopathy and blood transfusion in acute respiratory distress syndrome
  3490. Molecular analysis and genotype-phenotype correlation in patients with antithrombin deficiency from Southern Italy
  3491. T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response
  3492. 4 Bleeding in the Neonate
  3493. Recurrent pregnancy loss
  3494. Islet Equivalent’Stem Cells and Diabetes
  3495. Hemostasis, coagulation abnormalities, and liver disease
  3496. Mass spectrometry-based glycomic profiling and its applications to α1, 3-galactosyltransferase gene-knockout pig in xenotransplantation
  3497. f~ nveSt utures
  3498. Herpesvirus mediated activation of coagulation and fibrinolytic proteins
  3499. The Relationship Between HIV Infection and Acute Deep Vein Thromboses
  3500. Studies on physicochemical and biological properties of protease inhibitor from edible mushroom Pleurotus floridanus
  3501. Immunohistochemical examination of placenta in women with thrombophilia and pregnancy loss summary
  3502. Management of hematological malignancies in patients affected by renal failure
  3503. Chapter Q Rare Congenital
  3504. Oxygen transport to tissue XXXIV
  3505. The Effects of vanilloid-like agents on platelet aggregation
  3506. Management of complications related to central venous catheters in cancer patients: an update
  3507. Tamoxifen induces resistance to activated protein C
  3508. Pregnancy complications
  3509. Pulmonary Embolic Disorders
  3510. Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies
  3511. Faculty of Engineering Science Avram and Stella Goldstein-Goren Department of Biotechnology Engineering
  3512. Antagonism by bioactive polyphenols against inflammation: a systematic view
  3513. Age-related differences in thrombin generation using a mathematical model
  3514. Prediction and prevention of venous thrombosis in pregnancy
  3515. Haematological abnormalities in decompensated chronic liver disease
  3516. Hemostasis & Thrombosis
  3517. Fast Facts: Bleeding Disorders
  3518. Pharmacogenetic, clinical and demographic factors in the management of warfarin therapy
  3519. Crosstalk between the sympathetic nervous system, inflammation and coagulation in gestational diabetes: a therapeutic approach in postmenopausal hypertension
  3520. A systematic approach to the bleeding patient: correlation of clinical symptoms and signs with laboratory testing
  3521. Atherogenesis and Atherosclerosis in Primary Antiphospholipid Syndrome
  3522. Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review
  3523. Physiology of aging among healthy, older bottlenose dolphins (Tursiops truncatus): comparisons with aging humans
  3524. Guidelines on the use of therapeutic apheresis in clinical practice—evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
  3525. The Pathogenesis, Diagnosis, and Treatment of Polycythaemia Vera
  3526. The role of shed GP in Ebola virus pathogenicity
  3527. Role of plasminogen activator inhibitor type 1 in experimental (post-traumatic) sepsis
  3528. Hemoglobin, and Coagulation
  3529. Self-management of oral anticoagulation therapy–methodological and clinical aspects
  3530. The Role of p16INK4a Expression in the Age-related Risk of Venous Thromboembolism
  3531. Shoshana Revel-Vilk Margaret L. Rand
  3532. Acute Phase Proteins in Prototype Rheumatic Inflammatory Diseases
  3533. The Canadian Massive Transfusion Consensus Conference Proceedings
  3534. ANTI-PLATELETS ACTIVITY IN AFRICAN WOMEN ON PROGESTIN INJECTABLE CONTRACEPTIVES
  3535. Factor XI Deficiency: a study of clinical, laboratory and molecular modifiers of bleeding phenotype
  3536. Osteoporosis: Bones in Contention
  3537. A population based cohort study: the epidemiology of pediatric venous thromboembolism in Quebec, Canada
  3538. Network Based Simulation on HPC for Translational Medicine: an Application to Anticoagulation
  3539. Platelet-rich plasma and adipose-derived mesenchymal stem cells for regenerative medicine-associated treatments in bottlenose dolphins (Tursiops truncatus …
  3540. Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation
  3541. Idiopathic Parkinson’s disease, vascular risk factors and cognition: A critical review
  3542. The effect of inflammatory cytokines and coagulation factors on von Willebrand factor synthesis and cleavage
  3543. Albumin versus an artificial colloid in rectal surgery patients
  3544. CYP2C0, VKORC1 and CYP4F2 variant frequencies in patients on either low or high stable warfarin maintenance therapy in the Ghanaian population
  3545. Neurologic Complications of Organ Transplantation and Immunosuppressive Agents
  3546. Speaker Abstracts (SP01–SP50)
  3547. Inhibitors of blood-clotting mechanisms
  3548. Altered clot formation and anticoagulation in a familial Alzheimer’s disease mouse model
  3549. Characterization of the Functional Roles of Histidine-Rich Glycoprotein in Coagulation
  3550. 16th World Congress on In Vitro Fertilization
  3551. Hereditary Diseases and Blood Transfusion: Proceedings of the Nineteenth International Symposium on Blood Transfusion, Groningen 1994, Organized by …
  3552. Alterations in Coagulation in Dogs with Heart Disease
  3553. Evaluating Risk of Recurrent Venous Thromboembolism During the Anticoagulation Period in Patients with Malignancy
  3554. Evaluating risk of recurrent venous thromboembolism during the anticoagulation period in patients with malignancy
  3555. ISCHEMIC HEART DISEASE
  3556. Effects of hormone therapy and calcium supplementation on morbidity and mortality in postmenopausal women
  3557. Host defenses to extracellularbacteria
  3558. Host defenses to extracellular DavidS.-
  3559. Outcome of Puumala Hantavirus-induced Nephropathia Epidemica
  3560. Cognitive impairment after stroke and TIA: Etiology, diagnosis and prevention
  3561. Mast cells in human epithelial cancers
  3562. Hematology, An Issue of Critical Care Nursing Clinics
  3563. Ultrstructural and flow cytometric analysis of platelets and fibrin networks during the menstrual cycle and pregnancy
  3564. Biomarkers for predicting the outcome of Puumala hantavirus infection
  3565. Novel Translational Strategies to Treat Cardiac Injury and Dysfunction
  3566. Protective Role of Octreotide on the Toxic Effect of L-asparaginase (Elspar) on Pancreas of Rats
  3567. Structural and functional studies of histidine-rich glycoprotein in relation to its roles in angiogenesis and coagulation
  3568. Food Allergy and Gluten-free Weight Loss: Control Your Body Chemistry, Reduce Inflammation, and Improve Your Health
  3569. Hematopoietic Stem Cell Transplantation in the PICU
  3570. Development of a Liver Gene Therapy Strategy for Haemophilia B With Lentiviral Vectors
  3571. Clinical Aspects of Thrombophilia Testing
  3572. Demystifying the prothrombotic role of NETs
  3573. Impact of Erythrocytapheresis on Endogenous anticoagulants in Sickle Cell Disease
  3574. Fresh frozen plasma transfusion fails to influence the hemostatic balance in critically ill patients with a coagulopathy
  3575. Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy
  3576. The coagulopathy of acute sepsis
  3577. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a …
  3578. Should all patients with sepsis receive anticoagulation? Yes
  3579. Direct oral anticoagulants in antiphospholipid syndrome
  3580. The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome
  3581. Can vitamin K synthesis altered by dysbiosis of microbiota be blamed in the etiopathogenesis of venous thrombosis?
  3582. High frequency of decreased antithrombin level in pregnant women with thrombosis
  3583. Coagulopathy and its management in patients with severe burns
  3584. Hemostasis, bleeding and thrombosis in liver disease
  3585. Genetic characterization of antithrombin, protein C and protein S deficiencies in Polish patients
  3586. Aging, hypercoagulability, and leg necrosis in critical limb ischemia
  3587. The levels of tissue factor pathway inhibitor in sepsis patients receiving prophylactic enoxaparin
  3588. Superior sagittal sinus thrombosis after intrathecal chemotherapy and intravenous high-dose cytarabine in an acute myeloid leukemia case with t (8; 21)(q22; q22)
  3589. Thrombophilia in Korean patients with arterial or venous thromboembolisms
  3590. Sepsis-associated coagulopathy: diagnosis with hematologic biomarkers and a novel hemostatic score that may predict the risk of developing a multiple organ …
  3591. Pregnancy-related venous thromboembolism
  3592. Combined thrombophilia in a young male presenting as life threatening pulmonary embolism
  3593. Primary and secondary haemostasis changes related to aging
  3594. Sepsis and septic shock: current treatment strategies and new approaches
  3595. An overview of thrombophilia and associated laboratory testing
  3596. The prevalence and clinical manifestation of hereditary thrombophilia in Korean patients with unprovoked venous thromboembolisms
  3597. Anticoagulation in Patients with Liver Cirrhosis
  3598. Thrombosis in pregnancy and maternal outcomes
  3599. Isolated calf deep vein thrombosis
  3600. Translational aspects of developmental hemostasis: infants and children are not miniature adults and even adults may be different
  3601. Hemostatic and thrombotic issues in cardiac surgery
  3602. Severe Thrombophilia in Idiopathic Fatal Pulmonary Embolism
  3603. Thrombophilic risk factors for chronic thromboembolic pulmonary hypertension (CTEPH) in Korea
  3604. Prothrombotic genetic risk factors in patients with very early ST-segment elevation myocardial infarction
  3605. Etiopathogenesis, prevention, and treatment of thromboembolism in inflammatory bowel disease
  3606. naturalcoagulation inhibitors in liver diseases
  3607. AN Bakulev National Scientific and Practical Center for Cardiovascular Surgery, Moscow, 121552, Russian Federation Background. In patients with IHD, there …
  3608. Hemostatic parameters in Thalassemia patients; a single institute experience
  3609. Haemostatic and fibrinolytic changes in obese subjects undergoing bariatric surgery: the effect of different surgical procedures
  3610. 1073: NEW HEMOSTATIC SCORE ADDING PROTEIN-C AND ANTITHROMBIN MAY BETTER IDENTIFY SEPSIS-INDUCED COAGULOPATHY
  3611. Role of family history of venous thromboembolism and thrombophilia as predictors of recurrence: a prospective follow‐up study
  3612. Cardiovascular effects of Etanercept in patients with psoriatic arthritis: evidence from the cardiovascular risk in rheumatic diseases database
  3613. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches
  3614. Down regulated protein C plasma levels in the absence of factor V leiden mutation in HIV patients: An observational study in Maiduguri, North-Eastern Nigeria
  3615. Warfarin induced skin necrosis–Forgotten Diagnosis
  3616. Variation of factor XIII level during pregnancy
  3617. Prevalence of pulmonary embolism during pregnancy
  3618. Association of Inherited Thrombophilia with Placental Adverse Outcomes and Recurrent Pregnancy Loss.
  3619. INHERITED ANTITHROMBIN DEFICIENCY IN PATIENTS WITH RECURRENT THROMBOTIC EVENTS
  3620. Pattern of deranged haemostatic biomarkers among HIV patients: a descriptive case control cohort study in a tertiary health facility in northeastern Nigeria
  3621. Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is ‘shock liver’the unrecognized provocateur of ischemic limb necrosis?
  3622. Clinical aspects of the haemostasis-inflammation interface
  3623. Genetics in thrombophilia
  3624. Multiple Thrombosis Modifier Loci Identified Using a Sensitized Mutagenesis Screen
  3625. DEFICIENCY OF PROTEIN S AND FACTOR V PRESENTING AS ISCHEMIC STROKE IN A 14 YEARS OLD BOY
  3626. S-261 The clinical manifestation of hereditary thrombophilia in patients with unprovoked venous thrombosis
  3627. Remarks about the study of an unusual presentation of venous thrombosis in a child with idiopathic membranous nephropathy
  3628. Management of Coagulopathies in Liver Cirrhosis
  3629. A Multicenter Prospective Phase II Study of Antithrombin-III Based Treatment for Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation
  3630. Uncertain thrombophilia markers
  3631. Thrombophilia testing in young patients with ischemic stroke
  3632. Markers of coagulation activation in patients with hemoglobinopathy in Western Saudi Arabia
  3633. New products for the treatment of haemophilia
  3634. Enhanced thrombin generation and reduced intact protein S in processed solvent detergent plasma
  3635. Coagulopathy in liver disease: a balancing act
  3636. Coagulation phenotypes in septic shock as evaluated by calibrated automated thrombography
  3637. Endogenous thrombin potential as marker of procoagulant response that can be useful in early stage of sepsis
  3638. Inpatient Hypercoagulable Testing, a Single Institution Experience
  3639. HEREDITARY THROMBOPHILIA-RISK FACTOR FOR OBSTETRIC COMPLICATIONS
  3640. Thrombophilia screening: An artificial neural network approach
  3641. Added Value of Next-Generation Sequencing for Haemostasis Diagnosis
  3642. Interpretation of clotting tests in the neonate
  3643. Levels of Protein S and Risk of Thromboembolism
  3644. Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S
  3645. Role of thrombophilia testing: con
  3646. Altered fibrin clot properties in patients with cerebral venous sinus thrombosis: association with the risk of recurrence
  3647. Hypercoagulable state as demonstrated by thromboelastometry in hemoglobin E/beta-thalassemia patients: association with clinical severity and splenectomy status
  3648. Dysfunction in the coagulation system and schizophrenia
  3649. Causes of venous thrombosis
  3650. Interaction of hereditary thrombophilia and traditional cardiovascular risk factors on the risk of arterial thromboembolism: pooled analysis of four family cohort studies
  3651. Thromboprophylaxis in liver cirrhosis: No
  3652. Disseminated intravascular coagulation syndromes in obstetrics
  3653. The different faces of disseminated intravascular coagulation in solid tumors: how to identify and manage
  3654. Pharmacologic therapies in anticoagulation
  3655. Platelet function tests in bleeding disorders
  3656. Protein S and protein C deficiency with multiple infarcts in a human immunodeficiency virus-infected female child
  3657. The past and future of haemophilia: diagnosis, treatments, and its complications
  3658. Antiphospholipid antibodies and antiphospholipid syndrome during pregnancy: diagnostic concepts
  3659. A sustained decrease in plasma fibrinolytic potential following partial liver resection or pancreas resection
  3660. Hemostasis: a cell based model
  3661. Thrombophilia And Arterial Ischemic Stroke
  3662. Venous thromboembolism and thrombophilia testing
  3663. Haemostatic profile of patients with chronic liver disease-its correlation with severity and outcome
  3664. Clinical and biochemical characterization of the prothrombin Belgrade mutation in a large Serbian pedigree: new insights into the antithrombin resistance mechanism
  3665. Alcohol Consumption, High-Density Lipoprotein Cholesterol, Antithrombin III, and Body Mass Index Are Associated with Great Saphenous Vein Reflux in the Thigh
  3666. Classic thrombophilic gene variants
  3667. Heparin-induced thrombocytopenia
  3668. Evaluation of coagulopathy before and during induction chemotherapy for acute lymphoblastic leukaemia, including assessment of global clotting tests
  3669. Haemostatic management of obstetric haemorrhage
  3670. portal vein obstruction–epidemiology, pathogenesis, naturalhistory, prognosis and treatment
  3671. Renal and adrenal vein thromboses
  3672. Thromboembolic complications in inflammatory bowel disease
  3673. Coagulation profile during induction chemotherapy in childhood acute lymphoblastic leukemia
  3674. High prevalence of congenital thrombophilia in patients with pregnancy-related or idiopathic venous thromboembolism/pulmonary embolism
  3675. Structural and functional insights into enzymes of the vitamin K cycle
  3676. A Role for Platelets in Normal Pregnancy
  3677. Anticoagulant Activities of Olea Europaea Leaves and Fruit Extract
  3678. Management of Severe Bleeding in Cardiovascular Patients
  3679. Blood coagulation in immunothrombosis—At the frontline of intravascular immunity
  3680. Potential Use of Polysaccharides from the Brown Alga Undaria pinnatifida as anticoagulants
  3681. Changes in blood coagulation and anticoagulation factors activity in women with different risks of cardiovascular events
  3682. Herbs for atrial fibrillation
  3683. Functional analyses yield detailed insight into the mechanism of thrombin inhibition by the antihemostatic salivary protein cE5 from Anopheles gambiae
  3684. Lipid levels and risk of venous thrombosis: results from the MEGA-study
  3685. Low paediatric thrombin generation is caused by an attenuation of prothrombin conversion
  3686. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis
  3687. Coagulation Impairment in type 2 diabetes mellitus
  3688. In-vitro assessment of the effect of dabigatran on thrombosis of adult and neonatal plasma: comparisons using thromboelastography and microscopic visualization of …
  3689. Disseminated Intravascular Coagulation
  3690. Disseminated Intravascular Coagulation (DIC) and Thrombocytopenia in Pregnancy
  3691. Platelet haemostatic function in psychiatric disorders: Effects of antidepressants and antipsychotic drugs
  3692. Unexpected Multiple Organ Infarctions in a Poisoned Patient
  3693. Cerebral venous thrombosis in young adult with familial protein S deficiency
  3694. Homocysteine metabolism and haemostatic factor in Behcet’s disease
  3695. Thrombosis factors and oxidant/antioxidant markers in obese and hypertensive women during pregnancy
  3696. Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome
  3697. Pre-eclampsia: The Role of Hemostasis in Its Pathophysiology and Potential Future Therapeutic Options
  3698. Pegasparaginase treatment alters thrombin generation by modulating the protein C and S system in acute lymphoblastic leukaemia/lymphoma
  3699. Antiphospholipid antibody mechanisms of thrombosis
  3700. Epidemiology of venous thromboembolism
  3701. Hypercoagulability and Ischemic Stroke in Young Patients
  3702. Pediatric Antiphospholipid Syndrome
  3703. Thrombosis in adult patients with acute leukemia
  3704. Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome
  3705. Thrombophilia testing and venous thrombosis
  3706. ANTITHROMBIN III AS MARKER OF FIBROSIS IN CHRONIC HEPATITIS C
  3707. Bleeding diatheses: approach to the patient who bleeds or has abnormal coagulation
  3708. Thrombomodulin is a strong predictor of multiorgan dysfunction syndrome in patients with sepsis
  3709. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians
  3710. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events
  3711. How do we transfuse blood components in cirrhotic patients undergoing gastrointestinal procedures?
  3712. Balance between von Willebrand factor and ADAMTS13 following major partial hepatectomy
  3713. Thrombocytopenia associates with the severity of inflammation and variables reflecting capillary leakage in Puumala Hantavirus infection, an analysis of 546 Finnish …
  3714. Factor V Leiden, prothrombin and MTHFR mutation in patients with preeclamsia, intrauterine growth restriction and placental abruption
  3715. Thrombophilia and Pregnancy
  3716. Genetic aspects of thrombotic disease
  3717. Pathophysiology of AKI
  3718. Factors associated with rodent eradication failure
  3719. Thrombosis in inflammatory bowel diseases: what’s the link?
  3720. A case-based reasoning view of thrombophilia risk
  3721. High rates of thromboembolic events in patients with germ cell cancer undergoing cisplatin-based polychemotherapy
  3722. Hemodilution on cardiopulmonary bypass: thromboelastography patterns and coagulation-related outcomes
  3723. An unexpected complication of acute pancreatitis: Intra-cardiac thrombus
  3724. Cardiovascular involvement in inflammatory bowel disease: dangerous liaisons
  3725. Risk factors of infected pancreatic necrosis secondary to severe acute pancreatitis
  3726. Whole exome sequencing reveals severe thrombophilia in acute unprovoked idiopathic fatal pulmonary embolism
  3727. Investigation of Plasminogen Activator Inhibitor‐1 (PAI‐1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A case‐control study
  3728. Associations between pre‐eclampsia and protein C and protein S levels among pregnant Nigerian women
  3729. Phenotypic heterogeneity of hemostasis in severe hemophilia
  3730. Endotoxemia as a trigger of thrombosis in cirrhosis
  3731. Protein C deficiency in chronic Hepatitis C: correlation with histological extent of liver fibrosis
  3732. Interaction between Serum Thrombomodulin and Serum CRP Levels in Predicting Ischemic Heart Disease: A story in reverse direction
  3733. Clinical outcome of a portosplenomesenteric venous thrombosis in necrotizing acute pancreatitis with protein C and S deficiency treated by anticoagulation …
  3734. Idiopathic inflammatory myopathy and the risk of venous thromboembolism: a meta-analysis
  3735. Citrate anticoagulation during continuous renal replacement therapy
  3736. Disseminated intravascular coagulation–new pathophysiological concepts and impact on management
  3737. Heritable Thrombophilia
  3738. Reconstruction of near-total loss of the upper and lower lips due to purpura fulminans with local tissue and a dual-skin paddled anterolateral thigh flap
  3739. Thromboembolic disease in dogs and cats
  3740. Haematological conditions
  3741. Diagnosis and management of catastrophic antiphospholipid syndrome
  3742. Effects of exposure to air pollution on blood coagulation
  3743. Thrombotic Disorders
  3744. Rational and timely haemostatic interventions following cardiac surgery-coagulation factor concentrates or blood bank products
  3745. Point-of-care testing in burn patients
  3746. Inherited thrombophilia: a double-edged sword
  3747. A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center
  3748. Sepsis-associated coagulopathy
  3749. Evaluation of INR Elevation in Cirrhotic Patients as a Risk Factor for Esophageal Variceal Bleeding
  3750. Evaluation of INR Elevation in Cirrhotic Patients as a Risk Factor for Esophageal Variceal Bleeding
  3751. Ethnic diversity in the genetics of venous thromboembolism
  3752. Prolactin and naturalkiller cells: evaluating the neuroendocrine‐immune axis in women with primary infertility and recurrent spontaneous abortion
  3753. Activated partial thromboplastin time versus anti-factor Xa levels for monitoring unfractionated heparin therapy in children: an institutional experience
  3754. Use of essentiale Forte n in complex treatment of Antiphospholipid syndrome in women
  3755. Clinical adherence to thrombophilia screening guidelines at a major tertiary care hospital
  3756. Rivaroxaban Induced Protein S Deficiency
  3757. Cerebral venous thrombosis in a breast cancer patient taking tamoxifen: report of a case
  3758. Methylenetetrahydrofolate reductase gene polymorphisms and venous thrombosis
  3759. Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block
  3760. Antiphospholipid syndrome and kidney disease
  3761. Cytokines and C-Reactive Protein-Trigger of Imbalance of the Hemostasis System during Inflammation
  3762. Ex vivo thrombin generation patterns in septic patients with and without disseminated intravascular coagulation
  3763. Massive obstetric hemorrhage: Current approach to management
  3764. Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia
  3765. Optimal duration of anticoagulation
  3766. Impact of time-varying treatment exposures on the risk of venous thromboembolism in multiple myeloma
  3767. Aspirin and heparin in pregnancy
  3768. Risk of bleeding in end-stage liver disease patients undergoing cardiac catheterization
  3769. IN VITRO MILK CLOTTING AND ANTICOAGULANT PROPERTIES OF THE LATEX OF JATROPHA GOSSYPIFOLIA L.
  3770. The modulation of coagulation by aptamers: an up-to-date review
  3771. STUDY OF SOME HEMATOLOGICAL AND HAEMOSTASIS ASPECTS IN CHRONIC C VIRUS
  3772. Thrombosis in leukemia: incidence, causes, and practical management
  3773. Silencing of Anticoagulant Protein C Evokes Low-Incident but Spontaneous Atherothrombosis in Apolipoprotein E–Deficient Mice—Brief Report
  3774. Incidence and risk factors of thromboembolism with multiple myeloma in the presence of death as a competing risk: an empirical comparison of statistical …
  3775. New functional assays to selectively quantify the activated protein C‐and tissue factor pathway inhibitor‐cofactor activities of protein S in plasma
  3776. Thymoquinone modulates blood coagulation in vitro via its effects on inflammatory and coagulation pathways
  3777. Haemostasis disorders caused by envenomation by Cerastes cerastes and Macrovipera mauritanica vipers
  3778. Age features of the hemostatic system in people with insulin resistance and prediabetic carbohydrate metabolism disorders
  3779. Peculiarities of Hemostasis System in Pregnant Women with Fetal Loss Syndrome on the Background of Thrombophilia
  3780. Venous thromboembolism: an overview
  3781. Hypercoagulability progresses to hypocoagulability during evolution of acetaminophen-induced acute liver injury in pigs
  3782. Protein C deficiency resulting from two mutations in PROC presenting with recurrent venous thromboembolism
  3783. Differential effect of the ultra‐low dose and standard estrogen plus dydrogesterone therapy on thrombin generation and fibrinolysis in postmenopausal women
  3784. Risk factors for thrombosis development in Mexican patients
  3785. Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective
  3786. BALANCING THE THROMBOTIC RISK AND THE HEMORRHAGIC RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND DEEP VEIN THROMBOSIS …
  3787. Protective effects of S-adenosylmethionine (SAMe) and silybin on hepatorenal and hemostatic functions in dogs with endotoxemia
  3788. Treatment of Disseminated Intravascular Coagulation
  3789. In vitro exploration of latent prothrombin mutants conveying antithrombin resistance
  3790. Primary thrombophilia in Mexico: a single tertiary referral hospital experience
  3791. Dysfunctional fibrinolysis and cerebral venous thrombosis
  3792. Mechanisms for glyproline protection in hypercholesterolemia
  3793. A novel nonsense mutation Tyr301* of PROS1 causing protein S deficiency
  3794. Unseen face of varicella-zoster infection in adults
  3795. Venous thromboembolism as initial manifestation of adult onset Still’s disease
  3796. Neonatal haemostasis and the management of neonatal thrombosis
  3797. Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A …
  3798. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
  3799. Management of Thromboembolism could become Cheaper and Simpler
  3800. The Importance of Familiar Thrombophilias in the Clinical Practice. Novel Ways in Anticoagulant Therapy
  3801. The interplay between inflammation, coagulation and endothelial injury in the early phase of acute pancreatitis: clinical implications
  3802. Renal vein thrombosis in a newborn with abnormal factor VIII level: Clinical case report
  3803. Innate immunity, hemostasis and matrix remodeling: PTX3 as a link
  3804. Effect of compression devices on preventing deep vein thrombosis among adult trauma patients: a systematic review
  3805. Immunohaemostasis: a new view on haemostasis during sepsis
  3806. Hemostatic complications in renal transplantation
  3807. Polyphosphate as modulator of hemostasis, thrombosis, and inflammation
  3808. Circuit life versus bleeding risk: the impact of achieved activated partial thromboplastin time versus achieved filtration fraction
  3809. Pathogenesis and epidemiology of venous thromboembolic disease
  3810. Deep venous thrombosis in children with sickle cell disease
  3811. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis
  3812. Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy
  3813. Deficiency of protein C and protein S in recurrent pregnancy loss
  3814. Combined protein C and protein S deficiency with pregnancy
  3815. SUB-ACUTE STENT THROMBOSIS AND IN-STENT RESTENOSIS ASSOCIATED WITH ANTIPLATELETS CLOPIDOGREL RESISTANCE AND PROTEIN S …
  3816. Treatment with acetylsalicylic acid prevents short to mid-term radiographic progression of nontraumatic osteonecrosis of the femoral head: a pilot study
  3817. Allergy and venous thromboembolism: a casual or causative association
  3818. Therapeutic effect of low doses of acenocoumarol in the course of ischemia/reperfusion-induced acute pancreatitis in rats
  3819. Coagulation abnormalities in sepsis
  3820. MicroRNAs in hemostasis
  3821. Hemostatic abnormalities in critically ill patients
  3822. Assessment of the hemostatic parameters and platelet function on thromboelastometry and impedance aggregometry in hemodialysis patients qualified for kidney …
  3823. What’s new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia?
  3824. A case of deep vein thrombosis in the postpartum period
  3825. Venous thromboembolism does not share familial susceptibility with retinal vascular occlusion or glaucoma: a nationwide family study
  3826. Free protein s reference ranges in gravidas without hereditary and acquired thrombophilia
  3827. Clinical, laboratory, and hemostatic findings in cats with naturally occurring sepsis
  3828. PAI-1 study in thalassemia major patients receiving multiple blood transfusion
  3829. Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations
  3830. Proper diagnosis of antithrombin III deficiency
  3831. Investigation of Some Coagulation Parameters in Pregnant Womens with Preeclampsia
  3832. Risk Factors for Venous Thromboembolism
  3833. Plasma factor VIII levels as a biomarker for venous thromboembolism
  3834. Antiplatelets and antithrombotics in patients with liver insufficiency: from pathophysiology to clinical practice
  3835. Hyper-Homocysteinemia and other Inherited Thrombophilic Factors Inducing Retinal Vein Occlusion. The Employment of Novel Orals Anti-Coagulants is …
  3836. A novel PROS1 mutation, c. 74dupA, was identified in a protein S deficiency family
  3837. Deep Hypoalbuminemia in Patients with Immunoglobulin Light Chain Amyloidosis: A Risk Factor for Vascular Thromboembolic Events or Only a Causal Link?
  3838. Antiplatelet agents for the treatment of deep venous thrombosis
  3839. Thromboelastographic characterization of the activated clotting system in children with sickle cell trait or sickle cell disease
  3840. The C20068T gene variant in the 3end of the prothrombin gene and recurrent pregnancy loss: A pilot study
  3841. Warfarin Induced Skin Necrosis: A Diagnostic Challenge
  3842. Ultrasound screening for deep venous thrombosis detection: a prospective evaluation of 200 plastic surgery outpatients
  3843. The bleeding newborn: a review of presentation, diagnosis, and management
  3844. Analysis of thrombophilia test ordering practices at an academic center: a proposal for appropriate testing to reduce harm and cost
  3845. All we know about polycythemia vera: literature review and own experience
  3846. Platelet adhesion and thrombus formation in whole blood at arterial shear rate at the end of pregnancy
  3847. Differences in coagulation in clotting of vascular access in hemodialysis patients
  3848. Low‐dose maternal warfarin intake resulting in fetal warfarin syndrome: in search for a safe anticoagulant regimen during pregnancy
  3849. A comparison of extremity thrombosis rates in adolescent and young adult versus younger pediatric oncology patients at a children’s hospital
  3850. PLATELET INDICES AND RED BLOOD CELL INDICES IN RECURRENT PREGNANCY LOSS CASES
  3851. Endothelium and haemostasis
  3852. International Journal of Hematology Research
  3853. Ischemic limb gangrene with pulses
  3854. Anticoagulant flavonoid oligomers from the rhizomes of Alpinia platychilus
  3855. Transient Hemi-Lower Limb Ischemia in the Newborn: Arterial Thrombosis or Persistent Sciatic Artery?
  3856. Diagnostics of inherited bleeding disorders of secondary hemostasis: an easy guide for routine clinical laboratories
  3857. Plasminogen Activator Inhibitor-1 (PAI-1) in Steady State Sickle Cell Disease and Haemoglobin AA Phenotype Controls.
  3858. Coagulation factor VIII, IX and XI levels in north Indian patients with venous thromboembolism: first study from India
  3859. Intraprocedural stent thrombosis, antithrombin-III dependent heparin resistance and crush technique for bifurcation lesions: The “Devil’s Triangle”
  3860. Diagnostic heterogeneity in orthopaedic oncology makes standardized recommendations regarding anticoagulation difficult
  3861. Thromboelastography: clinical application, interpretation, and transfusion management
  3862. Features of the histological structure of trophoblast and chorionic villi with recurrent pregnancy loss in women with thrombophilias
  3863. Hereditary thrombophilia (rare multiple genetic defects combination) caused portal vein thrombosis complicated by hypersplenism and pancytopenia
  3864. Antithrombin: anti-inflammatory properties and clinical applications
  3865. Antibodies directed against annexin A2 and obstetric morbidity
  3866. Deficient protein C and protein S induced acute venous mesenteric ischemia: a case report
  3867. Haematological Changes of Critically ill Patients Admitted in CMH, Dhaka
  3868. ALTERED FIBRIN CLOT PROPERTIES IN PATIENTS WITH CEREBRAL SINUS VENOUS THROMBOSIS: ASSOCIATION WITH THE RISK OF RECURRENCE
  3869. ADVANCES IN HEMATOLOGY
  3870. The assessment of plasma hemostasis parameters in women with acute coronary syndrome with segment ST elevation
  3871. Potential diagnostic markers for disseminated intravascular coagulation of sepsis
  3872. AN UNUSUAL PRESENTATION OF DISSEMINATED INTRAVASCULAR COAGULATION AS SUBLINGUAL HEMATOMA DUE TO GRAM NEGATIVE …
  3873. Systemic lupus erythematosus and thrombosis
  3874. Eosinophilia and Antiphospholipid Antibodies: Double Thrombogenic Hits
  3875. Thrombophilia testing patterns amongst patients with acute venous thromboembolism
  3876. Bidirectional risk between venous thromboembolism and cancer in East Asian patients: synthesis of evidence from recent population-based epidemiological …
  3877. Issues in the diagnosis and management of hereditary antithrombin deficiency
  3878. Abraham Majluf-Cruz d, Jorge Vela-Ojeda e, Jaime García-Chávez f, Elba Reyes-Maldonado e*.
  3879. Identification of Thrombosis Modifier Genes Using ENU Mutagenesis in the Mouse.
  3880. Activated protein C retards recovery from coagulopathy in severe acute pancreatitis
  3881. Acquired Thrombophilias
  3882. A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events: impact on management
  3883. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study
  3884. Administration of antithrombin III attenuates posthepatectomy liver failure in hepatocellular carcinoma
  3885. Control of Intravascular Thrombosis
  3886. Controversies concerning the antiphospholipid syndrome in obstetrics
  3887. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome
  3888. Hemostatic abnormalities in dogs with naturally occurring heatstroke
  3889. Inflammation and thrombophilia in pregnancy complications: implications for risk assessment and clinical management
  3890. Ruptured intracranial aneurysm during pregnancy with false-negative computed tomography angiography findings: a case report
  3891. Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity
  3892. Assessing thrombocytopenia in the intensive care unit: the past, present, and future
  3893. A study of the naturalcoagulating inhibitors polymorphism in Iranian patients with the vine thrombosis
  3894. Description of selected diagnostic tools in assessing the risk of venous thromboembolic disease
  3895. Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe …
  3896. Thrombophilia with an onset symptom of intracranial venous thrombosis: A case report and review of the literature
  3897. Anesthesia management of the parturient with protein S and C deficiency for cesarean section
  3898. Tyrosine sulfation modulates activity of tick-derived thrombin inhibitors
  3899. Thrombophilia: the dermatological clinical spectrum
  3900. Usefulness of artificial jump graft to portal vein thrombosis in deceased donor liver transplantation
  3901. Do neutrophil extracellular traps contribute to the heightened risk of thrombosis in inflammatory diseases?
  3902. Catheter and coronary artery thrombosis during coronary intervention in a HIV infected patient
  3903. Biomarkers of coagulation and thrombosis
  3904. Genetic and acquired risk factors of thrombophilia among Palestinian women with recurrent pregnancy loss
  3905. Thrombophilia testing in provoked venous thromboembolism: a teachable moment
  3906. Disseminated intravascular coagulation: a practical approach
  3907. The relation of protein C and protein S levels with cardiovascular risk in patients with diabetic neuropathy
  3908. Pulmonary artery embolism during the course of colitis ulcerosa—the constant diagnostic challenge of invasive fungal infection
  3909. Venous thromboembolism and stroke in pregnancy
  3910. Follicular fluid alterations in endometriosis: label-free proteomics by MSE as a functional tool for endometriosis
  3911. Beyond warfarin: The advent of new oral anticoagulants
  3912. Coagulation factor levels in relation to venous thrombosis and cancer: Results from the MEGA study
  3913. Coagulation in patients with severe sepsis
  3914. Ovarian malignancy unmasked by venous gangrene in a patient on warfarin therapy: a case report
  3915. Nebulized recombinant human tissue factor pathway inhibitor attenuates coagulation and exerts modest anti-inflammatory effects in rat models of lung injury
  3916. Serum D-dimer is a potential predictor for thromboembolism complications in patients with renal biopsy
  3917. New oral anticoagulants: clinical parameters and uses in practice
  3918. Bleeding and thrombosis: Women’s issues
  3919. Risk factors and management of venous thromboembolic diseases in donor of living donor Liver transplant
  3920. Venous thromboembolism in patients with liver diseases
  3921. Antithrombin in the treatment of burn trauma
  3922. Utility of thrombophilia testing in patients with venous thrombo-embolism
  3923. Stroke in women (Sudanese experience)
  3924. Evaluation Of Protein C Levels In Sickle Cell Disease Subjects Seen At The University Of Benin Teaching Hospital, Nigeria.
  3925. How do you decide on hormone replacement therapy in women with risk of venous thromboembolism?
  3926. Can plateletcrit be a marker for recurrent pregnancy loss?
  3927. Bleeding and thrombosis in cancer patients
  3928. The prevention and treatment of venous thromboembolism in pregnancy
  3929. Venous Thromboembolism in Intensive Care
  3930. The Interface between Immunotransfusion and Hemostasis and Thrombosis Testing
  3931. In-depth analysis of clotting dynamics in burn patients
  3932. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH
  3933. Effect of testing for cancer on cancer‐and venous thromboembolism (VTE)‐related mortality and morbidity in patients with unprovoked VTE
  3934. Effects of aging on the coagulation fibrinolytic system in outpatients of the cardiovascular department
  3935. Genetic risk factors in venous thromboembolism
  3936. The acquired form of ADAMTS-13 deficiency as the cause of thrombotic microangiopathy in a pregnant woman with recurrent cerebral circulation disorders, venous …
  3937. Leech therapy in the management of congested free flaps
  3938. Hematological Changes with Aging
  3939. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from …
  3940. New anticoagulants for the prevention and treatment of venous thromboembolism
  3941. Peter E. Fischer, Thomas G. DeLoughery, Gail Gesin, and Martin A. Schreiber
  3942. Patterns of venous thromboembolism prophylaxis during treatment of acute leukemia: results of a North American web-based survey
  3943. Four-factor prothrombin complex concentrate for coagulopathy reversal in patients with liver disease
  3944. Improvement of psychotic symptoms and the role of tissue plasminogen activator
  3945. Thrombin generation and international normalized ratio in inherited thrombophilia patients receiving thromboprophylactic therapy
  3946. Additional treatments for high-risk obstetric antiphospholipid syndrome: a comprehensive review
  3947. Fact checking the lore of hypercoagulable work up
  3948. ANTITHROMBOTIC THERAPY IN PATIENTS WITH METABOLIC SYNDROME AFTER ABDOMINAL DELIVERY
  3949. Blood Coagulation During Sepsis and Septic Shock: Is There Still Room
  3950. β-thalassemia patients and gynecological approach: review and clinical experience
  3951. Subtypes of SERPINC1 mutations and the thrombotic phenotype of inherited antithrombin deficient individuals in Chinese Han population
  3952. Heparin-induced thrombocytopenia
  3953. Hormone replacement therapy and venous thrombosis
  3954. The first case of breast cancer in thalassemic patient: case report and review of literature
  3955. The risk of venous thromboembolism in patients with hepatitis C
  3956. Epidemiology, risk factors, and in-hospital mortality of venous thromboembolism in liver cirrhosis: A single-center retrospective observational study
  3957. Histones differentially modulate the anticoagulant and profibrinolytic activities of heparin, heparin derivatives, and dabigatran
  3958. Role of invasive imaging in acute and long‐term assessment of bioresorbable scaffold technology
  3959. Unexplained recurrent miscarriages are associated with an aberrant sperm protamine mRNA content
  3960. In vitro inhibition of thrombin generation by sulfated polysaccharides from the tropical red seaweed Gracilaria birdiae Plastino & Oliveira
  3961. Discovery of a potential plasma protein biomarker panel for acute-on-chronic liver failure induced by hepatitis B virus
  3962. Association of sarcoidosis with increased risk of VTE: a population-based study, 1976 to 2013
  3963. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant) …
  3964. A step toward balance: thrombin generation improvement via procoagulant factor and antithrombin supplementation
  3965. Medicinal and nutraceutical importance of sulphated polysaccharides from marine sources: Emphasis on fucoidan
  3966. ANTITHROMBIN LEVELS IN ADULT STROKE PATIENTS ATTENDING THE UNIVERSITY OF BENIN TEACHING HOSPITAL, EDO STATE
  3967. A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES)
  3968. A conceptual and practical approach to haemostasis in paediatric liver disease
  3969. Is either arterial or venous antithrombin III level linked to outcome in elderly males versus females with severe sepsis?
  3970. Thalidomide‐prednisone maintenance following autologous stem cell transplant for M ultiple M yeloma: effect on thrombin generation and procoagulant markers in …
  3971. Unusual involvement of the portal vein in polycythemia vera-genetic perspective
  3972. Incidence of anticardiolipin antibodies and lupus anticoagulant factor among women experiencing unexplained recurrent abortion and intrauterine fetal death
  3973. Elevated risk of venous thromboembolic events in patients with inflammatory myopathies
  3974. DAMPs: Damage-Associated Molecular Pattern Molecules in Hemostasis
  3975. Acquired disorders of coagulation
  3976. Comparison of the effects of anticoagulants used in blood collection to determine blood parameters of free-living stingrays from the Potamotrygon genus …
  3977. Systemic thromboembolism in pregnancy: Heritable and acquired thrombophilias
  3978. Plasma concentrations of protein Z and protein Z-dependent protease inhibitor in patients with essential thrombocythemia
  3979. Update on acute liver failure
  3980. Varicella complicated by cellulitis and deep vein thrombosis
  3981. Catastrophic antiphospholipid syndrome: The current management approach
  3982. Thrombophilia in patients with chronic immune thrombocytopenia
  3983. A primary role for kinin B1 receptor in inflammation, organ damage, and lethal thrombosis in a rat model of septic shock in diabetes
  3984. Period repair manual: naturaltreatment for better hormones and better periods
  3985. Shock induced endotheliopathy (SHINE) in acute critical illness-a unifying pathophysiologic mechanism
  3986. Is diabetes a hypercoagulable state? A critical appraisal
  3987. Mechanical heart valve prosthesis
  3988. The dirty side of the intrinsic pathway of coagulation
  3989. Single Nucleotide Variant rs2232710 in the Protein Z-Dependent Protease Inhibitor (ZPI, SERPINA10) Gene Is Not Associated with Deep Vein Thrombosis
  3990. General introduction and outline of the thesis
  3991. Massive Hemorrhage
  3992. What can hide a neonatal sepsis with subsequent foot amputation?
  3993. Arterial ischemic stroke in children and young adults
  3994. Thrombosis in cancer patients: etiology, incidence, and management
  3995. Perioperative thromboprophylaxis in Cushing’s disease: what we did and what we are doing?
  3996. Massive thrombosis of the right atrium extended to the superior vena cava at the diagnosis of acute myeloid leukemia
  3997. Gender related issues in thrombosis and hemostasis
  3998. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system
  3999. Acute visceral vein thrombosis as a manifestation of complex inherited thrombophilia
  4000. Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases
  4001. Anticoagulant therapy in sepsis. The importance of timing
  4002. Thrombophilia and the Risk of Recurrent Venous Thromboembolism—Reply
  4003. Impact of thrombophilia screening on venous thromboembolism management practices
  4004. Manifestations and clinical impact of pediatric inherited thrombophilia
  4005. The optimal duration of anticoagulation in patients with unprovoked venous thromboembolism
  4006. Characterization of the glycosylation of newborn and adult alpha-2-macroglobulin
  4007. Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide
  4008. Thrombocytopenia in dengue: interrelationship between virus and the imbalance between coagulation and fibrinolysis and inflammatory mediators
  4009. Clinical outcomes of a pharmacy-led blood factor stewardship program
  4010. Anticoagulation: Heparins and Vitamin K Antagonists
  4011. Anticoagulant proteins in a population of Mexican mestizo donors
  4012. Prospects for the therapeutic application of sulfated polysaccharides of brown algae in diseases of the cardiovascular system
  4013. Gold nanoparticles in the engineering of antibacterial and anticoagulant surfaces
  4014. Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors
  4015. Anti-aging effect and gene expression profiling of dung beetle glycosaminoglycan in aged rats
  4016. Regulating Hemostasis: The Factor Va Cofactor Effect
  4017. Thrombophilia screening: universal, selected, or neither?
  4018. The role of hypercoagulability in ischemic colitis
  4019. Special Disease Considerations in the Neonate
  4020. Thromboelastographic evaluation of coagulation in patients with liver disease
  4021. Portal vein thrombosis–a primer for the general physician
  4022. Thrombophilia testing has limited usefulness in clinical decision-making and should be used selectively
  4023. Convenient, traditional and alternative therapies for cardiovascular disorders
  4024. Cerebral venous thrombosis: genetic aspects
  4025. Blood coagulating effect of marigold (Tagetes erecta L.) leaf and its bioactive compounds
  4026. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis
  4027. Pathogenesis of thromboembolism and endovascular management
  4028. Methylenetetrahydrofolate reductase polymorphisms as possible risk factors of venous thrombosis–too weak to take care, too frequent to be ignored…
  4029. Plasma free fatty acid levels influence Zn2+‐dependent histidine‐rich glycoprotein–heparin interactions via an allosteric switch on serum albumin
  4030. Scoring systems for estimating the risk of recurrent venous thromboembolism
  4031. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia
  4032. The current state of adverse event reporting in hemophilia
  4033. Summary of guidelines of the American Venous Forum
  4034. Genetic Study for G-Protein Coupled Receptor from Saccharomyces Cerervisiae and From Sera of Patients with Heart Thrombosis
  4035. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study
  4036. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia
  4037. Popular naturally occurring antioxidants as potential anticoagulant drugs
  4038. Use of three procoagulants in improving bleeding outcomes in the warfarin patient with intracranial hemorrhage
  4039. Prophylaxis and Management of Deep Vein Thrombosis in Trauma Patients
  4040. Global hemostasis in healthy bitches during pregnancy and at different estrous cycle stages: evaluation of routine hemostatic tests and thromboelastometry
  4041. Progress in the research on venous thromboembolism
  4042. Targeting of antithrombin in hemophilia A or B with RNAi therapy
  4043. A review of hormonal contraception and venous thromboembolism in adolescents
  4044. Protein C Thr315Ala variant results in gain of function but manifests as type II deficiency in diagnostic assays
  4045. The clinical presentation and genotype of protein C deficiency with double mutations of the protein C gene
  4046. Medico-legal aspects of pulmonary thromboembolism
  4047. Unusual cause of adrenal insufficiency
  4048. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence
  4049. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome
  4050. Disseminated intravascular coagulation in pregnancy–Clinical phenotypes and diagnostic scores
  4051. Systemic embolism risk factors in kidney transplant recipients during long-term post-operative period
  4052. Managing extended oral anticoagulation after unprovoked venous thromboembolism
  4053. Incidence and Management of toxicity associated with LAsparaginase in the treatment of ALL and NK/Tcell lymphoma: An Observational Study
  4054. Neuropsychiatric lupus: a mosaic of clinical presentations
  4055. Venous thromboembolism related to cytomegalovirus infection: A case report and literature review
  4056. Antiphospholipid Antibodies and APS Nephropathy
  4057. Thrombophilic evaluation in patients with acute pulmonary embolism
  4058. Incidence, laboratory detection and prognostic relevance of hypoxic hepatitis in cardiogenic shock
  4059. The role of ABO blood type in thrombosis scoring systems
  4060. Fibrinolysis in living donor liver transplantation recipients evaluated using thromboelastometry: impact on mortality
  4061. Progress in research into the genes associated with venous thromboembolism
  4062. The antiphospholipid syndrome in patients with systemic lupus erythematosus
  4063. Deep venous thrombosis and chikungunya virus
  4064. Assessment of Prothrombin Time, Activated Partial Thromboplastic Time Platelets Count and Serum Alpha Amylase in Acute Pancreatitis Sudanese Patients
  4065. The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation
  4066. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
  4067. Thrombosis, microangiopathies, and inflammation
  4068. Carbohydrate-based therapeutics: a frontier in drug discovery and development
  4069. SciTz Anesthesia: Clinical Research
  4070. Puumala hantavirus-induced hemorrhagic fever with renal syndrome must be considered across the borders of nephrology to avoid unnecessary diagnostic …
  4071. Coagulation Disorders in Intensive Care Patients
  4072. Low molecular weight heparin treatment and impact of inherited thrombophilia type in pregnancies with previous adverse outcome
  4073. Visceral adiposity is an independent determinant of hypercoagulability as measured by thrombin generation in morbid obesity
  4074. Haematological problems in intensive care
  4075. European Myeloma Network guidelines for the management of multiple myeloma-related complications
  4076. Extrahepatic portal vein obstruction and portal vein thrombosis in special situations: Need for a new classification
  4077. Three-dimensional virtual surgery models for percutaneous coronary intervention (PCI) optimization strategies
  4078. Albumin and colloid osmotic pressure
  4079. Association between genetic polymorphisms and deep vein thrombosis in a Chinese population
  4080. Antiphosphatidylethanolamine Antibodies: New Pieces to the Puzzle of the Antiphospholipid Syndrome?
  4081. Neurological and neurosurgical emergencies in patients with hematological disorders
  4082. Perioperatively acquired disorders of coagulation
  4083. Management of systemic unfractionated heparin anticoagulation during therapeutic plasma exchange
  4084. Antithrombin III: Plasma Activity and Reference Range Among Nigerian Blood Donors
  4085. Evaluation of Fibrinogen Level among Patients with Diabetes Mellitus Type2
  4086. Thrombotic venous diseases of the liver
  4087. New strategies for effective treatment of vitamin K antagonist‐associated bleeding
  4088. Examining the transplacental passage of apixaban using the dually perfused human placenta
  4089. Retrospective study of rFVIIa, 4‐factor PCC, and a rFVIIa and 3‐factor PCC combination in improving bleeding outcomes in the warfarin and non‐warfarin patient
  4090. EFFECTIVENESS OF TEST OF TROMBOELASTOGRAFIA AGAINST GLOBAL COAGULATION TESTS AS A GUIDE IN TREATMENT OF PATIENTS WITH …
  4091. Thrombophilia and the Risk of Recurrent Venous Thromboembolism
  4092. A phylogenomic analysis of the role and timing of molecular adaptation in the aquatic transition of cetartiodactyl mammals
  4093. Causative factors of deep vein thrombosis of lower limb in Indian population
  4094. Case 5/2017-A 28-Year-Old Woman with Cor Pulmonale Due to Pulmonary Hypertension Secondary to Chronic Pulmonary Thromboembolism
  4095. Clinical Profile of Cerebral Venous Thrombosis: Cases Admitted to HSK Hospital Bagalkot
  4096. Hematologic manifestations of systemic illness
  4097. Coagulation Monitoring
  4098. Advances in the treatment of bleeding disorders
  4099. Antiphospholipid antibodies and procoagulant profile in Tunisians with inflammatory bowel diseases
  4100. A thrombotic storm
  4101. Serum D-dimer as an indicator of immediate mortality in patients with in-hospital cardiac arrest
  4102. Pathophysiology of trauma-induced coagulopathy and management of critical bleeding requiring massive transfusion
  4103. Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia
  4104. Hemostasis and Anticoagulation Therapy
  4105. Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation
  4106. Novel carriers for oral delivery of hemophiliac factor IX
  4107. Coagulation
  4108. Obstetric outcomes of recurrent pregnancy loss patients diagnosed wıth inherited thrombophilia
  4109. Anticoagulant, antiplatelet and antianemic effects of Punica granatum (pomegranate) juice in rabbits
  4110. Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes
  4111. Thromboembolism in pregnancy
  4112. Adverse drug reactions and cutaneous manifestations associated with anticoagulation
  4113. Disseminated Intravascular Coagulation
  4114. Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing
  4115. Composite hybrid membrane materials for artificial organs
  4116. The effect of chronic liver disease on venous thromboembolism among medically managed patients in Singapore General Hospital
  4117. Evaluating the anticoagulant effect of medicinal plants in vitro by cheminformatics methods
  4118. Vitamin K antagonists (Coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism
  4119. Antiphospholipid syndrome
  4120. How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation
  4121. Point-of-care coagulation tests monitoring of direct oral anticoagulants and their reversal therapy: state of the art
  4122. Pulmonary Emboli: An Unusual Case Presentation
  4123. Platelet dysfunction in pre-eclamptic mothers
  4124. Laboratory Monitoring of Direct Oral anticoagulants
  4125. Management and outcome of cerebral venous thrombosis after head trauma: a case series
  4126. ANTITHROMBIN III LEVELS IN TYPE 2 DIABETES MELLITUS PATIENTS SEEN AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY, EDO …
  4127. Statistical Correlations of the Spontaneous Abortion with Trombophilia and Other Associated Pathologies
  4128. Oral surgery in liver transplant candidates: a retrospective study on delayed bleeding and other complications
  4129. Retinoic acid inhibits tissue factor and HMGB1 via modulation of AMPK activity in TNF-α activated endothelial cells and LPS-injected mice
  4130. Endothelial cell senescence and thrombosis: Ageing clots
  4131. Functional human 3D microvascular networks on a chip to study the procoagulant effects of ambient fine particulate matter
  4132. Coagulation disorders and their cutaneous presentations: Pathophysiology
  4133. Changes to fibrinolysis in patients with systemic lupus erythematosus are associated with endothelial cell damage and inflammation, but not antiphospholipid …
  4134. Literature review in field of drugs influencing blood clotting
  4135. Evaluation of naturalProducts of Putative Haemostatic Effect
  4136. Prevalence of hereditary thrombophilia in patients older than 75 years with venous thromboembolism referred for thrombophilia screening
  4137. Challenges and opportunities for the application of boron clusters in drug design
  4138. Evaluation of the Diagnostic Performance of Fibrin Monomer in Comparison to d-Dimer in Patients With Overt and Nonovert Disseminated Intravascular Coagulation
  4139. Intraoperative disseminated intravascular coagulation during thoracolumbar decompression in a patient with metastatic carcinoma of the prostate: etiology, diagnosis …
  4140. Novel technologies to engineer graft for tolerance induction
  4141. Treatment of Catastrophic Antiphospholipid Syndrome
  4142. Coagulation activation in patients with sickle cell disease in Basra, Iraq
  4143. Current pathological and laboratory considerations in the diagnosis of disseminated intravascular coagulation
  4144. Four-factor prothrombin complex concentrates: effectiveness in the reversal of anticoagulation
  4145. Aberrant maternal inflammation as a cause of pregnancy complications: A potential therapeutic target?
  4146. Coagulopathy in Cirrhosis
  4147. Blood biomarker discovery in drug-free schizophrenia: the contribution of proteomics and multiplex immunoassays
  4148. Thrombotic Disorders
  4149. Acute occlusion of the Percheron artery during pregnancy: a case report and a review of the literature
  4150. Human thrombomodulin regulates complement activation as well as the coagulation cascade in xeno‐immune response
  4151. Markers of blood coagulation and fibrinolysis in patients with early and delayed microsurgical reconstructions in the lower extremities
  4152. Microparticles as biomarkers of venous thromboembolic events
  4153. Pathophysiological significance and therapeutic applications of snake venom protease inhibitors
  4154. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation
  4155. Measurement of some coagulation profile (PT, APTT, INR and platelets count among pregnant women in Khartoum State
  4156. An observational study of haemostatic changes, leptin and soluble endoglin during pregnancy in women with different BMIs
  4157. Endothelial Cell Sensitization by Death Receptor Fractions of an Anti–Dengue Nonstructural Protein 1 Antibody Induced Plasma Leakage, Coagulopathy, and …
  4158. Venous Thromboembolism: Diagnosis and Treatment
  4159. Venous thromboembolism after allogeneic pediatric hematopoietic stem cell transplantation: a single-center study
  4160. Approach to thrombosis at unusual sites: Splanchnic and cerebral vein thrombosis
  4161. Recent advances in hemophilia B therapy
  4162. Hematological problems in the neonate
  4163. THROMBOPHILIA AS A RISK FACTOR FOR LOW BIRTH WEIGHT
  4164. Serum concentrations of angiopoietin-2 and soluble fms-like tyrosine kinase 1 (sFlt-1) are associated with coagulopathy among patients with acute pancreatitis
  4165. A study on prevalence of hyperhomocysteinemia and its correlation with carotid intima media thickness in ischemic stroke patients.
  4166. Safety and efficacy of warfarin in patients with moderate thrombocytopenia
  4167. Prevalence of JAK2V617F mutation in deep venous thrombosis patients and its clinical significance as a thrombophilic risk factor: Indian perspective
  4168. Immediate postoperative management and complications on the intensive care unit
  4169. The role of deep venous thrombosis prophylaxis after anterior cruciate ligament reconstruction
  4170. Hemostasis, disorders of coagulation and transfusion in cirrhosis
  4171. Inherited thrombophilia in women with poor aPL‐related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric …
  4172. Venous Thromboembolism Prophylaxis in Neurosurgery
  4173. Prevention and therapeutic strategies of thromboembolic events in patients with inflammatory bowel diseases: a report of three cases
  4174. A Prospective, Randomized Comparative Study Evaluating the Analgesic Efficacy and Safety Profile of Thoracic Epidural Block Versus Thoracic Paravertebral Block …
  4175. How to effectively manage the event of bleeding complications when using anticoagulants
  4176. Aetiological diagnosis of middle-aged and elderly cryptogenic ischaemic cerebral vascular disease
  4177. Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and …
  4178. Screening of Lupus Anticoagulant in Women with Recurrent Miscarriage Attending Wad Medani Obstetrics and Gynecology Teaching Hospital Gezira State, Sudan
  4179. The crossroad of inflammation and diabetes: role of toll-like receptor
  4180. Future perspectives for the treatment of sickle cell anemia
  4181. Quality indicators for critical international normalized ratio measurements in a hemostatic laboratory
  4182. Diagnosis and treatment of lower extremity deep vein thrombosis: Korean practice guidelines
  4183. Determination of the utility of oligonucleotide sequences specifically designed to disrupt the interaction of microRNA-494 with the PROS1 mRNA transcript
  4184. Recent advances in pathophysiology of disseminated intravascular coagulation: the role of circulating histones and neutrophil extracellular traps
  4185. Risk factors for intracardiac thrombosis in the right atrium and superior vena cava in critically ill neonates who required the installation of a central venous …
  4186. Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients
  4187. Management of venous thromboembolism in patients with hereditary antithrombin deficiency and pregnancy: case report and review of the literature
  4188. Haematology
  4189. Acquired Coagulation Disorders
  4190. Risk factors and treatment strategies in patients with retinal vascular occlusions
  4191. Anticoagulant action of low, physiologic, and high albumin levels in whole blood
  4192. Hematological Pharmacogenetics
  4193. Exactin: A specific inhibitor of Factor X activation by extrinsic tenase complex from the venom of Hemachatus haemachatus
  4194. FACTOR 5 LEIDEN STUDY OF GENETIC POLYMORPHISMS AS GENETIC FACTORS THAT CAUSE CARDIOVASCULAR DISEASE IN THE POPULATION OF …
  4195. The new Israeli feed safety law: challenges in relation to animal and public health
  4196. Hemostatic variables, plasma lactate concentration, and inflammatory biomarkers in dogs with gastric dilatation-volvulus
  4197. Genetic analysis should be included in clinical practice when screening for antithrombin deficiency
  4198. Anticoagulation in pregnancy and puerperium: With a focus on the benefits and risks of the applications of vitamin K antagonists on the prevention of mechanical heart …
  4199. Italian intersociety consensus on DOAC use in internal medicine
  4200. Endothelial Activation and Injury: The Mechanisms of Rickettsial Vasculiti
  4201. Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management
  4202. Unexplained Infertility and Reproductive Immunology (RI)
  4203. Bleeding and Thrombosis in the Elderly
  4204. Prediction of esophageal variceal bleeding in liver cirrhosis: is there a role for hemostatic factors?
  4205. Cerebral venous thrombosis
  4206. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis
  4207. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant) …
  4208. Neutrophil extracellular traps: a walk on the wild side of exercise immunology
  4209. Atherothrombosis and oxidative stress: mechanisms and management in elderly
  4210. New Caledonia: A ‘Hot Spot’for Valuable Chemodiversity: Part 2: Basal Angiosperms and Eudicot Rosids
  4211. Alfredo Ulloa-Ricardez, Lizett Romero-Espinoza, María de Jesús Estrada-Loza 3, Héctor
  4212. Assessment of bleeding risk in patients with cirrhosis
  4213. Blood thinners and gastrointestinal endoscopy
  4214. COMPARISON OF THE PROCOAGULANT AND IMMUNOMODULATORY PROPERTIES OF NUCLEAR, MITOCHONDRIAL, AND BACTERIAL DNA WITH …
  4215. Hypercoagulability and Sickle Cell Disease
  4216. Drug-induced thrombophilic or prothrombotic states: an underestimated clinical problem that involves both legal and illegal compounds
  4217. The potential role of senescence as a modulator of platelets and tumorigenesis
  4218. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen—results from a …
  4219. Spinal cord infarction in a patient with hereditary spherocytosis: a case report and discussion
  4220. Epidemiology of familial aggregation of venous thromboembolism
  4221. Haematology
  4222. Limited dose warfarin throughout pregnancy in high-risk patients with mechanical valves: a randomized clinical trial
  4223. Synthesis of functionalized alkyl substituted benzoquinones by Rh-catalyzed additions of boronic acids
  4224. Common feed and animal derived food contaminants in Israel
  4225. Surface Modification of a Blood Contacting Polydimethylsiloxane Microfluidic Oxygenator
  4226. Fatal pulmonary thromboembolism in patients with diabetic ketoacidosis: a seven-case series and review of the literature
  4227. Pathogenesis and treatment of hemophilia
  4228. To investigate in vitro the pathogenic mechanism of anti-PS/PT antibodies to better define their role in the diagnosis of APS syndrome
  4229. Management of idiopathic venous thromboembolism
  4230. Procoagulant Substance and Mechanism of Myristica fragrans
  4231. Measuring coagulation in burns: an evidence-based systematic review
  4232. Drug treatment of venous thromboembolism in the elderly
  4233. A STUDY OF D-DIMER AND P-SELECTIN AS BIOMARKERS OF THROMBOEMBOLISM IN TREATMENT NAÏVE HIV PATIENTS IN AMINU KANO TEACHING …
  4234. Prediction of acute pancreatitis severity via the combined analysis of inflammatory biomarkers and coagulation parameters
  4235. Primary Platelet Disorders
  4236. Tamoxifen-associated portal vein thrombosis causing severe oesophageal variceal bleeding
  4237. Defibrotide in the treatment of hepatic veno-occlusive disease
  4238. Evaluation of a single dimension gel electrophoresis with immunofixation, with and without heparin, for heparin binding site defect in antithrombin deficiency
  4239. In vitro inhibition of thrombin generation by sulfated polysaccharides from the red seaweed Halymenia sp. delivery on the Ceará coast, Brazil
  4240. Prevalence of the factor V E666D mutation and its correlation with activated protein C resistance in the Chinese population
  4241. A randomized trial of restarting warfarin at maintenance versus loading doses following an elective procedure
  4242. Administration of bone marrow stromal cells in sepsis attenuates sepsis-related coagulopathy
  4243. Overview of hemostasis and thrombosis and contribution of laboratory testing to diagnosis and management of hemostasis and thrombosis disorders
  4244. Correlation between Packed Cell Volume and‎ Concentration of Clotting Factors FI, FVII, and‎ FVIII in Smokers Polycythemic males in Babylon‎ Province
  4245. Feasibility and Safety of Local Treatment with Recombinant Human Tissue Factor Pathway Inhibitor in a Rat Model of Streptococcus pneumoniae Pneumonia
  4246. Conventional and age-specific risk factors for venous thrombosis in older people: the AT-AGE study
  4247. Disordered hemostasis and renal disorders
  4248. Acute and chronic venous thrombosis: Pathogenesis and new insights
  4249. The Role of Proteomics and Transcriptomics in the Development of Antithrombotics
  4250. Adverse effects of glucocorticoids: coagulopathy
  4251. Haematological conditions in the obstetric patient
  4252. Modulation of factors involved in placental haemostasis and angiogenesis by low-molecular-weight-heparins
  4253. Perioperative hypercoagulability
  4254. Extracorporeal membrane oxygenation as a bridge to lung transplantation: a single-center experience in the present era
  4255. Management of bleeding associated with new oral anticoagulants
  4256. Paradox: Does liver insufficiency protect the patient? A hypothesis
  4257. Low molecular weight heparin treatment and impact of inherited thrombophilia type in pregnancies with previous adverse outcome
  4258. Optimized treatment of heparinized blood fractions to make them suitable for analysis
  4259. Stent thrombosis caused by metal allergy complicated by protein S deficiency and heparin-induced thrombocytopenia: a case report and review of the …
  4260. A case of bilateral branch retinal vein occlusion after taking tamoxifen
  4261. Platelet-derived microvesicles in cardiovascular diseases
  4262. Thrombin generation in abdominal sepsis is Rho-kinase-dependent
  4263. Platelets and infections–complex interactions with bacteria
  4264. Risk indicators for venous thrombosis in first-degree relatives of patients with recurrent venous thromboembolism in Chinese
  4265. The effects of perioperative tamoxifen therapy on microvascular flap complications in transverse rectus abdominis myocutaneous/deep inferior epigastric perforator …
  4266. Treatment of rare factor deficiencies in 2016
  4267. Viral hepatitis and anti-phospholipid antibodies positivity: a systematic review and meta-analysis
  4268. Review of Blood Transfusion Strategies among Trauma Patients
  4269. Inherited Thrombophilia in Children with Sickle Cell Disease in Wad Medani Pediatric Teaching Hospital, Gezira State, Sudan (2013-2015)
  4270. Characteristics of patients diagnosed with renal vein thrombosis and glomerulopathy: a case series
  4271. Issues with monitoring of unfractionated heparin in cirrhosis
  4272. Non syndromic childhood onset congenital sideroblastic anemia: A report of 13 patients identified with an ALAS2 or SLC25A38 mutation
  4273. Pediatric arterial ischemic stroke: epidemiology, risk factors, and management
  4274. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis
  4275. Kcentra for Urgent Warfarin Reversal
  4276. The Effect of Acute Exercise on Coagulation Factors and the Mechanical Properties of Fibrin Fibers
  4277. Outline: Pediatric Venous Thromboembolism
  4278. Screening Of Haemostatic Activity Of Nigella Sativa Seed Extract
  4279. Effect of fresh frozen plasma on the in vitro activation of U937 monocytes: a potential role for the age of blood donors and their underlying cytokine profile
  4280. Novel Dielectric Coagulometer Identifies Hypercoagulability in Patients with a High CHADS2 Score without Atrial Fibrillation
  4281. Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis
  4282. Factor XII-mediated contact activation related to poor prognosis in disseminated intravascular coagulation
  4283. Prospective evaluation of blood coagulability and effect of treatment in patients with stroke using rotational thromboelastometry
  4284. Therapeutic apheresis in hematologic, autoimmune and dermatologic diseases with immunologic origin
  4285. Current management of heparin-induced thrombocytopenia
  4286. Serum markers thrombophilia in pregnant women with Systemic Lupus Erythematosus
  4287. Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulation
  4288. Stroke in pregnancy and the puerperium
  4289. What is the best strategy in treating catastrophic antiphospholipid syndrome?
  4290. Decreased TFPI-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels
  4291. A thromboelastography study on the evaluation of clot formation in platelet-depleted whole blood in the presence of unfractionated heparin or low-molecular weight …
  4292. DERANGEMENT IN PROTEIN S AND C4b BINDING PROTEIN LEVELS AS AN ACQUIRED THROMBOPHILIA IN HIV INFECTED ADULTS ATTENDING APIN …
  4293. OBSTRUCTIVE SHOCK
  4294. Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study
  4295. Clinical Implications Of Apc-Resistance And Factor 5 Leiden Mutational Testing Over A Five Year Period At Yale-New Haven Hospital
  4296. Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing
  4297. Trans Fats and Risks of Cardiovascular Diseases: Facts or Artifacts?
  4298. Coagulation in acutely ill patients with severe chronic liver disease: insights from thromboelastography
  4299. The significance of inflammatory mediators in the clinical interpretation of patients with stable angina of II-III fc
  4300. Main Features of Impaired Fibronolytic and Protolytic Activity of Blood Plasma in Patients with Osteoarthritis Depending on Comorbidity
  4301. The discovery of dabigatran etexilate for the treatment of venous thrombosis
  4302. Choice of fluid therapy and bleeding risk after cardiac surgery
  4303. The pathophysiology, diagnosis and treatment of the acute coagulopathy of trauma and shock: a literature review
  4304. Overview of the causes of venous thrombosis
  4305. Effect of hemodilution in vitro with hydroxyethyl starch on hemostasis
  4306. Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency
  4307. D-dimer is a predictor of 28-day mortality in critically ill patients receiving continuous renal replacement therapy
  4308. Thromboembolism Associated with Fertility Treatment
  4309. Disseminated intravascular coagulation in critically ill patients
  4310. How to manage patients on rivaroxaban in the emergency department: a statement of the Italian society of emergency medicine advisory board
  4311. Rotational thromboelastometry (ROTEM) in obstetrics
  4312. Coagulation disorders and platelet hyperactivity in idiopathic membranous nephropathy
  4313. A novel interaction between complement inhibitor C4b-binding protein and plasminogen that enhances plasminogen activation
  4314. Determination of Reference Values for Activated Partial Thromboplastin Time in Healthy Sudanese Adults in Gezira State, Sudan
  4315. Contraception and venous thromboembolism: risk factors and clinical considerations
  4316. Disseminated intravascular coagulation
  4317. Maternal metabolism and vascular adaptation in pregnancy: the PPAR link
  4318. Haematology: drugs, tests, and disorders
  4319. Higher levels of procoagulant microparticles in women with recurrent miscarriage are not associated with antiphospholipid antibodies
  4320. Tamoxifen (selective estrogen-receptor modulators) and aromatase inhibitors as potential perioperative thrombotic risk factors in free flap breast reconstruction
  4321. Vascular dysfunction in patients with young β-thalassemia: relation to cardiovascular complications and subclinical atherosclerosis
  4322. Recent trends in common chemical feed and food contaminants in Israel
  4323. Tau oligomers in sera of patients with Alzheimer’s disease and aged controls
  4324. Association of Factor V-leiden and Prothrombin G20210A Mutations with Deep Venous Thrombosis in Patients attending Khartoum Hospitals, Khartoum State, Sudan …
  4325. Transient desialylation in combination with a novel antithrombin deficiency causing a severe and recurrent thrombosis despite anticoagulation therapy
  4326. Role of global assays in thrombosis and thrombophilia
  4327. Activation of endothelium, coagulation and fibrinolysis is enhanced and associates with renal anti-neutrophil cytoplasmic antibody-associated vasculitis
  4328. Hemostasis disturbances in patients with acute pancreatitis and the ways of its correction
  4329. Recurrence of superficial vein thrombosis in patients with varicose veins
  4330. Determination of Hematological Parameters of Sudanese Newborns: Correlation with Maternal Parameters in Wad Medani Obstetrics and Gynecology Teaching …
  4331. The surgical review: an integrated basic and clinical science study guide
  4332. Biochemical characterization of prothrombin complex concentrates in China
  4333. Portal vein thrombosis in patients with liver cirrhosis: insights to risk factors, clinical presentation and outcome
  4334. The role of platelet and its interaction with aspirin
  4335. Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation
  4336. HAEMOSTATIC PARAMETERS AMONG HAART NAÏVE HIV/AIDS PATIENTS IN UNIVERSITY OF ILORIN TEACHING HOSPITAL, ILORIN
  4337. Vascular endothelial injury induced by anti-endothelial cell antibody in allogeneic hematopoietic stem cell transplantation
  4338. 3-Factor prothrombin complex concentrates in infants with refractory bleeding after cardiac surgery
  4339. βig-h3 represses T-cell activation in type 1 diabetes
  4340. Whole exome sequencing in thrombophilic pedigrees to identify genetic risk factors for venous thromboembolism
  4341. Epigenetic alterations in sepsis
  4342. Decrease in antithrombin III and prothrombin serum levels contribute to coagulation disorders during leptospirosis
  4343. Viscoelasticity and ultrastructure in coagulation and inflammation: two diverse techniques, one conclusion
  4344. DETERMINATION OF TISSUE-TYPE PLASMINOGEN ACTIVATOR AND PLASMINOGEN ACTIVATOR INHIBITOR-1 IN YOUNG ADULTS WITH HYPERTENSION AT …
  4345. ANTITHROMBIN AND HOMOCYSTEINE AS MARKERS FOR HYPERCOAGULABILITY IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS AND …
  4346. Coagulation assessment: underutilized diagnostic tools in zoo and aquatic animal medicine
  4347. 4 Hemostasis and Platelet Disorders
  4348. Meeting report of the 2014 joint international congress of the I nternational L iver T ransplantation S ociety, L iver I ntensive C are G roup of E urope, and E uropean L …
  4349. Venous Thromboembolism: Assessing Novel Risk Factors and Treatments
  4350. Changes in platelet function with inflammation in patients undergoing vascular surgery.
  4351. Placental Pharmacology—Implications for Therapy in Pregnancy
  4352. Endocrine-related factors and risk of venous thromboembolism
  4353. ANTI-ANNEXIN V LEVELS AND HAEMATOLOGICAL INDICES IN SICKLE CELL ANAEMIA PATIENTS IN VASOOCLUSIVE CRISIS AT LAGOS UNIVERSITY …
  4354. Simultaneous targeting of CD14 and factor XIa by a fusion protein consisting of an anti-CD14 antibody and the modified second domain of bikunin improves survival in …
  4355. Aging: Thromboembolic Disease, Metabolic Syndrome, Type 2 Diabetes Mellitus, and Alzheimer’s Disease
  4356. Epidemiology and risk factors of acute venous thrombosis
  4357. Fetal & neonatal hematology, oncology and immunology
  4358. Phosphatidylserine and phosphatidylethanolamine bind to protein Z cooperatively and with equal affinity
  4359. Retinal vascular occlusion: a window to diagnosis of familial and acquired thrombophilia and hypofibrinolysis, with important ramifications for pregnancy …
  4360. Monitoring of Anticoagulation in Cirrhosis
  4361. Symposium 1 Transcriptional regulation in hematopoiesis and leukemogenesis
  4362. Investigating patients’ knowledge and use of the patient information leaflet regarding their warfarin therapy.
  4363. Increased coagulation and suppressed generation of activated protein C in aged mice during intra-abdominal sepsis
  4364. 16 Hematologic Emergencies
  4365. ICAM-1–targeted thrombomodulin mitigates tissue factor–driven inflammatory thrombosis in a human endothelialized microfluidic model
  4366. Systemic thromboembolism in pregnancy: venous thromboembolism
  4367. Design, Fabrication and Characterization of Thrombolytic Activity of Bauhinia Racemosa Extract Loaded Nanoemulsion.
  4368. Neonatal hematology
  4369. Anticoagulation management for postoperative atrial fibrillation after cardiothoracic surgery
  4370. Factor IXa Inhibitors
  4371. Thrombosis and thrombophilia
  4372. Application of Nucleic Acid Aptamers and Scavengers for Thrombosis and Cancer
  4373. A Study on Platelet Count-Splenic Diameter Ratio as a Non-Invasive Predictor of Oesophageal Varices in Cirrhosis
  4374. Extracellular Granzyme K mediates endothelial inflammation through the cleavage of Protease Activated Receptor-1
  4375. Diagnostic criteria for late onset neonatal sepsis
  4376. Development of bread products containing Chordaria cladosiphon (mozuku) and its bioactive extract fucoidan: a thesis presented in partial fulfilment of the …
  4377. Genetics in Hematology
  4378. Clinical picture in adulthood and unusual and peculiar clinical features of FMF
  4379. Detection of Factor V G1691A, Prothrombin G20210A and Methylene tetra hydrofolate reductase C677T Gene mutations among Sudanese Women with Recurrent …
  4380. Final Scientific Program
  4381. Study of platelet activation
  4382. HEMOSTASIS AND BLOOD TRANSFUSION
  4383. THE EFFECTS OF CRYSTALLOID SOLUTIONS ON THE HUMAN BLOOD COAGULATION SYSTEM
  4384. Genetic and Epigenetic Determinants of Tissue Factor Pathway Inhibitor Plasma Levels
  4385. Physiological, Pharmacological and Clinical Factors Associated with Thrombosis in Pediatric Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass
  4386. Pharmacological and Clinical Factors Associated with Thrombosis in Pediatric Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass
  4387. Severe acute pancreatitis: Predicting with ecto-5′-nucleotidase (CD73) and treatment with activated protein C
  4388. Headaches during pregnancy and peripartum
  4389. THE PROCOAGULANT ROLE OF NUCLEIC ACIDS IN THE CONTACT SYSTEM
  4390. Prehospital blood transfusion after combat injury and platelet function in an animal model of complex military trauma
  4391. EXAMINING ZINC RELEASE FROM PLATELETS AND ITS MODULATION OF CLOT STRUCTURE AND FIBRINOLYSIS
  4392. Inherited thrombophilia and pregnancy complications
  4393. Studies of the Endothelial Protein C Receptor
  4394. Mitigating the Unmet Needs of Hemophilia Patients: A Case Study of the Development Strategy Behind a Novel siRNA Hemophilia Combination Medical Device.
  4395. Vascular Neurology Board Review: Questions and Answers
  4396. Impact of Intravenous Lignocaine on Intraoperative Haemodynamics, Recovery Characteristics, Post-OP Pain Scores, Post OP Analgesic Requirement & Return of …
  4397. Leukocytes in venous thrombosis
  4398. The effect of Chitosan Dextran gel as a haemostatic and anti adhesion agent in the central nervous system and evaluation of haemostatic mechanism of skeletal …
  4399. Prevention of Intravascular Catheter-Related Infections
  4400. Oncology and Haematology E-Book: Key Articles from the Medicine journal
  4401. Chapitre 2: Idiopathic Parkinson’s Disease, Vascular Risk Factors and Cognition: A Critical
  4402. Enhanced hemostasis management strategies in cardiac surgery
  4403. management strategies in cardiac surgery
  4404. CLINICAL PROFILE AND LABORATORY CORRELATES OF DEEP VENOUS THROMBOSIS: THE PREDICTABILITY OF POINT OF CARE DDIMER TESTING …
  4405. A historical perspective, modern epizootic situation in the world and in Ukraine, immunity and the perspective of the vaccine of African swine fever
  4406. Mechanisms of antiphospholipid antibody-mediated thrombosis
  4407. Tau protein and its variants in the diagnosis of Alzheimer’s disease
  4408. Evaluation of procoagulant tissue factor expression in canine hemangiosarcoma cell lines
  4409. Venous thromboembolism and cancer
  4410. Prophylactic Fresh Frozen Plasma: Time for a Re-Think?
  4411. The Role of Tissue Factor in Canine Hemangiosarcoma
  4412. 0.9% saline versus Plasma-Lyte 148 for intravenous fluid therapy
  4413. 58th National Congress of the Hungarian Society of Laboratory Medicine
  4414. Long-Term Consequences of Venous Thromboembolism in Women
  4415. Diagnostic and prognostic usefulness of neutrophil extracellular traps in disseminated intravascular coagulation: Histone-induced pro-coagulative phenotype of …
  4416. Managing follow-up care for IVC filter retrieval through implementation of an IVC filter registry
  4417. A Study of Carotid Intima Media Thickness Among Thalassemia Patient in HUSM
  4418. Postoperative Care Handbook of the Massachusetts General Hospital
  4419. Proteomic and functional deregulations in Philadelphia negative Myeloproliferative Neoplasms
  4420. EFFECT OF LIFESTYLE AND DIETARY MODIFICATIONS ON PREHYPERTENSIVE CASES OF LOWER SOCIOECO-NOMIC POPULATION IN AHMEDABAD …
  4421. Women with inherited bleeding disorders and their offspring-the unresolved issues
  4422. Impact of Health Education on Breast Self-Examination Among Nursing Students.
  4423. The experience of laparoscopic sewing of perforated duodenal ulcers
  4424. Laparoscopic Inguinal Hernia Repair: TEP versus TAPP
  4425. Dispatcher assisted telephone cardiopulmonary resuscitation using a french-language compression-ventilation pediatric protocol
  4426. PL-1 Spred1 regulates the self-renewal activity of hematopoietic stem cells
  4427. Hypothesis-Driven Proteomic Data-Analysis of Plasma from Subjects in the At-Risk Mental State
  4428. HEMATOLOGY/ONCOLOGY
  4429. Age-related features and pathology of blood in children
  4430. Mouse venous thrombosis upon silencing of anticoagulants depends on tissue factor and platelets, not FXII or neutrophils
  4431. Management of symmetrical peripheral gangrene
  4432. New therapies for hemophilia
  4433. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation.
  4434. Symmetrical peripheral gangrene: mechanisms for limb loss in the ICU in patients with retained pulses
  4435. The obstetric complications in women with hereditary thrombophilia
  4436. Thrombophilia, risk factors and prevention
  4437. Danger of false negative (exclusion) or false positive (diagnosis) for ‘congenital thrombophilia’in the age of anticoagulants
  4438. Protein C and Anti-Thrombin-III Deficiency in Children With Beta-Thalassemia
  4439. Purpura fulminans
  4440. Decreased protein C function predicts mortality in patients with cirrhosis
  4441. Prothrombotic markers in Thalassemia major patients: A paradigm shift.
  4442. Basics of coagulation
  4443. Thromboelastometry in critically ill patients with disseminated intravascular coagulation
  4444. Sepsis-induced digital ischaemia in a professional pianist, in the absence of vasopressors
  4445. Terahertz therapy at frequencies of the molecular spectrum of nitric oxide: Results and prospects of clinical use
  4446. Gene Therapy in Hemophilia: From Hype to Hope
  4447. Role of Antithrombin III, Plasminogen, Protein C and Protein S in Deep Vein Thrombosis in Indian Population
  4448. Risk Factors, Clinical Manifestations, Treatment Duration and Outcomes in Carriers of Severe Inherited Thrombophilias
  4449. 1655: PROTEIN C IS A POTENT BIOMARKER TO IDENTIFY HIGH-RISK PATIENTS WITH SEPSIS-ASSOCIATED COAGULOPATHY
  4450. Foreword: the prevention and management of thrombosis in obstetrics and gynecology
  4451. Changes of Hemostasis Indicators in Women in Accuracy Practice
  4452. 1425: ADDING PROTEIN C AND ANTITHROMBIN TO DIC SCORING SYSTEM HELPS PREDICT MODS AND MORTALITY IN SEPSIS
  4453. Laboratory Evaluation of Long-Term Thrombophilic Disorders
  4454. PB2206 HEMOSTATIC MARKERS OF HYPERCOAGULABILITY IN PRIMARY MYELOFIBROSIS PATIENTS, RELATION WITH JAK2V617F ALLELE BURDEN
  4455. HEMOSTATIC MARKERS OF HYPERCOAGULABILITY IN PRIMARY MYELOFIBROSIS PATIENTS, RELATION WITH JAK2V617F ALLELE BURDEN
  4456. Recent Advances in Thrombosis and Hemostasis—Part V
  4457. NEONATAL PURPURAFULMINANS-A RARE CLINICAL PRESENTATION
  4458. Hypercoagulable state in sickle cell disease
  4459. Longer duration and proper titration of low molecular weight heparin (LMWH), are independent factors for successful pregnancy outcome. retrospective …
  4460. Inherited thrombophilia and pregnancy: diagnosis and thromboprophylaxis
  4461. Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation
  4462. Effect on Haemostatic Proteins in Plasma Prepared from Fresh and Overnight Stored Whole Blood
  4463. Association of apolipoproteins CI, C-II, C-III and E with coagulation markers and venous thromboembolism risk
  4464. PULMONARY THROMBOEMBOLISM AND ROLE OF FACTOR V LEIDENIN ITS DEVELOPMENT-REVIEW OF LITERATURE
  4465. Sickle cell disease: Hemostatic and inflammatory changes, and their interrelation
  4466. Secondary hemostasis studies of crude venom and isolated proteins from the snake Crotalus durissus terrificus
  4467. Complement component consumption in sepsis correlates better with hemostatic system parameters than with inflammatory biomarkers
  4468. The Coagulation Cascade Profile of Peripheral Arterial Disease Patients: Initial Steps to Personalized Medicine
  4469. Current and emerging biologics for the treatment of hemophilia
  4470. Is tri-iodothyronine a better choice than activated protein C in sepsis treatment?
  4471. Thrombophilia Caused by Beta2-Glycoprotein I Deficiency: In Vitro Study of a Rare Mutation in APOH Gene
  4472. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti‐idiotype monoclonal antibodies: reply
  4473. Levels of protein C, protein S, and anti-thrombin III in acute ischemic stroke patients at Haj Adam Malik Hospital, Medan
  4474. Comparison of Clinical and Hematologic Factors Associated with Stenosis and Aneurysm Development in Patients with Atherosclerotic Arterial Disease
  4475. The central role of thrombin in bleeding disorders
  4476. Recurrent cerebellar infarction associated with hereditary heterozygous protein C deficiency in a 35‑year‑old woman: A case report and genetic study on the …
  4477. How we manage haemostasis during sepsis
  4478. Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors
  4479. Effect of poor glycaemic control on plasma levels and activity of protein C, protein S, and antithrombin III in type 2 diabetes mellitus
  4480. Commentary: controversies in thrombosis and hemostasis part 2–does sticky platelet syndrome exist?
  4481. Cardiovascular risk markers and major adverse cardiovascular events in psoriatic arthritis patients
  4482. Early post-traumatic pulmonary-embolism in patients requiring ICU admission: more complicated than we think!
  4483. Laboratory evidence for hypercoagulability in cirrhotic patients with history of variceal bleeding
  4484. Plasma exchange in catastrophic antiphospholipid syndrome
  4485. General Discussion and Perspectives
  4486. The significance of thrombophilia in paediatric thromboembolism
  4487. Aberrant Promoter Hypermethylation Mediated Regulation of Thrombomodulin Gene in High Altitude Induced Deep Vein Thrombosis
  4488. New therapies using nonfactor products for patients with hemophilia and inhibitors
  4489. Therapeutic apheresis in the treatment of catastrophic antiphospholipid syndrome
  4490. P185 Regulation of coagulation by zinc: characterisation of zinc-dependent heparin neutralisation by fibrinogen and histidine-rich-glycoprotein
  4491. Hemostasis and Thrombosis in Extreme Physiological and Pathological Conditions
  4492. Role of thrombophilia in splanchnic venous thrombosis in acute pancreatitis
  4493. Coagulation Factor XII Does Not Contribute to Mouse Venous Thrombosis Induced By Silencing of Antithrombin and Protein C
  4494. Hypercoagulable states and thrombophilias: risks relating to recurrent venous thromboembolism
  4495. Venous thrombosis in children, adolescents and young adults with acute lymphoblastic leukemia receiving chemotherapy in the Republic of Belarus
  4496. Recurrent esophagogastric variceal bleeding due to portal vein thrombosis caused by protein S deficiency
  4497. Disseminated intravascular coagulation
  4498. Hematologic Disease in Implantation Failure
  4499. Novel therapeutics for hemophilia and other bleeding disorders
  4500. Microvascular thrombosis and ischaemic limb losses in critically ill patients
  4501. Venous Thrombosis in Children with Acute Lymphoblastic Leukemia Treated on DCOG ALL-9 and ALL-10 Protocols: The Effect of Fresh Frozen Plasma
  4502. An overview of hemostasis
  4503. Incidence and features of thrombosis in children with inherited antithrombin deficiency
  4504. Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks
  4505. Rivaroxaban treatment for Warfarin-refractory thrombosis in a patient with hereditary protein S deficiency
  4506. Genetics of hypercoagulable and hypocoagulable states
  4507. Neutrophil accumulation and NET release contribute to thrombosis in HIT
  4508. Liver Diseases and the Hemostasis (Rewiew) Part 1. Non-Cholestatic Diseases of the Liver and Hemostasis
  4509. Novel therapies and current clinical progress in hemophilia A
  4510. Thrombophilia and Cardiac Thrombi
  4511. Neutrophils mitigate the systemic host response during endotoxemia in mice
  4512. TFPI blockade: removing coagulation’s brakes
  4513. Obesity, thrombotic risk, and inflammation in cancer
  4514. HEMOSTASIS DISOREDRS IN ACUTE PANCREATITIS
  4515. Platelet function in preeclampsia–a systematic review and meta-analysis
  4516. The blood compatibility challenge. Part 3: Material associated activation of blood cascades and cells
  4517. Coagulation Abnormalities in Sepsis
  4518. NaoXinTong Capsule inhibits carrageenan-induced thrombosis in mice
  4519. The dynamics of coagulation hemostasis markers in patients with an increased body mass index with polytrauma
  4520. Staphylococcus aureus, master manipulator of the human hemostatic system
  4521. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta‐analysis
  4522. Novel insights in thrombosis pathophysiology using Mice with Impaired anticoagulation
  4523. Variations of plasma D-dimer level at various points of normal pregnancy and its trends in complicated pregnancies: a retrospective observational cohort study
  4524. Hemostatic abnormalities in dementia: a systematic review and meta-analysis
  4525. High prevalence of inherited thrombophilia and antiphospholipid syndrome in myocardial infarction with non-obstructive coronary arteries: Comparison with …
  4526. Use of coagulation point-of-care tests in the management of anticoagulation and bleeding in pediatric cardiac surgery: a systematic review
  4527. Principal component analysis on recurrent venous thromboembolism
  4528. Fibrinogen measurement in liver disease: validation of the functional fibrinogen thromboelastography assay and a novel mathematical predictive model
  4529. The role of plasma transfusion in massive bleeding: protecting the endothelial glycocalyx?
  4530. Prothrombotic states in women with infertility and psychosomatic disorders
  4531. Cerebral venous thrombosis and acute pulmonary embolism following varicella infection
  4532. Analysis of PROC and PROS1 single nucleotide polymorphisms in a thrombophilia family
  4533. Assessment of Protein C and Protein S of Pregnancy Loss Victims Igwe, Chioma Ada1 Adias Teddy Charles2 Eze Evelyn Mgbeoma3 Nwachuku Edna Ogechi3
  4534. Haematopoietic Stem Cell Transplantation in Children Shifts the Coagulation System towards a Pro-Coagulant State
  4535. Comparison of two thrombin generation methods, CAT and ST-Genesia, in liver transplant patients
  4536. Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels
  4537. Hemophilia: past, present, and future
  4538. Inherited thrombophilia in unprovoked venous thromboembolism: Is non’O’blood group an additional culprit in Indian patients?
  4539. Inhibitors in Coagulation
  4540. Impact of interleukin 6 promoter polymorphisms (−174 G > C, −572 G > C and −597 G > A) on plasma IL-6 levels and their influence on the development of DVT …
  4541. Concurrence of symmetrical peripheral gangrene and venous limb gangrene following polytrauma: a case report
  4542. Prevention and management of thromboembolism in pregnancy when heparins are not an option
  4543. Fucoidan extracted from Undaria pinnatifida: Source for nutraceuticals/functional foods
  4544. Serum homocysteine and disease severity in sickle cell anemia patients in Lagos
  4545. A case report of intraoperative coagulopathy secondary to chronic vitamin K deficiency
  4546. Inherited thrombophilia and the risk of arterial ischemic stroke: a systematic review and meta‐analysis
  4547. Identification of cost-saving opportunities for the use of antithrombin III in adult and pediatric patients
  4548. Improved understanding of the pathophysiology of sepsis: Setting the scene for potential novel adjunctive therapies
  4549. Diminished coagulation capacity assessed by calibrated automated thrombography during acute Puumala hantavirus infection
  4550. Hemostasis and thrombosis in the oldest old
  4551. Interplay between genetics and epigenetics in modulating the risk of venous thromboembolism: a new challenge for personalized therapy
  4552. Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes
  4553. Sparganin A alleviates blood stasis syndrome and its key targets by molecular docking
  4554. Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation
  4555. Evaluation of Antithrombotic Activities of Solanum xanthocarpum and Tinospora cordifolia
  4556. Obesity, Thrombotic Risk, and Inflammation in Cancer
  4557. β-Antithrombin, subtype of antithrombin deficiency and the risk of venous thromboembolism in hereditary antithrombin deficiency: A family cohort study
  4558. Simultaneous optimization of ultrasonic-assisted extraction of antioxidant and anticoagulation activities of compounds from Leonurus japonicus Houtt. by …
  4559. Assessment of the procoagulant potential and associated risk factors in pregnant patients with inflammatory bowel diseases
  4560. Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study
  4561. Protein C Protein S deficiency
  4562. Clinical Reasoning: a teenager with persistent headache
  4563. Efficacy of oral factor Xa inhibitor for venous thromboembolism in a patient with antithrombin deficiency
  4564. Maternal adaptations to pregnancy: Hematologic changes
  4565. Correlation between active disease and hypercoagulability state in patients with systemic lupus erythematosus
  4566. Normal Cellular Changes during Pregnancy and the Puerperium
  4567. Risk factors for venous thromboembolism (VTE) recurrences in Thai patients without cancer
  4568. Protein S in preventing thrombosis
  4569. An audit of thrombophilia testing in patients with ischemic stroke or transient ischemic attack: the futility of testing
  4570. Hemophilia in a changing treatment landscape
  4571. Acute myeloid leukemia with severe coagulation disorder and concomitant central nervous system bleeding–a clinical diagnostic case report
  4572. Thrombotic Manifestations in the Antiphospholipid Syndrome—An Overview
  4573. Risk of venous thrombosis in antithrombin deficiency: a systematic review and Bayesian meta-analysis
  4574. Bleeding Disorders, Thrombosis and Anticoagulation
  4575. Livedoid vasculopathy presenting in a patient with sickle cell disease
  4576. Section I: Biology and Evaluation
  4577. Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial
  4578. Assisted reproductive techniques in a patient with history of venous thromboembolism: a case report and review of literature
  4579. Comparing D-dimer status in children with familial Mediterranean fever during and in between acute attacks
  4580. Portal Cavernoma Cholangiopathy Due To Extrahepatic Portal Vein and Supra-Mesenteric Vein Thromboses Associated with Congenital Protein C Deficiency …
  4581. Congenital Bleeding Disorders 12
  4582. Determination of circulating endothelial cells and endothelial progenitor cells using multicolor flow cytometry in patients with thrombophilia
  4583. Heparin‐induced thrombocytopenia‐associated thrombosis: from arterial to venous to venous limb gangrene
  4584. Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report
  4585. Blood Coagulation During Sepsis and Septic Shock: Is There Still Room for anticoagulants?
  4586. Familial pulmonary thromboembolism with a prothrombin mutation and antithrombin resistance
  4587. Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients
  4588. Next-generation sequencing of 17 genes associated with venous thromboembolism reveals a deficit of non-synonymous variants in procoagulant genes
  4589. Chemical constituents from Gueldenstaedtia verna and their anti-inflammatory activity
  4590. Thromboembolism in Beta-Thalassemia Disease
  4591. Plasma fibrin clot properties are unfavorably altered in women following venous thromboembolism associated with combined hormonal contraception
  4592. Recurrent pulmonary embolism associated with deep venous thrombosis diagnosed as protein s deficiency owing to a novel mutation in PROS1: A case …
  4593. Congenital Bleeding Disorders
  4594. Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non‐recurrent disease
  4595. Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation
  4596. Phenotypic characterization of haemophilia B–Understanding the underlying biology of coagulation factor IX
  4597. HEPARIN COFACTOR II AND HAEMATOLOGICAL PARAMETERS AMONG PATIENTS WITH OBSTRUCTIVE SLEEP APNOEA: A SINGLE CENTRE STUDY IN …
  4598. Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: efficacy and the risk of hemorrhagic complications
  4599. Lactobacillus casei beneficially modulates immuno-coagulative response in an endotoxemia model
  4600. Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments
  4601. In-stent thrombosis after carotid artery stenting in a patient with protein C deficiency
  4602. Thrombophilia and multiple thrombosis post pancreatectomy due to insulinoma: Case report
  4603. Impaired platelet activity and hypercoagulation in healthy term and moderately preterm newborns during the early neonatal period
  4604. Thrombosis in pediatric patients with leukemia
  4605. Diagnosis and treatment of hemophilia
  4606. Thrombosis in hematological practice
  4607. Engineering a protein Z‐dependent protease inhibitor (ZPI) mutant as a novel antagonist of ZPI anticoagulant function for hemophilia treatment
  4608. Epidemiology of Budd-Chiari syndrome: a systematic review and meta-analysis
  4609. Effects of malignancy on blood coagulation in septic intensive care patients
  4610. 17 Pregnancy in Budd–Chiari Syndrome
  4611. Acute Pulmonary Embolism in a Teenage Female–A Case Report
  4612. Allelic Distribution of A1298C and C677T Polymorphisms of MTHFR in Central India.
  4613. Thrombophilic gene polymorphisms are associated with deep venous thrombosis in a cohort of Egyptian patients
  4614. Measurement of the Prothrombin Time, Activated partial thromboplastin time and Fibrinogen concentration in healthy dogs in Sudan
  4615. Rachael F. Grace and Russell E. Ware
  4616. Coagulation Enzymes Review and Review of Hemostasis: Putting It All Together
  4617. Extracorporeal Support in Liver Disease: Plasma Exchange/Plasmapheresis
  4618. Disseminated Intravascular Coagulation
  4619. In vitro anticoagulant activity of Mikania laevigata: deepening the study of the possible interaction between guaco and anticoagulants
  4620. Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism
  4621. Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis
  4622. Pediatric Hematology, An Issue of Hematology/Oncology Clinics of North America
  4623. Female gender as an additional risk factor for atherothrombotic complications of IHD
  4624. Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma
  4625. Principles and nursing management of anticoagulation.
  4626. The evaluation of two genetic polymorphisms of paraoxonase 1 in patients with pulmonary embolism
  4627. Contraception for adolescents with medically complex conditions
  4628. Common haemostasis issues in major bleeding and critical illness
  4629. Titer of antiphospholipid autoantibodies. Is it connected with clinical manifestation?
  4630. Preparation and hemocompatibility of electrospun bacteria cellulose sulfate/polyvinyl alcohol nanofibrous composite membrane
  4631. Hemorrhage and Thrombosis in Women
  4632. Pulmonary Embolism in a Donor of Living Donor Liver Transplantation
  4633. Significance of plasma fibrinogen level and antithrombin activity in sepsis: a multicenter cohort study using a cubic spline model
  4634. Radiosynovectomy in haemophilia
  4635. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE registry
  4636. Hemostasis in the very young
  4637. Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: a prospective evaluation
  4638. First report of plant-derived β-sitosterol with antithrombotic, in vivo anticoagulant, and thrombus-preventing activities in a mouse model
  4639. Protein S deficiency in patients from the French Basque Country with various thrombotic conditions: a rarer inherited trait in autochthonous individuals?
  4640. Screning for inherited thrombophilia in asymptomatic adults
  4641. Highly active antiretroviral therapy increases fibrinolytic and protein activity in pregnant women
  4642. Interaction between warfarin and astaxanthin: A case report
  4643. Prevention and management of bleeding risk related to invasive procedures in cirrhosis
  4644. Cardiovascular manifestations of inflammatory bowel disease: pathogenesis, diagnosis, and preventive strategies
  4645. Platelet Indices and Antiphospholipid Syndrome in Patients with Recurrent Pregnancy Loss
  4646. Anticoagulation in the cirrhotic patient
  4647. Coagulation and skin autoimmunity
  4648. Novel assays in the coagulation laboratory: a clinical and laboratory perspective
  4649. The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications
  4650. Early stage hemostasis differences in survivor and lethal cases with acute necrotizing pancreatitis
  4651. Congenital structural and functional fibrinogen disorders: A primer for internists
  4652. Herpes simplex virus (HSV) encephalitis in a young man: an unusual course
  4653. Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: normal values and variability
  4654. Acute Mesenteric Ischemia (AMI): A surgical perspective
  4655. Acute Mesenteric Ischemia (AMI): A surgical perspective
  4656. Thromboelastography values remain hypercoagulative 6 months after obesity surgery: a pilot study
  4657. Thrombophilia Profile of Portal Vein Thrombosis in Young
  4658. Role of microRNAs in regulation of cutaneous wound healing
  4659. Deep Vein Thrombosis: The Disease
  4660. Pregnancy and hemostasis: from physiology to pathological states
  4661. Assessment of Protein C Levels in Patients with Ischaemic Stroke in South-South Nigeria: A Study of Cases in University of Benin Teaching Hospital, Benin City
  4662. Statin therapy to revert hypercoagulability and prevent venous thromboembolism: a narrative review
  4663. Diagnosis and clinical management of ancylostomiasis induced eosinophilic gastroenteritis in a dog
  4664. Targeting platelet EPCR for better therapeutic factor VIIa activity
  4665. NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis
  4666. Combined reperfusion therapy to treat cryptogenic acute ischemic stroke during the first trimester of pregnancy: case report and literature review
  4667. ZBTB12 DNA methylation is associated with coagulation-and inflammation-related blood cell parameters: findings from the Moli-family cohort
  4668. Atypical presentation of critical left main disease in an HIV-infected patient
  4669. Heparin–protamine balance after neonatal cardiopulmonary bypass surgery
  4670. Drugs used in disorders of coagulation
  4671. Cavernous transformation of portal vein in the setting of protein C and anti-thrombin III deficiency
  4672. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism
  4673. In patients with superficial vein thrombosis the inflammatory response is increased and related to the recanalization rate
  4674. Biomarker profiles of coagulopathy and alveolar epithelial injury in acute respiratory distress syndrome with idiopathic/immune-related disease or common …
  4675. Plasma phenotypes of protein S Lys196Glu and protein C Lys193del variants prevalent among young Japanese women
  4676. Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: risk factors and effect on prognosis
  4677. Trombosis of mesenterial vessels in acute lymphoblastic leukemia (case report)
  4678. Evaluation of Anticoagulant Proteins and Fibrinolytic System Markers in Children with Pneumonia
  4679. Principles of anticoagulation in extracorporeal circuits
  4680. Efficiency of Body Fluid on Siamese Crocodile Blood Clotting
  4681. Activation of TF-Dependent Blood Coagulation Pathway and VEGF-A in Patients with Essential Thrombocythemia
  4682. Development and validation of a practical two-step prediction model and clinical risk score for post-thrombotic syndrome
  4683. The hypercoagulation state among major β-thalassemia patients at H. Adam Malik Hospital, Medan, Indonesia
  4684. Septic Shock
  4685. DROP IN VISION IN YOUNG INDIVIDUALS. ROLE OF OPHTHALMOLOGISTS IN THROWING LIGHT TO SYSTEMIC DISEASES
  4686. Thalassemia and Moyamoya syndrome: unfurling an intriguing association
  4687. Evaluation of Coagulation Profile and Transfusion Support in Preeclampsia Patients
  4688. Hemostatic changes in patients with chronic renal failure
  4689. Emicizumab for hemophilia A with factor VIII inhibitors
  4690. Pharmacological reversal of the direct oral anticoagulants—a comprehensive review of the literature
  4691. Haemostasis and innate immunity–a complementary relationship: a review of the intricate relationship between coagulation and complement pathways
  4692. Multiple coagulation factor deficiency
  4693. Coagulopathy in Cirrhotic Patients: Evaluation and Management
  4694. The role of inflammation in venous thromboembolism
  4695. Acute arterial thrombosis during adjuvant Adriamycin-cyclophosphamide chemotherapy in a patient with early breast cancer: A case report
  4696. Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature
  4697. Wake-Up Right-Sided Hemiparesis and Dysarthria in a Heavy Snorer
  4698. Assessment and management of venous thromboembolism risk during pregnancy and the puerperium (SAVE): The South African cohort
  4699. Low protein Z level: a thrombophilic risk biomarker for acute coronary syndrome
  4700. Antithrombin concentrate during pregnancy in congenital antithrombin deficiency: a single-center experience
  4701. Ultrasound for VTE surveillance and other plastic surgery applications
  4702. Neuroanesthesia and Coexisting Coagulation Problems
  4703. Mechanisms of Toxic Effects of Homocysteine on the Nervous System
  4704. Management of menopausal symptoms for women who are at high risk of thrombosis
  4705. Preliminary Data From the Study of Coagulative Profile of HIV Infected Individuals Suggest a Role For Point Mutations in the Gene in Protein S Deficiency in …
  4706. Evaluation of Protein C among Ladies with Placental complicated Pregnancy in Shendi Town
  4707. Transient deficiency of antithrombin during pregnancy in a woman with a history of reproductive losses
  4708. Prognostic significance of modern markers of severity and development of complications in acute cerebrovascular diseases
  4709. Coagulation and hemostasis in diabetic nephropathy
  4710. Klippel-Trénaunay syndrome
  4711. The role of plasma exchange in the management of autoimmune disorders
  4712. Drugs affecting coagulation
  4713. Alterations of anticoagulant proteins and soluble endothelial protein C receptor in thalassemia patients of Chinese origin
  4714. Effect and hemorheological mechanism of butyphthalide combined with Danshen and Ligustrazine Injection on cerebral infarction
  4715. Management of coagulation and anticoagulation in liver transplantation candidates
  4716. A proposal of the modification of Japanese Society on Thrombosis and Hemostasis (JSTH) disseminated intravascular coagulation (DIC) diagnostic criteria for sepsis …
  4717. Thromboprophylaxis in patients with acute spinal cord injury: a narrative review
  4718. Factors influencing recanalization of thrombotic venous occlusions
  4719. Higher Thrombin-Antithrombin III Complex Levels May Indicate Severe Acute Pancreatitis
  4720. Thrombophilia Testing
  4721. Venous thromboembolism in children with sickle cell disease: a retrospective cohort study
  4722. Catastrophic Antiphospholipid Syndrome
  4723. Coagulation and Hematology in Neurological Surgery, An Issue of Neurosurgery Clinics of North America
  4724. Predictive Value of Oxidized Low-Density Lipoprotein/β2-Glycoprotein-I Complexes (oxLDL/β2GPI) in Nonautoimmune Atherothrombosis
  4725. Prognostic value of pretreatment D-dimer level in small-cell lung cancer: a meta-analysis
  4726. Factor V Leiden and the Risk of Pulmonary Embolism
  4727. Severe Acute Kidney Injury With Significant Uremia in an Infant Found to Have Inferior Vena Cava, Bilateral Renal Vein, and Bilateral Renal Artery Thromboses
  4728. Plasma levels of vascular endothelial growth factor and selected hemostatic parameters in association with treatment response in multiple myeloma
  4729. Thrombolysis of Blood Clots Using Wirelessly Powered Inferior Vena Cava Filters
  4730. Future prospects for prophylactic and therapeutic management of venous thrombosis: antithrombotic substances with lower risk of hemorrhage?
  4731. In vivo assessment of anticoagulant and antiplatelet effects of Syzygium cumini leaves extract in rabbits
  4732. A review on the new and old anticoagulants
  4733. Hemostasis management and therapeutic plasma exchange: results of a practice survey
  4734. Detection of Methylenetetrafolate Reductase Polymorphisms (MTHFR C677T) in pregnant women with Unexplained Recurrent Pregnancy Loss at Elgezira State in …
  4735. Recommendations for the diagnosis and treatment of patients with polycythaemia vera
  4736. The problem of under-diagnosis and over-diagnosis of pulmonary embolism
  4737. Do inferior vena cava filters prevent pulmonary embolism in critically ill trauma patients and does the benefit outweigh the risk of insertion? A narrative review article
  4738. Portal Vein Thrombosis in Liver Cirrhosis
  4739. Complex compound of Pro-Gly-Pro-Leu with heparin: hypoglycemic, fibrinolitic and anticoagulant effects in rats with hyperglycemia
  4740. ECMO and anticoagulation: a comprehensive review
  4741. Meta-analysis of preclinical studies of fibrinolytic therapy for acute lung injury
  4742. Nontumoral Portal Vein Thrombosis in Patients with and Without Cirrhosis: Clinical Significance, naturalHistory of Varices and Efficacy of Anticoagulation
  4743. The effects of resveratrol in patients with cardiovascular disease and heart failure: a narrative review
  4744. Nontumoral portal vein thrombosis in patients with and without cirrhosis: clinical significance, naturalhistory of varices and efficacy of anticoagulation
  4745. Comparison of antithrombin III levels in type 2 diabetes mellitus patients with and without ulcers at Haji Adam Malik Hospital Medan Indonesia from may to july 2017
  4746. Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions
  4747. Thrombin inhibitory peptides derived from Mytilus edulis proteins: identification, molecular docking and in silico prediction of toxicity
  4748. Studies on Components of Blood & Their Functions
  4749. Update on diagnosis and anticoagulant therapy for venous thromboembolism
  4750. Redefining Clinical Outcomes in Hemophilia: The Impact of Personalized Treatment Strategies.
  4751. Roles of factor XII in innate immunity
  4752. From Witch Hunts to Autoantibodies: Overcoming Psychogenic Stigma to Uncover the Molecular Cause of Autoimmunity
  4753. Thrombophilia: Hereditary and Acquired
  4754. Impact of antithrombin supplementation and concomitant anticoagulation therapy in pediatric patients with disseminated intravascular coagulation
  4755. FXa direct synthetic inhibitors
  4756. 13 Plasmapheresis in Pediatric Renal
  4757. Genetic and clinical characterization of congenital fibrinogen disorders in Polish patients: Identification of three novel fibrinogen gamma chain mutations
  4758. Histopathological findings and increased D-dimer are predictive factors of systemic thromboses in eosinophilic granulomatosis with polyangiitis
  4759. Genetic risk assessment of thrombophilia in patients with adverse obstetric outcomes
  4760. Hemostatic System in Chronic Viral Hepatitis
  4761. Clinical characteristics and outcomes of patients with multiple simultaneous superficial vein thrombi
  4762. Venous thromboembolism in patients with liver cirrhosis: findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) registry
  4763. Clinical bleeding and thrombin generation in admissions to critical care with prolonged prothrombin time: an exploratory study
  4764. Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome
  4765. Plasmapheresis in Pediatric Renal Disease
  4766. Thromboprophylaxis in Patients with Abdominal Sepsis
  4767. Laboratory Diagnosis of Microangiopathic Hemolytic Anemia Including TTP, DIC, and HUS
  4768. Single nucleotide polymorphism in patients with vein thrombosis in the population of latvia
  4769. Inhibition of Inflammation‐Associated Thrombosis with ROS‐Responsive Heparin‐DOCA/PVAX Nanoparticles
  4770. Superior Mesenteric venous thrombosis in a patient with protein C deficiency
  4771. Management of rare coagulation disorders in 2018
  4772. Advances in clinical and basic science of coagulation: illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis
  4773. Bioassay-guided isolation of triterpene from brown alga Padina boergesenii possess anti-inflammatory and anti-angiogenic potential with kinetic inhibition of …
  4774. Thrombophilia and Pregnancy: Diagnosis and Management
  4775. Effectiveness and safety of 4-factor prothrombin complex concentrate (4PCC) in neonates with intractable bleeding or severe coagulation disturbances: a retrospective …
  4776. The Association between the Level of Antithrombin III and Mortality in Children with Sepsis
  4777. Four Thrombocytopenic Emergencies
  4778. Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?
  4779. Assessment of hemostatic disturbances in women with established rheumatoid arthritis
  4780. LEECH THERAPY IN MEDICAL SCIENCE–A REVIEW
  4781. Standardization and evaluation of the performance of the thrombin generation test under hypo-and hypercoagulability conditions
  4782. CASE OF ATYPICAL WARFARIN-INDUCED SKIN NECROSIS IN A CHILD WITH CONGENITAL HEART DISEASE
  4783. Central venous catheter-related venous thrombosis in children with end-stage renal disease undergoing hemodialysis
  4784. Rationale and design of two prospective, multicenter, observational studies on reproductive outcome in women with recurrent failures after spontaneous or …
  4785. Recurrence risk in patients with cryptogenic stroke, patent foramen ovale, and thrombophilia: a systematic review and meta-analysis
  4786. Thromboelastometry profile in critically ill patients: A single-center, retrospective, observational study
  4787. Predictive value of coagulation test parameters for acute upper gastrointestinal bleeding in patients with liver cirrhosis
  4788. Antioxidant, Anti-inflammatory, and Anticoagulation Properties of Aegiceras corniculatum and Acanthus ilicifolius
  4789. Understanding the clotting cascade, regulators, and clinical modulators of coagulation
  4790. Obstetric History and Cardiovascular Disease (CVD) Risk
  4791. Inhibitors in hemophilia: treatment challenges and novel options
  4792. Role of Activated Protein C Resistance in Complicated Pregnancy
  4793. Is infection an independent risk factor for venous thromboembolism? A population-based, case-control study
  4794. The influence of race on plasma thrombin generation in healthy subjects in singapore
  4795. Thrombophilia: Women-specific reference ranges can prevent misdiagnosis in women
  4796. Factor V Leiden G1691A, prothrombin G20210A, and MTHFR C677T and A1298C mutations in patients with sickle cell disease in Tunisia
  4797. Increased risk of thrombosis associated with peripherally inserted central catheters compared with conventional central venous catheters in children with leukemia
  4798. Dielectrophoresis erythrocytes images for predicting stroke recurrence based on analysis of hemorheological parameters
  4799. Clinical manifestation and mutation spectrum of 53 unrelated pedigrees with protein S deficiency in China
  4800. Venous thromboembolism in pregnancy
  4801. Hemostasis based on a novel ‘two-path unifying theory’and classification of hemostatic disorders
  4802. Heparin Induced Thrombocytopenia
  4803. Hematologic Issues in Sepsis
  4804. The impact of motor activity level of newborn calves with dyspepsia on correction efficiency of hypercoagulation state in them with the help of gamavit
  4805. An Artificial Intelligence Approach to Thrombophilia Risk
  4806. The Association between the Level of Antithrombin III and Mortality in Children with Sepsis. Open Access Maced J Med Sci
  4807. Disseminated Intravascular Coagulation
  4808. Estimation of Antithrombin III Level in Patients with Deep Venous Thrombosis in Khartoum State
  4809. Pro-inflammatory agents released by pathogens, dying host cells, and neutrophils act synergistically to destroy host tissues: a working hypothesis
  4810. Cerebral Venous Thrombosis in a Pediatric Patient with Antithrombin Deficiency
  4811. Study of levels of protein Z as a risk factor for thrombosis in children with nephrotic syndrome
  4812. Antithrombin plus alpha-1 protease inhibitor does not affect coagulation and inflammation in two murine models of acute lung injury
  4813. Biology and role of extracellular vesicles (EVs) in the pathogenesis of thrombosis
  4814. BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy
  4815. Estimation of Antithrombin III Level in Cord Blood of New Born from Gestational Diabetic Sudanese Women
  4816. Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe Jon C. Davidson …
  4817. The treatment of anti-phospholipid syndrome: a comprehensive clinical approach
  4818. Is generation of C3 (H2O) necessary for activation of the alternative pathway in real life?
  4819. Optimal antithrombin activity threshold for initiating antithrombin supplementation in patients with sepsis-induced disseminated intravascular coagulation: a multicenter …
  4820. Effect of remote ischemic preconditioning on hemostasis and fibrinolysis in head and neck cancer surgery: A randomized controlled trial
  4821. Activated protein C has no effect on pulmonary capillary endothelial function in septic patients with acute respiratory distress syndrome: Association of …
  4822. Thromboprophylaxis in Pregnancy
  4823. Management of antithrombin deficiency: an update for clinicians
  4824. Protein S exacerbates chronic liver injury and fibrosis
  4825. Venous thromboembolism in pediatric hematopoietic cell transplant: a multicenter cohort study
  4826. MAAIKE SOHNE, MARIJE TEN WOLDE, and HARRY R. BULLER
  4827. The multifaceted role of fibrinogen in tissue injury and inflammation
  4828. Nanoparticles in the lungs of old mice: Pulmonary inflammation and oxidative stress without procoagulant effects
  4829. Catastrophic Antiphospholipid Antibody Syndrome: Clinical Presentation, Management, and Guidance for Future Pregnancy
  4830. The extract from Agkistrodon halys venom protects against lipopolysaccharide (LPS)-induced myocardial injury
  4831. Neonatal systemic thrombosis: an updated overview
  4832. Optimisation of antithrombin resistance assay as a practical clinical laboratory test: development of prothrombin activator using factors Xa/Va and automation of assay
  4833. Hemostasis testing and therapeutic plasma exchange: results of a practice survey
  4834. Role of platelets in thrombin generation amongst patients with non-transfusion-dependent thalassaemia
  4835. Superficial vein thrombosis in non-varicose veins of the lower limbs and thrombophilia
  4836. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during …
  4837. Coagulopathies in critically ill patients
  4838. Surfing the blood coagulation cascade: insight into the vital factor Xa
  4839. Thrombophilia: Hereditary
  4840. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review
  4841. Methylene tetrahydrofolate reductase gene mutation in sickle cell anaemia patients in Lagos, Nigeria
  4842. Secondary Thromboprophylaxis in Hereditary Thrombophilia
  4843. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state
  4844. Management of Postpartum Hemorrhage
  4845. A study of congenital protein C deficiency with infancy onset of CADASIL in a Chinese baby
  4846. NLRP3 regulates platelet aIIbβ3 outside-in signaling, hemostasis and arterial thrombosis
  4847. Venous thromboembolism in autologous blood or marrow transplantation survivors: a report from the Blood or Marrow Transplant Survivor Study
  4848. Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th International Coagulation in Liver Disease …
  4849. Acute pulmonary embolism in Protein S deficiency: 2 rare case reports of young male presenting with breathlessness.
  4850. The evolution of recombinant factor replacement for hemophilia
  4851. Practical and Advanced Calculations in Transfusion Medicine, Apheresis, and Hemostasis
  4852. Elevated serum antiphospholipid antibodies in adults with celiac disease
  4853. Adjuvant radiotherapy does not affect hemostasis
  4854. Therapeutic potential of endogenous stem cells and cellular factors for scar-free skin regeneration
  4855. Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study
  4856. Inferior vena cava atresia predisposing to acute lower extremity deep vein thrombosis in children: A descriptive dual‐center study
  4857. Correlation of ns1 antigen titres with the severity of dengue fever in children
  4858. A review on hepatitis and haemostasis
  4859. Modern position of anticoagulants in acute pulmonary embolism: achievements, limitations, prospects
  4860. Changes in platelet function with inflammation in patients undergoing vascular surgery
  4861. Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis?
  4862. Novel interventions: what’s new and the future
  4863. Update on the diagnosis and anticoagulant treatment of the antiphospholipid syndrome
  4864. Thrombophilia as an Etiological factor of Recurrent Pregnancy Loss in Sudanese Women, Khartoum State, Sudan (2018)
  4865. Management of coagulation disorders in severe inflammation
  4866. Comparison of Plasma Fibrinogen Level and Complete Blood Count among Glycomic Control Diabetic Mellitus Patients Type 2 in Shendi Town
  4867. Periprocedural Considerations for Anticoagulated Atrial Fibrillation Patients
  4868. The secondary prevention of venous thromboembolism: Towards an individual therapeutic strategy
  4869. Hematologic Challenges in the Critically Ill: Obstetrics
  4870. Gene therapy for hemophilia: what does the future hold?
  4871. Antiphospholipid Syndrome
  4872. Describing the coagulation cascade: from a systems pharmacology model to a semi-mechanistic PKPD approach
  4873. Usage of a Microfluidic System to Investigate the Endothelial Glycocalyx in vitro
  4874. Utility of thrombophilia screening in pediatric renal transplant recipients
  4875. Obstetric antiphospholipid syndrome
  4876. Stability of Hemostatic potential of Thawed Plasma on storage at 2-60C for 5 days
  4877. Clinical use and laboratory testing of oral anticoagulation therapy: experience from Finland
  4878. Temporal trends, characteristics and outcomes of fibrinolytic therapy for ST‐elevation myocardial infarction among patients 80 years or older
  4879. Role of Prothrombin time International normalized ratio and activated partial thromboplastin time in beta thalassemia major: A cross sectional study
  4880. Prevention of deep venous thromboembolism in foot and ankle surgery
  4881. Comparison of the serum metabolic signatures based on 1H NMR between patients and a rat model of deep vein thrombosis
  4882. Determination Of Hemoglobin F Level in Normal Pregnant Women Reffered To Dar Elber Specialized Medical Center in Khartoum City
  4883. Study of coagulation and platelet dysfunction in chronic liver disease at a tertiary care hospital
  4884. Measurement of Prothrombin Time, Activated Partial Thromboplastin Time, Fibrinogen Concentration, Platelets count and indices in healthy police dogs in Sudan
  4885. Changes in the Velocity of Blood in the Portal Vein in Mild Acute Pancreatitis—A Preliminary Clinical Study
  4886. Association of SERPINC1 gene polymorphism (rs2227589) with pulmonary embolism risk in a Chinese population
  4887. Anticoagulant protein S targets the factor IXa heparin-binding exosite to prevent thrombosis
  4888. An update on the ‘danger theory’in inhibitor development in hemophilia A
  4889. Thrombocytopenia, Coagulation and Disease Severity in Puumala Hantavirus Infection
  4890. Role of endothelial cells in acute and chronic thrombosis
  4891. Evaluation of Protein S Level in Ladies with Placental Complicated Pregnancy
  4892. Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial
  4893. Direct oral anticoagulant drugs: On the treatment of cancer-related venous thromboembolism and their potential anti-neoplastic effect
  4894. Non-obstetric complications in preeclampsia
  4895. Enoxaparin pretreatment effect on local and systemic inflammation biomarkers in the animal burn model
  4896. The gut microbiota–a modulator of endothelial cell function and a contributing environmental factor to arterial thrombosis
  4897. Disseminated Intravascular Coagulation
  4898. Briefing Therapeutic Approaches in Anticoagulant, Thrombolytic, and Antiplatelet Therapy
  4899. The role of dynamic and diffusion weighted magnetic resonance imaging in differentiating malignant and benign portal vein thrombosis.
  4900. Aim: Besides primary ovarian tumor, a part of adnexal masses are metastatic colorectal cancers (CRC). Additionally, the risk of CRC is increased if the genitourinary …
  4901. Crosstalk of Inflammation and Coagulation in Infectious Disease and Their Roles in Disseminated Intravascular Coagulation
  4902. Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner
  4903. Prophylactics for lower-extremity deep venous thrombosis in high-risk patients after gynecologic surgery: a prospective study
  4904. Everything the clinician needs to know about evidence-based anticoagulation in pregnancy
  4905. Prevalence Of Asymptomatic Thrombophilia Among Pregnant Women Attending Antenatal Care Clinic At Mpigi Health Center IV
  4906. Genetic testing for thrombophilia-related genes: observations of testing patterns for factor V Leiden (G1691A) and prothrombin gene “Mutation”(G20210A)
  4907. Exploring the diversity, infectivity and metabolomic landscape of Rickettsial infections for developing novel therapeutic intervention strategies
  4908. Supportive Care
  4909. Comparison of antithrombin iii and pentoxifylline treatments in gram negative sepsis patients developing disseminated intravascular coagulation
  4910. Analysis of factor XIa, factor IXa and tissue factor activity in burn patients
  4911. Inhibitors in hemophilia A: a pharmacoeconomic perspective
  4912. Basic coagulation parameters among human immunodeficiency virus-infected adults in Gondar, Northwest Ethiopia: A comparative cross-sectional study
  4913. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting
  4914. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
  4915. Inherited thrombophilia and the risk of myocardial infarction: current evidence and uncertainties
  4916. Activated protein C in neuroprotection and malaria
  4917. Anticoagulation for Proximal Deep Vein Thrombosis
  4918. Four-factor prothrombin complex concentrate for the management of patients receiving direct oral activated factor X inhibitors
  4919. Bridging leaders’ link quality, medical education
  4920. Venous thromboses at unusual sites
  4921. Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the hematologist’s view
  4922. Physiologic changes and their Sequelae in pregnancy
  4923. Nonarteriosclerotic disorders of the arterial system
  4924. The Clinical Spectrum of Amyloidosis
  4925. Haematological Diseases
  4926. Cerebrovascular complications of cancer
  4927. Hypertension Associated with Atherosclerosis Risk Factors in Patients of Family Health Strategy Highlighting the Framingham Risk Score
  4928. Thrombophilia: clinical and laboratory assessment and management
  4929. Predicting Future Complications of Cirrhosis
  4930. Antithrombin levels are associated with the risk of first and recurrent arterial thromboembolism at a young age
  4931. A COMPREHENSIVE LITERATURE REVIEW ON THE ROLE INHERITED THROMBOPHILIA PLAYS IN VENOUS THROMBOEMBOLISM
  4932. Thromboembolism incidence and risk factors in children with cancer: a population-based cohort study
  4933. Diagnosis and exclusion of pulmonary embolism
  4934. Oral factor Xa inhibitors: Studies on reversal of their anticoagulant effect and on their influence on primary hemostasis, endothelial function and fibrinolysis
  4935. Coagulopathies and inflammatory diseases:’… glimpse of a Snark’
  4936. A brief review of cardiovascular diseases, associated risk factors and current treatment regimes
  4937. 9 Antepartum haemorrhage
  4938. Genetics of Vascular Diseases
  4939. Interleukin-6 as a biomarker in patients with hepatobiliary cancers
  4940. Effect of thrombin injection on cerebral vascular in rats with subarachnoid hemorrhage
  4941. Host defenses to extracellular bacteria
  4942. Recommendations regarding the genetic and immunological study of reproductive dysfunction
  4943. Tumor-derived apoptotic vesicles: with death they do part
  4944. ANTITHROMBIN LEVELS ARE ASSOCIATED WITH THE RISK OF FIRST AND RECURRENT ARTERIAL THROMBOEMBOLISM
  4945. Thrombosis associated biomarkers in morbid obesity and bariatric surgery: doctoral dissertation: biomedical sciences, medicine (06B)
  4946. Thrombosis associated biomarkers in morbid obesity and bariatric surgery
  4947. Venous Disorders and Cavernous Malformations
  4948. Redox mechanisms in migraine: novel therapeutics and dietary interventions
  4949. Determination of Plasma Fibrinogen Level in Diabetic Patients in Shendi Town
  4950. Sulfasalazine treatment can cause a positive effect on LPS-induced endotoxic rats
  4951. Illustrated state‐of‐the‐art capsules of the ISTH 2019 congress in Melbourne, Australia
  4952. Cancer-associated thrombosis: beyond clinical practice guidelines—a multidisciplinary (SEMI–SEOM–SETH) expert consensus
  4953. The Role of Thrombin Exosites 1 and 2 in the Activation of Factor XI by Thrombin
  4954. The systemic inflammatory response syndrome
  4955. If the Platelets Are Low, Is It HIT?
  4956. Dental Management of the Pregnant Patient
  4957. Venous thromboembolism in special populations: preexisting cardiopulmonary disease, cirrhosis, end-stage renal disease, and asplenia
  4958. Phytochemical screening and evaluation of in vitro antiinflammatory effect of hydro-methanolic extract of foeniculum vulgare seeds
  4959. Biophysical exploration of conformational environments in zymogen prothrombin and blood coagulant thrombin.
  4960. The influence of age, vitamin K and genetics on anticoagulation outcomes in adults and children
  4961. Assessment of the Effect of Green tea Consumption on Fibrinogen Among Adult Healthy Sudanese Volunteers
  4962. Effect of Allium Sativum (Garlic) Intake on Prothrombin Time and International Normalize Ratio
  4963. Protocol APIDULCIS Final Version 1.1 in date 16.1. 2018
  4964. A Randomized Study Of Effectiveness Of Analgesia With Preemptive Intraperitoneal Instillation Of Bupivacaine And Instillation Of Bupivacaine After The …
  4965. TO THE HEART OF STAPHYLOCOCCAL ENDOCARDITIS, NEW INSIGHTS IN THE PATHOGENESIS OF HEART VALVE INFECTIONS
  4966. Acquired thrombocytopenia
  4967. Prognostic hemostasis biomarkers in acute ischemic stroke: a systematic review
  4968. Intraoperative fluid management
  4969. Hemostasis and Thrombosis
  4970. Acquired Thrombocytopenia 15
  4971. Factor V Leiden 1691G> A and Prothrombin 20210G> A Genes Polymorphisms, Coagulation Profile and Risk Factors of Deep Vein Thrombosis among Sudanese …
  4972. Attitude, subjective norms, perceived behavioral control, and intention of egyptian nurses towards prevention of deep vein thrombosis among critically ill patients in …
  4973. Coagulation Abnormalities Play a Central Role in HIV Comorbidities and Should Be Therapeutically Targeted
  4974. Applications of Uncertainty Quantification to Coagulation Biology
  4975. Role of Activated Protein C Resistant and Anticoagulant Deficiency in Vascular Complication of Pregnancy in Shendi locality, Sudan.
  4976. Development of MS-based methods for identification and quantification of proteins altered during early pregnancy in dogs
  4977. SURGICAL BIOLOGY SECTION
  4978. Thrombophilic States
  4979. A thrombin-activatable factor X variant corrects hemostasis in a mouse model for hemophilia A
  4980. Cardioprotection by bioactive polyphenols: A strategic view
  4981. Stroke and diabetes
  4982. Insights into clinical and laboratory phenotypes of von Willebrand disease
  4983. Impact of Chronic Obstructive Respiratory Disease (COPD), respiratory symptoms and oxygen saturation on the risk of incident venous thromboembolism (VTE) and …
  4984. Role of Mannose-Binding Lectin and Complement Activation in Venous Thromboembolism
  4985. Pathophysiology of Venous Thromboembolism
  4986. Clinical Thrombosis
  4987. Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia: Plasminogen in wound healing
  4988. Response patterns of routinely measured inflammatory and coagulatory parameters in sepsis
  4989. Bleeding and the management of hemorrhagic disorders in pregnancy
  4990. Interferences of hemolysis, lipemia and high bilirubin on laboratory tests
  4991. Neonatal Bleeding and Thrombotic Disorders
  4992. A Study on the Coagulation Profile and Its Clinicopathological Correlation of the Haemophilia Patients at the Day Care Centre of Tirunelveli Medical College
  4993. Musculoskeletal Infection of the Hip
  4994. Coagulation Disorders in Congenital Heart Disease
  4995. The Role of Platelets in Sickle Cell Disease
  4996. Dynamics of blood circulation during diving in the bottlenose dolphin (Tursiops truncatus): the role of the retia mirabilia
  4997. Hemolytic-uremic syndrome in children in Norway: a study on epidemiology, surveillance, clinical aspects and outcome
  4998. Thrombophilia in pregnancy
  4999. BACKGROUND MATERIAL FOR FRIDAY 10TH MAY for the lectures presented by
  5000. Guidelines for the Management for Cancer Associated Thrombosis
  5001. Hospital readmission after ischemic stroke or TIA
  5002. Therapeutic heparin during the peripartum period
  5003. A study of Thromboprophylaxis in the Australian and New Zealand Fontan population
  5004. Internal Medicine: Hematology
  5005. Inherited Thrombophilia in the Era of Direct Oral anticoagulants
  5006. The risk of arterial thrombosis in carriers of naturalcoagulation inhibitors: a prospective family cohort study
  5007. Reduction of ADAMTS13 levels predicts mortality in SARS-CoV-2 patients
  5008. Factors affecting the formation and treatment of thrombosis by naturaland synthetic compounds
  5009. Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis
  5010. Coagulation System Activation for Targeting of COVID-19: Insights into anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines
  5011. Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections
  5012. Novel treatments for hemophilia through rebalancing of the coagulation cascade
  5013. Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis
  5014. Symmetrical peripheral gangrene in critical illness
  5015. Comparison of three modalities of plasmapheresis on coagulation: Centrifugal, single‐membrane filtration, and double‐filtration plasmapheresis
  5016. Response: Comment and Update on “Using Artificial Intelligence to Manage Thrombosis Research, Diagnosis, and Clinical Management”
  5017. The effect of naturalreducing agents on push-out bond strength of AH plus and BioRoot RCS to sodium hypochlorite treated root dentin
  5018. Maintaining plasma quality and safety in the state of ongoing epidemic–The role of pathogen reduction
  5019. Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
  5020. COVID‐19–related laboratory coagulation findings
  5021. Antithrombin–heparin complexes
  5022. Diet-Dependent and Diet-Independent Hemorheological Alterations in Celiac Disease: A Case-Control Study
  5023. Effect of immunoadsorption alone or combined with membrane filtration on hemostasis parameters
  5024. Treatment and secondary prophylaxis of venous thromboembolism with direct oral anticoagulants in patients with severe hereditary thrombophilia
  5025. Role of both protein c and antithrombin III as predictors of stage of liver disease in chronic viral hepatitis b or c infected patients
  5026. Thrombotic disorders (part 1)
  5027. Thrombotic disorders (part 1)
  5028. Cerebral infarction followed by myocardial infarction in a young adult with protein C and S deficiency
  5029. PROTEIN-C IS THE MOST POTENT HEMATOLOGIC BIOMARKER OF OUR NOVEL HEMOSTATIC SCORE CREATED TO IDENTIFY HIGH-RISK PATIENTS WITH …
  5030. Treatment of haemophilia: From replacement to gene therapy
  5031. FEATURES OF GENETIC POLYMORPHISMS AND CLINICAL MANIFESTATIONS OF PRIMARY THROMBOPHILIA IN CHILDREN
  5032. Thrombophilia: Consequences in pregnancy & malignancy
  5033. 1656: NOVEL HEMOSTATIC SCORE CREATED TO IDENTIFY PATIENTS WITH SEPSIS-ASSOCIATED COAGULOPATHY AND DIC
  5034. Thrombotic disorders (part 1): guest editorial
  5035. Response to letter to the editor: catastrophic antiphospholipid antibody syndrome and multiple organ dysfunctions in critically ill patients with COVID-19: Multiple …
  5036. THE PRICE OF SURVIVING SEVERE SEPTIC SHOCK
  5037. Thrombotic Events and anticoagulants in Beta-thalassemia Patients with Focus on anticoagulants for Atrial Fibrillation: A Brief Review
  5038. Pulmonary thrombosis in COVID-19 treated by thrombolysis: a small case series using streptokinase
  5039. A Ticking Time Bomb: Catastrophic Antiphospholipid Syndrome Associated with HIV
  5040. Hereditary Thrombophilia
  5041. From ancient leech to direct thrombin inhibitors and beyond: New from old
  5042. Extraction optimization, structural characterization, and anticoagulant activity of acidic polysaccharides from Auricularia auricula-judae
  5043. Pulmonary embolism and COVID-19: A paradigm change
  5044. Comparative study of hypercoagulability change in steady state and during vaso-occlusive crisis among Sudanese patients living with sickle cell disease
  5045. World Thrombosis Day, October 10, 2020
  5046. The effect of SARS‐Co‐V2 infection on prothrombotic and anticoagulant factors in dialysis patients
  5047. In vitro fertilization outcomes in women with antiphospholipid antibodies circulation
  5048. Complications thromboemboliques de la glomérulonéphrite extramembraneuse
  5049. The hemostatic system. 1st Part
  5050. Analysis of the Coagulation Profile in Children with HIV Infection–Effect of Disease and Anti Retroviral Therapy
  5051. Reproductive Failure and Thrombophilia: Not Enough Evidence for a Tight Bond
  5052. Pulmonary Embolism–a Thrombo-Inflammatory Complication of a Viral Infection. The Paradigm Shift in the COVID Era
  5053. Nonfactor Therapies: New Approaches to Prophylactic Treatment of Haemophilia
  5054. Thrombin-Induced Endothelial Cell Damage Is Mitigated By Human Anti-Thrombin III in a Microfluidic Device
  5055. Effect of heparanase and heparan sulfate chains in hemostasis
  5056. Pathogenetically justified tactics of management of pregnancy with retrochorial hematoma
  5057. Effect of age on the functioning of hemostasis system during hip joint endoprosthesis
  5058. Inherited and Acquired Thrombophilia and Infertility
  5059. Direct Oral anticoagulants in Antithrombin Deficiency: Initial Experience in a Single Center
  5060. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19
  5061. Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced …
  5062. THE MOLDOVAN MEDICAL JOURNAL
  5063. Association of Factor V Leiden G1691A and Prothrombin gene G20210A mutations with adverse pregnancy outcomes
  5064. Effects of Leptin Replacement on Risk Factors for Cardiovascular Disease in Genetically Leptin-deficient Subjects
  5065. Coagulation abnormalities in childhood acute lymphoblastic leukemia: assessing the impact of L-asparaginase therapy in Ghana
  5066. Plasma protein signatures of a murine venous thrombosis model and Slc44a2 knockout mice using quantitative-targeted proteomics
  5067. Al-Azhar University Journal for Virus Research and Studies
  5068. A Prospective Study of Specialized Coagulation Parameters in Admitted COVID-19 Patients and Their Correlation With Acute Respiratory Distress Syndrome …
  5069. Advances in the management of haemophilia: emerging treatments and their mechanisms
  5070. Inherited Thrombophilias
  5071. Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?
  5072. Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease
  5073. European principles of inhibitor management in patients with haemophilia: implications of new treatment options
  5074. Intravascular lung coagulopathy by COVID-19
  5075. Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management
  5076. Venous thromboembolism and thrombophilia testing
  5077. Altered coagulation profile in peripheral artery disease patients
  5078. Inflammatory response in relation to COVID-19 and other prothrombotic phenotypes
  5079. The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications
  5080. The haemostatic system in acromegaly: a single-centre case–control study
  5081. COVID-19 in adults: test menu for hospital blood science laboratories
  5082. Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots
  5083. Development of an Optical Method for the Evaluation of Whole Blood Coagulation
  5084. Personalized anesthesia in hematology
  5085. Carriers of haemophilia: pregnancy, childbirth and postpartum
  5086. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?
  5087. Role of vitamin D in treating COVID-19-associated coagulopathy: problems and perspectives
  5088. Stroke as a potential complication of COVID-19-associated coagulopathy: a narrative and systematic review of the literature
  5089. Thrombotic disorders (part 2)
  5090. A case-report of two patients with hereditary protein S deficiency treated by rivaroxaban
  5091. Illustrated State-of-the-Art Capsules of the ISTH 2021 Congress
  5092. Procoagulant and anticoagulant plasma indicators in diabetic dogs showing increased antithrombin III levels in canine diabetes mellitus
  5093. Nationwide cohort study of outcomes of acute myocardial infarction in patients with liver cirrhosis: A nationwide cohort study
  5094. Thrombin generation in cardiovascular disease and mortality–results from the Gutenberg Health Study
  5095. Coagulopathy in COVID‐19
  5096. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia
  5097. Thromboelastograph: a prognostic marker in sepsis with organ dysfunction without overt bleeding
  5098. Anticoagulant treatment in COVID-19: a narrative review
  5099. Thromboembolic events in pregnant and puerperal women after COVID‐19 lockdowns: A retrospective cohort study
  5100. Pulmonary embolism during pregnancy: a 17-year single-center retrospective MDCT pulmonary angiography study
  5101. Acute Coronary Syndromes in Pregnancy
  5102. Exploring the pathways of inflammation and coagulopathy in COVID-19: A narrative tour into a viral rabbit hole
  5103. Thrombophilia and Hormonal Therapy in Adolescents
  5104. Hemostatic challenges in neonates
  5105. Thrombosis and thrombocytopenia in antiphospholipid syndrome: their association with mean platelet volume and hematological ratios
  5106. Managing thromboembolic risk in patients with hereditary and acquired thrombophilias
  5107. Biologically guided isolation and ADMET profile of new factor Xa inhibitors from Glycyrrhiza glabra roots using in vitro and in silico approaches
  5108. The role of solute carrier family 44 member 2 in the pathophysiology of venous
  5109. Genetic mutations among a group of patients with unstimulated thrombosis in Sulaymaniyah Northeastern Iraq
  5110. Recent advances in the research and management of sepsis-associated DIC
  5111. Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19?
  5112. When and how to use direct oral anticoagulants in patients with advanced chronic liver disease?
  5113. Abnormal hemostatic parameters and risk of thromboembolism among patients with COVID-19 infection
  5114. Splanchnic venous thrombosis in a nephrotic patient following COVID-19 infection: a case report
  5115. Thromboelastometry for assessing risks of free flap thrombosis in patients undergoing microvascular surgery
  5116. The pathophysiology of the haematological manifestations of COVID-19: a review
  5117. Classic Thrombophilias and Thrombotic Risk Among Middle‐Aged and Older Adults: A Population‐Based Cohort Study
  5118. The genetics of venous thromboembolism: a systematic review of thrombophilia families
  5119. Coagulopathy is Initiated with Endothelial Dysfunction and Disrupted Fibrinolysis in Patients with COVID-19
  5120. Prevalence of cancer in patients with superficial vein thrombosis and its clinical importance
  5121. Local Thrombolysis in Acute and Extended Portal Vein and TIPS Thrombosis in a Patient with Decompensated Cirrhosis and Protein S Deficiency.
  5122. Biomarkers associated with COVID-19 disease progression
  5123. Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis
  5124. Assessment of protein C antigen, free protein S, and protein C activity in pregnancy: A cross-sectional study of pregnant Nigerian women.
  5125. COVID-19 Associated Coagulopathy: The Thrombin Burst
  5126. Immune-inflammatory, coagulation, adhesion, and imaging biomarkers combined in machine learning models improve the prediction of death 1 year after ischemic …
  5127. Trauma-induced coagulopathy: overview of an emerging medical problem from pathophysiology to outcomes
  5128. Effects of body composition on the procoagulant imbalance in obese patients
  5129. COVID-19 and its implications for thrombosis and anticoagulation
  5130. The hematology laboratory’s response to the COVID‐19 pandemic: A scoping review
  5131. Cerebral venous sinus thrombosis following primary varicella infection in a child
  5132. Platelets compensate for poor thrombin generation in type 3 von Willebrand disease
  5133. Anticoagulation in COVID–19: An Update
  5134. ADAMTS-13–VWF axis in sickle cell disease patients
  5135. Does Lung Ultrasound Have a Role in the Clinical Management of Pregnant Women with SARS COV2 Infection?
  5136. Protein S for portal vein thrombosis in cirrhotic patients waiting for liver transplantation
  5137. Catastrophic antiphospholipid syndrome
  5138. Inherited thrombophilia and venous thromboembolism: testing rules in clinical practice
  5139. Modern concepts of the fibrinolytic system
  5140. Pathogeny of cerebral venous thrombosis in SARS-Cov-2 infection
  5141. New insights into the pathogenesis, risk factors, and treatment of portal vein thrombosis in patients with cirrhosis
  5142. Cerebrovascular disease in patients with COVID-19: a review of the literature and case series
  5143. European medicinal leeches—new roles in modern medicine
  5144. The Many Faces of Cytokine Release Syndrome-Related Coagulopathy
  5145. Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis
  5146. Basic principles of viscoelastic testing
  5147. Inherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta‐analysis
  5148. Haemophilia: factoring in new therapies
  5149. Microvascular thrombosis and clinical implications
  5150. Coagulation DysfunctionA Hallmark in COVID-19
  5151. Thrombophilic Complications in the Development of Gestional Hypertension
  5152. Pulmonary embolism in Behcet’ s disease: a case report
  5153. Thrombin generation measured by two platforms in patients with a bleeding tendency: Reply
  5154. Thrombophlebia and Pregnancy, Predicting Perinatal Complications and Optimizing Administration Tactics
  5155. Thrombophilia as a Risk Factor for Thrombosis
  5156. A descriptive monocentric study in Algeria of adults with cerebral venous thrombosis
  5157. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis
  5158. Cis-Segregation of c. 1171C> T Stop Codon (p. R391*) in SERPINC1 Gene and c. 1691G> A Transition (p. R506Q) in F5 Gene and Selected GWAS Multilocus …
  5159. Obesity as a thrombogenic and cardiovascular risk factor in children
  5160. Neurology of inflammatory bowel disease
  5161. The effects of sugammadex on coagulation in pregnant rats
  5162. Identification and characterization of a novel variant in C-terminal region of Antithrombin (Ala427Thr) associated with type II AT deficiency leading to polymer formation
  5163. Platelet Indices in Preeclampsia and Normotensive Pregnancy in a Tertiary Care Centre: A Cross-sectional Study.
  5164. Thrombosis and COVID-19 pneumonia: the clot thickens!
  5165. COVID-19 infection and thrombosis
  5166. Portal Vein Thrombosis Associated with Trousseau Syndrome due to Urinary Bladder Squamous Cell Carcinoma in a Liver Cirrhosis Patient
  5167. Acute stroke in young adult secondary to moyamoya angiopathy unveiling HbE-β thalassemia
  5168. Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between‐subject variation
  5169. COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography
  5170. Assessment of some biomarkers related with recurrent miscarriages in Iraq
  5171. Direct oral anticoagulants in patients with severe inherited thrombophilia: a single-center cohort study
  5172. Successful Use of Thrombolysis in an Extremely Low Birth Weight, Premature Infant With Aortic Thrombosis
  5173. Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy
  5174. Hypercoagulable Conditions and VTOS
  5175. Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia
  5176. Platelet Function and Coronary Microvascular Dysfunction
  5177. Purpura Fulminans in a 20-Year-Old Female Púrpura Fulminante numa Jovem de 20 Anos
  5178. Practical approach to transfusion management of post‐partum haemorrhage
  5179. Disseminated Intravascular Coagulation (DIC)
  5180. Disseminated Intravascular Coagulation
  5181. Disseminated intravascular coagulation
  5182. Low prevalence of antiannexin A5 antibodies in unprovoked venous thrombosis
  5183. Purpura Fulminans in a 20-Year-Old Female
  5184. The State of Microcirculatory Hemodynamics in Patients with Moderate and Severe COVID-19
  5185. COVID-19-associated vasculitis and vasculopathy
  5186. Late onset Vitamin K deficiency bleeding disorder presenting as nodular purpura in a 3-month-old exclusively breastfed infant
  5187. Effect of gender‐affirming hormone use on coagulation profiles in transmen and transwomen
  5188. A case series of Factor V Leiden mutation in pregnancy
  5189. Loop-mediated isothermal amplification (LAMP)-based method for detecting factor V Leiden and factor II G20210A common variants
  5190. Pregnancy and Its Outcome in a Rare Case of Combined Protein C and Protein S Deficiency with Severe Adenomyosis
  5191. Why Is Heparin, Despite Being an Anticoagulant, Rarely Associated with Blood Clotting? A Systematic Review
  5192. Evaluation of thrombophilia testing in the inpatient setting: A single institution retrospective review
  5193. The concept of rebalanced hemostasis in patients with liver disease: communication from the ISTH SSC working group on hemostatic management of patients with …
  5194. Midbrain infarction in inherited protein S deficiency: a rare association
  5195. New frontiers in acute stroke management
  5196. Evidence for a rebalanced hemostatic system in pediatric liver transplantation: a prospective cohort study
  5197. Frequency of thrombophilia associated genes variants: population-based study
  5198. Pregnancy-related thrombosis risk in patients with protein C deficiency and comparison with pregnant women with heterozygous factor V Leiden mutation
  5199. APS pregnancy–The offspring
  5200. Antibody profiles comprising anti phosphatidylserine/prothrombin differently affect thrombin generation and protein C resistance in antiphospholipid antibody carriers
  5201. Comparative Analysis of the Hemostasiological Profile in Sheep and Patients with Cardiovascular Pathology as the Basis for Predicting Thrombotic Risks …
  5202. Assessment of Coagulation and Haematological Parameters among Pregnant Women in Port Harcourt
  5203. Disseminated intravascular coagulation: epidemiology, biomarkers, and management
  5204. Three-factorial genetic thrombophilia with recurrent thrombotic events in a Saudi patient: A case report
  5205. Preservation of thrombin generation in cirrhosis despite abnormal results of international normalized ratio: implications for invasive procedures
  5206. The prothrombotic state in cancer
  5207. “War to the knife” against thromboinflammation to protect endothelial function of COVID-19 patients
  5208. COVID-19 and thrombosis predisposition
  5209. Necrotizing fasciitis: pillaging the acute phase response
  5210. Novel CD55 Mutation Associated With Severe Small Bowel Ulceration Mimicking Inflammatory Bowel Disease in a Pair of Siblings
  5211. The effect of direct oral anticoagulants on antithrombin activity testing is abolished by DOAC-stop in venous thromboembolism patients
  5212. Dynamic changes in coagulation, hematological and biochemical parameters as predictors of mortality in critically ill COVID–19 patients: a prospective …
  5213. A study in respect of transfusion related complications in hemophiliacs with special reference to developing factor inhibitors
  5214. Pregnancy in Budd–Chiari Syndrome
  5215. Interaction of thrombophilic SNPs in patients with unexplained infertility—multifactor dimensionality reduction (MDR) model analysis
  5216. Protein C and Protein S Levels in β-Thalassemia Major Patients in Erbil, Kurdistan Region
  5217. Osteogenic and angiogenic properties of heparin as a system for delivery of biomolecules for bone bioengineering: A brief critical review
  5218. Postpartum cerebral venous thrombosis associated with protein S deficiency: A case report
  5219. Thrombophilia and Primary Budd–Chiari Syndrome
  5220. Prevalence and outcomes of thrombotic and hemorrhagic complications in pediatric acute promyelocytic leukemia in a tertiary Brazilian center
  5221. Evaluation of Bivalirudin as the Primary Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation for SARS-CoV-2–Associated Acute Respiratory …
  5222. Author Desk
  5223. Uptake of Pharmacological Prophylaxis for Venous Thromboembolism in Postpartum Women After Introduction of Formal Risk Assessment Tool–a Quasi …
  5224. EVALUATION OF PROTEIN C, PROTEIN S AND FIBRINOGEN OF PREGNANT WOMEN WITH MALARIA IN OWERRI METROPOLIS
  5225. Inflammatory bowel disease and thrombosis: A national inpatient sample study
  5226. Determination of the risk of Venous thromboembolism (VTE) in women on injectable contraceptives using d-dimer, fibrinogen levels and platelet count.
  5227. Characteristics of ischaemic stroke associated with COVID-19
  5228. DESCRIPTION OF THE RESULTS OF THE CLOTTING TIME EXAMINATION OF LEE AND WHITE METHOD IN DIABETES MELLITUS PATIENTS AT TOTO KABILA …
  5229. A Composite Study of Coagulation Milieu in Covid-19: Experience from a Tertiary Care Centre from India
  5230. Protein C or Protein S deficiency associates with paradoxically impaired platelet‐dependent thrombus and fibrin formation under flow
  5231. Thromboses and Hemostasis Disorders Associated with COVID-19: The Possible Causal Role of Cross-Reactivity and Immunological Imprinting
  5232. Neonatal Sepsis and Hemostasis. Diagnostics 2022, 12, 261
  5233. Hemophilia–Impact of Recent Advances on Management
  5234. Determination of von Willebrand factor level in patient with sickle cell diseasein vaso‐occlusive crisis
  5235. COVID-19 infection and haematological involvement: a review of epidemiology, pathophysiology and prognosis of full blood count findings
  5236. Opsoclonus-myoclonus syndrome with severe clinical course and beneficial outcome: A case report
  5237. Coagulation and anticoagulants
  5238. ABO Blood Groups and Thrombophilia Markers in Patients With Unstimulated Thrombosis in Kurdistan Region of Iraq
  5239. The Novel Coronavirus and Haemostatic Abnormalities: Pathophysiology, Clinical Manifestations, and Treatment Recommendations
  5240. Arteriopathy by doppler ultrasound study and neuropathy by electromyography and nerve conduction study in diabetic foot
  5241. Thrombophilia screening revisited: an issue of personalized medicine
  5242. Reference interval of antithrombin, protein C, and protein S activities in healthy adults in Iran, the effect of age, sex, oral contraceptive intake, and menopause
  5243. Inhibitors of the blood coagulation process in patients with essential thrombocythemia
  5244. Thromboelastography (TEG) in normal pregnancy and its diagnostic efficacy in patients with gestational hypertension, gestational diabetes mellitus, or preeclampsia
  5245. Mitral Valve Thrombosis in a Neonate: Thrombolysis with rTPA and Unfractionated Heparin
  5246. Cerebrovascular manifestations in hematological diseases: an update
  5247. A molecular revolution in the treatment of hemophilia
  5248. anticoagulants and the Hemostatic System: A Primer for Occupational Stress Researchers
  5249. Clinical utility of viscoelastic testing in chronic liver disease: A systematic review
  5250. Thrombin generation and thromboelastometry tests in dogs with chronic kidney disease
  5251. Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk
  5252. Challenges in Management of VTE in Children With Cancer: Risk Factors and Treatment Options
  5253. Genetic Risk Profiling Associated with Recurrent Unprovoked Venous Thromboembolism
  5254. A narrative review of the impact of surgery and anaesthesia on acute kidney injury
  5255. naturalInhibitor; Antithrombin and Protein S Levels among Neonates Suffering from Sepsis
  5256. Immediate post-operative complications (I): Post-operative bleeding; vascular origin: Thrombosis pancreatitis
  5257. A 41-year-old Man With Weakness and Involuntary Tremors on the Right Upper Extremity
  5258. COVID-19: Sleep, Circadian Rhythms and Immunity–Repurposing Drugs and Chronotherapeutics for SARS-CoV-2
  5259. Ovarian vein thrombosis: a narrative review
  5260. Hematologic Disorders
  5261. Is coagulation-protein consumption upon admission linked to COVID-19 severity and mortality?
  5262. A New Experimental Porcine Model of Venous Thromboembolism
  5263. Always track the etiology of thromboembolism in younger adults: brain tumor revealed by recurrent pulmonary embolism in a young man
  5264. Point-of-Care Viscoelastic Tests in the Management of Obstetric Hemorrhage
  5265. Complement in hemolysis-and thrombosis-related diseases
  5266. Serpins in hemostasis as therapeutic targets for bleeding or thrombotic disorders
  5267. Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study
  5268. The impact of physician education regarding the importance of providing complete clinical information on the request forms of thrombophilia-screen tests at …
  5269. Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease
  5270. Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and …
  5271. Outcomes of head and neck microvascular reconstruction in hypercoagulable patients
  5272. Cardiovascular manifestations of COVID-19 infection
  5273. Viscoelastometric versus standard coagulation tests to guide periprocedural transfusion in adults with cirrhosis: A meta‐analysis of randomized controlled trials
  5274. Obstructive jaundice: understanding the pathophysiology
  5275. Asparaginase: Understanding and Overcoming Toxicities
  5276. Neonatal Sepsis and Hemostasis
  5277. Low dose combined oral contraceptives induced thrombotic anterior wall myocardial infarction: a case report
  5278. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
  5279. Tissue factor–bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study
  5280. Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation
  5281. Effect of Pulmonary Tuberculosis on Protein C, S, and Antithrombin-III among Therapy-naïve Ghanaian Adults; A Comparative Cross-Sectional Study
  5282. D-dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: a narrative review
  5283. Thrombin–Fibrin (ogen) Interactions, Host Defense and Risk of Thrombosis
  5284. A history of coagulopathy in liver disease: legends and myths
  5285. The Influence of a Knitted Hydrophilic Prosthesis of Blood Vessels on the Activation of Coagulation System—In Vitro Study
  5286. A Rare Case of Warfarin Induced Haemoperitoneum: A Case Report
  5287. Precision cardiovascular medicine in China
  5288. Mitigating the risk of liver biopsy
  5289. Causes of recurrent miscarriage after spontaneous pregnancy and after in vitro fertilization
  5290. Anticoagulation in patients with advanced liver disease: an open issue
  5291. Thromboembolic events after high‐intensity training during cisplatin‐based chemotherapy for testicular cancer: case reports and review of the literature
  5292. Antithrombin p. Thr147Ala: the first founder mutation in people of African origin responsible for inherited antithrombin deficiency
  5293. Anticoagulant treatment for splanchnic vein thrombosis in liver cirrhosis: a systematic review and meta-analysis
  5294. D-dimer, an important pathophysiological factor of deadly diseases including SARS
  5295. Cerebral venous sinus thrombosis as a complication of primary varicella infection in a child, case report
  5296. Venous thromboembolism in pediatric patients with sickle cell disease: A north American survey on experience and management approaches of pediatric …
  5297. Role of albumin in the preservation of endothelial glycocalyx integrity and the microcirculation: a review
  5298. Tyrosine-O-sulfation is a widespread affinity enhancer among thrombin interactors
  5299. Trends in pulmonary embolism mortality rates by age group in the United States, 1999–2019
  5300. Single-Vessel Massive Coronary Thrombosis in a Patient with COVID-19 In-fection: A Case Report
  5301. Coagulopathy in COVID-19
  5302. Argatroban for anticoagulation in pediatric and adult ECMO
  5303. Venous thromboembolism in pediatrics
  5304. Dynamic changes of coagulation and fibrinolytic biomarkers in perioperaive arthroplasty patients
  5305. Correction of Coagulopathy of Liver Disease Prior to Procedures
  5306. Overview of COVID-19’s relationship with thrombophilia proteins
  5307. Protein C deficiency presenting as an acute infero-posterior ST elevation myocardial infarction in a young man; A case report and focused literature review
  5308. Atrial fibrillation during pregnancy: a 9-month period with limited options
  5309. Coagulation issues in vascular anomalies
  5310. Laboratory limitations of excluding hereditary protein C deficiency by chromogenic assay: discrepancies of phenotype and genotype
  5311. Impaired fibrinolysis in the antiphospholipid syndrome
  5312. Retrospective review on the safety and efficacy of direct oral anticoagulants compared with warfarin in patients with cirrhosis
  5313. Rapid identification of a pathogenic variant of PROS1 in a thrombophilic family by whole exome sequencing: A case report
  5314. Scientific premise for the involvement of neutrophil extracellular traps (NETs) in vaccine‐induced thrombotic thrombocytopenia (VITT)
  5315. The pathophysiology of sepsis—2021 update: Part 1, immunology and coagulopathy leading to endothelial injury
  5316. COVID‐19 and the clinical hematology laboratory
  5317. Gall bladder carcinoma associated with anticoagulation-resistant, progressive, multi-focal venous thrombosis and gangrene of all limbs: a case report and review of …
  5318. COVID-19 Coagulopathy: From Pathogenesis to Treatment
  5319. Clot activators and anticoagulant additives for blood collection. A critical review on behalf of COLABIOCLI WG-PRE-LATAM
  5320. Identification of potential coagulation pathway abnormalities in SARS-Cov-2 infection; insights from bioinformatics analysis
  5321. The potential role of Transient Elastography in assessing patients with Primary Budd Chiari Syndrome
  5322. The relationship between insulin sensitivity and serum antithrombin 3 activity in patients with type 2 diabetes
  5323. Venous thromboembolism in children: from diagnosis to management
  5324. Heparin and SARS-CoV-2: Multiple Pathophysiological Links
  5325. Coagulopathy in acute Puumala hantavirus infection
  5326. Pathogen reduction of blood bank components: a matter of swings and roundabouts
  5327. Diagnostic potential of coagulation-related biomarkers for sepsis in the emergency department: protocol for a pilot observational cohort study
  5328. Management of Patient with Pregnancy and Brain Tumor
  5329. THE Peculiarities of prophylaxis of pulmonary thromboembolism after total hip endoprosthesis in dysplastic coxarthrosis
  5330. Spectrum of neuroimaging findings in COVID-19
  5331. Venous malformations and blood coagulation in children
  5332. Skin manifestations with COVID-19: the purple skin and toes that you are seeing may not be deep tissue pressure injury
  5333. Esplenectomía laparoscópica y derivación esplenorrenal proximal para hipertensión portal por trombosis de la vena porta en un paciente con deficiencia de …
  5334. Prevalence and outcomes of thrombophilia in patients with acute pulmonary embolism
  5335. Evolution of nonmalignant portal vein thrombosis in liver cirrhosis: a pictorial review
  5336. Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated …
  5337. A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant
  5338. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study
  5339. Massive late postoperative bleeding after abdominal surgery in a haematologic patient with postoperative CoV-2 infection
  5340. Ethnoracial variations in venous thrombosis: implications for management, and a call to action
  5341. Rare case of diffuse large B-cell lymphoma presenting with central pontine myelinolysis
  5342. A novel protocol to reduce bleeding associated with alteplase treatment of HVAD pump thrombosis
  5343. Risk of ischemic stroke in patients with COVID-19 infection: A Systematic Review and Meta-Analysis
  5344. Protein C deficiency: Report of a challenging case with recurrent multiorgan thrombosis
  5345. Anticoagulation Therapy After the Fontan Procedure
  5346. COVID-19 and stroke–Updated review
  5347. Evaluation of solvent/detergent‐treated plasma safety and efficacy in orthotopic liver transplant and thrombotic thrombocytopenic purpura patients: A single center …
  5348. Association between congenital thrombophilia and outcomes in pulmonary embolism patients
  5349. Hemostasis Basics: Figures and Facts
  5350. Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study
  5351. Intracardiac thrombosis in the three-year-old boy with normal left ventricle systolic function in MIS-C associated with COVID-19
  5352. The interactions of nintedanib and oral anticoagulants—Molecular mechanisms and clinical implications
  5353. Blood Transfusions for Burn Patients
  5354. Resistance to thrombomodulin correlates with liver stiffness in chronic liver disease a prospective single-center cohort study
  5355. Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)—Part III
  5356. Genetic Variants in the Protein S (PROS1) Gene and Protein S Deficiency in a Danish Population
  5357. Mortality and host response aberrations associated with transient and persistent acute kidney injury in critically ill patients with sepsis: a prospective cohort …
  5358. Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry
  5359. Thromboembolic complications in COVID-19 disease, a brief update
  5360. Peculiar, poorly known, rare congenital bleeding disorders presenting thrombotic events: an understudied chapter of molecular, blood coagulation defects
  5361. Veno-occlusive disease in children and adolescents after hematopoietic stem cell transplantation: Did the Modified Seattle Criteria fit the characteristics of …
  5362. Effect of blood loss during caesarean section on coagulation parameters
  5363. The Potential Role of Transient Elastogra-phy in Assessing Patients with Primary Budd Chiari Syn-drome
  5364. Osteonecrosis of the Femoral Head in Patients with Hypercoagulability—From Pathophysiology to Therapeutic Implications
  5365. An exceptional case of severe combined inherited thrombophilia successfully treated with rivaroxaban
  5366. Bilateral Pulmonary Embolism associated with Varicella Zoster Meningoencephalitis in an Immunocompetent Adult: A case report and literature review
  5367. Case Series
  5368. Direct oral anticoagulants: evidence and unresolved issues
  5369. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia
  5370. Covid-19 & Prophylaxis of Ischemic Stroke
  5371. A 19-Year-Old Man with a History of Recreational Inhalation of Nitrous Oxide with Severe Peripheral Neuropathy and Central Pulmonary Embolism
  5372. A Novel Approach Towards Green Synthesis of Nanodiamonds as Biocompatible Agents
  5373. More than Just Pneumonia: Acute Pulmonary Embolism in Two Middle-Aged Patients with COVID-19
  5374. Role of antithrombin iii and tissue factor pathway in the pathogenesis of sepsis
  5375. Changes in the plasma microvesicle proteome during the ovarian hyperstimulation phase of assisted reproductive technology
  5376. Acute intestinal infarction caused by initially unexplained splanchnic venous thromboses in a patient with protein C deficiency: A thought-provoking …
  5377. COVID-19 associated symmetrical peripheral gangrene: A case series
  5378. Brothers in arms: platelets and neutrophils in ischemic stroke
  5379. Novel Mutation p. Asp374Val of SERPINC1 in a Turkish Family with Inherited Antithrombin Deficiency
  5380. Multiple Complications Secondary to L-asparaginase In a Child with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia: Case Report with …
  5381. Astragalin inhibits cigarette smoke-induced pulmonary thrombosis and alveolar inflammation and disrupts PAR activation and oxidative stress-responsive MAPK …
  5382. Galápagosization of sepsis management in Japan: a nationwide survey of current practices
  5383. Bleeding and Thrombosis 37
  5384. Coronavirus disease (COVID-19) and disseminated intravascular coagulation syndrome
  5385. Long-term pituitary downregulation before frozen embryo transfer improves clinical outcomes in women positive for serum autoantibodies
  5386. Inherited thrombophilia and anticoagulant therapy for women with reproductive failure
  5387. Etiology of Budd-Chiari syndrome
  5388. A network-regulative pattern in the pathogenesis of kidney injury following severe acute pancreatitis
  5389. Trends of Ordering Hypercoagulability Work-Up at an Academic Medical Center
  5390. Venous thromboembolism in anorexia nervosa: four cases from a specialized unit. Indication for thromboprophylaxis?
  5391. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study
  5392. Cancer-associated thrombosis in pediatric patients
  5393. Longitudinal Dynamics of Coagulation and Angiogenesis Markers in Cancer Patients During and After Chemotherapy
  5394. Cerebral venous sinus thrombosis in the COVID-19 pandemic
  5395. Hypercoagulability in nephrotic syndrome
  5396. Hereditary Antithrombin Deficiency Presenting with Deep Venous Thrombosis During the Second Pregnancy
  5397. Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis
  5398. Frequency of thrombophilia associated genes. Population–based study.
  5399. Extensive Myocardial Infarction complicated with Stroke as First Presentation of HIV in A young Sudanese Male: Case Report
  5400. Bleeding and Thrombosis
  5401. Association between the use of female hormones and the thrombin generation: Cross-sectional analysis of the Longitudinal Study on Adult Health (ELSA-Brasil)
  5402. Rapid evolution of our understanding of the pathogenesis of COVID-19–implications for therapy
  5403. Venous thrombosis risk factors in pregnant women
  5404. Apixaban Use in Patients with Protein C and S Deficiency: A Case Series and Review of Literature
  5405. A case of catastrophic anti phospholipid syndrome with superimposed aspergillus infection
  5406. Legg–Calvé–Perthes disease overview
  5407. Sonoclot Signature Analysis: A New Point-of-Care Testing Method for Defining Heat Stroke-Induced Coagulopathy
  5408. Portal Vein Thrombosis following Total Colectomy due to Colonic Inertia: A Case Report and Evaluation of Risk Factors
  5409. Congenital Vitamin K-Dependent Clotting Factors Deficiency Type 1: A Rare Bleeding Disorder
  5410. The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders
  5411. The proteolytic inactivation of protein Z-dependent protease inhibitor by neutrophil elastase might promote the procoagulant activity of NETs
  5412. Venous Thromboembolism: Genetics and Thrombophilias
  5413. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia
  5414. Procalcitonin: Can it impact the length of antimicrobials
  5415. Cellular and Molecular Mechanisms of Antithrombogenic Plants: A Narrative Review
  5416. Maxillofacial and oral surgery in patients with thrombophilia: safe territory for the oral surgeon? A single-center retrospective study
  5417. COVID-19 pathophysiology predicts that ischemic stroke occurrence is an expectation, not an exception—A systematic review
  5418. COVID-19 related coagulopathy: what is known up to now
  5419. Hematological paraneoplastic syndrome and heparin-induced thrombocytopenia in untreated parotid acinic cell carcinoma-A case report
  5420. Acroischemia in a Patient with Tracheostomy in COVID-19: A Case Report
  5421. Interventional algorithm in gastrointestinal bleeding—an expert consensus multimodal approach based on a multidisciplinary team
  5422. The metabolic and immunological characteristics of pregnant women with COVID-19 and their neonates
  5423. Factor V Leiden G1691A and Prothrombin Gene G20210A Mutations on Pregnancy Outcome
  5424. Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia
  5425. Renal microvascular lesions in lupus nephritis
  5426. The Use of Values WNR and GNR to Distinguish between and Diagnose Different Types of Pancreatitis